tnib_10q.htm

0001354488-13-006363.txt : 20131114 0001354488-13-006363.hdr.sgml : 20131114 20131114154748 ACCESSION NUMBER: 0001354488-13-006363 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20130930 FILED AS OF DATE: 20131114 DATE AS OF CHANGE: 20131114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TNI BIOTECH, INC. CENTRAL INDEX KEY: 0001559356 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 593226705 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54933 FILM NUMBER: 131219735 BUSINESS ADDRESS: STREET 1: 477 SOUTH ROSEMARY AVENUE, SUITE 315 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 BUSINESS PHONE: 407-680-3097 MAIL ADDRESS: STREET 1: 477 SOUTH ROSEMARY AVENUE, SUITE 315 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 10-Q 1 tnib_10q.htm QUARTERLY REPORT tnib_10q.htm

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

þQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2013

oTRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934

From the transition period from ___________ to ____________

Commission File Number __________________

TNI BIOTECH, INC.

(Exact name of small business issuer as specified in its charter)

Florida		20-1968162
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

618 East South Street #500, Orlando, Florida 32801

(Address of principal executive offices)

888-613-8802

(Issuer's telephone number)

6701 Democracy Blvd., Suite 300, Bethesda, Maryland, 20817

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes þ No o.

Indicate by a check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” ”accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

	Large Accelerated Filer o		Accelerated Filer o

	Non-Accelerated Filer o		Smaller Reporting Company þ

Indicate by a check mark whether the company is a shell company (as defined by Rule 12b-2 of the Exchange Act: Yes o No þ.

As of November 14, 2013 there were 63,736,639 shares of Common Stock outstanding.

TABLE OF CONTENTS

	PART I FINANCIAL STATEMENTS

Item 1	Financial Statements	4

Item 2	Management's Discussion and Analysis of Financial Conditions and Results of Operations	18

Item 3	Quantitative and Qualitative Disclosures About Market Risk	23

Item 4	Controls and Procedures	23


	PART II OTHER INFORMATION

Item 1	Legal Proceedings	24

Item 1A	Risk Factors	24

Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	24

Item 3	Default upon Senior Securities	24

Item 4	Mine Safety Disclosures	24

Item 5	Other Information	25

Item 6	Exhibits	26

JUMPSTART OUR BUSINESS STARTUPS ACT

The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2012, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

We may lose our status as an emerging growth company on the last day of our fiscal year during which (i) our annual gross revenue exceeds $1,000,000,000 or (ii) we issue more than $1,000,000,000 in non-convertible debt in a three-year period. We will lose our status as an emerging growth company (i) if at any time we are deemed to be a large accelerated filer. We will lose our status as an emerging growth company on the last day of our fiscal year following the fifth anniversary of the date of the first sale of common equity securities pursuant to an effective registration statement.

As an emerging growth company we are exempt from Section 404(b) of the Sarbanes-Oxley Act of 2002 and Section 14A(a) and (b) of the Securities Exchange Act of 1934. Such sections are provided below:

Section 404(b) of the Sarbanes-Oxley Act of 2002 requires a public company’s auditor to attest to, and report on, management’s assessment of its internal controls.

Sections 14A(a) and (b) of the Securities and Exchange Act, implemented by Section 951 of the Dodd-Frank Act, require companies to hold shareholder advisory votes on executive compensation and golden parachute compensation.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This following information specifies certain forward-looking statements of management of the Company. Forward-looking statements are statements that estimate the happening of future events and are not based on historical fact. Forward-looking statements may be identified by the use of forward-looking terminology, such as may, shall, could, expect, estimate, anticipate, predict, probable, possible, should, continue, or similar terms, variations of those terms or the negative of those terms. The forward-looking statements specified in the following information have been compiled by our management on the basis of assumptions made by management and considered by management to be reasonable. Our future operating results, however, are impossible to predict and no representation, guaranty, or warranty is to be inferred from those forward-looking statements.

The assumptions used for purposes of the forward-looking statements specified in the following information represent estimates of future events and are subject to uncertainty as to possible changes in economic, legislative, industry, and other circumstances. As a result, the identification and interpretation of data and other information and their use in developing and selecting assumptions from and among reasonable alternatives require the exercise of judgment. To the extent that the assumed events do not occur, the outcome may vary substantially from anticipated or projected results, and, accordingly, no opinion is expressed on the achievability of those forward-looking statements. We cannot guaranty that any of the assumptions relating to the forward-looking statements specified in the following information are accurate, and we assume no obligation to update any such forward-looking statements.

PART I FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

TNI BIOTECH, INC.

BALANCE SHEETS

(Unaudited)

	September 30, 2013			December 31, 2012

ASSETS

Current Assets:
Cash and cash equivalents	$	207,709		$	313,095
Prepaids and other current assets		45,000			-
Total current assets		252,709			313,095

Fixed Assets:
Computer equipment, net of accumulated depreciation
of $800 and $118 respectively		4,612			944

Intangible Assets:
Patents and licenses, net of amortization
of $3,703,633 and $1,570,114, respectively (Note 7)		19,265,260			18,688,270

Deposits		17,435			24,928
Total assets	$	19,540,016		$	19,027,237



LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:
Accounts payable	$	629,797		$	286,698
Payable to officer		76,000			76,000
Accrued liabilities		654,892			427,211
Current portion patent liability		185,000			200,000
Notes payable		857,197			432,363
Total current liabilities		2,402,886			1,422,272

Non-current Liabilities:
Notes payable related party		121,128			121,128
Long-term portion patent liability		-			140,000
Total non-current liabilities		121,128			261,128
Commitments and contingencies (note 8)
Total Liabilities		2,524,014			1,683,400

Stockholders' Equity:
Common stock - par value $0.001; 500,000,000 shares authorized;
62,589,869 and 45,489,368 shares issued and outstanding respectively		62,589			45,489
Additional paid in capital		272,668,542			196,632,775
Stock issuances due		1,508,835			3,690,960
Prepaid services		(20,967,754	)		(6,082,771	)
Accumulated deficit		(236,256,210	)		(176,942,616	)
Total stockholders' equity		17,016,002			17,343,837
Total liabilities and stockholders' equity	$	19,540,016		$	19,027,237

The accompanying notes are an integral part of these financial statements.

TNI BIOTECH, INC.

STATEMENTS OF OPERATIONS

(Unaudited)





	THREE MONTHS ENDED						NINE MONTHS ENDED
	September, 30 2013			September 30, 2012			September, 30 2013			September 30, 2012


Revenues, net	$	-		$	-		$	-		$	-

Operating expenses:
Selling, general and administrative		12,608,401			280,456			33,461,690			569,121
Research and development expense		6,412,711			26,514			15,510,310			26,514
Depreciation and amortization expense		719,040			10,863			2,134,231			11,012
Total operating expenses		19,740,152			317,833			51,106,231			606,647

Loss from operations		(19,740,152	)		(317,833	)		(51,106,231	)		(606,647	)

Other income (expense):
Interest expense		(205,416	)		-			(1,098,868	)		-
Loss on settlement of debt					-			(7,108,495	)		-
Total other income (expense)		(205,416	)		-			(8,207,363	)		-

Loss from continuing operations		(19,945,568	)		(317,833	)		(59,313,594	)		(606,647	)

Gain from discontinued operations								-			260,746

Net Loss	$	(19,945,568	)	$	(317,833	)	$	(59,313,594	)	$	(345,901	)


Basic and diluted loss per share:
Loss from continuing operations	$	(0.34	)	$	(0.01	)	$	(1.08	)	$	(0.03	)
Gain from discontinued operations		-			-			-			0.01
	$	(0.34	)	$	(0.01	)	$	(1.08	)	$	(0.02	)

Weighted average number of shares outstanding		59,334,545			30,853,117			55,127,859			19,706,741

The accompanying notes are an integral part of these financial statements.

TNI BIOTECH, INC.

STATEMENTS OF STOCKHOLDERS' EQUITY

FOR THE PERIOD ENDED SEPTEMBER 30, 2013

(Unaudited)

	Common Stock						Additional Paid		Stock to			Prepaid			Accumulated
	Shares			Amount			in Capital		Be Issued			Services			Deficit			Total


Balance, December 31, 2012		45,489,368			45,489			196,632,775		3,690,960			(6,082,771	)		(176,942,616	)		17,343,837

Issuance of common stock for prepaid services		10,228,000			10,228			51,193,872					(51,204,100	)					-

Return of Stock for prepaid services		(350,000	)		(350	)													(350	)

Amortization of prepaid services													36,319,117						36,319,117

Issuance of common stock for Jill Smith/LDN License		300,000			300			2,714,700		(2,715,000	)								-

Issuance of common stock for Penn State License		300,000			300			2,549,700											2,550,000

Issuance of common stock issued for Charitable Donation		100,000			100			749,900											750,000

Issuance of common stock in exchange for debt		1,545,833			1,546			7,128,615											7,130,161

Issuance of common stock for loan expenses and interest		297,500			297			1,078,114		54,750									1,133,162

Issuance of common stock for cash and exercise of warrants		4,679,168			4,679			3,688,809											3,693,488

Issuance and modification of common stock warrants								6,932,057											6,932,057

Stock to be issued										478,125									478,125

Net loss																(59,313,594	)		(59,313,594	)

Balance, September 30, 2013		62,589,869		$	62,589		$	272,668,542	$	1,508,835		$	(20,967,754	)	$	(236,256,210	)	$	17,016,002

The accompanying notes are an integral part of these financial statements.

TNI BIOTECH, INC.

STATEMENTS OF CASH FLOWS

(Unaudited)

	NINE MONTHS ENDED
	Sepember 30, 2013			September 30, 2012

CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(59,313,594	)	$	(342,671	)
(Gain) loss from discontinued operations		-			260,746
Loss from continuing operations		(59,310,364	)		(606,647	)

Adjustments to reconcile loss from continuing operations to
net cash flows used in operating activities:
Depreciation		682			327
Amortization		2,133,549			10,685
Amortization of stock issued for prepaid services		36,318,767			53,745
Loss on settlement of debt		7,055,994
Stock warrant expense		6,932,057
Stock issued for donation		750,000
Stock issued for interest		1,133,162
Changes in operating assets and liabilities:
Accrued liabilities		227,681			125,876
Prepaid and other current assets		(37,507	)		27,700
Accounts payable		343,098			82,850
Net cash used in operating activities
from continuing operations		(4,456,111	)		(305,464	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of computer equipment		(4,350	)		(1,062	)
Purchase of Penn State License		(160,539	)
Net cash used in investing activities
from continuing operations		(164,889	)		(1,062	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of stock warrants		3,640,363
Proceeds from sale of stock		531,250			212,680
Proceeds from notes payable		499,001			250,400
Payments made on patent liability		(155,000	)		(15,000	)
Net cash provided by financing activities
from continuing operations		4,515,614			448,080

Net increase (decrease) in cash		(105,386	)		141,554
Cash at beginning of year		313,095			12
Cash at end of year	$	207,709		$	141,566

The accompanying notes are an integral part of these financial statements.

TNI BIOTECH, INC.

STATEMENTS OF CASH FLOWS

(Unaudited)

	NINE MONTHS ENDED
	September 30, 2013		September 30, 2012

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

Cash paid for interest	$	-	$	-

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

Accrued liabilities for purchase of Smith LDN patent	$	2,715,000	$	-

Conversion of debt and accrued interest to common stock	$	74,167	$	-

Common shares issued for Penn State License	$	2,550,000	$	-

Common shares issued for prepaid services	$	51,204,100	$	-

TNI BioTech, Inc.

Notes to the Financial Statements

September 30, 2013

(Unaudited)

1. Organization and Description of Business

TNI BioTech, Inc. (the “Company” or “TNIB”) was initially incorporated in Florida on December 2, 1993 as Resorts Clubs International, Inc. (“Resorts Club”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on June 27, 1998. The Company began trading in November 1999 through the filing of a 15C-211. On November 3, 2004, Galliano merged with Resorts Club International, Inc. Resorts Club was the surviving corporation. On August 10, 2010, Resorts Club changed its name to pH Environmental Inc (“pH Environmental”). On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012 pH Environmental executed a share exchange agreement for the acquisition of all of the outstanding shares of TNI BioTech, Inc.

TNI BioTech is a biopharmaceutical company focused on developing and commercializing therapeutics to treat cancer, HIV/AIDS and autoimmune diseases by combating these chronic and often life-threatening diseases through the activation and rebalancing of the body’s immune system. The Company has been developing active and adoptive forms of immunotherapies through the acquisition of patents, INDs (investigational new drug) and clinical data and all proprietary technical information, know-how, procedures, protocols, methods, prototypes, designs, data and reports, which are not readily available to others through public means, and which are owned, generated or developed through experiments or testing by Dr. Plotnikoff, Professor Shan, Dr. Bernard Bihari, Dr. Ian Zagon, Dr. Jill Smith, Dr. Patricia J. McLaughlin and Moshe Rogosnitzky. The Company currently has offices in Frederick, Maryland and Orlando, Florida.

Going Concern

The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through private equity financings and short-term debt. Management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its products and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources. Based on the Company’s operating plan, existing working capital at September 30, 2013 was not sufficient to meet the cash requirements to fund planned operations through September 30, 2014 without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business.

The Company has experienced a net loss from operations of $59,313,594 and has used cash and cash equivalents for operations in the amount of $4,456,111 during the nine months ended September 30, 2013, resulting in stockholders’ equity of $17,016,002.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), as amended for interim financial information. The financial information as of December 31, 2012 is derived from the audited financial statements presented in the Company’s Form 10 Registration Statement filed with the Commission on April 22, 2013 and the Amended Registration Statements on Form 10-/A filed on June 7, 2013, July 18, 2013, August 23, 2013, September 25, 2013, and October 11, 2013 for the year ended December 31, 2012. The unaudited interim financial statements should be read in conjunction with the Company’s Form 10 Registration Statement, which contains the audited financial statements and notes thereto, together with Management’s Discussion and Analysis of Financial Condition and Results of Operations, for the years ended December 31, 2012 and 2011.

Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management’s opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the nine months ended September 30, 2013 are not necessarily indicative of results for the full fiscal year.

Use of Estimates

The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.

Cash, Cash Equivalents, and Short-Term Investments

The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets.

Fair Value of Financial Instruments

In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “Financial Instruments,” the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments. Cash, accounts payable, payable to officer, and patent liability are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable to a related party also approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.

Computer Equipment

Computer equipment is stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense from continuing operations for the nine months ended September 2013 and 2012 was $682 and $327, respectively.

Intangible Assets

Costs incurred to acquire and/or develop the Company’s product licenses and patents are capitalized and amortized by straight-line methods over estimated useful lives of seven to sixteen years. Intangible assets are stated at the lower of cost or estimated fair market value. During the nine months ended September 30, 2013, the Company capitalized $2,710,539 of such costs incurred for the acquisition of the Company’s patents. (See Note 10 of the Company’s Form 10 Registration Statement). Amortization expense for the nine months ended September 30, 2013 and 2012 was $2,133,549 and $10,685, respectively. The Company estimates its amortization expense related to these assets will approximate $2,800,000 each year for the next five years.

Impairment of Long-Lived Assets

The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360, “Property, Plant and Equipment.” If the carrying amount of the asset, including any intangible assets associated with that asset, exceeds its estimated undiscounted net cash flow, before interest, the Company will recognize an impairment loss equal to the difference between its carrying amount and its estimated fair value. No impairment losses were recognized for the nine months ended September 30, 2013 or for the corresponding period in 2012.

Research and Development Costs

Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.

Income Taxes

The Company follows FASB ASC Topic 740, “Income Taxes,” which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of September 30, 2013, the Company has no accrued interest or penalties related to uncertain tax positions.

Share-Based Compensation and Issuance of Stock for Non-Cash Consideration

The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable.

The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “Equity-Based Payments to Non-Employees.” The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.

Net Loss per Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.

Recent Accounting Standards

Any new accounting pronouncements issued by the Financial Accounting Standards Board, as applicable, have been or will be adopted by the Company upon or before the expiration of the extended transition period provided under Section 102(b)(1) of the JOBS Act.

3. Promissory Notes

In April 2013 the Company issued two short-term promissory notes to third party investors totaling $200,000. Under the terms of the notes, the Company was required to issue a total of 20,000 shares of restricted common stock to the note holders as loan origination fees. The notes matured 14 days from the date of issuance. Under the terms of the notes, if the loans were not repaid, the note holders would collectively receive 20,000 shares of restricted common stock on the maturity date and every 30 days thereafter that the notes remain unpaid. As of the date of this filing, the notes have not been repaid.

On March 11, 2013 the Company issued four short-term promissory notes to third party investors totaling $249,000. Under the terms of the notes, the Company was required to issue a total of 25,000 shares of restricted common stock to the note holders as loan origination fees. The notes matured on March 25, 2013. Under the terms of the notes, if the loans were not repaid, the note holders would collectively receive 25,000 shares of restricted common stock on the maturity date and every 30 days thereafter that the notes remain unpaid. As of the date of this filing, the notes have not been repaid.

The Company has an outstanding note payable to K-C Operations (an unrelated party) issued on October 15, 2009. The balance as of September 30, 2013 and December 31, 2012 was $326,333 and $398,000, respectively. The note matured on October 31, 2010 and accrues interest at a rate of 6% per annum and is convertible to shares of common stock at a rate of $0.20 per share.

The Company has an outstanding note payable to Robert Johnson (former officer and director) issued on September 30, 2006 with a balance as of September 30, 2013 and December 31, 2012 of $21,547 and $21,547, respectively. The note matured on September 30, 2007 and is convertible to shares of common stock at a rate of $0.20 per share.

The Company has an outstanding note payable to Lexicon (an unrelated party) issued on January 15, 2009. The note is due upon demand. The balance as of September 30, 2013 and December 31, 2012 was $10,317 and $12,817, respectively. The note bears an interest rate of 6% per annum and is convertible to shares of common stock at a rate of $0.01 per share.

During the nine months ended September 30, 2013, the Company issued 1,545,833 shares of common stock for the retirement of $74,167 of promissory notes payable and accrued interest. The Company recognized a loss on conversion of the above debt of $7,108,495 and $0 in the nine months ended September 30, 2013 and 2012 respectively.

4. Capital Structure—Common Stock and Common Stock Purchase Warrants

Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend.

As of September 30, 2013 and September 30, 2012, the Company was authorized to issue 500,000,000 common shares at a par value of $0.001 per share.

Stock Warrants

Using the Black-Scholes Model, the Company calculated the fair value of $6,932,057 for stock warrants issued during the nine months ended September 30, 2013. Variables used in the Black-Scholes option-pricing model, include (1) a discount rate of 0.71%, (2) an expected remaining life between 2 and 5 years and (3) expected volatility of 130%.

During the third quarter of 2013, the Company issued 1,652,500 shares of its restricted common stock through common stock purchase warrant exercises. The warrants were exercised at a price of $0.50 per share and the Company received proceeds of $826,250 for equity from the exercise of the warrants.

Following is a summary of outstanding stock warrants at September 30, 2013 and December 31, 2012 and activity during the periods then ended:

	Number of Shares		Exercise Price		Weighted Average Price

Warrants as of December 31, 2012		7,260,000	$	1.00 – 1.50	$	1.02

Issued in nine months ended September 30, 2013		2,567,918	$	1.00 – 1.50	$	2.56

Expired		–		–

Exercised		3,324,168	$	0.50 – 0.75	$	0.63

Warrants as of September 30, 2013		6,503,750	$	1.00 – 1.50	$	1.83

Summary of outstanding warrants as of September 30, 2013:

Expiration Date	Number of Shares		Exercise Price	Remaining Life (years)
Second Quarter 2015	1,025,000	$	2.00-3.00	1.8
Third Quarter 2015	221,250	$	2.00-3.00	2.0
Second Quarter 2016	337,500	$	1.50	2.8
Third Quarter 2017	985,416	$	1.00	4.0
Fourth Quarter 2017	3,491,666	$	1.00-1.50	4.3
First Quarter 2018	229,584	$	15.00	4.5
Second Quarter 2018	33,334	$	15.00	4.8

5. Stock Compensation

Founders’ Shares and Shares Issued for Services

During the nine months ended September 30, 2013, the Company issued 10,228,000 shares of common stock for prepaid services, which included founder shares. The Company valued these shares based upon the fair value of the common stock at the date of the agreements. The consulting fees are amortized over the contract periods, which are typically twelve months. The Company recognized an expense from common stock issued for services of $17,101,965 and $0 for the nine months ended September 30, 2013 and 2012, respectively. The amortization of prepaid services totaled $36,318,767 and $0 for the nine months ended September 30, 2013 and 2012, respectively.

6. Discontinued Operations

In April 2012, TNI BioTech, Inc., divested itself of certain assets and liabilities related to its previous activities in the hospitality business (“Resorts Club”) by transferring them to Resorts Club International Corporation Georgia. Accordingly, the operations of that business have been reflected as discontinued operations in the financial statements.

The result of this transfer was a Gain from discontinued operations in 2012 of $260,746. This transfer is not expected to affect the cash flow of the remaining operations.

These financial statements reflect the results of Resorts Club as a discontinued operation for all periods presented.

The net sales and earnings of discontinued operations were as follows:

	Three Months Ended September 30,		Three Months Ended September 30,		Nine Months Ended September 30,		Nine Months Ended September 30,
	2013		2012		2013		2012

Net Sales		-		-		-		-

Earnings before Income Taxes		-		-		-		260,746

Income Taxes		-		-		-		-

Net Earnings from Discontinued Operations		-		-		-		260,746

Cash flows from operating and investing activities of discontinued operations for the nine months ended September 30, 2013 and 2012 were $0 and $260,746, respectively.

7. Licenses and Supply Agreements

Patent and Subsidiary Acquisition

The Company entered into a share exchange agreement April 24, 2012 to acquire all of the outstanding shares of TNI BioTech IP, Inc., (“TNI IP”) a biotechnology firm incorporated in Florida formed to acquire patents related to the treatment of cancer and HIV/AIDS and autoimmune diseases, using Met-enkephalin (“MENK”) and Naltrexone (“LDN”). The goal of TNI IP’s management is to enable mankind and civilization to combat fatal diseases by activating and mobilizing the body’s own immune system using TNI IP’s patented use of MENK.

The first patents acquired by TNI IP were acquired from Dr. Nicholas P. Plotnikoff and Professor Fengping Shan in 2012. Dr. Plotnikoff and Dr. Shan have been specializing in research activities directed toward the study of cytokines, which are hormones naturally produced by the immune system. The primary cytokine, among many others currently being studied by TNI IP, is MENK. The Company is focused on the treatment of cancer, HIV/AIDS and other infectious diseases through the use of our lead compounds.

TNI IP changed its name from TNI BioTech, Inc., to TNI BioTech IP, Inc. on April 23, 2012. TNI BioTech IP, Inc., is the wholly-owned subsidiary of the Company. TNI IP was acquired in exchange for 20,250,000 shares of the Company’s common stock of which 8,000,000 shares were issued for the acquisition of the patent and the remaining 12,250,000 shares were issued to the founders of TNI IP in exchange for all of their right, title and interest in their TNI IP shares. The goodwill arising on the acquisition of TNI BioTech IP, Inc. was valued at $98,000,000 and license agreements arising from the acquisition of TNI BioTech IP, Inc. was valued at $16,006,000.

At the time of the acquisition, the valuation of goodwill and other intangible assets were determined using the fair market price for the Company’s common stock which were exchanged for shares of TNI BioTech IP, Inc. In the fourth quarter of 2012, the Company performed an annual valuation to determine whether any goodwill or intangible assets that had been acquired by the Company were impaired. The result of this valuation was that material impairments were identified. The Company recognized an impairment of the goodwill arising on the acquisition of TNI BioTech IP, Inc. of $98,000,000.

Patent License Agreements

On August 13, 2012, the Company signed a License Agreement with Ms. Jacqueline Young for the intellectual property developed by Dr. Bernard Bihari relating to treatments with opioid antagonists such as naltrexone and Met-enkephalin for a variety of diseases and conditions including malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, chronic herpes virus infections, chronic herpes viral infections such as chronic genital herpes caused by the herpes simplex virus Type 2 and chronic infections due to the Epstein-Barr virus and a treatment method for humans infected with HTLV-III (AIDS) virus including patients clinically diagnosed as suffering from AIDS and those suffering from AIDS-related complex (ARC). The Bihari patents were acquired in exchange for 540,000 shares of the Company’s common stock with a fair market value of $972,000 and assumed liabilities of $400,000 which is payable to Ms. Young over a twenty-four month period in equal installments to reimburse her for the costs of a New York City office in accordance with the patent license agreement. The patent liability at September 30, 2013 totaled $185,000. The cost of the patent totaled $1,372,000. Additionally, the Company will pay the licensor a royalty payment of 1% of gross MENK sales and pay a 1% sublicense fee on any sublicense revenue.

On December 24, 2012, the Company signed an agreement for the acquisition of patent rights for the intellectual property of Dr. Jill Smith and LDN Research Group, LLC (the “Patent License Agreement”), whose members are Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Moshe Rogosnitzky and orphan drug designation by the FDA to a novel late-stage drug, trademarked “LDN,” for the treatment of Pediatric Crohn’s disease. The patent covers methods and formulations for treatment of the inflammatory and ulcerative diseases of the bowel, using naltrexone in low doses as an opioid antagonist. Endogenous opioids and opioid antagonists have been shown to play a role in stimulating and rebalancing the immune system and the healing and repair of tissues. These patents were acquired in exchange for 300,000 shares of the Company’s common stock with a fair value of $2,715,000 and expenses of $165,384, which totaled $2,880,384. The Company has an exclusive, worldwide license to make, have made, use, lease, import, offer for sale and sell Licensed Products and to use the method under the patent rights. The agreement will terminate on the expiration or abandonment of the last patent to expire or ten years after the sale of the first licensed product. The Company may terminate the agreement upon 90 days’ written notice, provided all sublicenses are terminated and all amounts due and owing are paid to the licensor parties. The licensor parties may terminate the agreement ten days' after notice to the Company if the Company is ten days late in payment or there is a breach that remains uncured for ten days after written notice of such breach.

In partial consideration of the Patent License Agreement, the Company agreed to pay to the members the applicable milestone payments listed below after substantial achievement of each milestone event is achieved by the Company, its Affiliates or Sublicensees.

A.	Upon initiation of each phase III trial, the Company will pay $350,000.
B.	Upon positive completion of each phase III clinical trial of the therapeutic use of an LDN compound in the field of Use, the Company will pay $150,000.

C.	When an NDA is accepted for review by the FDA, the Company will pay $250,000.
D.	When FDA approval to market the NDA is approved, the Company will pay $750,000.

E.	Upon the first dosing of the first patient in a phase III clinical trial for each Licensed Product, the Company will pay 250,000 shares of the Company’s common stock.
F.	Upon the first sale of each Licensed Product, the Company will issue 400,000 shares of the Company’s common stock.

G.	Upon the achievement of $20 Million USD in cumulative sales for each licensed product covered by NDAs, the Company will issue 500,000 shares of the Company’s common stock.

The Company must pay an annual license fee in the low six-figure range and mid single digit percentage royalties on the net sales of each licensed product with an annual minimum royalty payment in the low six-figure range. The Company will pay a sublicense fee between 10-20% calculated on the payments the Company receives from any such sublicense.

As part of the Patent License Agreement, TNI BioTech has the right to apply to the Food and Drug Administration (FDA) for the transfer of the orphan drug status, the investigational new drug applications (INDs), and the right to acquire the relevant clinical data set from Dr. Smith. The FDA has designated orphan drug status for the use of low dose naltrexone in the treatment of pediatric patients with Crohn’s disease and ulcerative colitis.

The Patent License Agreement calls for the formation of a Development Committee to monitor the clinical progress of the Licensed Products and will consist of independent scientific and technical leaders who are highly regarded by the scientific community in the Field of Use of each Licensed Product. The development committee consists of at least one representative from the Licensor Parties and one representative from the Company in addition to outside experts in the field.

Naltrexone in low dose is a platform immunomodulatory technology that the Company expects to clinically test in the treatment of other immune-mediated or immune-deficient diseases for which it has previously acquired additional patents.

The Company signed an exclusive licensing agreement with The Penn State Research Foundation on January 18, 2013 to license all of the intellectual property developed by Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Dr. Jill P. Smith for the treatment of cancer titled “Opioid Growth Factor and Cancer” and “Combination Therapy with Opioid Growth Factor and Taxanes for the Treatment of Cancer” (the “Licensing Agreement”). These licenses were acquired in exchange for 300,000 shares of the Company’s common stock with a fair value of $2,550,000 and expenses of $160,539, which totaled $2,710,539.

The patent covers methods and formulations related to the treatment and prevention of different cancers. More specifically, the present inventions describe the use of drugs that interact with opioid receptors (naltrexone, naloxone and the pentapeptide growth factor Met-enkephalin) to inhibit and arrest the growth of cancer. Endogenous opioids and opioid antagonists have been shown to play a role in stimulating and rebalancing the immune system and the healing and repair of tissues. Such efficacy has been discovered to be partially due to the functional manipulation of the zeta opioid receptor through exogenous and endogenous Met-enkephalin. This receptor has been determined to be present in a variety of cancers, including pancreatic and colon cancer.

As part of the Licensing Agreement, TNI BioTech is working to acquire the orphan drug designation (IND) and clinical data set from Dr. Jill Smith.

The Licensing Agreement calls for TNI BioTech to (a) use commercially reasonable efforts to develop, commercialize, market and sell Licensed Products in a manner consistent with the Business Plan; (b) expend a minimum of $110,000 (per annum) to develop and commercialize Licensed Products as soon as practicable, consistent with sound business practices and judgment; (c) be responsible for obtaining all requisite regulatory approvals needed to use or sell Licensed Products in the Field of Use; and (d) make the first commercial sale of a Licensed Product by December 31, 2016.

The Licensing Agreement provides that the Company must make an initial license fee of $100,000 and the issuance of 300,000 shares and an annual license maintenance fee in the low ten thousand dollar amount range. The Company will also make payments to licensor upon the achievement of certain milestone events such as initiations of Phase II or Phase III clinical trials in a low hundred thousand dollar amount, acceptance of the NDA by the FDA in a low hundred thousand amount and FDA approvals in a high hundred thousand dollar amount. The Company will issue shares upon reaching certain milestones including the issuance of a mid ten thousand amount of shares upon the first dosing of patients in clinical trials, the issuances of a low hundred thousand number of shares upon the initial sale of a licensed product and a milestone fee of a low hundred thousand share amount upon reaching sales of $20 million in cumulative sales. If the Company achieves all of the milestones, an additional $1,350,000 will be paid and an additional 375,000 shares will be issued.

The Company will also pay the licensor a percentage of net sales in the mid single digit range of the licensed products each quarter subject to a minimum royalty payment in the low hundred thousand dollar range. The Company must also pay the licensor a low double-digit percentage of any payments received from any sublicenses.

The Licensing Agreement calls for the formation of a Development Committee to monitor the clinical progress of the Licensed Products, which will consist of independent scientific and technical leaders who are highly regarded by the scientific community in the Field of Use of each Licensed Product.

The Licensing Agreement terminates on the expiration or abandonment of the last patent to expire or become abandoned. The Company may terminate the Licensing Agreement at any time upon 60 days’ prior written notice and ceasing to make and sell all licensed products, the termination of all sublicenses and payment of all monies owed under the Licensing Agreement. The licensor may terminate the agreement 30 days after notice to the Company if the Company is 30 days late in payment or a breach that remains uncured for 45 days after written notice of such breach.

In confirmation letters dated April 3, 2013, the Company received acknowledgement from the Department of Health and Human Services confirming the Food and Drug Administration’s (FDA) receipt of the change in sponsorship of the investigational new drug application (IND) for Naltrexone HCL and the orphan drug designation for [met5]-enkephalin and the orphan drug designation for the use of low dose naltrexone in the treatment of pediatric patients with Crohn’s Disease.

On March 15, 2013 the Company executed a Patent License Agreement with Professor Fengping Shan. The Company obtained exclusive rights to develop and commercialize the licensed technology. The licensed technology is the intellectual property developed and owned by Professor Shan (i) relating to the treatment of a variety of diseases and conditions with MENK including multiple forms of lymphoma and cancer and (ii) a treatment method for humans infected with the HLTV-III (AIDS) virus including AIDS and AIDS related complex (ARC). The licensed technology includes the methods and formulations for these treatments including but not limited to all INDs, communications with regulatory agencies, patient data, and letters relating to these treatments. The licensed technology also includes the following patents: 200710158742.7 MENK, its application is in treating leukemia and other blood cancers; No. 200710051586.4 MENK, its application is in preparation of human and animal vaccines; No. 200610046249.1, a nasal spray formulation containing MENK; No. 201210290150.1 LDN, combined with MENK, its application is in preparation of an anticancer drug (Pending); No. 201210302259.2 LDN, combined with MENK, its application is in preparation of leukophoresis for anticancer (Pending); No. 200810229085.5 Compound MENK as a drug for colon cancer and pancreatic cancer; No. o. 200910011030.1, Naltrexone as well as analougues being anticancer drug. Under this license, the Company must issue a mid six-figure number of shares to Prof. Shan and a low hundred thousand dollar amount for the upfront license fee, and reimburse Prof. Shan for all out of pocket expenses in connection with the patents in mid five figure range. The Company will pay Prof. Shan a mid single digit percentage running royalty of gross sales subject to decreases if third party intellectual property is needed to complete such sale or product but in no event less than a high percentage of a low single digit percentage and a low single digit percentage of all sublicense revenue. This agreement shall last for the duration of each of the licensed patents however the Company may terminate the license agreement on 120 days' written notice to Professor Shan.

8. Commitments and Contingencies

Distribution and Production

Effective August 16, 2013, the Company executed a manufacturing agreement with Laboratorios Ramos, S.A. (“Laboratorios Ramos”) a current good manufacturing practice (“cGMP”) facility for IRT-103 low-dose naltrexone (“LDN”). Under the agreement, Laboratorios Ramos will produce LDN tablets, capsules and cream in accordance with the technical specifications provided by TNI, the FDA’s good manufacturing practices and the practices of Nicaragua and of any other regulatory governing body countries where the products will be exported. Laboratorios Ramos must obtain all permits and licenses necessary to carry out the manufacturing and packaging of LDN.

Supervision and Inspection of Manufacturing in Nicaragua

On April 23, 2013, the Company signed a contract with ViPharma for the Supervision and Inspection of Manufacturing Processes as part of its negotiations for a contract for the manufacturing of LDN in a tablet, capsule and/or cream. The contract sets out the terms and conditions under which ViPharma will carry out the services of inspecting and supervising the manufacturing and packaging processes of LDN and ensure compliance with the FDA’s good manufacturing practices and the Company’s specifications. ViPharma will carry out its obligations in whatever Latin American country the Company ultimately decides to manufacture LDN within. Under the contract, ViPharma has the exclusive rights to supervise and inspect all manufacturing processes of LDN in Latin America. The Contract began on April 23, 2013 and has a duration of 10 years, with automatic renewal every 5 years thereafter unless either party is in breach of the contract or either party terminates the agreement, without cause, with 90-days’ written notice. In the event of a breach by either party, the non-breaching party must give notice to the breaching party and the breaching party has a 45-day period to cure.

9. Related Party Transactions

Effective September 15, 2012, TNI BioTech, Inc. entered into a one-year employment agreement with Joseph Griffin, the brother of the Company's Chief Executive Officer, in which base salary, the grant of a common stock, and health insurance coverage were defined. As a signing bonus, Mr. Griffin received 250,000 shares of restricted common stock of the Company. For the nine months ended September 30, 2013, the Company paid gross compensation totaling $62,338.

In 2012, Webfoot, Inc., provided financing to the Company and as of September 30, 2013, the Company owed Webfoot, Inc. $121,128. Webfoot, Inc., is owned by the son of Noreen Griffin. On February 21, 2013, the Company entered into a formal loan agreement to evidence the amount owed on December 31, 2012. The loan bears interest at an annual rate of 6%. The interest is repayable at maturity. The note matures on February 21, 2014.

In 2012, Noreen Griffin made payments on the Company's behalf covering the costs of incorporation and merger-related expenses. At September 30, 2013, the Company owed Ms. Griffin $30,000. On February 13, 2013, the Company entered into a formal loan agreement to evidence repayment of the amount owed on December 31, 2012. The loan bears interest at an annual rate of 6%. The interest is repayable at maturity.

In 2012, Griffin Enterprises, Inc. made payments on the Company's behalf covering the cost of incorporation and merger-related expenses. Griffin Enterprises, Inc. is wholly-owned by Noreen Griffin. At September 30, 2013, the company owed Griffin Enterprises, Inc. $46,000. On February 21, 2013, the Company entered into a formal loan agreement to evidence repayment of the amount owed on December 31, 2012. The loan bears interest at an annual rate of 6%. The interest is repayable at maturity.

On January 3, 2013, the Company formalized the terms under which Kelly O’Brien Wilson, the daughter-in-law of the Company's Chief Executive Officer has been employed. Ms. Wilson had been working with the Company in 2012 and her three-year employment agreement is effective as of December 1, 2012. The agreement was amended on September 1, 2013. The terms of the agreement define her base salary, a grant of a common stock, and health insurance coverage. As a signing bonus, Ms. Wilson is entitled to receive 50,000 shares of common stock of the Company. For the nine months ended September 30, 2013, the Company paid gross compensation totaling $63,903. Ms. Wilson has not received the 50,000 shares of common stock that were part of her original agreement and previously disclosed in our Form 10 Registration Statement.

10. Subsequent Events

The following is a schedule of shares issued subsequent to September 30, 2013.

	Shares

Shares issued for default on promissory notes		90,000
Shares issued to investors		48,000
Shares issued for warrant exercise		837,500
Shares issued for debt conversion		150,000

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. The Company’s actual results could differ materially from those set forth on the forward looking statements as a result of the risks set forth in the Company’s filings with the Securities and Exchange Commission, general economic conditions, and changes in the assumptions used in making such forward looking statements.

General

TNI BioTech, Inc. (the “Company”) was initially incorporated in Florida on December 2, 1993 as Resorts Clubs International, Inc. (“Resorts Club”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on June 27, 1998. The Company began trading in November 1999 through the filing of a 15C-211. On November 3, 2004, Galliano merged with Resorts Club International, Inc. Resorts Club was the surviving corporation. On August 10, 2010, Resorts Club changed its name to pH Environmental, Inc. (“pH Environmental”). On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012 pH Environmental executed a share exchange agreement for the acquisition of all of the outstanding shares of TNI BioTech, Inc. (“TNI”).

We have invested a significant portion of our time and financial resources in the acquisition and development of our most advanced drug candidate, IRT-103 low-dose naltrexone (“LDN”). While we currently have 3 other drug candidates in clinical trials, we anticipate that our ability to generate significant product revenues in the near term will depend primarily on the successful development, regulatory approval, marketing and commercialization of IRT-103 (LDN) by us or by one of our potential partners. It is uncertain whether IRT-103 (LDN) will have successful results in its development, regulatory approval, marketing and commercialization.

The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through private equity financings. Management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, the transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidate and achieving a level of revenue adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional funds. Management intends to fund future operations through additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources.

Business Strategy

The Company’s business strategy focuses on several key areas:

●	The establishment of treatment facilities throughout Africa, the Caribbean and South America for cancer, HIV/AIDS and other autoimmune diseases that can benefit from IRT-101, IRT-102 and IRT-103 patented technology and therapies;

●	The large scale treatment in emerging nations for HIV/AIDS as an immune-enhancing therapy using IRT-103 LDN;

●	The large scale (outsourced) manufacturing and distribution of IRT-103 LDN, either in pill form, or cream for those unable to handle the medication in pill form, throughout Africa and expanding to other developing nations; and

●	The Joint Venture with the Hubei Qianjiang Pharmaceutical Company that will provide the funding required for the Phase III trials in China in exchange for TNIB providing exclusive licensing rights in China. TNIB will also receive a percentage of the gross revenue from sales in China.

The Company has entered into a relationship with a number of groups including: GB Oncology & Imaging Group, LLC, the Brewer Group, AHAR Pharma, as well as a number of United States doctors that own and operate clinics in the United States and Nigeria. We are also working with large employers who operate on-site clinics.

In November 2012, TNI signed an exclusive distributor agreement with G-Ex Technologies/St. Maris Pharma and GB Pharma Holdings LLC for the Federal Republic of Nigeria. Under the terms of the agreement, G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC will have exclusive marketing and distribution rights to IRT-103 LDN and LDN cream in Nigeria.

The Government of Malawi has been remodeling a section of the Queens's Hospital as an oncology center. Once it is complete, TNI BioTech, with the assistance of GB Oncology & Imaging Group, LLC and the other groups, is ready to ship the equipment to the oncology center within the next 90 to 120 days. Once the facility is operational, American Hospital Resort has agreed to assist in the operation of the clinic in Malawi and the implementation of TNI BioTech therapies. In the case of Malawi, a number of not-for-profits are funding the project through donations. There is no need to build a facility as we are currently working with known operators.

Operations in Nigeria will be operational within 90 days and operations in Malawi should be operational by 2014.

TNI, in conjunction with GB Energie LLC, under the leadership of Dr. Gloria B. Herndon, established GB Oncology and Imaging Group LTD (“GBOIB”) to meet the demands for oncological and infectious diseases expertise. Dr. Herndon has been involved in healthcare related issues in Africa since the mid 1990s and is a consulting resource for the National Institute of Health (“NIH”) regarding the impact of the HIV/AIDS pandemic on the insurance industry and the dissemination of AIDS-related information to the United States Department of State. The goal of TNI/GBOIG, together with the ministries of health across Africa, is to provide better access to and public awareness of the prevention, diagnosis and treatment of cancer and chronic infectious diseases. TNI plans to work with onsite clinics which will permit TNI to complete patient assessments at little or no cost and prescribe treatments used to modulate the immune system of the patients with various chronic diseases, especially HIV/AIDS and/or cancer so that it decreases the inflammatory attack on normal cells and allows an improvement in normal functions of the nerves or gastrointestinal cells. As a result, treatment with LDN is potentially synergistic in combination with current drugs for autoimmune diseases such as Crohn’s disease. In advanced cases, the patients can be transferred to TNI’s offsite treatment facility for further evaluation and treatment, where they can benefit from TNI’s patented technology and therapies.

Through these clinics, TNI intends to begin delivery of Lodonal IRT-103, the Company’s proprietary LDN, for the treatment of HIV/AIDS and/or cancer in 2013. The contract with the Republic of Malawi calls for 25,000 pills a day, increasing to 500,000 pills a day within 24 months. TNI anticipates people will take IRT-103 365 days a year. The contracts with Equatorial Guinea will begin with about 10,000 people per day growing to about 125,000 people per day over the next two years.

TNI is focused on our lead therapies designed for the treatment of cancer, HIV/AIDS, Crohn’s disease, fibromyalgia and MS. Management believes there are clear market opportunities with a significant amount of unmet needs and a robust potential for partnering activities.

Distribution and Production

On April 23, 2013, TNI has entered into a contract for the supervision and inspection of manufacturing processes with ViPharma. The supervision and manufacturing agreement provides ViPharma with exclusive rights to supervise and inspect all manufacturing processes of LDN in Latin America. The initial term of the agreement is ten years with automatic five-year renewal terms provided neither party is in breach. The agreement may be terminated by (i) mutual agreement, (ii) in the event of a breach after a 45 day cure period or (iii) by either party upon provision of written notice at least 90 days before the end of the agreement, provided however that if TNI terminates the contract without cause it will be required to pay ViPharma a penalty.

TNI executed a manufacturing agreement with Laboratorios Ramos, S.A. (“Laboratorios Ramos”), a current good manufacturing practice (“cGMP”) facility, for IRT-103 LDN effective August 16, 2013. Under the agreement, Laboratorios Ramos will produce LDN tablets, capsules and cream in accordance with the technical specifications provided by TNI, the FDA’s good manufacturing practices and the practices of Nicaragua and of any other regulatory body governing the countries where the products will be exported. Laboratorios Ramos must obtain all permits and licenses necessary to carry out the manufacturing and packaging of LDN. The manufacturing agreement has a one-year term, renewable by a signed agreement by the parties at least 60 days before the expiration of the agreement. The agreement may be terminated earlier through mutual agreement or upon expiration of a 30-day cure period following notice from the non-breaching party to the breaching party of a material failure of the obligations under the agreement. Additionally, TNI may terminate the agreement upon at least 30 days written notice if Laboratorios Ramos does not act in strict accordance with the technical specifications provided by TNI and with the FDA’s good manufacturing practices or those of any regulatory body of the importing countries.

Meeting with FDA Regarding LDN

In May 2013, the Company received confirmation of a Type C meeting with the FDA to discuss the Phase 3 clinical development program for a proposed 505(b)(2) application for Low Dose Naltrexone (“LDN”) in the treatment of adults and pediatric patients with Crohn’s disease. The meeting was held on June 26, 2013 and the Company received the minutes from the meeting on July 17, 2013. The Company presented its development plan to the FDA that supports its Phase III clinical studies and NDA filing. After conclusion of the Type C meeting, the Company plans to move into Phase III clinical studies in early 2014.

Meeting with FDA Regarding MENK

The Company received confirmation of a Type B meeting with the FDA on August 20, 2013 to discuss the Phase 3 clinical development program and CMC plans for Met-enkephalin in combination with gemcitabine in the treatment of pancreatic cancer.

Subsidiaries

TNI, a Florida corporation, formed its United Kingdom subsidiary, TNI BioTech, LTD (the “Subsidiary”) on August 6, 2013. TNI BioTech, LTD received approval to be considered an enterprise micro, small or medium-sized enterprise (“SME”) with the European Medicines Agency (“EMA”) on August 21, 2013. The designation provides the Company with significant discounts when holding meetings or submitting filings to the EMA. On September 19, 2013, TNI BioTech, LTD submitted a pre-submission package to the EMA regarding Crohn’s Disease. The EMA granted the Company a meeting that took place on September 27, 2013. The Company is eligible to benefit from the provisions for administrative and financial assistance for SMEs set out in Regulation (EC) No 2049/2005.

Agreements

TNI BioTech International, Ltd., a wholly-owned subsidiary of TNI executed a Distribution Agreement effective September 17, 2013 with AHAR Pharma, a company formed under the laws of the Federal Republic of Nigeria (the “Distributer”). Subject to the terms and conditions of the Agreement, the Distributer will distribute the Company’s low-dose naltrexone under the name Lodonal™ throughout Nigeria on an exclusive basis.

Results of Operations – Six Months Ended June 30, 2013

Revenues

We had no revenues from operations for the period ending September 30, 2013 and for the years ended December 31, 2012 and 2011. We do not anticipate having any significant future revenues until we have sufficiently funded operations.

Operating Expenses

Selling, general and administrative

Selling, general and administrative ("SG&A") expenses were $33,461,690 for the nine months ended September 2013, compared to $565,891 for the corresponding period in 2012.

In the nine months ended 2013, total cash spent on SG&A was $3,371,286, compared to $565,891 for the corresponding period in 2012. Significant cash items included consulting services ($1,003,133 in 2013, compared to $76,745 for the nine months ended September 30, 2012), professional fees ($827,282 in 2013, compared to $54,816 in 2012), payroll ($795,308 in 2013, compared to $283,253 in 2012), and travel ($315,710 in 2013, compared to $290 in 2012). In addition, the Company recorded non-cash SG&A expenses of $30,087,174 in the nine months ended September 2013 ($4,230 in 2012), comprised mainly of costs of issuance of shares for services ($22,388,033 in 2013, compared to $0 in 2012) and stock warrants ($6,950,655 in 2013, compared to $0 in 2012). The increase year over year in SG&A expense was attributable primarily to increased sales and marketing activities to promote the sale of the Company's products in South America and Africa, and the cost of raising additional equity to fund ongoing operations and business development.

Research and development

Research and development ("R&D") expenses were $15,510,310 for the nine months ended September 2013, compared to $26,514 for the corresponding period in 2012.

In the nine months ended 2013, total cash spent on R&D was $1,460,816, compared to $26,514 for the corresponding period in 2012. Significant cash items included contracted technical services ($823,984 in 2013, compared to $22,500 for the nine months ended September 30, 2012), professional fees ($71,592 in 2013, compared to $0 in 2012), payroll ($327,335 in 2013, compared to $0 in 2012), and travel ($40,931 in 2013, compared to $1,503 in 2012). In addition, the Company recorded non-cash R&D expenses of $14,049,394 in the nine months ended September 2013 ($0 in 2012), comprised mainly of costs of issuance of shares for services. The increase year over year in R&D expense was attributable primarily to the increase in R&D required to launch new clinical trials and implement the Company's product development program.

Depreciation and amortization

Depreciation and amortization expense was $2,134,231 for the nine months ended September 2013, compared to $11,012 for the corresponding period in 2012. The Company amortizes the costs incurred to acquire patents and licenses over the period of the related agreements. The increase year over year in depreciation and amortization expense reflects the fact that most of the Company's patents and licenses were acquired after October 1, 2012.

Interest Expense

Interest expenses are comprised of loan origination fees and interest owed by the Company. Interest expense for the nine months ended September 30, 2013 was $1,098,868 compared to $0 for the corresponding period in 2012. Higher interest expense in 2013 reflects the increase in the amount of interest-bearing notes payable outstanding in 2013.

Loss on settlement of debt

In the nine months ended September 30, 2013, certain lenders to the Company exercised their rights to convert all or a portion of their notes payable to equity. The Company recorded an expense of $7,108,495, reflecting the fair value of the stock issued in exchange for the notes. There was no expense in the corresponding period in 2012.

Liquidity

Liquidity is measured by our ability to secure enough cash to meet our contractual and operating needs as they arise. We do not anticipate generating sufficient net positive cash flows from our operations to fund the next twelve months. We had cash of $207,709 at September 30, 2013, compared to $313,095 at December 31, 2012.

Our cash reserves will not be sufficient to meet our operational needs and we need to raise additional capital to pay for our operational expenses and provide for capital expenditures. In addition to the Company's operational expenses, which are estimated at $400,000 per month, we estimate that we need approximately $7-15 Million in the next twelve months to fully develop our products and for Phase III clinical trials for Crohn’s disease. If we are not able to raise additional working capital, we may have to cease operations altogether.

For the nine months ended September 30, 2013 and 2012, net cash used in operating activities from continuing operations of $4,456,111 and $305,464, respectively. For the nine months ended September 30, 2013 and 2012, net cash used in investing activities from continued operations of $164,889 and $1,062, respectively. The change in 2013 is due to the purchase of computer equipment and payment for the Penn State License.

During the nine months ended September 30, 2013 proceeds from the exercise of stock warrants totalled $3,640,363 compared to $0 for the corresponding period in 2012. Proceeds from stock sales were $531,250 in 2013 compared to $212,680 in 2012. We also generated $449,001 from the sale of notes payable for the nine months ended September 30, 2013 compared to $250,400 for the same period in 2012.

Research Operations

We continue to build our research and development (“R&D”) organization and capabilities focusing primarily on new uses for opioid-related immunomodulatory therapies, such as low-dose naltrexone (“LDN”) and Met-enkephalin (“MENK”). These therapies stimulate and otherwise alter the immune system in such a way that provide the potential to treat a variety of diseases that have abnormalities in the immune system.

Our R&D priorities include development of methionine-enkephalin (MENK, IRT-101), a small synthetic peptide that is naturally occurring in the body, and low dose naltrexone (LDN, IRT-103), an opioid receptor antagonist. Our pipeline provides two therapies with an extremely wide range of indications that can be pursued. Both molecules have the ability to balance and/or correct the immune system in order to treat a variety of autoimmune diseases including multiple sclerosis, immune disorders such as Crohn’s disease, cancer, and viral infections such as HIV/AIDS.

Our R&D is overseen and managed internally, working with individuals, universities, and Contract Research Organizations (CROs) in order to utilize patents that we have licensed or acquired since our inception. We continue to seek to expand our pipeline by reviewing other compounds, technologies or capabilities. We also seek out promising compounds and innovative technologies developed by third parties to incorporate into our discovery and development processes or projects.

Drug discovery and development is time-consuming, expensive and unpredictable. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), out of 5,000-10,000 screened compounds, only 250 enter preclinical testing, five enter human clinical trials and one is approved by the FDA. The process from early discovery or design to development to regulatory approval can take more than 10 years. Drug candidates can fail at any stage of the process, and candidates may not receive regulatory approval even after many years of research.

As of June 30, 2013, we had two compounds (IRT-101 and IRT-103) in research and development. We currently have two active development programs in oncology and Crohn’s disease; both moving into Phase 3 clinical trials in early 2014.

Research and Development (R&D) Expenses

	Three Months Ended							Six Months Ended
(in US Dollar Millions)	September 30, 2013		September 30, 2012		% Change			June 30, 2013		June 30, 2012		% Change
Research and development expenses	$	6,413	$	27		23,519	%	$	15,510	$	27		57,344	%

The Company's R&D activities commenced in the third quarter of 2012, the Company having only completed the initial acquisition of MENK-related patents required for research in the second quarter of that year.

The Company's R&D efforts were focused in the first nine months of 2013 on the development of two products - LDN and MENK - for use in opioid-related immunomodulatory therapies. In the first nine months of 2013, the Company reported R&D expenditures of $15,510,310. Approximately 75% of that amount was spent on the development of LDN, the balance on MENK.

The following table provides information about significant regulatory actions by, and filings pending with the FDA and regulatory authorities in the European Union, as well as additional indications and new drug candidates in late-stage development.

NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT

CANDIDATE	INDICATION

IRT-101	Pancreatic Cancer
IRT-103	Crohn’s Disease

Summary

Our ability to continue as a going concern is dependent entirely on raising funds through the sale of equity or debt. We anticipate that we will continue our attempt to raise capital through private equity and debt transactions, develop a credit facility with a lender, or the exercise of options and warrants; however, such additional capital may not be available to us at acceptable terms or available at all. In the event that we are unable to obtain additional capital, we would be forced to cease operations altogether.

Off-Balance Sheet Arrangements

During the nine months ended September 30, 2013, we did not engage in any off balance sheet arrangements as defined in item 303(a)(4) of the SEC’s Regulation S-K.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not Applicable.

ITEM 4. CONTROLS AND PROCEDURES

Changes in Internal Controls over Financial Reporting

There were no changes in our internal controls over financial reporting that occurred during the period covered by this report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act. As of the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of our disclosure controls and procedures as defined in Rules 13(a)-15(e) under the Securities Exchange Act of 1934 (“the Exchange Act”). Based on this evaluation, the principal executive officer and principal financial officer concluded that our disclosure controls and procedures are ineffective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.

Management assessed the effectiveness of the internal controls over financial reporting as of September 30, 2013, using the framework set forth in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based upon this assessment, our management concluded that, as of September 30, 2013, the internal controls over financial reporting were not effective. The reportable conditions and material weakness relate to a limited segregation of duties and lack of an audit committee. The limited segregation of duties within our company and the lack of an audit committee are due to the small number of employees. Management has determined that this control deficiency constitutes a material weakness. This material weakness could result in material misstatements of significant accounts and disclosures that would result in a material misstatement to our interim or annual financial statements that would not be prevented or detected. In addition, due to limited staffing, we are not always able to detect minor errors or omissions in reporting.

Going forward, management anticipates that additional staff will be necessary to mitigate these weaknesses, as well as to implement other planned improvements. Additional staff will enable us to document and apply transactional and periodic controls procedures, permit a better review and approval process and improve quality of financial reporting. However, the potential addition of new staff is contingent on obtaining additional financing, and there is no assurance that we will be able to do so.

PART II OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 1A. RISK FACTORS

We believe there are no changes that constitute material changes from the risk factors previously disclosed in our Registration Statement on Form 10, filed with the SEC on April 22, 2013 and the Amended Registration Statements on Form 10-/A filed on June 7, 2013, July 18, 2013, August 23, 2013, September 25, 2013 and October 11, 2013. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Between July 1, 2013 and September 30, 2013, various warrant holders purchased an aggregate total of 1,652,500 shares of TNI BioTech, Inc. (the “Company”) at an exercise price of $0.50 per share. In addition, the Company sold an aggregate sum of 465,000 shares of its common stock at $1.25 and $1.00 per share pursuant to a private placement (the “Private Placement”). In total, the Company received $826,250 as consideration for the exercise of the previously-issued warrants (the “Warrants”) and $531,250 for the purchase of common stock under the Private Placement, for an aggregate sum of $1,357,500.

The issuance of the Company’s common stock in connection with the Warrants and Private Placement was completed in a private transaction by the Company not involving any public offering pursuant to Section 4(a)(2) and Rule 506 of Regulation D of the Securities Act of 1933, as amended (the “Securities Act”). The shares purchased under the Warrants and Private Placement were issued bearing restrictive legend and may not be resold by the purchasers unless such shares are registered or an exemption from registration is available. The Company determined, based on representations of the investors, that the investors were “accredited investors” as defined under Rule 501(a) of the Securities Act.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5. OTHER INFORMATION

African Contracts

In the African countries where the Company currently has contracts, international laws require the exporting company provide a certificate of Free Sale. It has taken TNI BioTech longer than anticipated to obtain the certificate of Free Sale, which has delayed the shipments of products to Africa.

Confirmation of Transfer of IND Application and Orphan Drug Designation

Meeting with FDA Regarding LDN

In May 2013, the Company received confirmation of a Type C meeting with the FDA to discuss the Phase III clinical development program for a proposed 505(b)(2) application for Low Dose Naltrexone (“LDN”) in the treatment of adults and pediatric patients with Crohn’s disease. The meeting was held on June 26, 2013 and the Company received the minutes from the meeting on July 17, 2013. The Company presented its development plan to the FDA that supports its Phase III clinical studies and NDA filing. After conclusion of the Type C meeting, the Company plans to move into Phase III clinical studies in early 2014.

Meeting with FDA Regarding MENK

The Company received confirmation of a Type B meeting with the FDA on August 20, 2013 to discuss the Phase III clinical development program and CMC plans for Met-enkephalin in combination with gemcitabine in the treatment of pancreatic cancer.

ITEM 6. EXHIBITS

Exhibit Number		Name of Exhibit

31.1		Certification of Chief Executive Officer, pursuant to Rule 13a-14(a) of the Exchange Act, as enacted by Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Chief Financial Officer, pursuant to Rule 13a-14(a) of the Exchange Act, as enacted by Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Chief Executive Officer and Chief Financial Officer, pursuant to 18 United States Code Section 1350, as enacted by Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TNI BioTech, Inc.

Date: November 14, 2013	By:	/s/ Noreen Griffin
		Noreen Griffin
		Chief Executive Officer

EX-31.1 2 tnib_ex311.htm CERTIFICATION tnib_ex311.htm

EXHIBIT 31.1

CHIEF EXECUTIVE OFFICER CERTIFICATION

I, Noreen Griffin, certify that:

1. I have reviewed this quarterly report on Form 10-Q of TNI BioTech, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusion about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change to the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of a quarterly report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: November 14, 2013	By:	/s/ Noreen Griffin
		Noreen Griffin
		Chief Executive Officer

EX-31.2 3 tnib_ex312.htm CERTIFICATION tnib_ex312.htm

EXHIBIT 31.2

CHIEF FINANCIAL OFFICER CERTIFICATION

I, Peter Aronstam, certify that:

1. I have reviewed this quarterly report on Form 10-Q of TNI BioTech, Inc.

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: November 14, 2013	By:	/s/ Peter Aronstam
		Peter Aronstam
		Chief Financial Officer

EX-32.1 4 tnib_ex321.htm CERTIFICATION tnib_ex321.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of TNI BioTech, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2013 as filed with the Securities and Exchange Commission (the “Report”), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.


Date: November 14, 2013	By:	/s/ Noreen Griffin
		Noreen Griffin
		Chief Executive Officer

EX-32.2 5 tnib_ex322.htm CERTIFICATION tnib_ex322.htm

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.


Date: November 14, 2013	By:	/s/ Peter Aronstam
		Peter Aronstam
		Chief Financial Officer

EX-101.INS 6 tnib-20130930.xml 0001559356 2013-01-01 2013-09-30 0001559356 2012-12-31 0001559356 2013-09-30 0001559356 2012-01-01 2012-09-30 0001559356 us-gaap:CommonStockMember 2013-01-01 2013-09-30 0001559356 us-gaap:CommonStockMember 2012-12-31 0001559356 us-gaap:CommonStockMember 2013-09-30 0001559356 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-09-30 0001559356 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0001559356 us-gaap:AdditionalPaidInCapitalMember 2013-09-30 0001559356 TNIB:StockToBeIssuedMember 2013-01-01 2013-09-30 0001559356 TNIB:StockToBeIssuedMember 2012-12-31 0001559356 TNIB:StockToBeIssuedMember 2013-09-30 0001559356 TNIB:PrepaidServicesMember 2013-01-01 2013-09-30 0001559356 TNIB:PrepaidServicesMember 2012-12-31 0001559356 TNIB:PrepaidServicesMember 2013-09-30 0001559356 us-gaap:RetainedEarningsMember 2013-01-01 2013-09-30 0001559356 us-gaap:RetainedEarningsMember 2012-12-31 0001559356 us-gaap:RetainedEarningsMember 2013-09-30 0001559356 2011-12-31 0001559356 2012-09-30 0001559356 2013-07-01 2013-09-30 0001559356 2012-07-01 2012-09-30 0001559356 us-gaap:WarrantMember us-gaap:MinimumMember 2013-01-01 2013-09-30 0001559356 us-gaap:WarrantMember us-gaap:MinimumMember 2012-12-31 0001559356 us-gaap:WarrantMember us-gaap:MinimumMember 2013-09-30 0001559356 us-gaap:WarrantMember 2013-01-01 2013-09-30 0001559356 us-gaap:WarrantMember 2012-12-31 0001559356 us-gaap:WarrantMember 2013-09-30 0001559356 us-gaap:WarrantMember us-gaap:MaximumMember 2013-01-01 2013-09-30 0001559356 us-gaap:WarrantMember us-gaap:MaximumMember 2012-12-31 0001559356 us-gaap:WarrantMember us-gaap:MaximumMember 2013-09-30 0001559356 us-gaap:ComputerEquipmentMember 2013-01-01 2013-09-30 0001559356 us-gaap:ComputerEquipmentMember 2012-01-01 2012-09-30 0001559356 2013-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares TNI BIOTECH, INC. 0001559356 10-Q 2013-09-30 false --12-31 No No Yes Smaller Reporting Company Q3 2013

313095

252709

45000

313095

207709

944

4612

18688270

19265260

19027237

19540016

24928

17435

1422272

2402886

432363

857197

200000 185000

427211

654892

76000

286698

629797

1683400

2524014

261128

121128

140000

121128

19027237

19540016

17343837

17016002

-176942616

-236256210

-6082771 -20967754 3690960 1508835

196632775

272668542

45489

62589

0.001

500000000

45489368

62589869

45489368

62589869

63736639

118

800

1570114

3703633

-59313594

-345901

-19945568

-317833

260746

-59313594

-606647

-19945568

-317833

-8207363

-205416

-7108495

1098868

205416

-51106231

-606647

-19740152

-317833

51106231

606647

19740152

317833

2134231

11012

719040

10863

15510310

26514

6412711

26514

33461690

569121

12608401

280456

-1.08

-0.02

-0.34

-0.01

0.01 -1.08 -0.03 -0.34 -0.01

55127859

19706741

59334545

30853117

-260746

343098

82850

-37507

27700

227681 125876 1133162 750000 6932057 7055994 36318767 53745

2133549

10685

682

327

-4456111

-305464

160539

4350

1062

-164889

-1062

155000 15000

499001

250400

531250

212680

3640363

4515614

448080

313095

207709

141566

-105386

141554

TNI BioTech, Inc. (the Company or TNIB) was initially incorporated in Florida on December 2, 1993 as Resorts Clubs International, Inc. (Resorts Club). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (Galliano) was incorporated in Delaware on June 27, 1998. The Company began trading in November 1999 through the filing of a 15C-211. On November 3, 2004, Galliano merged with Resorts Club International, Inc. Resorts Club was the surviving corporation. On August 10, 2010, Resorts Club changed its name to pH Environmental Inc (pH Environmental). On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012 pH Environmental executed a share exchange agreement for the acquisition of all of the outstanding shares of TNI BioTech, Inc.   TNI BioTech is a biopharmaceutical company focused on developing and commercializing therapeutics to treat cancer, HIV/AIDS and autoimmune diseases by combating these chronic and often life-threatening diseases through the activation and rebalancing of the bodys immune system. The Company has been developing active and adoptive forms of immunotherapies through the acquisition of patents, INDs (investigational new drug) and clinical data and all proprietary technical information, know-how, procedures, protocols, methods, prototypes, designs, data and reports, which are not readily available to others through public means, and which are owned, generated or developed through experiments or testing by Dr. Plotnikoff, Professor Shan, Dr. Bernard Bihari, Dr. Ian Zagon, Dr. Jill Smith, Dr. Patricia J. McLaughlin and Moshe Rogosnitzky. The Company currently has offices in Frederick, Maryland and Orlando, Florida.   Going Concern   The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through private equity financings and short-term debt. Management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its products and achieving a level of revenues adequate to support the Companys cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources. Based on the Companys operating plan, existing working capital at September 30, 2013 was not sufficient to meet the cash requirements to fund planned operations through September 30, 2014 without additional sources of cash. These conditions raise substantial doubt about the Companys ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Companys assets and the satisfaction of liabilities in the normal course of business.  The Company has experienced a net loss from operations of $59,313,594 and has used cash and cash equivalents for operations in the amount of $4,456,111 during the nine months ended September 30, 2013, resulting in stockholders equity of $17,016,002.

Basis of Presentation   The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and the rules and regulations of the U.S. Securities and Exchange Commission (SEC), as amended for interim financial information. The financial information as of December 31, 2012 is derived from the audited financial statements presented in the Companys Form 10 Registration Statement filed with the Commission on April 22, 2013 and the Amended Registration Statements on Form 10-/A filed on June 7, 2013, July 18, 2013, August 23, 2013, September 25, 2013, and October 11, 2013 for the year ended December 31, 2012. The unaudited consolidated financial statements should be read in conjunction with the Companys Form 10 Registration Statement, which contains the audited financial statements and notes thereto, together with Managements Discussion and Analysis of Financial Condition and Results of Operations, for the years ended December 31, 2012 and 2011.   Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is managements opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the nine months ended September 30, 2013 are not necessarily indicative of results for the full fiscal year.   Use of Estimates   The preparation of the Companys financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.             Cash, Cash Equivalents, and Short-Term Investments   The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.   Concentration of Credit Risk   Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets.   Fair Value of Financial Instruments   In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, Financial Instruments, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments.  Cash, accounts payable, payable to officer, and patent liability are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments.   The carrying value of notes payable to a related party also approximate fair value since they bear market rates of interest and other terms.  None of these instruments are held for trading purposes.   Computer Equipment   Computer equipment is stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense from continuing operations for the nine months ended September 2013 and 2012 was $682 and $327, respectively.   Intangible Assets   Costs incurred to acquire and/or develop the Companys product licenses and patents are capitalized and amortized by straight-line methods over estimated useful lives of seven to sixteen years. Intangible assets are stated at the lower of cost or estimated fair market value.  During the nine months ended September 30, 2013, the Company capitalized $2,710,539 of such costs incurred for the acquisition of the Companys patents. (See Note 10 of the Companys Form 10 Registration Statement).  Amortization expense for the nine months ended September 30, 2013 and 2012 was $2,133,549 and $10,685, respectively.  The Company estimates its amortization expense related to these assets will approximate $2,800,000 each year for the next five years.   Impairment of Long-Lived Assets   The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360, Property, Plant and Equipment. If the carrying amount of the asset, including any intangible assets associated with that asset, exceeds its estimated undiscounted net cash flow, before interest, the Company will recognize an impairment loss equal to the difference between its carrying amount and its estimated fair value.  No impairment losses were recognized for the nine months ended September 30, 2013 or for the corresponding period in 2012.   Research and Development Costs   Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Companys behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.   Income Taxes   The Company follows FASB ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.   The Companys policy is to record interest and penalties on uncertain tax positions as income tax expense. As of September 30, 2013, the Company has no accrued interest or penalties related to uncertain tax positions.   Share-Based Compensation and Issuance of Stock for Non-Cash Consideration   The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable.   The Companys accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, Equity-Based Payments to Non-Employees. The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendors performance is complete.               Net Loss per Share   Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Companys net loss position.                Recent Accounting Standards   The Company qualifies as an emerging growth company as defined in Section 101 of the Jumpstart our Business Startups Act (JOBS Act) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2012, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.   Any new accounting pronouncements issued by the Financial Accounting Standards Board, as applicable, have been or will be adopted by the Company upon or before the expiration of the extended transition period provided under Section 102(b)(1) of the JOBS Act.

Use of Estimates   The preparation of the Companys financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.

Cash, Cash Equivalents, and Short-Term Investments   The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.

Concentration of Credit Risk   Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets.

Fair Value of Financial Instruments   In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, Financial Instruments, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments.  Cash, accounts payable, payable to officer, and patent liability are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments.   The carrying value of notes payable to a related party also approximate fair value since they bear market rates of interest and other terms.  None of these instruments are held for trading purposes.

Computer Equipment   Computer equipment is stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense from continuing operations for the nine months ended September 2013 and 2012 was $682 and $327, respectively.

Intangible Assets   Costs incurred to acquire and/or develop the Companys product licenses and patents are capitalized and amortized by straight-line methods over estimated useful lives of seven to sixteen years. Intangible assets are stated at the lower of cost or estimated fair market value.  During the nine months ended September 30, 2013, the Company capitalized $2,710,539 of such costs incurred for the acquisition of the Companys patents. (See Note 10 of the Companys Form 10 Registration Statement).  Amortization expense for the nine months ended September 30, 2013 and 2012 was $2,133,549 and $10,685, respectively.  The Company estimates its amortization expense related to these assets will approximate $2,800,000 each year for the next five years.

Impairment of Long-Lived Assets   The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360, Property, Plant and Equipment. If the carrying amount of the asset, including any intangible assets associated with that asset, exceeds its estimated undiscounted net cash flow, before interest, the Company will recognize an impairment loss equal to the difference between its carrying amount and its estimated fair value.  No impairment losses were recognized for the nine months ended September 30, 2013 or for the corresponding period in 2012.

Research and Development Costs   Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Companys behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.

Income Taxes   The Company follows FASB ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.   The Companys policy is to record interest and penalties on uncertain tax positions as income tax expense. As of September 30, 2013, the Company has no accrued interest or penalties related to uncertain tax positions.

Net Loss per Share   Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Companys net loss position.

Recent Accounting Standards   The Company qualifies as an emerging growth company as defined in Section 101 of the Jumpstart our Business Startups Act (JOBS Act) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2012, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.   Any new accounting pronouncements issued by the Financial Accounting Standards Board, as applicable, have been or will be adopted by the Company upon or before the expiration of the extended transition period provided under Section 102(b)(1) of the JOBS Act.

In April 2013 the Company issued two short-term promissory notes to third party investors totaling $200,000. Under the terms of the notes, the Company was required to issue a total of 20,000 shares of restricted common stock to the note holders as loan origination fees. The notes matured 14 days from the date of issuance. Under the terms of the notes, if the loans were not repaid, the note holders would collectively receive 20,000 shares of restricted common stock on the maturity date and every 30 days thereafter that the notes remain unpaid. As of the date of this filing, the notes have not been repaid.   On March 11, 2013 the Company issued four short-term promissory notes to third party investors totaling $249,000. Under the terms of the notes, the Company was required to issue a total of 25,000 shares of restricted common stock to the note holders as loan origination fees. The notes matured on March 25, 2013. Under the terms of the notes, if the loans were not repaid, the note holders would collectively receive 25,000 shares of restricted common stock on the maturity date and every 30 days thereafter that the notes remain unpaid. As of the date of this filing, the notes have not been repaid.   The Company has an outstanding note payable to K-C Operations (an unrelated party) issued on October 15, 2009. The balance as of September 30, 2013 and December 31, 2012 was $326,333 and $398,000, respectively. The note matured on October 31, 2010 and accrues interest at a rate of 6% per annum and is convertible to shares of common stock at a rate of $0.20 per share.   The Company has an outstanding note payable to Robert Johnson (former officer and director) issued on September 30, 2006 with a balance as of September 30, 2013 and December 31, 2012 of $21,547 and $21,547, respectively. The note matured on September 30, 2007 and is convertible to shares of common stock at a rate of $0.20 per share.   The Company has an outstanding note payable to Lexicon (an unrelated party) issued on January 15, 2009.  The note is due upon demand.  The balance as of September 30, 2013 and December 31, 2012 was $10,317 and $12,817, respectively.  The note bears an interest rate of 6% per annum and is convertible to shares of common stock at a rate of $0.01 per share.    During the nine months ended September 30, 2013, the Company issued 1,545,833 shares of common stock for the retirement of $74,167 of promissory notes payable and accrued interest.  The Company recognized a loss on conversion of the above debt of $7,108,495 and $0 in the nine months ended September 30, 2013 and 2012 respectively.

Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend.   As of September 30, 2013 and September 30, 2012, the Company was authorized to issue 500,000,000 common shares at a par value of $0.001 per share.   Stock Warrants    Using the Black-Scholes Model, the Company calculated the fair value of $6,932,057 for stock warrants issued during the nine months ended September 30, 2013. Variables used in the Black-Scholes option-pricing model, include (1) a discount rate of 0.71%, (2) an expected remaining life between 2 and 5 years and (3) expected volatility of 130%.   During the third quarter of 2013, the Company issued 1,652,500 shares of its restricted common stock through common stock purchase warrant exercises. The warrants were exercised at a price of $0.50 per share and the Company received proceeds of $826,250 for equity from the exercise of the warrants.   Following is a summary of outstanding stock warrants at September 30, 2013 and December 31, 2012 and activity during the periods then ended:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">Number of</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">Exercise</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">Weighted</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Shares</td> <td style="text-align: center; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Price</td> <td style="text-align: center; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Average Price</td></tr> <tr> <td style="line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="line-height: 115%">Warrants as of December 31, 2012</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%">7,260,000</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%">$</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%">1.00 1.50</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%">$</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%">1.02</td></tr> <tr style="background-color: white"> <td style="line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="line-height: 115%">Issued in nine months ended September 30, 2013</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%">2,567,918</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%">$</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%">1.00-1.50</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%">$</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%">2.56</td></tr> <tr style="background-color: white"> <td style="line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td> </td></tr> <tr style="background-color: #CCEEFF"> <td style="line-height: 115%">Expired</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"></td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"></td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td></tr> <tr style="background-color: white"> <td style="line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="line-height: 115%">Exercised</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%">3,324,168</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%">$</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%">0.50-0.75</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%">$</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%">0.63</td></tr> <tr style="background-color: white"> <td style="line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="line-height: 115%">Warrants as of September 30, 2013</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%">6,503,750</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%">$</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%">1.00 15.00</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%"> $</td> <td style="vertical-align: bottom; text-align: right; line-height: 115%">1.83 </td></tr> </table>    Summary of outstanding warrants as of September 30, 2013:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr> <td style="vertical-align: bottom; width: 67%">   Expiration Date</td> <td style="vertical-align: top; width: 1%; line-height: 115%"> </td> <td style="vertical-align: top; width: 1%; line-height: 115%"> </td> <td style="vertical-align: top; width: 8%; text-align: center; line-height: 115%">Number of Shares</td> <td style="vertical-align: top; width: 1%; line-height: 115%"> </td> <td style="vertical-align: top; width: 1%; line-height: 115%"> </td> <td style="vertical-align: top; width: 1%; line-height: 115%"> </td> <td style="vertical-align: top; width: 8%"> Exercise Price</td> <td style="vertical-align: top; width: 1%; line-height: 115%"> </td> <td style="vertical-align: top; width: 1%; line-height: 115%"> </td> <td style="vertical-align: top; width: 1%; line-height: 115%"> </td> <td style="vertical-align: top; width: 8%; text-align: center; line-height: 115%">Remaining Life (years)</td> <td style="vertical-align: top; width: 1%; line-height: 115%"> </td></tr> <tr> <td style="vertical-align: bottom; line-height: 115%">Second Quarter 2015</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; text-align: right; line-height: 115%">1,025,000</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%">$</td> <td style="vertical-align: top; text-align: right; line-height: 115%">2.00-3.00</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; text-align: right; line-height: 115%">1.8</td> <td style="vertical-align: top; line-height: 115%"> </td></tr> <tr> <td style="vertical-align: bottom; line-height: 115%">Third Quarter 2015</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; text-align: right; line-height: 115%">221,250</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%">$</td> <td style="vertical-align: top; text-align: right; line-height: 115%">2.00-3.00</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; text-align: right; line-height: 115%">2.0</td> <td style="vertical-align: top; line-height: 115%"> </td></tr> <tr> <td style="vertical-align: bottom; line-height: 115%">Second Quarter 2016</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; text-align: right; line-height: 115%">337,500</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%">$</td> <td style="vertical-align: top; text-align: right; line-height: 115%"> 1.50</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; text-align: right; line-height: 115%">2.8</td> <td style="vertical-align: top; line-height: 115%"> </td></tr> <tr> <td style="vertical-align: bottom; line-height: 115%">Third Quarter 2017</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; text-align: right; line-height: 115%">985,416</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%">$</td> <td style="vertical-align: top; text-align: right; line-height: 115%">1.00</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; text-align: right; line-height: 115%">4.0</td> <td style="vertical-align: top; line-height: 115%"> </td></tr> <tr> <td style="vertical-align: bottom; line-height: 115%">Fourth Quarter 2017</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; text-align: right; line-height: 115%">3,491,666</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%">$</td> <td style="vertical-align: top; text-align: right; line-height: 115%">1.00-1.50</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; text-align: right; line-height: 115%">4.3</td> <td style="vertical-align: top; line-height: 115%"> </td></tr> <tr> <td style="vertical-align: bottom; line-height: 115%">First Quarter 2018</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; text-align: right; line-height: 115%">229,584</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%">$</td> <td style="vertical-align: top; text-align: right; line-height: 115%">15.00</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; text-align: right; line-height: 115%">4.5</td> <td style="vertical-align: top; line-height: 115%"> </td></tr> <tr> <td style="vertical-align: bottom; line-height: 115%">Second Quarter 2018</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; text-align: right; line-height: 115%">33,334</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%">$</td> <td style="vertical-align: top; text-align: right; line-height: 115%">15.00</td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; line-height: 115%"> </td> <td style="vertical-align: top; text-align: right; line-height: 115%">4.8</td> <td style="vertical-align: top; line-height: 115%"> </td></tr> </table>

Founders Shares and Shares Issued for Services   During the nine months ended September 30, 2013, the Company issued 10,228,000 shares of common stock, for prepaid services, which included founder shares.  The Company valued these shares based upon the fair value of the common stock at the date of the agreements.  The consulting fees are amortized over the contract periods, which are typically twelve months.  The Company recognized an expense from common stock issued for services of $17,101,965 and $0 for the nine months ended September 30, 2013 and 2012, respectively. The amortization of prepaid services totaled $36,318,767 and $0 for the nine months ended September 30, 2013 and 2012, respectively.

In April 2012, TNI BioTech, Inc., divested itself of certain assets and liabilities related to its previous activities in the hospitality business (Resorts Club) by transferring them to Resorts Club International Corporation Georgia.  Accordingly, the operations of that business have been reflected as discontinued operations in the financial statements.   The result of this transfer was a Gain from discontinued operations in 2012 of $260,746. This transfer is not expected to affect the cash flow of the remaining operations.   These financial statements reflect the results of Resorts Club as a discontinued operation for all periods presented.   The net sales and earnings of discontinued operations were as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2">Three Months Ended September 30,</td> <td style="font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td colspan="2">Three Months Ended September 30,</td> <td style="font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td colspan="2">Nine Months Ended September 30,</td> <td style="font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td colspan="2">Nine Months Ended September 30,</td> <td style="font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-size: 12pt; text-align: center">2013</td> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-size: 12pt; text-align: center">2012</td> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-size: 12pt; text-align: center">2013</td> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-size: 12pt; text-align: center">2012</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%">Net Sales</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Earnings before Income Taxes</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">260,746</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Income Taxes</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net Earnings from Discontinued Operations</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">260,746</td> <td> </td></tr> </table>   Cash flows from operating and investing activities of discontinued operations for the nine months ended September 30, 2013 and 2012 were $0 and $260,746, respectively.

Patent and Subsidiary Acquisition   The Company entered into a share exchange agreement April 24, 2012 to acquire all of the outstanding shares of TNI BioTech IP, Inc., (TNI IP) a biotechnology firm incorporated in Florida formed to acquire patents related to the treatment of cancer and HIV/AIDS and autoimmune diseases, using Met-enkephalin (MENK) and Naltrexone (LDN). The goal of TNI IPs management is to enable mankind and civilization to combat fatal diseases by activating and mobilizing the bodys own immune system using TNI IPs patented use of MENK.    The first patents acquired by TNI IP were acquired from Dr. Nicholas P. Plotnikoff and Professor Fengping Shan in 2012.  Dr. Plotnikoff and Dr. Shan have been specializing in research activities directed toward the study of cytokines, which are hormones naturally produced by the immune system. The primary cytokine, among many others currently being studied by TNI IP, is MENK.  The Company is focused on the treatment of cancer, HIV/AIDS and other infectious diseases through the use of our lead compounds.   TNI IP changed its name from TNI BioTech, Inc., to TNI BioTech IP, Inc. on April 23, 2012.  TNI BioTech IP, Inc., is the wholly-owned subsidiary of the Company. TNI IP was acquired in exchange for 20,250,000 shares of the Companys common stock of which 8,000,000 shares were issued for the acquisition of the patent and the remaining 12,250,000 shares were issued to the founders of TNI IP in exchange for all of their right, title and interest in their TNI IP shares. The goodwill arising on the acquisition of TNI BioTech IP, Inc. was valued at $98,000,000 and license agreements arising from the acquisition of TNI BioTech IP, Inc. was valued at $16,006,000.   At the time of the acquisition, the valuation of goodwill and other intangible assets were determined using the fair market price for the Companys common stock which were exchanged for shares of TNI BioTech IP, Inc.  In the fourth quarter of 2012, the Company performed an annual valuation to determine whether any goodwill or intangible assets that had been acquired by the Company were impaired. The result of this valuation was that material impairments were identified. The Company recognized an impairment of the goodwill arising on the acquisition of TNI BioTech IP, Inc. of $98,000,000.   Patent License Agreements   On August 13, 2012, the Company signed a License Agreement with Ms. Jacqueline Young for the intellectual property developed by Dr. Bernard Bihari relating to treatments with opioid antagonists such as naltrexone and Met-enkephalin for a variety of diseases and conditions including malignant lymphoma, chronic lymphocytic leukemia, Hodgkins lymphoma, and non-Hodgkins lymphoma, chronic herpes virus infections, chronic herpes viral infections such as chronic genital herpes caused by the herpes simplex virus Type 2 and chronic infections due to the Epstein-Barr virus and a treatment method for humans infected with HTLV-III (AIDS) virus including patients clinically diagnosed as suffering from AIDS and those suffering from AIDS-related complex (ARC).  The Bihari patents were acquired in exchange for 540,000 shares of the Companys common stock with a fair market value of $972,000 and assumed liabilities of $400,000 which is payable to Ms. Young over a twenty-four month period in equal installments to reimburse her for the costs of a New York City office in accordance with the patent license agreement.  The patent liability at September 30, 2013 totaled $185,000. The cost of the patent totaled $1,372,000.  Additionally, the Company will pay the licensor a royalty payment of 1% of gross MENK sales and pay a 1% sublicense fee on any sublicense revenue.   On December 24, 2012, the Company signed an agreement for the acquisition of patent rights for the intellectual property of Dr. Jill Smith and LDN Research Group, LLC (the Patent License Agreement), whose members are Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Moshe Rogosnitzky and orphan drug designation by the FDA to a novel late-stage drug, trademarked LDN, for the treatment of Pediatric Crohns disease. The patent covers methods and formulations for treatment of the inflammatory and ulcerative diseases of the bowel, using naltrexone in low doses as an opioid antagonist. Endogenous opioids and opioid antagonists have been shown to play a role in stimulating and rebalancing the immune system and the healing and repair of tissues. These patents were acquired in exchange for 300,000 shares of the Companys common stock with a fair value of $2,715,000 and expenses of $165,384, which totaled $2,880,384.  The Company has an exclusive, worldwide license to make, have made, use, lease, import, offer for sale and sell Licensed Products and to use the method under the patent rights. The agreement will terminate on the expiration or abandonment of the last patent to expire or ten years after the sale of the first licensed product. The Company may terminate the agreement upon 90 days written notice, provided all sublicenses are terminated and all amounts due and owing are paid to the licensor parties. The licensor parties may terminate the agreement ten days' after notice to the Company if the Company is ten days late in payment or there is a breach that remains uncured for ten days after written notice of such breach.   In partial consideration of the Patent License Agreement, the Company agreed to pay to the members the applicable milestone payments listed below after substantial achievement of each milestone event is achieved by the Company, its Affiliates or Sublicensees.   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%; text-align: justify">A.  </td> <td style="width: 97%; text-align: justify">Upon initiation of each phase III trial, the Company will pay $350,000.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">B.  </td> <td style="text-align: justify">Upon positive completion of each phase III clinical trial of the therapeutic use of an LDN compound in the field of Use, the Company will pay $150,000.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">C.  </td> <td style="text-align: justify">When an NDA is accepted for review by the FDA, the Company will pay $250,000.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">D.  </td> <td style="text-align: justify">When FDA approval to market the NDA is approved, the Company will pay $750,000.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%; text-align: justify">E.  </td> <td style="width: 97%; text-align: justify">Upon the first dosing of the first patient in a phase III clinical trial for each Licensed Product, the Company will pay 250,000 shares of the Companys common stock.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">F.  </td> <td style="text-align: justify">Upon the first sale of each Licensed Product, the Company will issue 400,000 shares of the Companys common stock.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">G.  </td> <td style="text-align: justify">Upon the achievement of $20 Million USD in cumulative sales for each licensed product covered by NDAs, the Company will issue 500,000 shares of the Companys common stock.</td></tr> </table>   The Company must pay an annual license fee in the low six-figure range and mid single digit percentage royalties on the net sales of each licensed product with an annual minimum royalty payment in the low six-figure range. The Company will pay a sublicense fee between 10-20% calculated on the payments the Company receives from any such sublicense.   As part of the Patent License Agreement, TNI BioTech has the right to apply to the Food and Drug Administration (FDA) for the transfer of the orphan drug status, the investigational new drug applications (INDs), and the right to acquire the relevant clinical data set from Dr. Smith. The FDA has designated orphan drug status for the use of low dose naltrexone in the treatment of pediatric patients with Crohns disease and ulcerative colitis.   The Patent License Agreement calls for the formation of a Development Committee to monitor the clinical progress of the Licensed Products and will consist of independent scientific and technical leaders who are highly regarded by the scientific community in the Field of Use of each Licensed Product. The development committee consists of at least one representative from the Licensor Parties and one representative from the Company in addition to outside experts in the field.   Naltrexone in low dose is a platform immunomodulatory technology that the Company expects to clinically test in the treatment of other immune-mediated or immune-deficient diseases for which it has previously acquired additional patents.   The Company signed an exclusive licensing agreement with The Penn State Research Foundation on January 18, 2013 to license all of the intellectual property developed by Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Dr. Jill P. Smith for the treatment of cancer titled Opioid Growth Factor and Cancer and Combination Therapy with Opioid Growth Factor and Taxanes for the Treatment of Cancer (the Licensing Agreement).  These licenses were acquired in exchange for 300,000 shares of the Companys common stock with a fair value of $2,550,000 and expenses of $160,539, which totaled $2,710,539.   The patent covers methods and formulations related to the treatment and prevention of different cancers. More specifically, the present inventions describe the use of drugs that interact with opioid receptors (naltrexone, naloxone and the pentapeptide growth factor Met-enkephalin) to inhibit and arrest the growth of cancer. Endogenous opioids and opioid antagonists have been shown to play a role in stimulating and rebalancing the immune system and the healing and repair of tissues. Such efficacy has been discovered to be partially due to the functional manipulation of the zeta opioid receptor through exogenous and endogenous Met-enkephalin. This receptor has been determined to be present in a variety of cancers, including pancreatic and colon cancer.   As part of the Licensing Agreement, TNI BioTech is working to acquire the orphan drug designation (IND) and clinical data set from Dr. Jill Smith.   The Licensing Agreement calls for TNI BioTech to (a) use commercially reasonable efforts to develop, commercialize, market and sell Licensed Products in a manner consistent with the Business Plan; (b) expend a minimum of $110,000 (per annum) to develop and commercialize Licensed Products as soon as practicable, consistent with sound business practices and judgment; (c) be responsible for obtaining all requisite regulatory approvals needed to use or sell Licensed Products in the Field of Use; and (d) make the first commercial sale of a Licensed Product by December 31, 2016.   The Licensing Agreement provides that the Company must make an initial license fee of $100,000 and the issuance of 300,000 shares and an annual license maintenance fee in the low ten thousand dollar amount range. The Company will also make payments to licensor upon the achievement of certain milestone events such as initiations of Phase II or Phase III clinical trials in a low hundred thousand dollar amount, acceptance of the NDA by the FDA in a low hundred thousand amount and FDA approvals in a high hundred thousand dollar amount. The Company will issue shares upon reaching certain milestones including the issuance of a mid ten thousand amount of shares upon the first dosing of patients in clinical trials, the issuances of a low hundred thousand number of shares upon the initial sale of a licensed product and a milestone fee of a low hundred thousand share amount upon reaching sales of $20 million in cumulative sales. If the Company achieves all of the milestones, an additional $1,350,000 will be paid and an additional 375,000 shares will be issued.    The Company will also pay the licensor a percentage of net sales in the mid single digit range of the licensed products each quarter subject to a minimum royalty payment in the low hundred thousand dollar range. The Company must also pay the licensor a low double-digit percentage of any payments received from any sublicenses.   The Licensing Agreement calls for the formation of a Development Committee to monitor the clinical progress of the Licensed Products, which will consist of independent scientific and technical leaders who are highly regarded by the scientific community in the Field of Use of each Licensed Product.   The Licensing Agreement terminates on the expiration or abandonment of the last patent to expire or become abandoned. The Company may terminate the Licensing Agreement at any time upon 60 days prior written notice and ceasing to make and sell all licensed products, the termination of all sublicenses and payment of all monies owed under the Licensing Agreement. The licensor may terminate the agreement 30 days after notice to the Company if the Company is 30 days late in payment or a breach that remains uncured for 45 days after written notice of such breach.   In confirmation letters dated April 3, 2013, the Company received acknowledgement from the Department of Health and Human Services confirming the Food and Drug Administrations (FDA) receipt of the change in sponsorship of the investigational new drug application (IND) for Naltrexone HCL and the orphan drug designation for [met5]-enkephalin and the orphan drug designation for the use of low dose naltrexone in the treatment of pediatric patients with Crohns Disease.   On March 15, 2013 the Company executed a Patent License Agreement with Professor Fengping Shan.  The Company obtained exclusive rights to develop and commercialize the licensed technology.  The licensed technology is the intellectual property developed and owned by Professor Shan (i) relating to the treatment of a variety of diseases and conditions with MENK including multiple forms of lymphoma and cancer and (ii) a treatment method for humans infected with the HLTV-III (AIDS) virus including AIDS and AIDS related complex (ARC).  The licensed technology includes the methods and formulations for these treatments including but not limited to all INDs, communications with regulatory agencies, patient data, and letters relating to these treatments.  The licensed technology also includes the following patents: 200710158742.7 MENK, its application is in treating leukemia and other blood cancers; No. 200710051586.4 MENK, its application is in preparation of human and animal vaccines; No. 200610046249.1, a nasal spray formulation containing MENK; No. 201210290150.1 LDN, combined with MENK, its application is in preparation of an anticancer drug (Pending); No. 201210302259.2 LDN, combined with MENK, its application is in preparation of leukophoresis for anticancer (Pending); No. 200810229085.5 Compound MENK as a drug for colon cancer and pancreatic cancer; No. o. 200910011030.1, Naltrexone as well as analougues being anticancer drug. Under this license, the Company must issue a mid six-figure number of shares to Prof. Shan and a low hundred thousand dollar amount for the upfront license fee, and reimburse Prof. Shan for all out of pocket expenses in connection with the patents in mid five figure range. The Company will pay Prof. Shan a mid single digit percentage running royalty of gross sales subject to decreases if third party intellectual property is needed to complete such sale or product but in no event less than a high percentage of a low single digit percentage and a low single digit percentage of all sublicense revenue. This agreement shall last for the duration of each of the licensed patents however the Company may terminate the license agreement on 120 days' written notice to Professor Shan.

Distribution and Production   Effective August 16, 2013, the Company executed a manufacturing agreement with Laboratorios Ramos, S.A. (Laboratorios Ramos) a current good manufacturing practice (cGMP) facility for IRT-103 low-dose naltrexone (LDN). Under the agreement, Laboratorios Ramos will produce LDN tablets, capsules and cream in accordance with the technical specifications provided by TNI, the FDAs good manufacturing practices and the practices of Nicaragua and of any other regulatory governing body countries where the products will be exported. Laboratorios Ramos must obtain all permits and licenses necessary to carry out the manufacturing and packaging of LDN.   Supervision and Inspection of Manufacturing in Nicaragua   On April 23, 2013, the Company signed a contract with ViPharma for the Supervision and Inspection of Manufacturing Processes as part of its negotiations for a contract for the manufacturing of LDN in a tablet, capsule and/or cream. The contract sets out the terms and conditions under which ViPharma will carry out the services of inspecting and supervising the manufacturing and packaging processes of LDN and ensure compliance with the FDAs good manufacturing practices and the Companys specifications. ViPharma will carry out its obligations in whatever Latin American country the Company ultimately decides to manufacture LDN within. Under the contract, ViPharma has the exclusive rights to supervise and inspect all manufacturing processes of LDN in Latin America. The Contract began on April 23, 2013 and has a duration of 10 years, with automatic renewal every 5 years thereafter unless either party is in breach of the contract or either party terminates the agreement, without cause, with 90-days written notice. In the event of a breach by either party, the non-breaching party must give notice to the breaching party and the breaching party has a 45-day period to cure.

Effective September 15, 2012, TNI BioTech, Inc. entered into a one-year employment agreement with Joseph Griffin, the brother of the Company's Chief Executive Officer, in which base salary, the grant of a common stock, and health insurance coverage were defined.  As a signing bonus, Mr. Griffin received 250,000 shares of restricted common stock of the Company.  For the nine months ended September 30, 2013, the Company paid gross compensation totaling $62,338.  .   In 2012, Webfoot, Inc., provided financing to the Company and as of September 30, 2013, the Company owed Webfoot, Inc. $121,128.  Webfoot, Inc., is owned by the son of Noreen Griffin.  On February 21, 2013, the Company entered into a formal loan agreement to evidence the amount owed on December 31, 2012.  The loan bears interest at an annual rate of 6%.  The interest is repayable at maturity.  The note matures on February 21, 2014.   In 2012, Noreen Griffin made payments on the Company's behalf covering the costs of incorporation and merger-related expenses.  At September 30, 2013, the Company owed Ms. Griffin $30,000.  On February 21, 2013, the Company entered into a formal loan agreement to evidence repayment of the amount owed on December 31, 2012.  The loan bears interest at an annual rate of 6%. The interest is repayable at maturity.   In 2012, Griffin Enterprises, Inc. made payments on the Company's behalf covering the cost of incorporation and merger-related expenses.  Griffin Enterprises, Inc. is wholly-owned by Noreen Griffin.  At September 30, 2013, the company owed Griffin Enterprises, Inc. $46,000.  On February 21, 2013, the Company entered into a formal loan agreement to evidence repayment of the amount owed on December 31, 2012.  The loan bears interest at an annual rate of 6%. The interest is repayable at maturity.   On January 3, 2013, the Company formalized the terms under which Kelly OBrien Wilson, the daughter-in-law of the Company's Chief Executive Officer has been employed. Ms. Wilson had been working with the Company in 2012 and her three-year employment agreement is effective as of December 1, 2012. The agreement was amended on September 1, 2013. The terms of the agreement define her base salary, a grant of a common stock, and health insurance coverage.  As a signing bonus, Ms. Wilson is entitled to receive 50,000 shares of common stock of the Company. For the nine months ended September 30, 2013, the Company paid gross compensation totaling $63,903. Ms. Wilson has not received the 50,000 shares of common stock that were part of her original agreement and previously disclosed in our Form 10 Registration Statement.

The following is a schedule of shares issued subsequent to September 30, 2013.   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt/115% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/115% Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt/115% Times New Roman, Times, Serif; text-align: center">Shares</td> <td style="font: 8pt/115% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt/115% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/115% Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 8pt/115% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/115% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="width: 90%; font: 8pt/115% Times New Roman, Times, Serif">Shares issued for default on promissory notes</td> <td style="width: 1%; text-align: right; font: 8pt/115% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/115% Times New Roman, Times, Serif"> </td> <td style="width: 7%; text-align: right; font: 8pt/115% Times New Roman, Times, Serif">90,000</td> <td style="width: 1%; font: 8pt/115% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt/115% Times New Roman, Times, Serif">Shares issued to investors</td> <td style="text-align: right; font: 8pt/115% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/115% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/115% Times New Roman, Times, Serif">48,000</td> <td style="font: 8pt/115% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt/115% Times New Roman, Times, Serif">Shares issued for warrant exercise</td> <td style="text-align: right; font: 8pt/115% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/115% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/115% Times New Roman, Times, Serif">837,500</td> <td style="font: 8pt/115% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt/115% Times New Roman, Times, Serif">Shares issued for debt conversion</td> <td style="text-align: right; font: 8pt/115% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/115% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/115% Times New Roman, Times, Serif">150,000</td> <td style="font: 8pt/115% Times New Roman, Times, Serif"> </td></tr> </table>

Following is a summary of outstanding stock warrants at September 30, 2013 and December 31, 2012 and activity during the periods then ended:   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif"> <tr style="font: 8pt Times New Roman, Times, Serif"> <td style="text-align: center; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">  </td> <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">Number of</td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">Exercise</td> <td style="text-align: center; padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">  </td> <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">Weighted</td></tr> <tr style="font: 8pt Times New Roman, Times, Serif"> <td style="text-align: center; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: black 1.5pt solid; vertical-align: bottom">Shares</td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: black 1.5pt solid; vertical-align: bottom">Price</td> <td style="text-align: center; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: black 1.5pt solid; vertical-align: bottom">Average Price</td></tr> <tr style="vertical-align: middle; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">  </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">  </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom">  </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">  </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom">  </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom">  </td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255); font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Warrants as of December 31, 2012</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">7,260,000</td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">1.00 1.50</td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">1.02</td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; background-color: White"> <td style="vertical-align: middle; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"> </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"> </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"> </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"> </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"> </td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="vertical-align: middle; font: 8pt Times New Roman, Times, Serif">Issued in nine months ended September 30, 2013</td> <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif">2,567,918</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif">1.00-1.50</td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom">$</td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom">2.56</td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; background-color: White"> <td style="vertical-align: middle; font: 8pt Times New Roman, Times, Serif">  </td> <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom"></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"> </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="vertical-align: middle; font: 8pt Times New Roman, Times, Serif">Expired</td> <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"> </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"> </td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; background-color: White"> <td style="vertical-align: middle; font: 8pt Times New Roman, Times, Serif">  </td> <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"> </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"> </td></tr> <tr style="vertical-align: middle; font: 8pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 8pt Times New Roman, Times, Serif">Exercised</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">3,324,168</td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">0.50-0.75</td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">0.63</td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; background-color: White"> <td style="vertical-align: middle; font: 8pt Times New Roman, Times, Serif">  </td> <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"> </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"> </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"> </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"> </td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="vertical-align: middle; font: 8pt Times New Roman, Times, Serif">Warrants as of September 30, 2013</td> <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif">6,503,750</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif">1.00 15.00</td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"> $</td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom">1.83 </td></tr> </table>

The net sales and earnings of discontinued operations were as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> Three Months Ended September 30,</td> <td style="font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td colspan="2"> Three Months Ended September 30,</td> <td style="font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td colspan="2"> Nine Months Ended September 30,</td> <td style="font-size: 12pt"> </td> <td style="font-size: 12pt"> </td> <td colspan="2"> Nine Months Ended September 30,</td> <td style="font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-size: 12pt; text-align: center">2013</td> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-size: 12pt; text-align: center">2012</td> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-size: 12pt; text-align: center">2013</td> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-size: 12pt; text-align: center">2012</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%">Net Sales</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Earnings before Income Taxes</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">260,746</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Income Taxes</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net Earnings from Discontinued Operations</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">260,746</td> <td> </td></tr> </table>

682

327

2133549 10685

45489368

62589869

17343837

17016002

45489

62589

196632775

272668542

3690960

1508835

-6082771

-20967754

-176945847

-236256210

10228000 10228 51193872 -51204100 -350000 -350 -350 36319117 36319117 300000 300 2714700 -2715000 300000 2550000 300 2549700 100000 750000 100 749900 1545833 7130161 1546 7128615 297500 1133162 297 1078114 54750 4679168 3693488 4679 3688809 6932057 6932057 478125 478125

-59313594

-342671

-59313594

7260000

6503750

1.00

1.02

1.83

1.50

1.00

2.56

1.50

0.50

0.63

0.75

260746

The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable.   The Companys accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, Equity-Based Payments to Non-Employees. The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendors performance is complete.

2567918

3324168

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 8pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif; width: 67%">  Expiration Date</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif; text-align: center; width: 8%">Number of Shares</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif; width: 8%">Exercise Price</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif; text-align: center; width: 8%">Remaining Life (years)</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 8pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">Second Quarter 2015</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">1,025,000</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">$</td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">2.00-3.00</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">1.8</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 8pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">Third Quarter 2015</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">221,250</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">$</td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">2.00-3.00</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">2.0</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 8pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">Second Quarter 2016</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">337,500</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">$</td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif"> 1.50</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">2.8</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 8pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">Third Quarter 2017</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">985,416</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">$</td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">1.00</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">4.0</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 8pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">Fourth Quarter 2017</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">3,491,666</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">$</td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">1.00-1.50</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">4.3</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 8pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">First Quarter 2018</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">229,584</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">$</td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">15.00</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">4.5</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 8pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">Second Quarter 2018</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">33,334</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">$</td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">15.00</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; text-align: right; font: 8pt Times New Roman, Times, Serif">4.8</td> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>

2715000 74167 2550000 51204100

EX-101.SCH 7 tnib-20130930.xsd 0001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0002 - Statement - Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0004 - Statement - Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0005 - Statement - Statements of Shockholders Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0006 - Statement - Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0007 - Disclosure - 1. Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 0008 - Disclosure - 2. Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0009 - Disclosure - 3. Promissory Notes link:presentationLink link:calculationLink link:definitionLink 0010 - Disclosure - 4. Capital Structure-Common Stock and Common Stock Purchase Warrants link:presentationLink link:calculationLink link:definitionLink 0011 - Disclosure - 5. Stock Compensation link:presentationLink link:calculationLink link:definitionLink 0012 - Disclosure - 6. Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 0013 - Disclosure - 7. Lincenses and Supply Agreements link:presentationLink link:calculationLink link:definitionLink 0014 - Disclosure - 8. Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0015 - Disclosure - 9. Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0016 - Disclosure - 10. Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0017 - Disclosure - 2. Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0018 - Disclosure - 4. Capital Structure-Common Stock and Common Stock Purchase Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 0019 - Disclosure - 6. Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 0020 - Disclosure - 11. Subsequent Events (Tables) link:presentationLink link:calculationLink link:definitionLink 0021 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0022 - Disclosure - 4. Capital Structure-Common Stock and Common Stock Purchase Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 0023 - Disclosure - 6. Discontinued Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 tnib-20130930_cal.xml EX-101.DEF 9 tnib-20130930_def.xml EX-101.LAB 10 tnib-20130930_lab.xml Common Stock Equity Components [Axis] Additional Paid-In Capital Stock To Be Issued Prepaid Services Accumulated Deficit Warrants Award Type [Axis] Minimum Range [Axis] Maximum Computer equipment Property, Plant and Equipment, Type [Axis] Warrants 1 Warrants 2 Warrants 3 Warrants 4 Warrants 5 Warrants 6 Warrants 7 Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets: Cash and cash equivalents Prepaids and Other Current assets Total current assets Fixed Assets: Computer equipment, net of accumulated depreciation of of $800 and $118 respectively Intangible Assets: Patents and licenses, net of amortization of $3,703,633 and $1,570,114, respectively (Note 8) Deposits Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable Payable to officer Accrued liabilities Current portion patent liability Notes payable Total current liabilities Non-current Liabilities: Notes payable related party Long-term portion patent liability Total non-current liabilities Total Liabilities Stockholders' Equity: Common stock - par value $0.001; 500,000,000 shares authorized; 62,589,869 and 45,489,368 shares issued and outstanding respectively Additional paid in capital Stock issuances due Prepaid services Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Accumulated depreciation Amortization Common Stock, Par Value Common Stock, Shares Authorized Common Stock, Shares Issued Common Stock, Shares Outstanding Income Statement [Abstract] Revenues, net Operating expenses: Selling, general and administrative Research and development expense Depreciation and amortization expense Total operating expenses Loss from operations Other income (expense): Interest expense Loss on settlement of debt Total other income (expense) Loss from continuing operations Gain from discontinued operations Net loss Basic and diluted loss per share: Loss from continuing operations Gain from discontinued operations Basic and diluted loss per share Weighted average number of shares outstanding Statement [Table] Statement [Line Items] Beginning Balance, Shares Beginning Balance, Amount Return of Stock for prepaid services, Shares Return of Stock for prepaid services, Amount Issuance of common stock in exchange for debt, Shares Issuance of common stock in exchange for debt, Amount Issuance of common stock for prepaid services, Shares Issuance of common stock for prepaid services, Amount Amortization of prepaid services Issuance of common stock for Jill Smith/LDN license, Shares Issuance of common stock for Jill Smith/LDN license, Amount Issuance of common stock for Penn State License, Shares Issuance of common stock for Penn State License, Amount Issuance of common stock issued for charitable donation, Shares Issuance of common stock issued for charitable donation, Amount Issuance of common stock for loan expenses and interest, Shares Issuance of common stock for loan expenses and interest, Amount Issuance and modification of common stock warrants Issuance of common stock for cash and exercise of warrants, Shares Issuance of common stock for cash and exercise of warrants, Amount Stock to be issued Net loss Ending Balance, Shares Ending Balance, Amount Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES (Gain) loss from discontinued operations Loss from continuing operations Adjustments to reconcile loss from continuing operations to net cash flows used in operating activities: Depreciation Amortization Amortization of stock issued for prepaid services Loss on settlement of debt Stock warrant expense Stock issued for donation Stock issued for interest Changes in operating assets and liabilities: Accrued liabilities Prepaid and other current assets Accounts payable Net cash used in operating activities from continuing operations CASH FLOWS FROM INVESTING ACTIVITIES Purchase of computer equipment Purchase of Penn State License Net cash used in investing activities from continuing operations CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from exercise of stock warrants Proceeds from sale of stock Proceeds from notes payable Payments made on patent liability Net cash provided by financing activities from continuing operations Net Increase (decrease) in cash Cash, beginning of period Cash, end of period SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Cash paid for interest SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Accrued liabilities for purchase of Smith LDN patent Conversion of debt and accrued interest to common stock Common Shares issued for Penn State License Common shares issued for prepaid services Organization, Consolidation and Presentation of Financial Statements [Abstract] 1. Organization and Description of Business Accounting Policies [Abstract] 2. Summary of Significant Accounting Policies Debt Disclosure [Abstract] 3. Promissory Notes Notes to Financial Statements 4. Capital Structure-Common Stock and Common Stock Purchase Warrants Equity [Abstract] 5. Stock Compensation 6. Discontinued Operations 7. Lincenses and Supply Agreements Commitments and Contingencies Disclosure [Abstract] 8. Commitments and Contingencies Related Party Transactions [Abstract] 9. Related Party Transactions Subsequent Events [Abstract] 10. Subsequent Events Summary Of Significant Accounting Policies Policies Basis of Presentation Use of Estimates Cash, Cash Equivalents, and Short-Term Investments Concentration of Credit Risk Fair Value of Financial Instruments Computer Equipment Intangible Assets Impairment of Long-Lived Assets Research and Development Costs Income Taxes Share-Based Compensation and Issuance of Stock for Non-Cash Consideration Net Loss per Share Recent Accounting Standards Capital Structure-Common Stock And Common Stock Purchase Warrants Tables Schedule of outstanding stock warrants Summary of outstanding warrants Discontinued Operations Tables Schedule of discontinued operations Subsequent Events Tables EX-101.PRE 11 tnib-20130930_pre.xml XML 12 R17.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Summary Of Significant Accounting Policies Policies
Basis of Presentation	Basis of Presentation The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), as amended for interim financial information. The financial information as of December 31, 2012 is derived from the audited financial statements presented in the Company’s Form 10 Registration Statement filed with the Commission on April 22, 2013 and the Amended Registration Statements on Form 10-/A filed on June 7, 2013, July 18, 2013, August 23, 2013, September 25, 2013, and October 11, 2013 for the year ended December 31, 2012. The unaudited interim financial statements should be read in conjunction with the Company’s Form 10 Registration Statement, which contains the audited financial statements and notes thereto, together with Management’s Discussion and Analysis of Financial Condition and Results of Operations, for the years ended December 31, 2012 and 2011. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management’s opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the nine months ended September 30, 2013 are not necessarily indicative of results for the full fiscal year.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.
Cash, Cash Equivalents, and Short-Term Investments	Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets.
Fair Value of Financial Instruments	Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “Financial Instruments,” the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments. Cash, accounts payable, payable to officer, and patent liability are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable to a related party also approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.
Computer Equipment	Computer Equipment Computer equipment is stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense from continuing operations for the nine months ended September 2013 and 2012 was $682 and $327, respectively.
Intangible Assets	Intangible Assets Costs incurred to acquire and/or develop the Company’s product licenses and patents are capitalized and amortized by straight-line methods over estimated useful lives of seven to sixteen years. Intangible assets are stated at the lower of cost or estimated fair market value. During the nine months ended September 30, 2013, the Company capitalized $2,710,539 of such costs incurred for the acquisition of the Company’s patents. (See Note 10 of the Company’s Form 10 Registration Statement). Amortization expense for the nine months ended September 30, 2013 and 2012 was $2,133,549 and $10,685, respectively. The Company estimates its amortization expense related to these assets will approximate $2,800,000 each year for the next five years.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360, “Property, Plant and Equipment.” If the carrying amount of the asset, including any intangible assets associated with that asset, exceeds its estimated undiscounted net cash flow, before interest, the Company will recognize an impairment loss equal to the difference between its carrying amount and its estimated fair value. No impairment losses were recognized for the nine months ended September 30, 2013 or for the corresponding period in 2012.
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.
Income Taxes	Income Taxes The Company follows FASB ASC Topic 740, “Income Taxes,” which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of September 30, 2013, the Company has no accrued interest or penalties related to uncertain tax positions.
Share-Based Compensation and Issuance of Stock for Non-Cash Consideration	The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “Equity-Based Payments to Non-Employees.” The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.
Net Loss per Share	Net Loss per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.
Recent Accounting Standards	Recent Accounting Standards The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2012, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. Any new accounting pronouncements issued by the Financial Accounting Standards Board, as applicable, have been or will be adopted by the Company upon or before the expiration of the extended transition period provided under Section 102(b)(1) of the JOBS Act.

EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0":BN0#M@$``$X0```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%U/@S`4AN]-_`^DMP9* M4>#T;*N M@@486RJ9$A;%)`"9*5'*:4H^)B]AGP36<2EXI22D9`66C(:7%X/)2H,-?+6T M*2FFYL[?FBG5/)OQ*=`DCGLT4]*!=*%K>I#AX`ER M/J]<\+STC]2KA1B'QEN\86I;97'H/0 M3H5FYG>!3=V;WQI3"@C&W+A77GL,NJSHES*S3Z5FT>$F'90JS\L,A,KFM=^! MR&H#7-@"P-55U(Y1S4NYY3Z@WRZVM!W8F4&:]VL;G\B1(.&X1L)Q@X3C%@E' M#PG''1*./A*.>R0<+,8"@L51&19+95@\E6$Q58;%51D66V58?)5A,5:&Q5D3 M+,Z:8''6!(NS)O_EK,ZG-:#M]>\?I6US)"Y8MZK`GOD7OVYZ3+G@!L2[,S[7 MGAW@9^]#'#[UC8W2UN=?`Z?OPC;@-M6A]HW`N!)V$;]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7 M^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X M8<'%#U1?````__\#`%!+`P04``8`"````"$`C`BHSJ(!``#W#@``&@`(`7AL M+U]R96QS+W=O"%2J_/'JE**O-9]=F[\JZQNB52M]^).KF]YE(8MV.:N][Q\X M=T6M.NE&IE3?'6*>VO7,$_C#VX6BD?DDI;*9^S&'+\]&0Q"HH9ORX&)L1J M8(+*H88#*!TQ3TG'U=*J\L7;8$4WU.LBC,&A+A5:*0$IT43/#EABZ&QC`1B; M>V(U]Y@8$,1J0*!RJ.$`2D?,4M)Q_MB&"1ZGW_<9PT%='+PV22=,[)F!1PR= MVPCF*)OPMB1].8DQ)H=ZQJ`CAKI2:*&`'`W*1DQ3^L:'94L-%CX=^>D7%9%T MKL2^&73$T+F59JAUJ=4`*D=0+P\"W1Z`>LX`/F>6*>T;??*[=6")>2=I,_U# MS1030XT&)0/4:`!E(\AWB;A,\(O/U?47````__\#`%!+`P04``8`"````"$` M>#%!_0X#```>"```#P```'AL+W=O!L51FM%"2#\(U-^'5\/NWRY72 MRU>EE@$`2#,(JXA)VYDJ7U,)2+R)3:4XSDW-NRR)*X[@7 ME53(<(-PH?\'0\WG@O&Q8G7)I=V`:%Y0"_1-+BH3#B_GHN#/FXP"6E7WM`3> M'T48%-38228LSP;A*2S5BC<^Z+JZJ44!N_U.W`FCX2[)1QUD?$[KPLX@O2TZ MZ)5VT[3G3CHIG@5?F7V06P8?+T)F:N6.@K3KW:H#!%9^ZT5D-H?].(YWWWYR MLE/<#1N$TD4HW4,F391IKM@R5T4&KB"3MQJA@.0[/4Z/ MHXRHRR03$JF M=5E2O7:Z3,5""F@%*BVY9DSAE%*>7!()A2A@O"XZ&D;.K M2=(R:8^,A6$*/"YKGB&'8(@^AFCY](S\$N!S:;CQY9C6556LR?5"<[`>PNE` MS^ZIM+QZ[E(HA=W8U;7>R/-:P`@5#9Q&V[7_W0R#;*!EH'-GFH(LS`\U MS`8W7])R:Q*#0UX-?ZNA>\CDW?40CL9ME[1<>MQ>P'_?OMBF2:`P.WE27&M8'``= MEZA-'GBW<(3"8&5QN[N%N!Y]VM+W:AW\```#_ M_P,`4$L#!!0`!@`(````(0"4R*S<=@4```\6```8````>&PO=V]R:W-H965T M&ULE)A;;ZLX$,??5]KO@'AOP-R)DAR52W>/=%9:K?;R3(F3 MH(80`;V<;[]C3()G2`E]*0WY\??\/?8P\>K;1WG4WGC=%-5IK;.%J6O\E%?; MXK1?Z__\_?00Z%K39J=M=JQ.?*W_Y(W^;?/K+ZOWJGYI#IRW&BB;;M'BJ/AF6:GE%FQ4F7"LMZCD:U MVQ4Y3ZK\M>2G5HK4_)BU$']S*,[-1:W,Y\B56?WR>G[(J_(,$L_%L6A_=J*Z M5N;+[_M356?/1_#]P9PLOVAW'T;R99'755/MV@7(&3+0L>?0"`U0VJRV!3@0 MTZ[5?+?6']DRM4S=V*RZ"?JWX.^-\K_6'*KWW^IB^Z,X<9AMR)/(P'-5O0CT M^U;<@H>-T=-/70;^K+4MWV6OQ_:OZOUW7NP/+:3;!4?"V'+[,^%-#C,*,@O+ M%4IY=80`X*]6%F)IP(QD']WUO=BVA[5N>PO7-VT&N/;,F_:I$)*ZEK\V;57^ M)R'62TD1JQ>!:R_"K"^+V+T(7`<1*W"9ZWTA%*=7@>N@\E4_X+R;%+@.(G-# M,>0,=PE+LC;;K.KJ78-=`'/8G#.QI]@2E"^9DO-ZS=UGJ8.<"9%'H;+6?5V# MK#2PWMXV7K@RWF")Y#T2C1'?Q$A\0<2"$++)Y<8@R_`CZ840JQ$<76U!TE5; MMQ?>)7H!B^@OXT;R!FA?[5AXW'A,^"2T9(P0D71,*"+(#BR_^78$##M&B=XG M(T<2@>5X->@2@W>)Y"Z13A'('@0RWYZ`USK,W35VW\;!1Q)1[=D.1N+[2'(? M22<19!'VUGR+`B89)/%'$E$MT@S>)9*[1#I%('O>5^P)F&20!!])Q.M*";,\ M,W!,LK]B%;$"TW$]G.)$!6S;\9@7DHJ3JHCKA"N],4J87DN(_E/U.^9ZS)X-U)S*H(ED#?1=)$W@`UO_.F2*1XB M'GT\_9%$I$>?A:9#XHM5@)F!1W9QHGYO,=NQ;#))J4HP9K*AS"&'(78X[4S` MQ%E`G$FD7YRA#TO3'4:6Z5,1F_F!3V-W*N*9GN<,,XSL,U4)QK4N'#^RVQ5ZHAVZ:Q,@G-C$T:52\[96E>L>H[`W4%T5`EF#$ M)--[L$S7862KQCVB5EKZ,DFP##/#(/#(HDFG=7!"16,PWZ=L(Y!/LE$B)AG5 M!*FX\0UD[%/*]-/EPZ9U0J*33NM@GZ)!F.]3MA/()]EV$9/,9#['7(@8I()NFX'RNWM;"+H=C81\EDV$60[;JAT M5MBH:"#F&Y7M!C(Z6K:2":51H]-BA9BODG9<""3PQ[HYC]B MDIG((`&4T/H,(N!6!A$`YH8BC\S!`18R)XXN[C>NW5.DN@Y]E339,[(4P#:" M3>*0/1LCQC8#UV:,Z"2(@1[=\@.7M%KB&&YHM:#3,CW?H=F4YVSRV*;D]9[' M_'ALM+QZ%6=H-NRFZ]WK^=ZC)8XSR/V(+>&097P_@?/`[KYQ?0".X\[9GO^1 MU?OBU&A'OH.AS(4/];B6!WKR0UN=NT.DYZJ%@[CNWP,&PO=V]R:W-H965T8EY?GG,,ARYLGT:%'IC27 M?8G3*,&(]516O&]*_/W;_=4<(VU(7Y%.]JS$STSCF]7[=\N#5#O=,F80./2Z MQ*TQPR*.-6V9(#J2`^MAII9*$`-#U<1Z4(Q4;I'HXBQ)IK$@O,?>8:$N\9!U MS2F[DW0O6&^\B6(=,<"O6S[HHYN@E]@)HG;[X8I*,8#%EG?]#SFZ_@Z!J?5LN(0@4T[4JPN\6VZ MV!0X7BU=?GYP=M!OWI%NY>&#XM4GWC-(-I3)%F`KY/C+>M`:J74!`-JY%]7S'-(6$@DV4.0PJ.P"`)Q+F;;$^30J9DF>@AQMF3;WW%IB1/?:2/'3BU(+%4RR%Y,<(L?XI5,"S)K?6I<0SC"`* M#>5Y7.5YLHP?(:?T1;,^UZ2GBLU184L!>($1(G_+^/NL'U&LV*+8U%FVM?\` MWH$M&^U[KIB]HIV00(8N)['B$H-YV#C/7WT]G-?,7DN#:X94*DPW7.('YZKBY4JC7%,W)-WKU<+Y\* MTEQ`XE#5%7OO19'5%.&74TNZ_%"#[S?'SPNIW=\8\DU5=(22(YN!G"T"-3VO M[;4-2MM-68$#GG:KP\<([9PPG,H-P!..+&PO(]P;2` MC(+,S`VX4D%J"``^K:;B6P,RDK_UUUM5LG.$W#6R#IBRK.)2R"JNE)'F'_&E M,TB(Q>ZP&*[#8L^9N:O`"1;PL&=5@-F'`-=!93$+EG//^6\-6[CIDY/D+-]N M.G*S8,=!W/22\_WKA`MDR:P(+V.>?I0FR`\7V7&5""V1!9F@4-O7K>."HIT"G[D3(:,Y#40#(5T;SY'^*- MJ\#&A00JYM9ZY+$@>1#*2)J:&RFC.0-)#213$2KP\F]!_GL M6"`>O(UCP/"*ZZ[V(TDN2PPD-9!,1;20X6'/A\S)>L@"@9!E-'L#20PD-9!, M1;3XH+6H\8DV-5N"'W:NBI>80*J@%SQ(M0?M2#0IKJ&'/2#>/6P#203B0V1C M-5QGTKG2D23]9ZJ0YH3/$T;#O3OY1BX_<@)=7EKA(KJ5`5&L&$@B$/_>SU(# MR=156MQPV*EQ/\BT$A\GZ_$)Q(5C>TRCYWB333V0^BE`G`#C,IG8=$"<_I19 MS^%/%\G4)9H#!Q[^O(6>K7L8H$`WX>O/WP\LWQ]W52*AN[%4:@D?_LKTH2W2 MC?!33]E#/Z^%(\Y(,5OU68T'*-`:IS/MB@/+O4>=2*@?M7JM5$+"R,I;!D9% M)$4,:.HQS5OW_W`B3DK-B8`F)5E,2R)86DD&Z&XN[8.)4""<..##=**N$C41 M`Z>8J1KUS6U"G+EPR04<;L983'I)LL0&@9LZ"F^"N&%-'&8C'=]F!-^ MS"?F!_S8#6&F,'5B+X0#V<1W?K@3.9T^P`_AD#,7Q$$()\D#?!%"!P?<'H5@ M@K[D)_Q'WIVJEEHU/D)2YGV[Z\0,+F[8T/8.A,$,#7F#411^*V&8`N&ULK)I;<^*X%H7?3]7Y#Q3O`YB; M@RK)5,#@"P:,:\[,,P$G4`TXA4FG^]^?+'SWLNVEC9HRSS^ M^>.PKWU/3MDN/3[5K4:K7DN.ZW2S.[X_U?_WU^2/AWHM.Z^.F]4^/29/]9]) M5O_S^;__>?Q*3]^R;9*<:Z1PS)[JV_/Y@S6;V7J;'%99(_U(CG3D+3T=5F=Z M>WIO9A^G9+7)DP[[9KO5ZC/DCB=;??G7_FHO7:8GY<;.C.^##7CLE;T_U%XO% MEEUO/C_F`_3W+OG**O_7LFWZY9YVFW!W3&BTR2?NP&N:?N.A_H8C2FY"]B1W M(#K5-LG;ZG-_CM,O+]F];\]D=X_NB-\8V_QTDFQ-(THRC7:/*ZW3/5T`_:T= M=GQJT(BL?N2O7[O->?M4[W0;[8>>U>M3?.TURLU]:?V3D]_".BK$)+ MJ+0+%7J5*KV&U6W=H]$M-.BUT+`Z#=MJ#3HV7=<5`DTNM]9[3D0/%_RG/*D;IRK5:G."?_1YWTED1;)M(_16*_T;-; M'>O7!C?%;,DGG[,ZKYX?3^E7C2J:ID/VL>*?#Q:S:/SDM!-WH";BO\U#FH!< MY87+/-7IPFB&950\WY\[[>YC\SM-^'41,\082X\8R0@^N[FL8X*Q"28F<$W@ MF<`W06""J0E"$\Q,,#?!P@21"98FB"N@2?8HCVB*_0Z/N`SW2([N4(+2M+9A MB(R0*8X)QB:8F,`U@6<"WP2!":8F"$TP,\'\PCG9LC!W4H2)_TE1/M7DNW M:Z2"9)H#9`QD`L0%X@'Q@01`ID!"(#,@"".(%TROU(HQ@)MK()DH4P*H;9:5;A`/)5U1=I705(Z`*$I MD%!E5:4[>GG/5)"4GH/0`DBDLJY(+U60E(ZK0IJ)O%&OKK2O?Y+Q:-U$0:HF M`G$$,4PT%G5C%22O>5((54P$XJFLZG`8TKX*DM(!"$V!A"KKBO1,!4GI.0@M M@$0JZXKT4@5)Z;@JI)E(C:)F8MXN41=&5;/=K;\-4RH>6L9?\+9#79'HE;B& M;JT@G8$JHA$01Y!N/V^NVBW+F.1C=5S>Q`0T7"">RN(M&ZF:AJKC4C4`C2F0 M4&45JL:USM1QJ3H'C0602&5=OM:E.BY5XT+C@8^K9J-%VS/H8Z_!-RAR(_]* M/_[-2&JVI9.YC&YE@3KY.7._1XB<`O4[RO$QH@DFNH@\3/01!9@X111BX@S1 M'!,7B"),7"**M43=(]X.W_Z!:8GNF1;FTOYA@;ID=N4[S=B6&)51,M%!-"Y0 MCZ941\$;Z#N\$/TVZMD9+?*HC)*)#J)Q M@7Y5=NJ,4LM%+0^1?Y-\@(E31"&BV4WR

8A\B4JM0*)2:XHH1#23 MJ-2:2U1J+1!%B)82E5JQ1!=JCK?<=WC!PXUEAT!:S5GV0&^$1OQYDJA,62<. MHG&!?E5SH.6BEH?(OTD^P,0IHA#1[";Y.28N$$6(EC?)QUJB7G:\R;_#:K$G MH)6=0%K9`7(L0&.)RBDYD:B=;9:=BBK+#M"8'B[SXOQ5V4&B6R12 M[4MY#Y%_DWR`B5-$(:+93?)S3%P@BA`M"W3UJZXZ,J+FQ,-V\;SSD)S>DU&R MWV>U=?K)'Z33]OSSH\+B*?^PQVC_D\;1Y'U&VW/(J9-CO'7#(]27,=Z(X1'J MLAAOJ_`(]4R,-TEXA'Y]\)(OLH4ZPPZC)R3(7[KLA<88 M#PR[C#;GD<]M1ALPR!X6\L!FM,>%?&HSVNE"'MJ,]B,O M\`=&6US(AS8;7N(CFXTN<<=FM$N+.LX#HXT_Y!.;T?8?&PO=V]R:W-H965TRO'C#8;%_2T]),<@OZ1GNO.37 M4U+"Q^OKL+ADNS7;)_Z^?[]E)Y+Z>2: M'I,2^E^\99=">SOM;W%W2JX_WB]_[//3!5P\9\>L_%TY[?=.>V_U>LZOR?,1 MQOW+&B=[[;OZP-R?LOTU+_*7<@#NAK*C?,RSX6P(GA[O#QF,0(2]=TU?'OI/ MEK>SI_WAXWT5H/]FZ4?1^+M7O.4?T34[;+-S"M$&G80"SWG^0YBN#@)!XR%K M'58*_.O:.Z0OR?NQ_'?^L4RSU[<2Y'9A1&)@WN&WGQ9[B"BX&=BN\+3/C]`! M^+]WRL34@(@DOZKK1W8HWQ[ZSF3@WHT<"\Q[SVE1AIEPV>_MWXLR/_U/&EG* ME71B*R=PU4[&-S=V5&.XJL;3P=1UQY/IW>T]@*^KA@%7Y<3J[@2^KG("5^UD MW#D6$^4$KLJ)/;"GKN5..@3T3CF!J^Z)U=T+K/%J/'#57KH'9::L< M$TMK+/[079G>ZF8HIVRU`ORD3![OK_E'#[85F)3%)1&;E.59H+R8^PZL(#E3 MZ]7PV6*`52"\/`DW#WT(-30O8`7_?'3LT?WP)ZRZO;*9VS MV/X?$U6X@;T$%&SL!&1JSJ61`WVIC6BT:Y,ZVHP$C(2,1(PL&5DQLF9DP\B6 MD9B179.@:,.D1='^>@8+ZRJH.AAS21SP7T?0'MV1&5L;Z68^(P$C(2,1(TM& M5HRL&=DPLF4D9F37)"B&D!UTB*&PQC&4!&*HP[-@Q&MNFD4\V@$XV9.<4STZ\]Z=`'KG@+90-],U&QR"'DLV9!:S.RFX:L6=3:S*F#B4(`.>F7(?@KOWP6 M`DC&=0R$%QP#25RT0U&M%LI(A%OGC6Q&^;<8!;<8A;<81=\8H>!9D"FCZ+5, ME$:4*G,<)H5<)6 MQ%=XDZ_(6`F![8%KY@F.DL@J.T1))J'@W0@L$0C<&!O;+D3I"U%"FC,4<*N0 MHP@A/!J1M748C4SRT&@D(IJ3TVPARFVA.5**5LV^L=+!"@QJ!HOL!Z&QT@TC MA/"819;580HP@A/!J1`G48C6-)*K5K'LV0HP@AK+E(>CJ,1N5(S=%(1#0WP5-' ML;12FD_\2%O&'&TY&BE$`Z\12*SY@TW'&TYBA5J='6'K'"487*AO>7K M7%\D/S3*"D%B9Z+LD%UEH1K:LSI^/D>!1M.J;K)&MLOJIE#;&$\11TN#&KVB M6_I*68D'*(V^DRU];7QI[3<<;3F*C7M9<)%<8X>:8%E$FMS<\K^116;5:/(K MA&4AY]#"EE9(%H8";25EL6UX3LIV(=8JTJV,4$N#&O'FJDA?WZG"OG%CW&NA MMAS%"H'[JDK"I?0.-<":B/R_@R:R7$":*`0];TPW<^K+C,665D@3A@)M)35Q M1%;#-&&M(MVJJ4EMU>@4UT1:$4U(6;SF[C<<;3F*%=*:#-A*J3L)RF)51.W1 M0159JB!5%,*JD!XLQ)-L4?V9R/DZ0#ZR%J(HZ:"&+**2%0E@+=F2KZLN$T+<9 M"C12*V0\LR83)@9K%NEFQOG2H"_%D+[P$J&_"JV-+ZW`AJ,M1[%"6I0!.6%W MJ`F6151O'621Q1Z212$DRYCL-PN1T-`EPE"@K?1A,G.G9(:%VL1($'&T-.A+ M560/]!(A!^#:.#%RL#YON56L4"T'<;Q#3;`Q0K4:9/<6KZ.9 M6$@UY.ME\N6:4WI]31?I\5CT]OF[>'4,,N;'^QK+]]KF8P^>$$,W*'<]>.K9 MPB<>/-SC_,F:>4_0(WX'BF]/U*+\#M1AGB@)^!THQSQ1&?`[4)5YHD#@=Z`X M\T2=P.]`008O[[7=@;?ZGJKJAXX>WO9KLY_;X*CE&^:.!V\U\&]^&GM/\.,) MOP'5LK=H[1(4S9[?>@=J9T_4;-P;U,N>*-WX'2B;/5'!\3M0/7NBD(,[PWKT M\$;A)7E-X^3ZFIV+WC%]@6DSJIY%7N4[B?)#J1[(/>_`0``__\#`%!+`P04``8`"````"$`)Z*O/;T5NO+):9+R,36(YIL'*A*=9N8_-?_]Y_K0P#2%IF=*I*Q6MBV2`RNHL'C%2OAFQ^N"2KBL][:H:D;3 M9E&1VZ[CA'9!L])$AE4]AX/O=EG"GGAR+%@ID:1F.950OSADE>C8BF0.74'K MEV/U*>%%!13;+,_D>T-J&D6R^K8O>4VW.?A^(SY-.N[FXH*^R)*:"[Z3%M#9 M6.BEYZ6]M(%ILTXS<*#:;M1L%YL/9/7HNJ:]63<-^I6QDSA[;X@#/WVML_3O MK&30;=@GM0-;SE\4]%NJ/H+%]L7JYV8'?M1&RG;TF,N?_/07R_8'"=L=@"-E M;)6^/S&10$>!QG(#Q93P'`J`5Z/(U&A`1^A;\_^4I?(0FUYH!9'C$8`;6R;D M-Y_EK^Q5ZFK281\3` M:X\A/<*&:OJ2H(SSDJXWN5-68*6LFJY*><0/SF76*9S?EM.+8I-T.A- M>%[0\V,%B`F;-D1NZ,!?CQ@9]<<5W%968%TY['E1&3&H[`9AM"2+'C%2AJF; MWV(%UI6CGA>5$0/Z0U^&_1])A_=(*[`N/5A":<2@:<]S?1(.B)$RC.=\TPJL M*R\UTXA!Y3!PO"B8V&CU.W#E)KN]X6J15H$_\*-WQ"R;48/?GXE)7X[E;\LJ ML"X[W*@HBQB4=:U@&,-1OPGDR+GMV[H-6A<>#*%P"YHS9T3ES5G3/U#'=!K= MV+ZG[7=#&9OHV['"X?NQ;Q5!9\KSDH5@<(TK&.ZAUC^"N@U?3%6@9=L'WJ^$ MFJ^'&D'0>><'R-B^2J'[[:M5^O;KXTX0M,!Y[W=G+']7MJE?\0M9?=Q;T&W9 MNW*-7`FVRW%#4#=N4^W68FWFM%W)-_]BVA!TV[>6;1^,VK50&^*C'7($S1DU M+=EF>K\6<1>C=IYQQ)IHOGM7Q#5H?<;U86M!W2T^)7Q7NKESTJT%=>,632G_ MKW2#T_GE?:;/6PN:LH['LR\LSX61\*,Z>A,(A?[3_K'@H7DJL/LO MX%1>T3W[3NM]5@HC9SM8ZE@1Q$"-YWJ\D+QJSL9;+N$\WKP]P/,7@Q.F8P%X MQ[GL+M230_]$M_D/``#__P,`4$L#!!0`!@`(````(0#1W+>BB0(``.H%```9 M````>&PO=V]R:W-H965T(PG!))18,]8:G?PU!% M(1C?*7:4O+$>HGE-+?@WE6A-3Y/L/3A)]>'8WC`E6T#L12WL":65480/`$6_T.N8%61`@K5>Y@`A`O5(')WW(W19<)E>W[[L"?-,H MYP4]UO:[.GWFHJPL5'L"`;FXEOGSCAL&"05,$$\3:#+] M/X5X1UV`.VKI>J75"4'3P#M-2UT+1DL@]Y%Y'T.LKX4*,3K(G:-D>(811&&@ M/(_K))VMR"/DE)TUFVM--%9L>X4K!=@;/$+DEQ[_G?7>BA,[*ZX*SMO&;P![ M\!:_>.^U8O;7VL@)9.C2B M`?+28_IJK_99\&@PP',&HM+?E7JDO1&%3S M`I!A,(.HM1]6O["J[1I^KRP,6?=8P3>50Y>$`8@+I6R_<#TX?*77?P```/__ M`P!02P,$%``&``@````A`/MBI6V4!@``IQL``!,```!X;"]T:&5M92]T:&5M M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3HD#2 M27T;VN.``<.Z89 MUC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B;6%=W_S2 M=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[66 M\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV%;P!\HYK" M%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT`;Q)__/QY.1`R:"'1BR^?_/;L MR8NO/OW]N\*1R5D1SBB!4-?A.KL$S(P5SX15Q/*O!T0!A' MO3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2AAW0."QB M/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF)$E]>)]R) MW\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[#Y;H'3R+ M]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9>$\H8P,U9^2F M-+VWA`UHW(=!O-29#`P<7""P68,$5Q]1%0Y"G$#?7O,TD4"F MI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-58,ZT&:-U M3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1VVLUUAH> M\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[8>V^I+!3 M!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T74LF$^*K MHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY;6TSY1;G M-.F*EV(&9\F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G>:W/@G^Y\ M;#*#4FX=-@U-9O]2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"VENPL_CZGL?/F MS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%]V\BJK-T6U6]K__/WT$-E6VZ75)CW45;ZT/_+6 M_K;Z]9?%J6Y>VGV>=Q9$J-JEO>^ZX]QQVFR?EVD[JX]Y!4^V=5.F'7QL=DY[ M;/)TTR\J#PYW7>&4:5'9&&'>W!*CWFZ++'^LL],S;#!2%,#,>R$A9?0`"\-,J"UD:H$CZWO\^%9MN MO[0],0M"UV,`MY[SMGLJ9$C;RE[;KB[_0Q!3H3`(5T$\8*^>\QF/`A:(KZ,X MR*C?X&/:I:M%4Y\LJ!IX9WM,90VR.42^OB/8BL1^E^!^"9!M(0UO*QXOG#=0 M+E.0]14(121CA.=>(`[0NG"#'=_.38)!5]NZ,_MU"1X:4/L@1JG+UXC)$)-W3!T#5T3'>`QSXT'ZH08[.YV8A)L$/,,8@@1 M/3$_<-TA5;VF"3Z'G\/>_$L(P@PJ_79F$FPP&S:,V40(,N,!'TNF`Z8D$Y28 M;&X?UDZW@EQD$!27?2-!A"CI!#-2GN!COUJ9[^G/LQ'S9':#&P(%V\:5X]FA+SA_UBL2G,6;;`=UUF M%&1B8%P>PA,`JIL< MU[=3DVBC[H8YI>H.,4JWP(]B0]F$Z0@?:HX-I4')R8%].SD<[T0WHQO7\HP& M&U!-$5VQ+X*`4[4N+25GN,07%3>V!]_HQC73_2$*0C:N.!WA>]P30V%010;_A$"8SSFD]OH09H95?*$=3GH!1E=/'O`$5.-T]W*YRE#1D&BM,*@B?'F-C/Y)","7IO*)@G!@.D:B*=_D&'_M&8,S=M<*H!@G< M*!J=0@G$$[$;:T=H2N\NY^!CYPA,YU`8I/?`X=6@C5$!"04)%P[PX3`(*,.[ MS(.C,4`/#L9@FH?"G!EZ4(&"LZ%)<4)3%`M%[,.L&9)!2=YE(7QL(<%0X:J5 MB4&$<)AW76,:)2J.JH30\[WHL_,\W(Z-FEG^;[J9^U6TF;5"0J(*@U<7++[Z MQ#=U3'?YS[39%55K'?(MI-*=A="]#5Z]X8>N/O9W4<]U!U=F M_9][N"+-X:+*G0%X6]?=^8.\W+M;%/_Z^7"38*0T;7):B8:E^)4I M?+OX^&&^$_))E8QI!`F-2G&I=3OS?965K*;*$RUKX$XA9$TU7,J-KUK):&X' MU94_"H+8KREOL$N8R6LR1%'PC-V+;%NS1KL0R2JJP5^5O%6'M#J[)JZF\FG; MWF2B;B%BS2NN7VTH1G4V>]PT0M)U!76_D#'-#MGVXBR^YID42A3:@SC?B9[7 M//6G/B0MYCF'"DS;D61%BN_(;)5@?S&W_?G-V4YUOB-5BMUGR?.OO&'0;%@F MLP!K(9X,^IB;GV"P?S;ZP2[`=XER5M!MI7^(W1?&-Z6&U8Z@(%/7+'^]9RJ# MAD*,-XI,4B8J$(!W5'.S,Z`A],5^[GBNRQ2'L1=-@I``CM9,Z0=N(C'*MDJ+ M^H^#R#[*A8SV(2'8[^^/O%$2D2C^?XKOC&R!]U33Q5R*'8)-`W.JEIHM2&:0 M_.^*H!3#WAG8#@%9!:OPO(C)W'^&SF5[9'F.C/K$ZIP(@R/B@];1#2KNNIFN MA[!VEQW-(.`P.CD.#)8.&7>0Z"A@"UU=(GJ*,$]7\;*:@5,,V2>UL#_QTB&) M[6T2G/KBM+IW"4F.8WM*4-?U2@8>*(V/L7;2I4.<4@A[-@X'TJLN06!;$W+* MZ*G!9K]>S<`#M<$R+1TRM=TBGVZ&7F_>[DG%[Y$R\$`J'O3+(;&5BH+]J\^L M+C,]OA16N/M;70 M8$'<"&$/ER8Y\3Q\;WX"P``__\#`%!+`P04``8`"````"$` M4_CE"=E'```_U@``%````'AL+W-H87)E9%-T&ULU)W=?O M-V+?H4-!QT@1(,4/41_VS#@H4ISA6*)HD9H)[\9>-($F"0M`PVA`$N?JO,.Y M9'__S*KN0C=(4>-C[]GP6"2!ZJK,K/S.K.IO__AQ/,K>%[-J M6$Z^N[>UL7DO*R;]UDUSR>#?%1.BN_N71?5O3]^_]__ MV[=5-<]X=E)]=^]J/I_^_N'#JG]5C/-JHYP6$[ZY*&?C?,Z?L\N'U716Y(/J MJBCFX]'#[>_[;ZOA M]]_.OS\H^XMQ,9EG@)&]F,R'\^OL:.+S`_:W#^???_M00WWXL^Q5.9E?50P= M%(/VMZ?%="/;V>QEVYM;.^TOC\OW&]G6H]5?UF#LW0F,;]J3!\C?%)?#:C[+ MP>G[W8_[&7'1WO;[1'A'GVH<@L'T&)0?$Q^U-QW1[W MS>;FYM;N[K.=W?9+,1JMOYN4'R;9:9%7\.T@.ZJJ13'[8_NQ;X[+]D?I3#^7H\5DGL^N@6VT MXO%Z[#=5]J:8EK,Y)7S/\U$^Z1?`B9JHLOMO)_EB,)P7@P?\?GJ0K3WH MP%OTD>4M$]?M]I>1J_:JBNE^W_DZKZY,H?3U2_&WQ?!]/BHF\PZB)[-BF@\' ME0U^/;^"_G'JW*9NS_S-YT^?/[4_/"OGL'8_1\5N!C!&(-L4*!-^\-\CN[3=_RW]G1ST^!;V]IZFK'+TZ(_'[XO1AW. M.(*=)Y?#\U&1W4"8$Q:!##;=:-@O)E51-7",Q>._UFNO[?2>;.[T'N_LA.5[ MNT\V>UM2H2D4V?WC?#HKN[>WVS M+%4VS:]SD&UOQXE_G,U+R'S$URM5/=&@O M&MP(T3*#W++J<3E9CWQT&PF65F,WG'FF^6S>`>QE.;E94CLHLC6-CY@\_3^K7-?EB_E5.1O^6@S^D#W>[NT^?=9[^OB9L>JCW=XC_MQY_#0. M'LI$#.S+LM&12WSN9RB_OQ_M7%:1GM:J[[. MN$0UM;];-H1`G/TLUKE]6+"7>S4/W6FX.1H=KW,9@"];XIIK-NWI8WQ?MBL@BFH4V9`#"^4/&1:``+TA'G4YPT M7)!>=EE,P&YD_)<>R7NU9WQ05KF'?S?:`]4>E6:5A.?%G?EEDD\7XG,$P M?%#?B1IN/URSJ`G(Z15&(6B\8#_NXC^F4ME>(%'M)ZCV]:,)?ODMJOVLS)X7 M'F9TI/\D:/;3.VCV@^)FS=Z&\3FAY&2B[0U*N9?MC14_9_D\.[C-.5[Q9%!* M7WKR33%?S,SO=)-&&)ZAE,W\1I)5D/"ITO>>'L?[DQ#+?K3<#3* M3L?#^=7#EP?'>+'F^G\U)6^;:C46MY+BI)@H@,5YR%[^`Q"MFN8KH1FZ>RC\ MX+893IZ"J`'.GQR8KZ;3EZ;[2N@$UJC,)0MN<$T1#X,!^FKHOC3=%Z"3L1V3 M1$25U:'BDM!^R&?*@'5LR*V\8)&ZIBX^%K/^L"ID*N),OPG%+\RX&DO7>T2. MYX4Y]-T<(\FQ&Y3RK=G']F.-1K[UL653N*]TQN&H_'`G7W%_[_3'[/#EZU]. ML\,WKU]EKT]>O-D[.SK^(=O;/SOZ^>CLZ,5I6XO7-&@P*8VH?TFE.C,$)HS"UU[%!R42'[7&%P=&`6X/W#=[5[5H8.DH M$_PDL.MXWB?!6DN2W*.,Z835^1;Y>T;[VZCN'N3*_>O`WN*YH^.?7YQ^@>=. M%OC]N4L\BJ25)FNOD([N:O[VZ`Y^P\E[G'9)<,-5_P!^AT?'>\?[M\O4R:SL M%P5)1A.#5+\Y1T8MUX9]^;F*#*:YS\J1W#YTWW!X7_]L!S+-55&SWIO1XJ.7K$F`8B M#TH5JP=2I1"E5@\Y?7MR\O+%JQ?'9WLOLX.CT_V7KT_?OGEQFKT^S&J-26WF M\/6;5VC+U\<=&3,M;#ZQ+.E-4GS;.L>OC]=MK40\C@^R5;I9?+T/&W9(5.)%%A94'224^T1>DB+1I2DG%/+WIW&2Q">CTM4X)?EL#PK^O`JS+V1W2>DS_[CW_XWR$XIY/S' MO_V?#(;A`X8^YZ\'.#A2\Y@V:C_7_-8O9V1I<8C-`F+I9P`H(27@*RR`WNYE M6\^>D9%74:K"P%&+&BW.*U8D'^'^:CZ*`+!6.DIK;F1'EB-%8HL9XHG8(TG*Q$L\H1&+AG'8^JM9N;B\(ICGUR)["R[, M:?2J-K(?0&N83\IEX+*7\P'$`;;X?4*+90H^FDQ*;+M)X;_TXWL MC.4"8:49\(Y),9IK!I34>IUAIB>;+6`62I^0V,HLLU8*L[WNM&]$CJK!E]Q:7^$W9 MEM>L^7?I>M]V=%#O7MT11[AF? M)I#/+V>%)\2D/T6?O$\>.R2+M3,$J_S0-TF6J$X<772A:FNF!&S<>+;Z?%A. MT37CO%\L+)EM2".4Z$X*H-`8E$+:T9P#9`&RL/5*90]_U6?`,\NG]KPYN7/, ME[PG(YZ\;D0K3[2,PEY MM?*"TAR1^46QCE`Q*:%>=67M7$@6[GY0!]\W=$UJ#X M_*FZKLC1+XL-3A>BPZHIXE9;="0&)3KUO65>QI:*L\G,K21;!DK+,"WMH1N> M"JDX/B!:"6[7I0$-TTZ*#]E@MKA\8"OUD4E5&#*T<>YKPP)2/+-A827Z.5K5 MAPR;YI!>ID:`]:OR`TPM)VNP0#W9[SA)Y8A?QP5%HD'\;$Y'!+\/BFIX.=$O M<3F\9JG27O;A:J@<-!IG4LY1=F@4%'/^/A^.+"6`2!C^#>[3Q3GI%!;*-:-T M:#,'70K%(&;!)5_P>Z`U?T3J*:J?#=TIDT`$_Q1^.9AM9">C$5+144^TG]\O_7,_U:]A2URI9U&EY^*,6U&&.$J-/M5Y7_!"'-B&H7+5+L-Y."7X!/#TZP5295 M2<@+)"&Z0A=B7$OX+T5QI'J(T5DZ\6)!EK;8H,9ORB`2*,Y@NLDH%9;MR3). M@GIE*43E0ADNU==Q.JA7%J25!H)\,44-:HUJT:=*65TLD,FF&`-_3WF:TJQS M>JHA71VA?D1.!@T6(H$PSOM7P\*L7YX9)E)2LU!BRHA"_K80G8&L6DPEARE: MIL3Z)3:2$B)3&N8I7XSS:VB*.QO6,8>EP<\!74Q&8&/0+"B;C`"2[)YT@9"- M%/R@+&DDH^"9$+;IYRQ70BIO"L+:NZ4ME\L\&1CIC:=\CU:Q53)+Y##D.6@1 M<\7YT^NZ$C"$:G(9%(M0K8KBW3(D4Y6DP<,<,507>WUIYK5RET6E5WJ.T%%3 M^@.HQ\'M,X]%/4-0X>>QV1L4&H(A3(AB]&]2,5/$N0>#4\>3W'XH9^_T,Q3& MQ;RDLS`TJO7$1CQS@Z1.JX7:,89B-(@ZIA/(R&^",!/*LP`WWQH5M9H:O%9( M9V>91X:M'-&$P@$U,9QO&9PCNUN2Q%.X@&JPK:WPH.F=D1\.7RP4#YU'GS9P MAQ$B"@T`UGR"?LEQF(T,KL9<9^:TJ9C?KV^"]F!ZUO%B>85JPKB:`9XJ;2/% M1I9F09E4S@:T3/8![%+F["YJS#V`9R$TTC]:$-WG:59.$XY5E4/VJL5H[BR@ M)<`44/DIGPM]L)`RGN?PM*E_/CFG_&<>@)"2!&G/*2<6.(Z@XXI(23_D\-KG MJ<7*"=>DK[1BA;:H+I2!0=^P;)+24I"A(1.UF$H<+0AAS'D(ZS96-&`E0BQ] M[Q:57E=1M#80@>&0'UM+F#QI327O:+F#.TD%FP MG3!D`#?WVAQPKCWJ/=I]3)_4%HT@DEY'AY`4Q6Z]JU*V!$D=0;&^*G9&SS"M M98="X1,B-DHA6]MZTMO<>DPWS';'H&YO9*>+,7&<[<-I8BC)',2].R'R11`[ M*?H50V[IWE!1V*AX`DMP?&?AD(\"#K.!U0HM M'M/?@1_1IJ2<"62JV'8@SPTSACZR<%IJ8R>,JFVCB%U`0YE(OD#&O8BUBL1&F,28B(O17HGK[8U\08 M(\;A(VC_Z^31$@42]];52*,YDJ\T#V#468'8)^G6',=%\ZM_08"&3LO59$;S M:.L:"J7J[A`9)#8E*/6V9A/7.AG"A".>LWW0.@G.H!WB0^)-]8,:=30(>AOV MJZ<$JTD65EU_N!=6X#,+_HG]-5>/O]C:K:?QSQ!$APB7[QO1VMZ-@[0]K_OS M4I9IR]M*=VP/!-6UVI(=L`Y-?1L:KD7OA<21B%QW.R5Z'=]P,2)-"@,10$B4 M>>:O:%6C7TJOJ:6%_EY%G&^@=(Q+I')1RZYN;]U688LE<,T\*^9XX//RDF`( M[`V`QETU_7Q`>\C"^56/[M'U=AV$^[!&<3^:3=O--V9%C`]?USJUMT12-+%M M=H>F-@%[N=517_MN>2`:\L$9`S,0N"LE49#:3(F'^WC3"O2"B8`5@KTS4J_< M$;C<[>L*%?(#4I^88FB,*VR.$.TJE,R1#4)*K!`M"N:XB&%NU0Q(^PW2[7$F M^AWOW309OXZNS0N]QO%8-M[8>RV54D)[$TD!_B0%JTJ:7KHDA\O&('H%](K: M@V0'$EXDK&IMN1`VVAO;P\:D]>0?FMFS@IPE#-'SGB54@&,<4TZ)V34'X;?< M;R&!AZ'<#=N&4L5XI_['?0@+1YEQ0W4%\X[/0$0G@Y>,?9!LAU4IFHBZC?)% M/H0Y:@ZMA7`)>Y?@:&W@'&PLU1BP%'U)LWS1,N-6>T8@KJ^LP!`G4B5P:`U" M[6D)G49`9J<>I%XZG/X61Y3G7D`2$:QCB\^`S?FVWD*!F^KG%8A;E`BI)3T* M[TS8W\I4A5Z\U"BNMI[!%4]WW/SU_!W!<(36)-B\50NUI9*T^P0L??=;W2%2 M[*V0KK$O*V$67PN8VE\VW24AF2_@HTA;;#UZE=8#PB*W;\2I-/A'H#HT_DRW M?O=_;1=EW\I+^M?ZRX*CYY$CW6?$^6?JGSZRTJ$$8.5>A8V1KJ\HDQ%F21:N M\+@A^8CC3]9#K.JC3>$[0U*$HA8HP@*U(^$$)#EE#)(6=HCRBII9X5^+:@E& M,#5M/W6#EC80$F7;7T5]B5L_>4=\CV3;R0/KUB=G9C4`2W=5C7MCC)1`">NN MA`8NB!`[!7%ZB^LPJ85U@5<\)0B+P_XDJ"5/F>(.;RQ!O;,"F8D`%+P1DK&$ ML9@;0\SY6D&')<-7?P;?]_&%R=)Y]I%`URB3^O02[YI1P<#4"GRP*#HLM:\8 M3Z>SW#1=9/O$;:03W@RK3EGVL%9,&&W2%[[Q)BE3C)G%FR!.]/G7*#:1BSS" M;%8R#-1G M8["W\KE[VB,I(25OYMJ@G$$7N:))TI7ZIA%OH3R*B][_W#O]/D#,_>=$?MI M&]7]O=/]!]D9=K6?/97?2MS@4`*=_COAG^%#3D+^JL,1'*R\QQ^DN=V.C3G` MN:5/9H=XB3[BC*QRE1V3:W]3(N3Z]B(?2]9L`AO^T.:=?[^22CVBE@X,_Y3U M==[T]]64^LQW]Z;H>[IIBWO?VV9'YJ5`T+=C4N[_-C(J3K'$;I-D2!,*[CV0 M9*2X0D2(Y5\IE@O\/GD$R`ANA.VA*93@7&I1ODJ22ZEC%N1BXBZWLW&S3.V6 MD)+#/3.L$O"9UFV:N![MX`/ZI/*N)3.FAX0CI0Q\AF;:1*F0%/G\26H-G>N\ M6!]&PGGM'(ARS>PUFCKY`FU0@^%QQ38P%KK0DJ_!`YN2V/WH[DJB(W7@)(61==)V8"?(X$CK"*`\MD`NZH*CTC[3"E M('DI`/F]QC@2W+E1(]VGF$C\HMP#MMBVV/.@?#"NC)`H#RFL@`N4"M&2+W8"(7QQC-X1;X! M/3?U;$YR3`@Y"4<%-T@%-']Y%D#HX-J:SJ0&B\52\F^=2H_TIP5W&$[CQ>A` M#93[4LY_Q`X:F:0`O7,LQJ"-&VF)YIAFD%^"^KZ0-RQW%RO[2AG$0J>!F`,/ M`T6*7D:$X#(JS%94SR\5S]:'*"2=R)L5>5HXA=Y77P\?BT"B=?CA3AY]G8S@ MEVW+3*\]?KIM\*WMJ+L`IJ@/6'8,RQ'Q]]()R^Y>5EBXB((H8K5MR=5D\!"! M"M44(WM0;!9.A8H)E,?FPTL&D0MHH)@?4-!Y-_L._UK=C?R%Y5W>W5#TS.08 MU=JSA1_$$G9K,C1R9=@"OAH5,L05Q,]5E M(G6`=_M5J5"MTFA^*W(8MFO;O2>T2^SN/-/RYO\+AH3H,;!K=14D$SK%406X M\G2BG,*[QTHND.HR-5NO;`,/;\V"/3#TEGI-:U9URWS'"!,):7ARN[>U0U;Z MT3/G3!!^_!278(DYI?+/$BK%+8`4D"/PA[NI$:*H/]W10K>%#;;B@M7V@B:% MRAP[MN.6!?4[3Y!%PDZ*C[C(C:2WA>"(,&Y(CK:< M?[^$AIC&U#2W4ERBK_1D@%,0#)O994RM]&?^*`K+VOJFKK,;VV$N:"JB*5E'/Y?U;6L'@(]31E#^@V.W?!PV<+ M+MO.8[IW_K4NVXEW9I$_.J%0YJ:LMC*-,8J^XS_%;_L>#S$[\HSX"H)*Z(RB M"AU4E+)4#VTWF(:H2\J.4.8.P(46*[0O/<@C(.FC%V)'-46AL:66.-\^H M#<`B"R6MU"P*K\AVNYFW%%NM3XS=M:]T$?PJU9PRE76L8XH)@%Q,:N<,.W9> MS#](50J0-KJR<<"O:Z\"7Z%'G,8,E.!90[4YI*1@^"B4!DK2#4K3H M6764<),'4B"=TO!"XIB\P;>I3UP>($'QQ.6^U.FRD,Z_7QJ=M`28`5BVZ5`M MZIO$G+O1`E>:<-3K@X/85[Z2RCHN"IJ<%B:Z?=SPG2/7U/`K]?(4ZW5[4#6' M@52UKS^AD85]:EJYZ>FAJRA:65-!VA:"GX7*C6:$R%$7K&,=O,"J?`T!K$ZL M&(SN#**\O*QCZH(QZF>P_`0.B_1P0[N4&@TD,51-C?QY<9736"F(""9F@_6I M3NS'0^$&5BHG-9;U^.K1)8Q6>%TT>*N3;#AIGA$+N,D'ZY"P-.47] M*'=VJ5[*".K[60L(+D9NNZ0>(6)_T\^6F'>YQW>AI8_^"J.F]1*&;^5**9^3 MS?/JG2JKXDT26_BC86%<'&L(*":S%A5$MT!&A`4U;=IH M$7UC68TT.ZGG09`IK,J]#(G'8)YYNAB1_T$.0AC9A'A)Y,@NA1P]-`P"%D.. M)I@X\@/$9_G'=D99AG9UE)U:WPMV0>>+E+7(&NOVY!'6S76"S,D_/1N!(4TQ M^7^>A_#XM\Z,!]&(*4!R8(7UIIHF$3>@7^`2!$0S4O);S":H@K=-5L/#`C3D':`56RZ)04Q0",)H M!,7>*UC5]1M`:`+#)UIX]%Y*$E<'1(A&#P/;_#ZDH/!"0B2:U6?YV+=!ZZ;P M"-B:K.@@]9;1N:X`76JEF./""Q"@SS^:PPK/J+,GZ!4+\/1'I*/R26KBX M.\*``I/YM0:#E9Y%HD\\TE*W"2Z?&0B)#FG1Z)@9L]!^F-/V(F:9--U'QLBQ M5HE`R80U/QCUUGRQZ?^GHXAT#^Q"[^J5<'DV;Q)#JB6!\* MT5JL!J*3$*`/%P?EN9E'67IB]\!+;&5ZX-6/"8J?=<>/,G58:2\4V0-M?RNA M860!URFU5<9HIPL&@IC55^&I,LA..-LXN/;ME6L2N')D*2*4T) M1'MJ0+*O?B93N@NIJ_.=4HNJI#E%@:Y0+!B,K62\EL#8J#W@%(.R7N+]UE[) M_*5QIG%F2'::Q^Q,JAT">NN,;:H%$4*()J!2=S&Z'5):L?M'DUR6])T;897+ MUIT_;(W;5B%IGHOZ@TQ!-H9V=W-W??=?'DF^,(P#']<.$MB*65]$-NG8_W]. M1+FAD%+\'U2?L:Y50Z,Y:%@M,M+-6Z;D>N`*-!V M`%^'3+>$BP*ZK:UE":CX@250$.BEKH83I!"=#\21,&/_RK7D_>'*V07"JJ== M6R8K,9N$7(=S5FK:;FT[?M+6)SIQ^3)>V6):JST")8:C'KOIA;#K$*%4EU[, M9IH/+)D1'O4#^+FD119^=8()2G.11[R^)5#NP\VWPXCL&(&@&-+C/W'S/;1% M"Z!:U*.[K"4T*LYA*DN<@4;!CN,-'83+:VJ@OQK+%@;KW?MMXNK2OZ9*PNI+ M9YF6D4DYU,V\**OS19C^ZW77O>Z^F4;1M\.+=3!'"2IN\.\"?DK,12#:)+#X MAB^;N'MI9*S1W M&,.T;P*BYD`\C&:-]3U9%UC1C9+?-K2"'Y*BTSX(Q4ZZ9FO5.8"";=F!^?=1 M1%;];`O%&XP.'N#>BOIN>^@9FQ(`R;S8:-D,V0#E!6EMG]'J<9E=SLH/G"34 M)H1#H?@F^.16JX%&M)1:7+&UN16UVT^+\91(D&H:W=!9/-^J8Y:S^6):J4W& MVDQ_>OW\5'^HUU3^T@?=86*NIT41YJR:E[JV%6_3LQ0OJ])HKZ@6X(CCP^$, M/I1;8)V$WI+E47NXAL@L5Z>UCQ@=&$W M'M3T#'3JL,8>F4G-GTR*H9Y0V^?XK51(=`2"&CBL*\FK.,0[`(CSX0$<<[)> MN"4TS-5M_Z!AP0'.=:[#=I`@3!P9R0[D,"RD,R4_.'K#IOO$/R%,64V_.D'R M6RFR0\*$1F(\-"ZMM2I))S5XH//C:B#UOLQ;&L:/ZK9@M00+](AG\`#G'ZA& M-2>K@#ZN/&DJZR3.0@'8DU]*^LQU!:O8:HW#N^+I)O)5A$-A-^Z]3;0<'.@4 M=@CM31$9,$2&-JF>VUZZ>)(/R';I")TV##EN[JM"BPDKK6$M+]8%5E$M0P>$ M5B^3;24@O3/'\;*^*B;;>D1V[!I/,?9NFU?"@@))OL>7T!IZ1DX+AM0R"P"N MDIV.]!)L'ZRACAX2DTJKV@B"/>.0 MJYS\X(8Y\ISZ44YU,1&0,:`3&2/RUGCA![<;',+Q&:%G1V@P7;74AE_:-\]^C9?S[?[9IZCL;OG\=W[*%3*?;+_POY[*XX_M?FL[-$ MF2G9((%/+IHUJ4M:6?ZTOK]T\R?#%Y.8?YBJ*O`@FAKPKL\M4`)&OSUSU1&; MX%AM90;$A+!CG[WG86?[<6]G9\>&K.T\>RH^:Y67+00SN*-V2B`)!T[\8FJL M)5D5I6>0;C2CHBQZ=:0'`.SQ[RR6D(,QMO4LJ#'/U:ZJ1FFX2;@ M[:$$EWHIUGVGSLQ4IN M&`@WG'_E;D"@M>TM*OU/?"_\][ML10<4G^&_!'5?_*HM_7XB7[M^&)1FTE47`,T6=UZHZ)_AU?AQ7;&VK%T97H]?K5#!3.T)]&@^8 MKP.U?#K/V0J_I0].XDU+OX0@N;UAQ]%7;<(#0C7R[(H@VH-?J+W&\R/">4D! M(@$\,N3^8/-+W\NM!"ZE=]')*%MQ)E1?'J;F11NJ/;7N'=OS3'V+&[CPR6H- M,X3\KHK3%.8)W^A`I%@]PKEJ8$!\\K"R8.7L`J>)I;\Y/FT],1:OL6J=1^#W MZ%!J8EDV/:G?0QR7-M0J#:RO;P/+:L`:TQQ-"'D0LR:(:6I/`EI2Z`$MI8_] M'!QWAT"3Z)0VU\DKNHQC@OB(DG:.P<^WL6"2F`[=H^K;#6,831SW@6HP@%JV MC/BL8['V;K/;;>VNBWLD(5&@I,H2D$':HY;THOS(2\I$,5I&F0UH\NM^N7ZB M>]J\Z0(0V;RKF=Y:24I@/1_E_7?KIWT8F:5>E8."*R)2>.OD#IS,^.4,[MKC MWK.=[=[F[A-C(-^T.@45]F#P=1V$&QP`H#F$B#NM-N_:RAAM"W8=&8%@4Z6$39 MF!R.W/XZ7J[<]/3<#;GYZ(_.T/]XC)==?;RB]_J9.^JU-[ M[TOC[S(AQC>I;6M_;2F7E\U[0NEP[K7]`)%>XI( MULZMD6+/=81ZM_U$BR!=IF@_T!!@%WC;WW[^M()B3W>Z>E4>:/OAY%*'E'4C MYRO)B#!T0>RPG1',2JJ?/QW@E;07JMDR6\E7JUN((FVS]FQO++DC`7PII7C? M6A`ZKS4@4TN'7?;GH-=0:IV]V!8#[*R@ZIDZZ6Y]M#M[YZ5IGS^MXJW.U$_: MZ!V2.2*9GP#>'<*9AWDZXFE[DBY\G2&[&\$;E?V/30;M>;R*>TO^%6C5#E11 M9PR;:UK-]SF\W\#T[>D-+S-(+-%=A'BU8=KL;6];PB'Q\U*KXS[6U!-ZL3F2 MG@.OS`;;K$99SVF[L]B).*R+P)P-J@P^)G0M6$`IJ['LA.B3%(Q8*VZRD,0G M\>I"/R=T9H]8/X`XW-I*5?4+O?=X[78$PV?6F=$^AV.M,[=&1\.;CEB:BT<$ M0+B1O..P@U(:1+G?0=M8/!"39*&#!R##6?<>R*(2Z5)4ZCU[7,=3&B+H[K*9 MQBH*J%8E)Y9.&[!6>_<\EPY!UG9(/'%UQQ.B2MG.-3?P_R@0;5%XK%HHO>%V M3(AEFQLJVB/3F@2H)3='^HV>],M14*V4ZL=]*FC?!3U21+J(`Z6K]\\9(FEC M6TSDR2OG:XCQ?E@N&-?TF09OE!-]%GRJWR1><&2EO#?)Y:Y6SB.@L/+8!9V& M8C8HQO4N998.S(Z4@8N7P!(K^&VR:L;]H:!W>)@;3ZE6-5.;>+AZ(O:5AF84 M2\_7P#35JED1VU2Q->841^HV=T?$"'U%6V"W5_4,SL,=U>EA:&I9_HBB92ES M[F"%3N;UW;*>!?GB[VV.8#QYQ-:CMRD)J9@(M>3Y3:@2J$'*/&Z(EMQ34)\9 MB+YDX\8W:'7\2D"7Z-7E/TJ/(;X'(R.3R95C9Y9Y:9\4O-U`0M._"KRC!PGW M5&0!Z!ELLZ[HIW(WK?.*[Y`FDE6(\J4M>!/%S%4'@-"-U/$/SNR.@5>F@O2J MSJYOM>1DM($Z5F[FMJ>/@?A4$+>?7&]_\")B$ZJ?1S?V-L^_UZSU>..8.\J_ MM>+912?.:$V/M0@:VNN1MT1VX;6;B/N;%*J?`4$3FD(,7-S2LFW:/-G`H:(@ M6)\5/.7N1'H_]VH+U7[B!`X-AX1.R=<,!T.E7O>:JW?;#XB]Y&XH=2(&5!.J MI5=NN=$WW/KTR&Y=VI9^JL\_PM(FY82$26$D6&:^231O=G02E:]NS](W1R?> MU*";?.>Z#)9S[Y>ZE9.+.:##RGNSV8QPPW4$8FHT4!!,T`TZP#<'2[O)UUJ] M@,,O]+6]^-*=OKW0E/NJF*\7DW?%E(P9"DLP<\'\GQQBN.B8[M99\5&).7WW M\N!87WD(?5G2=A'0%Y)_7[IW17J,1DUK:%0?,KF-Y`[DM^X&G\]9OO[$2)6=I#?? M&N2T(83+;P^+R>54".&X`G4XX_3Y4^N^7'M*]]_:L,:.V:$4-LJ(P-/2KWX0 MJC'/W@QK'$*$Y3DKG3ZRC%[_>EZR$3J(%+H%<>+H6E#V#UNCFUQ0X&0[[194 M)I'MALW"C=#I5"&L_!940 MDX05.3??C,]6/XEBR^?)_=8WL'KK[FI/9W+*QOJ0\%IJ;HIWC&J>P`+6ZZ-+ MSN"_J1SR%5;>I%H MA'JHT4-`?H"71M?K=@VS):F#TH-W]76@$G+H(%I.5?K0-1T>@P-M)ID>$+)1 MK7I\,HM)+E1@^V*S-"\PLNNDO;J:O+K43'#BI6L:DX70_!3@<_$Q-M:(QC'! M!V_!DLX8E%J(C\P7"`C"[$LXRS:3%V=N=GQI_;F!CKW<9EZ:RW@P:S@=:4+X=3C[<@#;Y2;]KE6VYJD!;EI M\+3X$_'7&Q=0!'T1$/2E@ATXY'O"URAA,5R M!KE56\#S#*83]1H:`QN\8:\:&QC<:RE25S4U0`+>:1WOM:CB"DUAW3JUY@^J M,2#L9L%/>.N0S)FQ_5*$T``B]K%9J8415&/WFJ/AH?F)TP/$*!=<_NUSQ666 M(^GFL2`-#2J1X[Z"J^&+A)4[3';B;MA+MEO1^\W^VFOT77@[1%!XR^D471". M;4O"*W+T/XG.7'Z.X_$7M#,IBL!@DFUK^E+3)W:*+2<"#2=9W6+) M"6?!>S,_1@68[="(W+QP@YV)@D->1]]'U>'K%W48<&@WO4O!/L*=T M$(^*Q;MB/.3;'\O!)2;;!*IY1@OH/=>KOXTS4B.<8M=YYP;&,-I%'8+I#A`/ M!L-)_UW$/X[CZA0K-(<)^SE&M'8.PH<5S#@J/H;5SGAA0>8%I#A),G_2`?V" M_F"<`TYPS"CP&:1"CA[&N$VA1]PXX&J!?Q%Q`03KJ_WQ[.7/ZT='1]E]O<;B M08UO)#K62"=U\4?@IW""FQCB)/NA"7BKS^_DZD5DRY'0C>4/(YT_,HQ)XZY4@!L/G3YV7 M@IA_1LBM\"O@*AHQ'DPD-HN:B%^]I>^&)1R9.J; MNVT/:H7(Q)(.%.HHIRS,T4?8!YHO1J1WP46=2#&0#F//N?:(_@!WX1*SAN!Q M=)C#%@JZ4870A7O\ENWAAI)IW,',:0)\F;`>A*)C*'D%RT+^[F ME@2!3(@Q=+Q0MP(Z?0>08>5O'_)8TT;HTZM""8KXA&[I,"`FP<3RUP)X7;:%K=Y>3]O\)!&5K+9T'MM:W'N[V=I\B@:]A:I="Q M]Y0.OJ>/:NT5E4AHN\4O'K%![SEIP>LI1CCH`^ZK"CX2A!QSCVTXA*&#L-I- M_ADI84+@J+/0T]4TZ&U] M$%C3M8!S:Z,Y3._AO.K(JO=VZ1'H4)_PP#E@G$&(0$Q=RABF34)18-2(*G@==*9\^\HQ\IS#YP M][W6G)2X6Y`/3]+OXU!DV>A;USWUI)[!TA"2'0NY%/)DQ`'E!^-.%%6\G47K MUP9![6,YJ M2V2["Z"D6&C^1:F0@+!HQ,-T>XO&0HD$4SIQ&E]]F6S:'',5?9:.43K2JB". M<]EJ/',%AN[&O8BLV404RX;+-M$RGF9G'?%H&FR7ZR-*O":$]/Q][Q8QV.0L>HTJ^IHMD%C3->8A%M.!O>3C'NF?"W/WT[)4SSURG:*9L("'8*Z91K:[?;+-.E M=CW6=CR]TUGL^;`WK!H=9E\^RB(TCZ^3B]DTS(8,OB93+DW\ MIITA?N7&2;!Y*Q65,FP#_-8-P.^O!/X7=26QVC%&VK:E[V_)$*^J6,D1N,:, MW[1D2$%UZ'5P\Y)R"N(KI"1\P?462A&4J71(.$5:"V:#YY,;\'RQA M\M'89^D7*-E\AGZV"XB@->V1-:>T]DR$,:9^Z8:D-@`W$*>5G@LK!G;OI'4Z M)#R\"S91L=\5+K/R60Q<[F:W.Y#]<#MD+3W`:;SL%=>?J`+]]O1`#,V5?.:/ M(31"P!UC0Z%MEI`#NM6D=#AX>+!'P-UA?4RU':H6,^M4PBW?Z M;&VN;V_^KCF+C=YQ)51;@G030N&(ICIK6 M<530>CCY2H1THBI#*8F#."%*$JYKAP7Q35LH'N*EA>;^,(R?Q%A2!`"<$V:G M%P[JJ@VNH#630/*04,QH5Y,,F^`WS(5]:VMA#Z2,N\U%\HP$M=+ZS8:5O7?. M[J*S[5()64DL.?X#':0@5K8(.;RP@1<^4?=SY:.]39['//-F5[\AQL`\3.RS ML%NID'U[T[L"-8^C'6"V4@VI%\4B<^1.)9^I=W]X.%K7/1Q_J'3B'K'MUVT/ M!,LC!18/7(C8JL0K/%+DI5=)!Z8QAZ,CNL=+S%7SG#G`1*=S[;#7.$OZZ*7D M%5$GQ7ISCT7,"(V6[;,LD,2MUO55.D*XBGU#A<4BVW62`&Y`)UO9K1(]0Q\6[%-`\U0XABP4N= M%C+1,@DI)B1<4"]%D\LYE(,7Y('76\6#<.&=5J)(M#N*DP+;K\X==;+VG?R. M9'1%>B) M;_T5X2`?.C+0\E^4T]@-=6+A+Q9/-'DA"AI.KX3E.EIZF[B&UH4G"<\B,8_?_0>+M5)4R M[CS$(G%1GNR_54E18]$'!MUSL8+E`5!>2>V'5Z72N&)^"F6=X32D.Z/2^)4W M:,=L9-P'Z.2OBZ4I*60DC5F;!.4RN66\T//UXPV$S=5:`4*W5]+?2T6]P&A$ M^G45;PKO2;##53]ZDPGA@3%D1PY:;N,*B>\M=8T`;'PW+7`%36_V"L%$V1[I_`3TX=M28]WX'P#,Y;`5;B!:4>+4#=SQ^8^/1Q`W2H"CU_ M#87SBIWDU)K8@52D&<>@X:DXUF.Y1#*^J77$_*^+P>48#`"U_T`2 M`;N1]:GL[*?,17FNQFPSQ-A-N]6%IAJ-LQ=X6H[?4@R\/`2WGC<=64[,])C: MY7G(=Y'/3V*.-S@CJ9_W!P/G_N"!Y9.-LSRYVFQ1G7G-.U,JI*T+3>$NA<=W M9BF\8659@\+5-F)BIXJ^+'Q5@AOHD#1\=GFX(?=MI3#M9G)`]Q7G33W)ZU&R%$D#KCGL]A87@[D) M,:/WPX;6IS5:J878@M_*,C95=T=?BM'\ZA-TEI*`2I/'WX]JM_/_DG=FNW$E M-QA^E;YP$`\@]4BMQ58&&$#Q[I''AB7'%T$NM(VL0&XUU&YX_/;Y?I*UG*U; M.L/KL)J\5?!TB/\!26T\2SR;1-(;-4@@6(F8(EI;50J]HCMG()4P( M-]JJF.U91"&#P)PE02T&4`A`K9ISBX#!_+&=HH# MI^.D'=./@7JW2F@0&[,I]:;I3'7TK,E]4P"N\_4.#"?!05-F71,0%G&:`F$E M9*S?#SPPJ6NX&]4I;QOC7K&.Y#[\;\,=?0+91[D<%62[.=)HXZ85O9/..<5LDT!@UL7I M"PXL6T):H+-)7!FFA8=/IB<+;NK63@BI*3M^)K78X..OG$LEP-RS"-\J/BX3 M[BZ\1'13>;:[A4736U?"--C`>:+2**N"H=L[7A'N.V.AV(LELN5&AZF*BS!7H<@;;Q9_9I3>O4LN%%.C-?\8P_7_GDP*:LKPPY.GKEGZ0I[/QKO;JSHH6N>DN__W#$^:FGV+2, M7ZO6_395I?/Z4*V2D=2`.%V(Z\?#$+3Y.9CQ?1='+)!UQ)*2B+CKP`=S!HD' M'&H7S*B+D@F/3=V#1)6\Q0O:F3_?\YMBKGIM%9XGIOCE!0S+LHQ#Y5VI;K5! M/J%W]+V"^>B4NTU.K1'(TNB*34A\[LLE^9@&V9L1E#)F??7FH=L_K;SU77), M-ZGAGW0:A=?>WMW MLKTWWH3_X)WX%6C\&S*5*FD4,I-0"_$JD7ISLKDQV8./&^--)8:8Y`&E(X]Y MWP[QM45].1/`O\Y+S]E\^.[<>H7]5`^WM3&9[.R-)__EB=@3<>LTX6^GAGO&/:V!`@TTJ`15R45EQ7'ZDA0A.E&;HH($1?FJ_%!74/ MXH-;;4&]M?J0Y)MD<6*;22V`0'/)@JWD=^NJ:6K44@:5982R::8AF!_BWK?[ MSE5>0,>518M(BQ-HD0:7/ACP3)O(B98N9;:88:Q@GL1$%+=WK5*RQ:O/&]59 M)C$^&18S^G<`9>9X!'L?L9O:)3\:PB@,K#%"AT@UR/6S+H]UFD/3"S,71`Y8 M-6XBPT`6Q&)JZ%SR`ID9>+VJS9G'77F,9^=BK1)J+2VOKOK<=W<%!A4XST\+ M;%-/1^#3@GUF@1)(N;,^JM-[8AJNOF%IL&1D\$O3)W8>#:5U%"X./:&S MXYYSFV@*O>4=52_&.(`$#UXI^IMX3DFI<(4BKLS7Q*=\\B6&D2?,5UU0DD73 M-?R3Z)0Q<;HVP3@\.;+EVH2\0AZH)YD-*PWU6342?*R&@\VQC%_.-X?^\7NSH^*0R)5<877[I7ACM7?3_BV M?>#TQ1N_YT[0RVO"20Y>O3]:1X\)+UM7BGF=YM&X3_XA9QUG_JZ-NC-VK,EW M`T&+I[_3:0FL1.T63X]GW+9CSXFHVG^Z72^PLW.IQ"Q=#A2=9Q$U='.([^:> M?(0\7%T"=)HSI#N"`P3P,4T'>7B`62#LW`C'BKA8'-N4M)?PSMT^J6RN"Z6* MF6(YN3[C.C4G"`+"%[B@>.,V>NQ^V6ML,I`V5"$!%J$$/20RO>X>@>U>5`*6 MH,\Q-I$4SBE[0_>WV2G6#M2TK=;09+*H.MQ01YXTW#:F!*9DP;8G';=HW1WBRU2?I*7W!K(X2J?W'):@X;G76 M/'>9#MM/E)#!C*=B*589.*:Y+*B6-2%V*9I5(2H![:)I=^ M$,ERLC58'1X==2*^H)40X7)]T!$33P;)BW4,C>`Q,A4OSY.CSTRXEJ4,%1G7 MXL@\<4A0SPHF(VY!DEB1/D`J@!(&[7BZM.!!/GCOM$-"P=N6:FX_REXF1K;6 M)G9<@VQ>!#<0H:\$[.W0..#_D!J\6IF(L7V0:M880W$K!DB,QQ5[9K];^$EH M5])EKDBTG,MI,9NT5N?06IF8HL?Z=)^?G4CL^91!?]N!92CS==KD9?Z-5;A\ MZ"`R^3@AGXM]U-X:QE;-!RNS.FEI!&[7*(!:91A1:)4[I@I44XCA_"LZ3U3[ MEHMZLAA4I5TL6$S-FHB^9T*4K/$=LPM8#&G0VA-99)T133C4.^,:$>`_G.% MB7&QVQIN^,DEQ>^*(5#J%P6PU%?WB[T**W"U`&D4OB"[;ETR$5WS/@LGS,QQ M,7G-V3S[-'IQG+C9U6P/7;37^>C)UR8^&-$W41`+)'XK5>>5X)$ M9*RIQY[,8LX7_]8%)#%;'H,"@PMAML*E[@/H:A>BRHY!CA7-]:[E)!Y'`0*F MQ%FGG*A]B;N.`;'ZY'JJK-Y6ZC^@4.Y[9-BN)HV8S^%P19EC=2#B8U]Q"CV MG1/$7."0Y!]7Q"(B*$K+AL?VM>#K[E_R._E!EBG,Q^]!\Q8J<\$%L6_Y2=2( M+"/^5[9==ZG;P\QLTHJ/G,E7M5O!]JF*1&RN:+1M6T!"KE_SY6G0,[!Q6?') M>^#(\4QRA#V*=>A;\7N9IXUY-]X-3P%1;10'8F,V)6P5[Z68 MS!/1EAH>Y\&VEYKY?Y0$)#_E-:/#NIK,59>Z(=O^E.&C6Y-G@!ANI?\&2O=M M]!;CYN_XS?9[T+\>S%9S488'9Q]11XDLL`R2-3#XY$1SR?KID]>L* M?N*F:M'>5H>*_:VS$BU9#J,X$/QYIU?2`"GQ&>-2#9FY:*!TGCIC0#"=`WCYHNL-$+73\2F]2L/J-,W6:P17#FQ/LTGZ!G5F573^4 MQ:P4;7BP#R*V0.2Q+=ZI<;2@IH?I7]WRYM%VX"V6Y8J/I&^TIR*6"8:S4T?# M+J;'"RHCF5"A"BX_@]4K)5,9G[K*YMUF4&BH'=-H""1BZT+8!O3T=RR'DYJ/ M$&N=C\!O2>67#N9WOR",`&N??""UE"^9R)K!'-"!@9@O]O<=Q$Q^X4U&%`.Q MDT^7-/:'\2%4+LU<]-*S5'@/I2MID9TFH//PV1,!JC@\B&PH2,F762D-"E#4 M(^5@N;8LQ*E^:NOC9`[+8.<80F-'6IC6G,A=OE21&>+.V95.73T=QX4A-,NW M.WQ3?Y_ZH$EK9MF!Y.&AZ@`UN$*?A]YV//1K$#>N7@%KJ<4=?P8^7E##LM=36T!W-7,[NCB/,F3H_K%-+)]QB:;.AEM*+55/ M%EQY!Z0%5S&UR2;]=]QS:)!*1M@MB)QRYOB,(JV!K<0&ZN6HY'`J#26!IRO6 M-78'=R7TAT\`0)9KO5+8-CXAB=.%BZI>W2>R^$W!3_3I\[PQGR0XTACYWFI? MVR-O@7[-'\%&ED2+QU[(P_G<(:=]`#9N=M3O]@_H:#5Z>&2=@?/R`<;&S+#;M`$=N[])YJ[^=2YP#G1-CN"C\ MX'K%543FDFA=743^%JO0H9_?+)7$VTN`@=VS?7`ZW4-^-3D;IWE[^#N><$^Y M2X013C2=]N"R:'\:/=2]_@<=0=FGV?275)\X'.KVX-*19'`!J5%S=::=U'Z" MG#R,28\?I-!U^YD?(^^Q,M;S46O#P%JSB@7=E:7?%3#(<@J\?.F![6A-V)YE M?LO-HL&?(55?.YO\>K)M.DUL\A/UM%`>AO$!(@(%M0<%?+1F3AAEI#2/>K^P M?MQGWJ'"T`NW)\H;KAE08Z%-JS?'?_;]]S*5&PO"U10+$ED11;X[E MX"2;[0%7-\@Y2(&F*"B)LAGS1:6H.SM!_WMGEF^SED@NS976:(2<14H[\\PS ML[.SRQ5Y^?V3[VF?G6CKAL%4[YUW=ZG^D]WUME8U[:Q':QL+PR< MJ?[L;/7OK[[ZP^4V?O:<3P^.$VL@(MA.]8;LV7H;^S87;B> M&S\S6;KF+R\^W`=A9"\\@/K4,^UE)IL=[(GWW644;L-U?`[B.N%Z[2Z=?923 MSJ0#DJXN@YUO^?%66X:[()[J1GY*2S[YL)KJ0UU+3)Z'*P#QY__LPOB[/R9_ MWGW[[EWWW]]\]\\?G=6_?OEZ_[-?OM$[F1HB$WQ0+?.\6RD6/DXD=U(+KB[7 M84`,&0%-R-;%8Q!^"2S\#((!S,.O75UN?],^VQZB%D1:#E\$^=B:P M?2?YQMSVW$7DXM?6MN]ZS\EI`T^PP$B_Y[O@)CS9232<5L\"T60VC1$&9U,? MSU";?##)QI/5-MF_'K")TS6HU]6&/TX7LZ+:+FFZ]N-BC\,VNG)?$3W1_6*J M6Q;DD%ZWB[12AQU)V63>!7TG4S82RZ$+7K>C?(PM?IXB3$P]H1_'8_EC&>EZ1&N]< MW]EJM\X7[3-I9[&^A4[B>E]?Y_0%6PG#F MZA*F'+$3!18<:.G[N^<-U,$!S(ZP-W62[]5\^SZRGWL&JP;%&FQ#SUTABOLY MJ[Y3,N?#&VM^P_029*(H2H1:UGQT!*$WL\E3R63<&X['XXG9[YDF(WF11K0;K)PG!R?0 MTFC:1S``!)/^>#(T`$C7'#-5)T70!P"CP6`\Z$T,$_YG(\3Q$ZK!($BKQ($BKPZDIR!87%/L5<)`D5>)0@4 M>955PA+[*JP)*_8J0:#(JP2!(J]**S[3##Q1[E6"0)%7"8)3>S6;5LUO;BRV MZ+1?F4FKCU-=6,0WU\5FC3!/7831"B[>95>D8)T@.W=UZ3GK&&:DD7O_@'_C M<`/_+L(XADM=5YOS@+A]!&;+UU@>CZ`Y`7?W-=?!P,4)0T) M'I+AT_2$:[?)]1_A;%=J;:5T8C,(.#18I:,6#()+Q_,^X;#TCW4^$L+BTM7E MTYILHH"=+;C+`/=HX%M8P4W?)J-?<@"ZRAH9I8TT>[/QGF]W_L*)++;=A:E@ M9W&EN#B:L>&Z.'[ON?>![[#E,3T1\T,4QLXR9MMQV,IV&9Y^"9Y>*D@$3QO] M9HE^X$F8CS;Z8?GEH!.!%Z7Z(;B$]F0A@DITA`">H M0(`;I5(.(#Q5((#)2X8``K1``'`JHJ)-/X#K7[E*B(%")>@_EDK(,9F5G,HC M6EF6?D%_A946EWY;T4SR+01Z03,<5`!HI;(LQ:I*,<3MT-,*"N"@@@(+1ETY M0UZO+.5%)0H,!4I!H"P%$"@3@" M5F'48U`T`M-H4#0$4PC<&'S"/D&C@1LA%6$`/$IZ15$G]+@1XX0T$`BJ,B2) M!D-5BJ085.7(PA6&JA1)(*C*D-03JE(DQ:`J1Q)7J$J1!`(PHB1#4D^H2I$4 M@ZH<6;BBKRI%$@BJ,B3Q1/_(*;)#ETV3152R?CH#W MK'DR>TIFCN`+-I'$4RH=M.TL74!OUYJPV:4*9=!\J54[]Q39D-,QL MI"OW7T[?J]QEL07W6F?5FL[?3N"V]K".\78V"3,2Y=+WLSJ!`U^KK2!.P7*63]IQ!=9'N#0P$'5 M[+&TEJ`!]9K1HI0>&8#R^J)%Y0RWH,E'%"7)JV0:5(-%9!XD..Q0%[\BI7$$ M'F$:WB3\C6->5\VCK0DBZ?%?A/J;ZXZO"!Y*SS%**GELU?3'5Q5\\M!)R?4% MG,87['$S6U:7'\./K\E1)+$V@/>&$BOA5(I_F^2M-S/1XBQ74E/1X.'0P$'K MFNI5@\I1$54-*VS#%&R1(C\XY7]NFF^HTO"&FW!_\.Z?M#/M_1*%YO4P%O6+ MG>O!S5MPIQ1N=EO"5?[0GR4GT^U)5;*@:R348YQ263"G:BH+)*2R<`,DP06U M=%-9H#Z1U0=KB2SX+6YC65"8IK)P>VJ!RX0BIRDN:)+*XKD?"')O'O(CV\A= MX$*317!1684?<3),9(')3645?@3'45E@H+`BW MIK)R/YJ8B0J^!H+<#P_ZD8]5W'4I@HO**OS(QVI?,%:IK,*/?*RBR4UQ%7X$ MJ80O$SYH*JOP(Y\G3,$\06TL_,AS/Q#D_F5&Y2/>$(SX1$KA.WA'.,(Z3H2C M1$KA-3[*^X)1GD@I_,7'MRD8WXF4PE,@CUADP@?B%N4^ZO/LFH+LSNQ5EG7Y M@#$$*8%[,B]W'CSA(\3G@[!=Q5@`$8.P$!`Q:/[@+!^U.=PD(A?$]P<<1D4$ MW3QM/#NPXS!ZUG`G<2Z.=_I`4-Q?PC#GB)>`,WD10'^%IZG`@UHTX"5AB(]A MW$7:1$S>%WAZ>H(>R]!`ZP0-'W\XVVV"!EHG8OBDBO63B)@/P6:7>XC/I3AT MBXCXZ`:/SHJ/')YA`T"*2+IU=G%DY_''=RE#D)A;O+5(+H-/$]Q;B+%[9%A-RY,=P'*>O$/`Z`)20B MA-W]N8@7&450QL]V%&!OX;KNBQ@ML:CXK014_ZNGXC8SC/<8GS?$;D"3SP>` MWI6SMG=>?)=_.-6+]W]C=QB#8$J_]8/[.8R9B*E>O/^(MVZ#7@QWI8%T\W$+ MMP.#O]HNST>3ZQC+.QMW9^,SL.X.SR6!V?38PY[/K:VO2-;KS_P)E M^'"F"WBZ3XN''[&'-,&O)7KFQ=:#1R1%J;$I^$_%N:E.#A+X['Y-`!MN9)09 MT=GF#X^Z^A\```#__P,`4$L#!!0`!@`(````(0"%$'+]N0,``)H-```8```` M>&PO=V]R:W-H965T&ULE)?1CMHX%(;O5]IWB'Q?@@.$#B)4 MDXQFM]*N5'6W[;5)#%B3Q%G;##-OO\=Q"+8#;;@!DOSYS^=S?&RS_O16E<$K M%9+Q.D%X,D4!K7->L'J?H&__/G_XB`*I2%V0DM]4HD^;WW];G[AXD0=* M50`.M4S00:EF%88R/]"*R`EO:`U/=EQ41,&EV(>R$904[4M5&4;3:1Q6A-7( M.*S$&`^^V[&@1KS(6-%>T M@,JA0%=DR_F+?O4SW)I"$-D*=!#YWSG,8Z2CA'T8^_;*E4STQ;HB`_2L6K'T:$.RMC$G4F\'TRSZ/[36:="7QW)C@: M2Q*:4;4)>R**;-:"GP*8KL`M&Z(G/UZ!\?6L0#JT]E&+$[2$NB5(0FE>-]-U M^`K)SSM%:A3PV2NPJ\C."ET_8.A!(#7C0;18@^AR:;+4W+#C1E[)V&8IGRUDV7N_8-?6KS^;S@::>Q M^2*_G:]H+C8NWUV[!QQ]!WR#/AYN#M&@CX<:G\^M,?$+5=P MO&U_'N`_$(5CUW0"XAWGZGRA#W7]OZK-_P```/__`P!02P,$%``&``@````A M`&UUH'J!!@``(Q\``!D```!X;"]W;W)K&ULE%G; MCJ,X$'U?:?\!\3XAYI*;DHQZ=M2[(^U*J]5>GFE"$M0A1$!WS_S]ELL&4[83 MS$NK4QS7Q<=U;/#V\_?RXKWG=5-4UYW/9G/?RZ]9=2BNIYW_S]_/GU:^U[3I M]9!>JFN^\W_DC?]Y__-/VX^J?FW.>=YZX.':[/QSV]XV0=!DY[Q,FUEURZ_P MY%C59=K"S_H4-+O=7'XO;CF,-O`$V?@I:I>.?3;@9M@<&",?D8& M_JR]0WY,WR[M7]7';WEQ.K=`=P(5\<(VAQ]?\R:#&04WLS#AGK+J`@G`7Z\L M^-*`&4F_[_P0`A>']KSSH\4L6\`WHYI;RU<,VX+C+27CHL[R7)&3'G3QQ+SM_Z7L0OX&9?=]' M;+D-WF$V,HGY(C#PM\>P'A%`-GU*D,8P)?OT=)$YF$?FT\53^2(,PS"A/4Q$ MP_#*(^#T<3@^"'"#(B*VZOV+#`0F'F"2'D$*!8A[H1P,)$%Y:OZ2=>]8A!8@ MA]"P8-Q##Z(QF)HIME`-)E:A1#DL0\9%P7DV$4U+E:9DV)'#A`AUO'DF M1)-*$BIM00>0@,D>XTT_*(33MUS/1LG#<5I)0C_X)/:KD2VBOM-I2;SC!W$? M+T0OU!2%+\FUBXSB0"T*]P4FVHEJNZ7(7]JRQ&= M*%$._(6:_CSF#]%:K5)U*'\J(5HK5XA!WX]$XV@MFC19^+-("EO#;(W$,!6% M'P1X6"A,Z>AR;N^^<)*B(!HK&KI6.ZQD3^B."WN:Z(S4:BI-*$V$O:5*B+(W M26G"7FGZTU]GLK"GR0B>8N;C[)EZ$DH3Z;VE.FF0BOBYW7T](MI@3VVP@CV) MBR-24SD0)O'-ZB29I"J(-`M5A07:@\^DETF1GA$!3;=`!)$0)5`D1 M`N-):H-HVAJ=R20PUJ2$$QC.(X>76ARIA>'.P$0E],[Q)9XD*XC&:,,-4)T6 M!($2Y="!L:8\CPE$M%:K5!M*H$J($CA);6*.UJ))DX5`34JP`\>/+[&I*9V) MM-_JSO$EGJ0IB-8JDC(3X1?,X6>6V*(I"=A&*#+U!!U!5%K0G3-*/$E/$(T% M#9;C2AT6Y')TUI-8TQ/.HLO;/([3)E:*#:WZSMZ>3%(61--HGD()B7*05CXAR'W@P6BM5JY`S`185FIA(BP M)).$!=%:M+O"DMB$Q>ELAB.U,%)NR,ZPNK/=)9.T!=$8;=B*2H@E@4)N7`C4 MY.>Q['!ATK2Z,U$"54*4P$FRDPA!@<]I_>&Z,YD[0V+1%#;^:H3#-/:DI!#V MUG=VAL4D24$TC=:9S(K@KHST%E?)A72>%GUQJ_-X.OF?MN;Y9U>$FZ>H`.`(./)8O,DKOOT)R$\@?=/RYAHOGF" M=QW;DQB>X#64[BU:;9[@=&89$T-NL"O:GL`8$%[+$P:IV>P0WIHQ@XQAR[5Y M@B'PA=+V!*+#YS#+DQ`R%G>305\F7%'>TE/^1UJ?BFOC7?(C<"&^N-7BDE/\ M:*L;<`07E54+EY/X[QDNHW.XM)OSSZO'JFJ['Q`ZZ*^W]_\#``#__P,`4$L# M!!0`!@`(````(0`#ML$G!@,``&8)```9````>&PO=V]R:W-H965T;&L]G.'L+KE:WKZ4!7GF2@M9K6CH!93P*I&IJ'8K^NOGP\V, M$FU8E;)"5GQ%7[FFM^N/'Y8'J9YTSKDAP%#I%^KY.%'03#Q2R8JZA@6:@B'S#*1\'N9[$M>&4>B>,$,[%_G MHM9'MC(90E>[/?6!:+U,!#C#M1/%L13?AXBX<47^]M`GZ+?A!=WX3 MG04:#QHC$R);*`#<`G*06V!F2$O=CO@TA-OJ+QR(MFXW`\ M`3S9!')2DNRUD>4?APH;+L<2-2SP?629>.-I$(?727RW(VOPGAFV7BIY M(-`U(*EKACT8+H#XLB.P@M@-@E=T2@GL54,9GM=Q$"_]9TA=TF#N'`8^6TS8 M(GP0;95!;;@R@E$9PGA5OL/,W997^(8ZMN97K83XGGOY/!]/Q9]HM9<&!<YQ8$5SC;;2=IIL(C_YI?+38N"GKM__` ME*O9CG]C:B`6?@3:%&RLU)]V!D#2F"42<-C#?[,X?W&0Y7>8`%S:0T MQP=0]MLWI/5?````__\#`%!+`P04``8`"````"$`[\.WE.<%``"F'0``&``` M`'AL+W=O3PC77)3D M:+>K;8_42E75RS-+G`1MP!&PMV_?\6`('N,$OZPVDS\S'H_G9Q-OOG\69^>= M577.RZWKS^:NP\J,[_/RN'7_^?OYV])UZB8M]^F9EVSK?K':_;[[^:?-!Z]> MZQ-CC0,>RGKKGIKFLO:\.CNQ(JUG_,)*^.;`JR)MX&-U].I+Q=(]/E2L2>>O16L;%HG%3NG#8R_/N67NO-69%/<%6GU^G;Y MEO'B`BY>\G/>?*%3URFR]8]CR:OTY0QY?_I1FG6^\8/FOLBSBM?\T,S`G=<. M5,]YY:T\\+3;['/(0$R[4['#UGWPUX])Y'J[#4[0OSG[J`?_._6)?_Q:Y?O? M\Y+!;$.=1`5>.'\5TA][88*'/>WI9ZS`GY6S9X?T[=S\Q3]^8_GQU$"Y8\A( M)+;>?SVQ.H,9!3>S(!:>,GZ&`KZDHK5XZ_!<3>F MUD,_2M,@873"R8/PLG47K@/Q:YC9]YT?+S;>.\Q&)C6/K0;^7C6]PH/1]$." M80R'-#X]760A%I'%=(FA/+:&89A@/$QH$T:(8;Z'@X^7O=\V'R@%4V3$&LV"!:BI8Q=%*W5,2#:@QI@4Z^SFTR'T]'4'C0*+=7I1"KH:1% M3V>E^L4&7,YGB[OIB`?5&-*BIN./I^.#:GH^J%:#=28](U]T^N2I0C5Q+1R` M25EFB:&-16=81)-X"*[`0`<0;201@@A1F\5J=KBDZ$PC.1%2W"Y.H/.A,ZG% M,>RL@14?4$VFK><#($.=HQ$8^"N8BCL9Z2P0^[$H#>1ZW5P7ALTUL&(!JDE& M1A8$A`5W$M$!@`X@FE*:A6%;#:P`@&J2B/&@$!``X$EA?K\T.@G0$X15MH>% M87\-K4B`:C6CSJ1W34A(<+LTJ":N9?NKI3'LJJ%5^Z.:1)-$&$F$M/_T0URH MHZ`SJ8UCV+Q#*Q2@FB1E1$%(4'"G.CH!T`%$4ZMC.`V$5@1`-4G$2("0$`"K M$T]Y8\`G21@)"+4ZAN-`:$4#5)-H1AJ$A`9WJJ-#`!UHU3$3GB?PR=)&`D$E6R&\T!D!014DVA&($0$"+>K@VKB6G)![1W# M>2"R@@"J230)@?:GHN'+=D0@@+US_SR`CY$88^>!I>$\$%G1`-4DFJ1!B#]^ M*1F-T"`&VYT2R;8?O-)%8R18&LX%D14)4$T2DB0828B0`!MHPOM;I#.A,\%R MN)[9EH:#06S%!%2K*74F/:5XA`E37KSQ.1)$$D'A]=)P1(BMB(!J$DT2820E M0@1LI"FOI+$DP6#E=28U)\,)(;:"`ZI)3A(.:C3#-AX37MSN*E23:!(3ZA(T M[*^Q%2903:(9,2&00-]2_4F_R^&3),PH*@Q[;6R%"E23:#TJAEULV`1C0H\[ M!=.9@0Y@`&K!##M58L4,5*NY=2:]P9(19OCW7X_P,1)C#!DKPTZ56"$#U22: M$1G)"#*2*<=6?)!$D111FGAEV*S@$DQ9^[?7!*I)-(F,P6FOO15KKYX*5AW9 M+^Q\KIV,OXD;KP#NC'IK?QOW@,RC]FC]T-[2>?TW<$MV28_LC[0ZYF7MG-D! M?+8_*57M/5O[H>$7&"C&PO=V]R:W-H M965T&ULE%;;;J,P$'U?:?_!\GO#)2%M44B5;M7=2EMIM=K+ MLP,&K`)&MM.T?[\S&"B$I,V^1#`M"8ZE_NO2B3?1<6AVM`G[,!6RB>$/B08@L7.9/5]TX$?BB0\9;O" M_)3[;UQDN8%V!^`(C87)ZQW7,504:&9^@$RQ+"`!^"6EP*T!%6$O$?5!6"0F MC^A\.0LNW;D'<++EVMP+I*0DWFDCR[\6Y#5)6:XFM3MFV'JEY)Y`OP&M:X:[ MQPN!N,O),O19GDH2LD.2#;)$])(2T-=0V>>U%[@KYQFJ$;>86XN!WS=,CW`@ MFSXE2&.8TO'R=,H(1F4L%Z9R:P-#&?^XS'PL@\X7)[O1R>$BJ/O01.#U_#8# MBUD,,$&/&!D%R/E&$0Q-`GMO]9O4V(+.D`:C0VDT[WN+V8?^<5V315_O-@*G M89#7B9(OQZKO=Q;!8ZDV8D_9<,?`QINX\8/9Y8=V<.%8HXV,[\[:1X1'P@L5Q"QX8/=]#@QZ+=:&I"P\/_*`\N,?F M2_>,KC0K#V20#$+COIPX5WA(#I675SA43\S:[G0W"P^$VWDR%EX>5-/.?#M8 M2ZXR_H47A2:QW.$\]V$B]M'^KMDT5\UA?!%N(`N\1OHO<`?4+../3&6BTJ3@ M*7#:.BI[B]@7(VO('6X":6#Z-X\YW/8F[YPB^*,!D:SN]*NM%KMY9E@;*,Q MQ@(RF?G[K:;:T%W8#$X>DM@^%*=/70[N?OKPK3HZ7XNF+>O3QF4KSW6*4UYO MR]-^X_[S]^>'R'7:+CMMLV-]*C;N]Z)U/SS__-/36]U\:0]%T3D0X=1NW$/7 MG1_7ZS8_%%76KNIS<8)/=G5391V\;/;K]MP4V;:_J#JNN><%ZRHK3RY&>&R6 MQ*AWNS(O/M7Y:U6<.@S2%,>L`_[MH3RWEVA5OB15V=(<1+>2R[ M[WU0UZGRQ]_VI[K)7HZP[F],9ODE=O]B$KXJ\Z9NZUVW@G!K)#I=<[R.UQ#I M^6E;P@J4[$Y3[#;N1_:8BMA=/S_U`OU;%F^M\;_3'NJW7YIR^WMY*D!MR)/* MP$M=?U'0W[;J+;AX/;GZ MGYKZS8'2`^+M.5.%S!XA\D4>7,P@V"V]0"@5Y*.*LG%#UP$I6DCRUV?&HJ?U M5TA,KC')%8R-2"\(E4^@-W`$V4R.UU-WH:+`BHI*I>*6X!L0>^#&R7VGB)`- M$(L)*&0R46H)*,EY1NHBP!D$&(N'^$@2,=+`^#8BG4-8'"&(R7&>FP)O7!!@ M$"'P][F-R8& M&Y8A2.OG>_`SC`R=V\6>P6`)=]!3:%I\XS#5]!"$]!AT"`MHX_9WW;A+Y%.S MVY!O89/@Q`<5!E-@QGS0/!%TG836<0YBE^%=WL&FYB$G56@Z`^=A$)$^2G44 M+33WH^8G\L,Q[U=@Y-G.@3AO1]$Z'N3%C$1/`R-(K7)W64:;.H: MDE17HC'(34CAQ81]:B$B>)0>&\CF1LQC8?5-781Q8A(),UWB04H_8&R28`LC M/%\:;F01Y>_RDOXJ\G@@1BFP331HKDUF(3;/N\R$3\V$"2)2HD&Z$J4P@`5I>(,;+6#D&:&PL\7Y`Z2'6Q]&ABT&)T!5V5IK/X:C^#]'RJ MP^`*..-!-")L%>]R%G[%603QC42#\-XRCCV/='QJ(8"\O&4M_"YKZ=%4.^(< MB09=VL!73U\TMVA1`\1$V.*]RUWX%7>A4R71("VBVBEBI)M2&R(C[U:.U3Z' MV='S<[%'$Q4ED2C1H(M$,!8C4J2I!6&2^?ZX`$M%<9>E]&A*CQ18HD%(#[8] MO)BT>*H1^,64C6/?9J:FOS&P?R`<>H4UJ">/-@)!R(Q[\%1%Y[2%4+H%H[(V MNW?9B4`;@-_CD[4DTRW1H+E!/0NQ>:J1OEQ%-`!;Q;%R<`"*J4M,]HSF,3;# M*U;RXZT9@19@*TGJ+-&@62476XD@5K+L`:*_BG;,6%-:4;04W"OD(;LR%G4< M1JKY^\G\"Q4G\&LQX^@%.=<[8O_LB:?7EJG6.Q M@Y#>*H3&:?!<"%]T];D_%GFI.SC/Z?\]P/E=`6<)W@K`N[KN+B_42<5P(OC\ M/P```/__`P!02P,$%``&``@````A`.9:[YS%!@``%R(``!@```!X;"]W;W)K M%MJB;K+S+CN6YWRC_EUO#_DIJU?E)3_#D7U9G;(&/E9OZ_I2Y=FN;70ZK@U==]:G MK#AK&.&I>B1&N=\7VSPJM^^G_-Q@D"H_9@WTOSX4E[J+=MH^$NZ455_?+\MM M>;I`B-?B6#0_VJ#:XK1]^O)V+JOL]0C7_9U9V;:+W7X8A3\5VZJLRWVS@G!K M[.CXFOVUOX9(+\^[`JZ`:U]4^7ZC?69/J6%KZY?G5M"_1?Y1#_Y>U(?R(ZV* MW>_%.0?;,$Y\!%[+\BM'O^SX?T'C]:AUTH[`G]5BE^^S]V/S5_GQ6UZ\'1H8 M;ANNB%_8T^Y'E-=;,`IA5MB-;7F$#L#KXE3PU``CV??V_:/8-8>-9CHKV]5- M!OCB-:^;I.`AM<7VO6[*TW\(,=ZI/H@A@L"[",*LE>'9S'9F1#%%%'@740SK MX2X`V5X'O'==<%>68;O>G`N!2VZCP'L7Q5ZY3/=-]W$;C@@"[UT0?\4L?8X+ M5\2`]RX&>W18UCC$;<9$69.]/%?EQP*F(0QB?N#2=;3$`D8S;OY MI"1B)9$HB72*D%3!O6^^*MY(5L7HS`J0Z5V192P<'G:9X3F,KE%(3*B,E42B M)%*Y'Z;.G.M]01+%OR3,+AAX(RKJ&A\7*62$*-TPO/$JA.!4%)"X&%XNT/N@(":\1FHD5B.)&DDG$5D9+UOG M*\-B%U[[FQG3R2H=,(2P<##'OO`P&C5<9KD4B40$1);`\#I-GM9Q?Y9K5TA' M$C62WD#N3DE>N\XWAA6O;(S<^0*&T%22317.;:9&(LA$'L9J)%$CZ20B)QET MYB>4\59T7I(%)&`(W4TR/"R2S+;\&TG61;B;0'%_DKM(HD92@71]D;]SR+YX M+3L_Q;`"EE.,%O/\H1=(Q4[`O6LTH4)!@)5^;I,)%:F16(TD:B2=1&1EO*R= MKPR+85D9+>U95S'S;Q:CVWTH#J-1U_)]ND1%?8"[1F,UDJB15.[*5(+QVG:^ M+:R()5N,K,C)X,"F1`2J9%8C21J))U$9&<_5?$; M^&Q;SC,RIP(!79W)4RJ4CL.35L_3R9TC$LB$TUB-)&HD)7WQ36NP^R`+@XL> M3LSI+Y0&IVERD=D6"&CB*D,U$@E$Z&[WHV3AL3I(HD;2J?/(IDB=KS`UKN^] MD2AE\1X:2B12([$:202"NI>V;S+3]LD42!60K`O&?YA8#ZY>O!5-,/JUB.]O M`H0;0;`].-X(&@*&:SB.9UODOA%)4>";I.>99(!B"5D:L%D$&TI$2D(@$SKD M&+0,2B6*N?#P4->O/9+-D6I?D6@WJGSZ6"7@V\E]E=\:\QRR.(6"`75WZWPU M$JN11(WPK7_>W]M]05FXM8\;M9?L+?\CJ]Z*<[TXYGOHO[[B.\\5;NSCAZ:\ MM!NRKV4#&_+MGP?X`48.N[7Z"N!]63;=!_[3@?XG'2__`P``__\#`%!+`P04 M``8`"````"$`MJ8ZRBD$``#*#0``&0```'AL+W=OZ)U*M+=\BUQ;#TZ7_4.*V!XE#W=3TE8O:5EM&7TX='HI#`[Y? MW*`HI39_,.3;NAPPP4>Z`#E'!&IZ?G`>'%#:;:L:'+"T6P,ZQO;>C7+7LYW= MEB?H9XVN1/G=(F=\_334U5]UAR#;4"=6@0/&3XSZI6(0+':,U3FOP-?!JM"Q MN#3T&[Y^1O7I3*'<(3ABQJ+J-46DA(R"S,(+F5*)&P@`/JVV9D<#,E*\\.]K M7=%S;'OK1;A>^B[0K0,B-*^9I&V5%T)Q^X\@N:.4$/%&$?@>17QWX6U"-US] MA@KLQT.![U%E]=9('.&*)RDM:+';#OAJPH2[ER$E,CJLS'B6#%8')IG,@FP.Y`CC@ M:+(%B7X'6TR%V9(!)1*X^?1F'B1#+DGG0#8'<@70//COXH&IQ#9\*J69)3X9 M.2HIG/F:*),Q`\D,)%<1S5OP+MZ8"AQ<2*!B;G[N!,F'4";2W-Q$F\B,K(8J5HTG-`C:AIBE?C"ADHHXFX[P6+B3=<1 M-`PXT'-\$\$+:>(P(>]YF#-^PB;G._S$BV"F,'42/X(+V<3W0;07.9UO$$1P MR9D+DC""F^0.OHJ@@P/N3$(P2??%"?U=#*>Z(U:#CI"4)6]W@YC%Q0,=V]X! M4YBA(6\PBL+_3`BFP.4"NOP18RH?V`;3?V&[?P$``/__`P!02P,$%``&``@` M```A`$@V"*`5`P``W`D``!@```!X;"]W;W)K=>VS?+F^>J1$],*B[J!/O>!"-6IR+C]3;!OW[>7UUCI#2M,UJ* MFB7XA2E\L_KX8;D7\E$5C&D$#+5*<*%U$Q.BTH)55'FB837\D@M940VOR'-#UPVY?>4U M@VI#GTP'-D(\&NA#9D*PF)RMOK<=^"Y1QG*Z*_4/L?_"^+;0T.X9.#+&XNSE MCJD4*@HT7F#32$4)"<`35=QL#:@(?;:?>Y[I(L%!Z(7!;''M`QYMF-+WW'!B ME.Z4%M4?A_)-5AU+T++`9\LRG7NSQ60Z@H2XC*S!.ZKI:BG%'L&N`4G54+,' M_1B(+SN")`QV;<`)7F`$N2IHP]/*CX(E>8+2I2WFUF'@><1T"`*BG3*HC5!Z3CZ9=^D[98<(>9M8A!LH`&6_0@*$' M8*LG?;3DI!UHA#1LJKZTW:\A].WM]II5-H>NRFT$#DPOJ_"RW?E0\VTI`QY* MM1%W$/O[!-+^#R]FU5"@C0R]O-(ZHB&OZ4LT\190YK?+ M9=8-)=K(T,W\,73NZX/ MKE_Q]*X;P^^NC*-:&YK::=8_1&9: MG?9I$7G_W'AVW4F;+EX*T8DE-TO=J*F8W+)/K"P52L7.S,D`AD<7[6;XVA;N M-![&:S?;2?<+S-:&;MDW*K>\5JAD.7"Z&ULE%5=;YLP%'V?M/]@ M^;TX$-*T**1*5W6KM$G3M(]GQUS`*L;(=IKVW^\:$TK:;LM>(#;'Y]R/XYO5 MU:-JR`,8*W6;TSB:40*MT(5LJYS^^'Y[=D&)=;PM>*-;R.D36'JU?O]NM=?F MWM8`CB!#:W-:.]=EC%E1@^(VTAVT^*741G&'2U,QVQG@17](-2R9SSMY#>QM=Y_-++X+%O`8F.;?`.V6M][Z%WAM_`P M>W7ZMF_`5T,**/FN<=_T_A/(JG;8[04FY//*BJ<;L`(+BC11LO!,0C<8`#Z) MDMX96!#^V+_WLG!U3I,X2I/%\B)&/-F"=;?20L!!1G^`-=WR],GI/T#0H:3ON+1AG2/QV1IB*QVX\.*=+2C!6 MBUUX6"=ILF(/6#HQ8*X#!I\C)AX1#$5'950[7=F#O;*OK0_E.FQ,99X#.9*9 M_X^,!^<4GV/P23H?PP_*`9-.,(L1<:2,D-,3]&#L`:8UD7Y.*4@'T`G2:*JI MM/=KDD1_=.RAO_Y8'\18YF'GJ,YI^G:^Y\>B?[>2!Q]+#3OA)DZ-@GY[F4R\ MN/`W[1]V]0>/-88='`"3*K]L7Q@#X98H,!5\@*:Q1.B=O^()^G[<':?/)O'6 M?+F?9IO>LFS\@%.AXQ5\X::2K24-E$@YBY:8BPES)2R<[C!R'`W:X3CH?]8X M_@&M/_-]++5VAP4*L_$/9?T;``#__P,`4$L#!!0`!@`(````(0`389P`WP(` M`$D(```9````>&PO=V]R:W-H965TU[#`*L"BW76<_'UG6(S`=A/Z8IGQV7/FS,P. M7M^^U!5YYDH+V234=SQ*>)/*3#1%0G_]?+A:4:(-:S)6R88G])5K>KOY^&%] MD.I)EYP;`@R-3FAI3!N[KDY+7C/MR)8W\$LN5-Z- M6S/14,L0JSD<,L]%RN]ENJ]Y8RR)XA4SD+\N1:N/;'4ZAZYFZFG?7J6R;H%B M)RIA7CM22NHT?BP:J=BN`M\O_C5+C]S=PQE]+5(EMT*T?W_D!=3?KKD"_!3_HT7>B2WGXK$3V530W?S/[P(GO+VD;&!((HN5P^F;;X%!$^E^LBY!=RJH\&WEW&%-^^=V<"# M4XT^,AZ7T/,NVXFFLF^/(8*G4GWDW(X/,WWJ)PB<=]UTYZ8:Q]"X/:'WCUOL MXWT?U?%M0QWZ1*U?&!59JDLX-^8*D2C2<5S MX/2<)31(V5>!?3"RA41AG4L#*[S[6L(KF\/.\[";N93F^(`OF^%/P.8O```` M__\#`%!+`P04``8`"````"$``C7AL/X'``#$)P``&0```'AL+W=OCD3>??RVWPV^YE5=E(?[(!R. M@T%^6)7KXO!R'_SS]^W*0WX??,_KX./#SS_=O975EWJ;Y\T` M$0[U?;!MFN-B-*I7VWR?UCQ]6 MY?Z($,_%KFB^JZ#!8+]:_/9R**OL>8?G_A8FV>H46_WAA=\7JZJLRTTS1+B1 M3M1_YOEH/D*DA[MU@2<@V`=5OKD/'L/%,IT%HX<[!="_1?Y66_\?U-OR[9>J M6/]>''*@C7FB&7@NRR]D^MN:1'`>>=Z?U0S\60W6^29[W35_E6^_YL7+ML%T MIW@B>K#%^ONGO%X!48091BE%6I4[)(!_!_N"2@.(9-_4[UNQ;K;W01P/9VF: M3&93A'G.Z^9S03&#P>JU;LK]?]HJ-+%TE,A$P>\IRC")TNDLQ*"7'&/CB-^3 MXV283L>Q8_;BPI#GPN-R'G$FA;F\*$3_U92@Q[<:*R9I-A-EB)C[G?0T`]H\&6F1F]Z4]R^R5;?%N^D1S;'TK@)/TZ.3G1:Q[/B62KP% M7F56W6;C9L>HEL"[*CN?=",M8N-RUI>M.CYTLV/4_,Y\^NP;V;QJRMP6N:,Q MJB4L$H#YSJB:7YUYTB*&!">Z2+3J.,#-323F:XKG4UFSG%JR/C5T2V,E<&7,F)F0F-RR M@:I`+)&6M"WRG/'U;QREW!B/OX.$S][T5DTMF_62Z8B68=P^F%;ASQP_M+:DQM2GX'!\VG]@)7`1@.VDH:3:#8<'Q3 M?QG[K&M$#`O.NIV5AT4OBHU]BC4B_>`&^;,4&PL4>UM3I2*QLM"$RJ#HMA:3 M7&OE0<$X]IVR\(DUUB('"EOD+(]$H,SPMC=.%K%FXK.F$=EEX8A< M*`36--UL3^),-$LZ4(C$R7=^XRC-4R_BI-Z)?1DP(@>*L\292,1YXPKQB5-% MYR_F\ZZ_,66A'24L>A%GXA.G$3E8G"7.1"#.*+SI^Y0*Q19KRXG6ACKG79=Q ME+#HQ9S4W/&ZL&G2(&^+G"62"LQY4XNE`KE(&!&>T4:BZRQU;IT5)XNT%V\J M:Y:`SYO&2L`]%7CS-B1\VE2QO?7!F\W.RD.B%VVF/FT:D;T^')%;$P)MWKB; MICYO&A&K"MYP=E8>%KUX,_5YTX@<+,[R9BKQYFT-IPK%"K1E1'N%\(;3.$HU MVXLW4Y\WC MY]5+OLQWNWJP*E_IR!]5_G#7BO5]A*=T=KJ0X&DB:-1A@Z>)H8GI]-8Q?/21B:- MD@]J"D>#O@9WG1Y%G&EXP?Z)IEF2T[0(\L=D\:CO4O%D:64(#D_$09(<P]!]->037XR)5 MV>#RE/KO%K?E&UL MK)M=;^)*$H;O5]K_@+@_@&T@"4IR-,'?7UJMSNY>,\1)T`0<`7,R\^^WVMWM M=O7K(;$TY^*0>5Q5;K_5']4-OOWSQ_YU]'=U/.WJP]W8F[ M\7_^"O^X'H].Y\WAO4G77V^_[ZG"608[5Z^9,[3^][-Y..MI^^YEP^\WQV_>W/[;U M_HU"?-V][LX_FZ#CT7Z[2IX/]7'S]96>^XYO'W?T!$+VT;%ZNAM_<5;EW!E/[V\;@?Z[J]Y/G;]'IY?Z M/3KN'O/=H2*U*4\B`U_K^ILP31X%(N(=-!OYU'#U63YOOK^=_U^]QM7M^ M.5.Z%_1$XL%6CS_]ZK0E12G,Q%V(2-OZE1I`_Q_M=Z)KD"*;'\WG^^[Q_'(W M]I:3Q=7,<\A\]+4ZG<.="#D>;;^?SO7^?]*H>:(VB*N"T&=/D`N.GG*D3^7H M.A-G/EN*FU_PFRL_^E1^\\G<75Q=-ZV^X$AAF\>E3]W2^>1ZL9@OKZ\NWW*I M/.E3>2X^=\LKY4B?^AGISPMMI*'9M)$^ASWP$)H&4 MAT_)XN@4BC_47;L]Z,)S.CJ+X@\MS>7;3F7O;0:#OSEO[F^/]?N(9ACJGZ>W MC9BOG)4(IX>!O'T[,'XU+FA`B"A?1)B[,:6'NOR)!O/?]S2=W4[_I@&X538/ M:.-PB[6V$*--A/5M$-@@M$%D@]@&B0U2&V0VR&U0V*#L@"E)V^I+'>-WZ"O" M"'VU,@\:=`2WQ-06VL6W06"#T`:1#6(;)#9(;9#9(+=!88.R`YB8-%)^AY@B M#$W7K+-:7?%!V72-%I;`K4FK,)``2`@D`A(#28"D0#(@.9`"2-DE3&R:#'Z' MV"(,32Z4T@M3@S3RJ"VMD:UV:]*J#20`$@*)@,1`$B`ID`Q(#J0`4G8)4YO6 M4*9V?QFBIUMAW8BJQ7B0A!349`W$!Q(`"8%$0&(@"9`42`8D!U(`*;N$"4;E M!!-,+%RN.R'[@4N7",2UE,2C7+6]T9VYUNAOC;3@/I``2`@D`A(#28"D0#(@ M.9`"2-DE3%Y:RIF\E_NCL.8:2D(::GG60'P@`9`02`0D!I(`28%D0'(@!9"R M2YA@8E_8+:0N"R:LN6"26)W.LSI=:Z15]8$$0$(@$9`82`(D!9(!R8$40,HN M81I2_3U`0V'--92DV^F`^$`"("&0"$@,)`&2`LF`Y$`*(&67,,'$!F2`8HTY METPAC^;-SF0WM_J=L6H['J(`48@H0A0C2A"EB#)$.:("4!^@G:WVFGT36 M5&C7@Z*BI.'?4=E'%"`*$46(8D0)HA11ABA'5"`J&>*2BAI]@*2RI*=XIDNJ M*K^S'(MC!UL_0`%:A8@B1#&B!%&**$.4(RH0E0QQ_435/4`_6:0S_53=SDO" MI3U+ME9:>%\X;PX@UPX@ M'U&`*$04(8H1)8A21!FB'%&!J&2(ZR?*\@'ZR2J>Z:>0_+I$'."N'86H@W7* MRVO>2WUM91P#C;CC#7<,M95QC#1BCHXYB^;/+"KK[C/+X^^)^$KC_++;?GNH MJ=E4XO7LYCPZYE:'W[(^9U(H9!JV=A2B'F6D<*QS1U];&<=`(^YHG4>$VLHX M1AIQ1[.G9%*X]E;"EN*O^NU74M"73EJ+)@S?8FATW=8C:XUN6N0C"A"%B"*& M^",-*^5=+.45$K?HY,S>'6DKI_GBX\I=SN@_WE-];4-5:R>25=0&_596G1'V M6UFQ(F,EOHZA;[)-C^$JB4*Z.P9Z^GHWP;+N[G9V5R*W<_BHD2DX?40!HA!1 MQ!!ONBA8!S1=UK>LZ1)9";9747HR49B0HLTW6XOEU8UCSV':YH,$JTCG8]=5FJQIR/!87X.9AKKTW&JDT\H@!1 MB"A"%"-*$*6(,D0YH@)1R1#K?=ZP>JXQMR25)9Y'\YRIPEQKZE@K1[(RDK:. M&@5H%2**$,6($D0IH@Q1CJA`5#+$):4>/V#&]H2Y):E$';'6RJJ#?$0!HA!1 MA"A&E"!*$66(.NMA;?45DWKN?"BV!P@O*Q- MNY6AF%=%+NC#/*!K5X;*BN5".G90H*W,D7NH45=X<(S1*E&("^]8RJ3HF"'* M$14:F::6&O6H+"K>`2K+`IFIK!#UFGQ#`+@5>DO8QLL48? M9$7&^B@K<,=,AS=WS!$5"E'X9E?-CW%*YL!S(O8D`W(BMS`L)PKQG)CR4I;& MGK1B0P50H*UD3CQ1/D-.P"O27D:A6*,/;C7THAGQ6K!6EFQK*@=F7G:0%O)K-Q<+VC?RCM8J$V,5X0H MUNB#K,@6*-E@Z8;V93JLN7F.J%!(A;6FPY(Y\%Q0:X>,$&%NU9H*\5S`DBVM M6"X`!9Y":H3,;YSE$I(!;I%V,Q+%&I&Q629P,9&Q^!"Q3Q%3'6EOFPC6ICSM.B$4O+W)IOULJJFQ9$@49Z,;E97%L]+-0F1J,( M4:S1Y:PH*SU$K`4PU4',K3)$.:*"QYU/K,`E<^'I&+;)I5>D[%&B$4^'-?S7 MRHJE0\;JH$!;Z77$L\N?4%L8B2)$L48?9$/MLN7::P^A5`XCTS4^?(;,CWQN2K,OOJ^%RMJ]?7TVA;?Q?OA-&^Y/ZVQ?*%M0=GN1)? M3U,%"U>NZ$KS\H9]Q9NMQ(%'CX]'[[_)+0;XN'2E*=_M*PY%HU^V]41S*!K] M9JOO"D6350A$\^A*LRV%*W.ZTAPKPI4%76F.N>TKY-+K00Z]]B1FKY8D9:^2 MUROZ76G/\]VLZ.>3R&GGNA*;*+Q"&]B5V$OA%=K'KL26"J_0=G8E=E9XA;:P ME*V^*_2"XY?^+)*$/9$>*%&]]N(&/?9?YJLOU+&Q26MJTKJW273,L/)[K]!I MPTKLZ0D```HS```9````>&PO M=V]R:W-H965T%[8DV MZ'Y7S.X^8RS;1`-R`&YW__O-DI0J51T-8R+ZQ9>O,H^D.E5"E27N_ORYW0Q^ M%/O#NMS=#XV+\7!0[%;E\WKW>C_\SU_V'S?#P>&XW#TO-^6NN!_^*@[#/Q_^ M_:^[SW+__?!6%,P.]\.WX_'='(T.J[=BNSQROUV>:1_]Z^C MP_N^6#Y72=O-:#(>7XVVR_5N6"N8^Z]HE"\OZU6Q*%J^['\N5X07*C^D3QFF]'MR-2>KA[7M,5B&X?[(N7^^$WP\PG ML^'HX:[JH/^NB\]#Y^_!X:W\=/;KYW"]*ZBWR2?AP%-9?A>AWK-`E#R";+MR M(-T/GHN7Y?;K%^?3N2W3.Z(G%AYO.O17%848^2S$5]&JMR0R=`/P?; MM1@:U"/+G]7OS_7S\>U^.*&A\50-DD3MM$8WHQN9D9LZM_R"3=ZGSI-Y_OQ70RN[[YIT-> M-8ET=4WB5P]YVV32[_,.:9";=>?*#OKJ00WN(O''F8>E7JT/2]=\YK4:UYQ+ M?W`N#9VO6&-0U];'_7(?C^K16`WNQ?*X?+C;EY\#NF/0N#N\+\7]QS"%+@_K M>C"V`_WOQCF-4:'R3)A,K^Y&/VA"K9J81XPQU(@Y1XBA M+V07.K!T8.O`T8&K`T\'O@X"'80ZB'00ZR#10:J#3`=Y!XS(GM8C&M2_PR,A M(SSBWGUDT#%-,X0C.&6A`TL'M@X<';@Z\'3@ZR#00:B#2`>Q#A(=I#K(=)!W M@&((W2E^AR%"YGY(/^6D&6M3XK&)Z0;--)/:D-8E(!80&X@#Q`7B`?&!!$!" M(!&0&$@")`62`,'N#:97+1//5_^A!)"E6_< MWX\UN:1#MR9-IM?:Y&J#.&T!Q`)B`W&`N$`\(#Z0`$@()`(2`TF`I$`R('F7 M*#;1`Y!B4_]3,3\MB&C5BYJ0%]S-N0ZH^-%M-KQ-=$FP8TV"=H@=F!&M=GQ-M$EPJTV"-JB=!$`L(#80!X@+Q`/B M`PF`A$`B(#&0!$@*)`.2=XGBA5B+GV%&%:ZZT:#N/$"T0&0ALA$YB%Q$'B(? M48`H1!0ABA$EB%)$&:)<0:H78D797=V?_E@VZ@4H/=OR$']LD#HU9F-M:L@H M3EP@LA#9B!Q$+B(/D8\H0!0BBA#%B!)$*:(,4:X@U1ZQOCS#GGHYJMA3H^E- MZ]A M1ZT`42@3N_*7ZNT@DE$L'Z-6@BB5B2?D,QG%\KFBI?HJ5I9G^%HO1!5?F[5I MUU=`"Z-&FJ\3M6H,VP<1*Y,[/:,)N_)*);W42M`%,K$$_*1C&+Y M&+421*E,/"&?R2B6SQ4MU5>Q%.WZ6A>N+Z[%Q'I;K[X_EC2_Z`.MYR/OD@K4 M3=FZ7M`J=C?HLC.-`2W$SH^XRU[5M>ZQH431"FBC-%)^9RC M*GG5:K'L/L/J>I6N6%VCJ7Q8FHNM1G'_E&B!R&(DRX(V(YGH('(1>8RDEL]( M:@6(0D01(ZD5,Y):":(44<9(:N6,*BW5"['L/L.+>I6N>%$C;=II6[5SHXV2 MTPZ0Q5$G1Y;-47+@.HA<1!ZCD_(^1TGY`%&(*&)T4C[F*"F?($H198R,^@GA M:GRM[Q+E'()S3MASAL]5N%I$:5!G@LT1+1!9C.1XM!G)L>T@#*N]?IBDTA1 M[9Q#9#$Z.6IMCI):#B(7D=,.Q&N65TC9=H!6E3'43[]+$9R2-J,Y/!V$+F(/$92RV1Q^BDO,]14CY`%"**&)V4CSE*RB>(4D09HQ,? M=1S2,^=$X>3KCS23NL[2?:1I4*>",D>T0&0ALA$YB%Q$'B(?48`H1!0ABA$E MB%)$&:)<0>K]3Y06SO"BJ8O(&\$CK?G$+5';+]#WDV64G'-M(B,+HVQ$#B(7 MD8?(1Q0@"A%%B&)$":(4489(O,3<="'U1&U/_5)R_=[FMMB_%O-BLSD,5N6' M>.%X*N9=B^NWH6GCQA0[#R0!+1-JJ2S36R93>H6ZNCE#RXQ?KM9;J*%ZZ5KG M5R:]L]!S]&N3]L][^(U)V[L]_-:DK<8>;HSI*JJ[B79D*M^8HEZ#.52,,47U M!5NHM&**6@JV4*'$%)41;*'WS;_U]J+H^)[X1^KVWOA+,Z_J4=IU?)N2?F_7 MDDM])E&-W13U6#Q5*K6;HBR++51QI\OK.SS5;*FE+X>*[72%?2U4%:6N[SMG MJFI2U_>U4%62NKZOA:J*=`9]+;3+06I]9TUUG<8;(H7NG&,JVKYOOXN0_W/L2FM M/I5'^BY"565]H^^<%/0R]EB\=/=2ED?^1QR@_1;+P_\!``#__P,`4$L#!!0` M!@`(````(0!WQC!V,@$``$`"```1``@!9&]C4')O<',O8V]R92YX;6P@H@0! M**```0`````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````"&>TMIIS&D98F:G5QBXHR+-X1O*[%0`FBW?R_KNCJC)X_D?7EXOH]JOM-M M\@G.J\[4B&0Y2L"(3BJSK='S:I'>H,0';B1O.P,UVH-'?@T746 M7%#@DT@RG@I;HR8$2S'VH@'-?18;)H:;SFD>XM%ML>7BG6\!%WE^C34$+GG@ M^`!,[41$(U**"6D_7#L`I,#0@@83/"89P=_=`$[[/R\,R5E3J["W<:91]YPM MQ3&&UL(*($`2B@``$````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````G%5M3]LP$/X^:?^ARG=(7]C&4!K$VB(F M;0,MA7VTC'-MK"9V\%TZRJ_?.5%+.D*%^&;[7OS<E3N$@9- MQK,UO3=I:I7'AW?S3A6UCQ.@24)73 MM(G[4=C>1HF2.4PX<;R0.4(4/A]$5R`]:3=2.XRC-9VM09%U/=1/3-LPZ-U+ M!`]G'*RET](0P_)NS:9>YR62B_]8M\(,@#`*V:$YK)=MW_9:G\3#4>W!JWU/ MGZ%!PH9]C'--.>#UXD8ZZH(\:F.N432(&T#;+@K6AI@98K[$=]-T6]LV\ET- MWV0NC0*1U,6)6R.K5!.D;W%FD"R9#(B[R"W;Y?04-H`2D@1>5RCL0ERS..MV M8W//&T*2S*I59O.47X.8/51O")E(S,1E;O\>NF4@KMU2&OU4XZGYF@(JITLO MQ\Y;AB*IBD*ZC2\ET4NC^>&P9,2%4K8;V$BPX@N-:#GJER784\^.I1,QD:4F MF8N$7*6H02E&>^FZ!!G[F_1WBH6$IBMO:"Z@1SN$>#SIC#['?'O,JJF,O[[J
%M.;=3[NMV$N\?1DG& M\R+E&;6U/Q]$5SR$7>Z33#)IEI!N?5X:_+]QUWR.\>#DN#_J\Y?0.HO"YV\P M_@<``/__`P!02P$"+0`4``8`"````"$`FHKD`[8!``!.$```$P`````````` M````````````6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`(````(0"U M53`C]0```$P"```+`````````````````.\#``!?&PO=V]R M:W-H965T&UL4$L!`BT`%``&``@````A`)F`PXN=`@``&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$XYWB%+"0``TBH``!D````````````` M````+R(``'AL+W=O&PO=V]R:W-H965T MBB0(``.H%```9```` M`````````````+4O``!X;"]W;W)K&UL4$L!`BT` M%``&``@````A`/MBI6V4!@``IQL``!,`````````````````=3(``'AL+W1H M96UE+W1H96UE,2YX;6Q02P$"+0`4``8`"````"$`S%AF8W`%``"Y%0``&``` M```````````````Z.0``>&PO=V]R:W-H965T&UL4$L!`BT` M%``&``@````A`'Q9,?K'`@```P@``!@`````````````````X#X``'AL+W=O M&UL4$L!`BT`%``&``@````A`(40&UL4$L!`BT`%``&``@````A``.VP2<&`P``9@D``!D` M````````````````3:```'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.REKXSO`@`` MA`@``!@`````````````````IZD``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+:F.LHI!```R@T``!D````````````` M````?+H``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT`%``&``@````A`!FF0A":`@``E08``!D````` M````````````)\(``'AL+W=O&PO=V]R M:W-H965T&P_@<``,0G M```9``````````````````[(``!X;"]W;W)K&UL M4$L!`BT`%``&``@````A`$J]\`2F"P``W3L``!D`````````````````0]`` M`'AL+W=OBMH MWND)```*,P``&0`````````````````@W```>&PO=V]R:W-H965T&UL4$L% 3!@`````@`"``D@@``*+L```````` ` end XML 14 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Statements of Operations (Unaudited) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Income Statement [Abstract]

Revenues, net

Operating expenses:

Selling, general and administrative 12,608,401 280,456 33,461,690 569,121

Research and development expense 6,412,711 26,514 15,510,310 26,514

Depreciation and amortization expense 719,040 10,863 2,134,231 11,012

Total operating expenses 19,740,152 317,833 51,106,231 606,647

Loss from operations (19,740,152) (317,833) (51,106,231) (606,647)

Interest expense (205,416) (1,098,868)

Loss on settlement of debt (7,108,495)

Total other income (expense) (205,416) (8,207,363)

Loss from continuing operations (19,945,568) (317,833) (59,313,594) (606,647)

Gain from discontinued operations 260,746

Net loss $ (19,945,568) $ (317,833) $ (59,313,594) $ (345,901)

Loss from continuing operations $ (0.34) $ (0.01) $ (1.08) $ (0.03)

Gain from discontinued operations $ 0.01

Basic and diluted loss per share $ (0.34) $ (0.01) $ (1.08) $ (0.02)

Weighted average number of shares outstanding 59,334,545 30,853,117 55,127,859 19,706,741

X

- Definition

custom:GainLossFromDiscontinuedOperations

+ References

No definition available.

+ Details

Name: TNIB_GainLossFromDiscontinuedOperations

Namespace Prefix: TNIB_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

custom:LossFromContinuingOperations

+ References

No definition available.

+ Details

Name: TNIB_LossFromContinuingOperations

Namespace Prefix: TNIB_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Total costs of sales and operating expenses for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12317-112629

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12355-112629

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4613673-111683

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.13)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_IncomeLossFromContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of income (loss) from a disposal group, net of income tax before extraordinary items allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.12)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 13

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.14)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Article 5

+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 4

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6386349&loc=d3e3636-108311

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 15 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

4. Capital Structure-Common Stock and Common Stock Purchase Warrants
9 Months Ended

Sep. 30, 2013

Notes to Financial Statements

4. Capital Structure-Common Stock and Common Stock Purchase Warrants

Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend.

As of September 30, 2013 and September 30, 2012, the Company was authorized to issue 500,000,000 common shares at a par value of $0.001 per share.

Stock Warrants

Using the Black-Scholes Model, the Company calculated the fair value of $6,932,057 for stock warrants issued during the nine months ended September 30, 2013. Variables used in the Black-Scholes option-pricing model, include (1) a discount rate of 0.71%, (2) an expected remaining life between 2 and 5 years and (3) expected volatility of 130%.

During the third quarter of 2013, the Company issued 1,652,500 shares of its restricted common stock through common stock purchase warrant exercises. The warrants were exercised at a price of $0.50 per share and the Company received proceeds of $826,250 for equity from the exercise of the warrants.

Following is a summary of outstanding stock warrants at September 30, 2013 and December 31, 2012 and activity during the periods then ended:

Number of Exercise Weighted

Shares Price Average Price

Warrants as of December 31, 2012 7,260,000 $ 1.00 – 1.50 $ 1.02

Issued in nine months ended September 30, 2013 2,567,918 $ 1.00-1.50 $ 2.56

Expired – –

Exercised 3,324,168 $ 0.50-0.75 $ 0.63

Warrants as of September 30, 2013 6,503,750 $ 1.00 – 15.00 $ 1.83



Summary of outstanding warrants as of September 30, 2013:

Expiration Date
Number of Shares
Exercise

Price
Remaining Life (years)

Second Quarter 2015 1,025,000 $ 2.00-3.00 1.8

Third Quarter 2015 221,250 $ 2.00-3.00 2.0

Second Quarter 2016 337,500 $ 1.50 2.8

Third Quarter 2017 985,416 $ 1.00 4.0

Fourth Quarter 2017 3,491,666 $ 1.00-1.50 4.3

First Quarter 2018 229,584 $ 15.00 4.5

Second Quarter 2018 33,334 $ 15.00 4.8

X

- Definition

custom:CapitalStructurecommonStockAndCommonStockPurchaseWarrantsTextBlock

+ References

No definition available.

+ Details

Name: TNIB_CapitalStructurecommonStockAndCommonStockPurchaseWarrantsTextBlock

Namespace Prefix: TNIB_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: TNIB_NotesToFinancialStatementsAbstract

Namespace Prefix: TNIB_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 16 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 17 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

4. Capital Structure-Common Stock and Common Stock Purchase Warrants (Tables)
9 Months Ended

Sep. 30, 2013

Capital Structure-Common Stock And Common Stock Purchase Warrants Tables

Schedule of outstanding stock warrants
Following is a summary of outstanding stock warrants at September 30, 2013 and December 31, 2012 and activity during the periods then ended:

 Number of Exercise Weighted

Shares Price Average Price



Warrants as of December 31, 2012 7,260,000 $ 1.00 – 1.50 $ 1.02

Issued in nine months ended September 30, 2013 2,567,918 $ 1.00-1.50 $ 2.56



Expired – –



Exercised 3,324,168 $ 0.50-0.75 $ 0.63



Warrants as of September 30, 2013 6,503,750 $ 1.00 – 15.00 $ 1.83

Summary of outstanding warrants

Expiration Date
Number of Shares
Exercise

Price
Remaining Life (years)

Second Quarter 2015 1,025,000 $ 2.00-3.00 1.8

Third Quarter 2015 221,250 $ 2.00-3.00 2.0

Second Quarter 2016 337,500 $ 1.50 2.8

Third Quarter 2017 985,416 $ 1.00 4.0

Fourth Quarter 2017 3,491,666 $ 1.00-1.50 4.3

First Quarter 2018 229,584 $ 15.00 4.5

Second Quarter 2018 33,334 $ 15.00 4.8

X

- Details

Name: TNIB_CapitalStructurecommonStockAndCommonStockPurchaseWarrantsTablesAbstract

Namespace Prefix: TNIB_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: TNIB_SummaryOfOutstandingWarrants

Namespace Prefix: TNIB_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Article 5

+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 18 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

Statements of Cash Flows (Unaudited) (USD $)
9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss $ (59,313,594) $ (342,671)

(Gain) loss from discontinued operations 260,746

Loss from continuing operations (59,313,594) (606,647)

Adjustments to reconcile loss from continuing operations to net cash flows used in operating activities:

Depreciation 682 327

Amortization 2,133,549 10,685

Amortization of stock issued for prepaid services 36,318,767 53,745

Loss on settlement of debt 7,055,994

Stock warrant expense 6,932,057

Stock issued for donation 750,000

Stock issued for interest 1,133,162

Changes in operating assets and liabilities:

Accrued liabilities 227,681 125,876

Prepaid and other current assets (37,507) 27,700

Accounts payable 343,098 82,850

Net cash used in operating activities from continuing operations (4,456,111) (305,464)

CASH FLOWS FROM INVESTING ACTIVITIES

Purchase of computer equipment (4,350) (1,062)

Purchase of Penn State License (160,539)

Net cash used in investing activities from continuing operations (164,889) (1,062)

CASH FLOWS FROM FINANCING ACTIVITIES

Proceeds from exercise of stock warrants 3,640,363

Proceeds from sale of stock 531,250 212,680

Proceeds from notes payable 499,001 250,400

Payments made on patent liability (155,000) (15,000)

Net cash provided by financing activities from continuing operations 4,515,614 448,080

Net Increase (decrease) in cash (105,386) 141,554

Cash, beginning of period 313,095 12

Cash, end of period 207,709 141,566

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

Cash paid for interest

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

Accrued liabilities for purchase of Smith LDN patent $ 2,715,000

Conversion of debt and accrued interest to common stock 74,167

Common Shares issued for Penn State License 2,550,000

Common shares issued for prepaid services 51,204,100

X

- Definition

custom:AccruedLiabilities1

+ References

No definition available.

+ Details

Name: TNIB_AccruedLiabilities1

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

custom:AccruedLiabilitiesForPurchaseOfSmithLdnPatent

+ References

No definition available.

+ Details

Name: TNIB_AccruedLiabilitiesForPurchaseOfSmithLdnPatent

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

custom:AmortizationOfStockIssuedForPrepaidServices

+ References

No definition available.

+ Details

Name: TNIB_AmortizationOfStockIssuedForPrepaidServices

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

custom:CommonSharesIssuedForPennStateLicense

+ References

No definition available.

+ Details

Name: TNIB_CommonSharesIssuedForPennStateLicense

Namespace Prefix: TNIB_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

custom:CommonSharesIssuedForPrepaidServices

+ References

No definition available.

+ Details

Name: TNIB_CommonSharesIssuedForPrepaidServices

Namespace Prefix: TNIB_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

custom:ConversionOfDebtAndAccruedInterestToCommonStock

+ References

No definition available.

+ Details

Name: TNIB_ConversionOfDebtAndAccruedInterestToCommonStock

Namespace Prefix: TNIB_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

custom:LossOnSettlementOfDebt

+ References

No definition available.

+ Details

Name: TNIB_LossOnSettlementOfDebt

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

custom:PaymentsMadeOnPatentLiability

+ References

No definition available.

+ Details

Name: TNIB_PaymentsMadeOnPatentLiability

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

custom:PurchaseOfPennStateLicense

+ References

No definition available.

+ Details

Name: TNIB_PurchaseOfPennStateLicense

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

custom:StockIssuedForDonation

+ References

No definition available.

+ Details

Name: TNIB_StockIssuedForDonation

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

custom:StockIssuedForInterest

+ References

No definition available.

+ Details

Name: TNIB_StockIssuedForInterest

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

custom:StockWarrantExpense1

+ References

No definition available.

+ Details

Name: TNIB_StockWarrantExpense1

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAmortizationAndAccretionNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationNonproduction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of gain (loss), after tax expense or benefit and not previously recognized, resulting from the sale of a business component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4613673-111683

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.13)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_IncomeLossFromContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period net of cash paid for interest that is capitalized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a borrowing supported by a written promise to pay an obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock warrants.

+ References

No definition available.

+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

2. Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

2. Summary of Significant Accounting Policies
Basis of Presentation

The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), as amended for interim financial information. The financial information as of December 31, 2012 is derived from the audited financial statements presented in the Company’s Form 10 Registration Statement filed with the Commission on April 22, 2013 and the Amended Registration Statements on Form 10-/A filed on June 7, 2013, July 18, 2013, August 23, 2013, September 25, 2013, and October 11, 2013 for the year ended December 31, 2012. The unaudited consolidated financial statements should be read in conjunction with the Company’s Form 10 Registration Statement, which contains the audited financial statements and notes thereto, together with Management’s Discussion and Analysis of Financial Condition and Results of Operations, for the years ended December 31, 2012 and 2011.

Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management’s opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the nine months ended September 30, 2013 are not necessarily indicative of results for the full fiscal year.

Use of Estimates

The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.



Cash, Cash Equivalents, and Short-Term Investments

The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets.

Fair Value of Financial Instruments

In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “Financial Instruments,” the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments. Cash, accounts payable, payable to officer, and patent liability are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable to a related party also approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.

Computer Equipment

Computer equipment is stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense from continuing operations for the nine months ended September 2013 and 2012 was $682 and $327, respectively.

Intangible Assets

Costs incurred to acquire and/or develop the Company’s product licenses and patents are capitalized and amortized by straight-line methods over estimated useful lives of seven to sixteen years. Intangible assets are stated at the lower of cost or estimated fair market value. During the nine months ended September 30, 2013, the Company capitalized $2,710,539 of such costs incurred for the acquisition of the Company’s patents. (See Note 10 of the Company’s Form 10 Registration Statement). Amortization expense for the nine months ended September 30, 2013 and 2012 was $2,133,549 and $10,685, respectively. The Company estimates its amortization expense related to these assets will approximate $2,800,000 each year for the next five years.

Impairment of Long-Lived Assets

The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360, “Property, Plant and Equipment.” If the carrying amount of the asset, including any intangible assets associated with that asset, exceeds its estimated undiscounted net cash flow, before interest, the Company will recognize an impairment loss equal to the difference between its carrying amount and its estimated fair value. No impairment losses were recognized for the nine months ended September 30, 2013 or for the corresponding period in 2012.

Research and Development Costs

Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.

Income Taxes

The Company follows FASB ASC Topic 740, “Income Taxes,” which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of September 30, 2013, the Company has no accrued interest or penalties related to uncertain tax positions.

Share-Based Compensation and Issuance of Stock for Non-Cash Consideration

The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable.

The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “Equity-Based Payments to Non-Employees.” The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.



Net Loss per Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.



Recent Accounting Standards

The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2012, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

Any new accounting pronouncements issued by the Financial Accounting Standards Board, as applicable, have been or will be adopted by the Company upon or before the expiration of the extended transition period provided under Section 102(b)(1) of the JOBS Act.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 20 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

5. Stock Compensation
9 Months Ended

Sep. 30, 2013

Equity [Abstract]

5. Stock Compensation
Founders’ Shares and Shares Issued for Services

During the nine months ended September 30, 2013, the Company issued 10,228,000 shares of common stock, for prepaid services, which included founder shares. The Company valued these shares based upon the fair value of the common stock at the date of the agreements. The consulting fees are amortized over the contract periods, which are typically twelve months. The Company recognized an expense from common stock issued for services of $17,101,965 and $0 for the nine months ended September 30, 2013 and 2012, respectively. The amortization of prepaid services totaled $36,318,767 and $0 for the nine months ended September 30, 2013 and 2012, respectively.

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for accounts comprising shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income, and compensation-related costs for equity-based compensation. Includes, but is not limited to, disclosure of policies, compensation plan details, equity-based arrangements to obtain goods and services, deferred compensation arrangements, and employee stock purchase plan details.

+ References

No definition available.

+ Details

Name: us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

3. Promissory Notes
9 Months Ended

Sep. 30, 2013

Debt Disclosure [Abstract]

3. Promissory Notes
In April 2013 the Company issued two short-term promissory notes to third party investors totaling $200,000. Under the terms of the notes, the Company was required to issue a total of 20,000 shares of restricted common stock to the note holders as loan origination fees. The notes matured 14 days from the date of issuance. Under the terms of the notes, if the loans were not repaid, the note holders would collectively receive 20,000 shares of restricted common stock on the maturity date and every 30 days thereafter that the notes remain unpaid. As of the date of this filing, the notes have not been repaid.

On March 11, 2013 the Company issued four short-term promissory notes to third party investors totaling $249,000. Under the terms of the notes, the Company was required to issue a total of 25,000 shares of restricted common stock to the note holders as loan origination fees. The notes matured on March 25, 2013. Under the terms of the notes, if the loans were not repaid, the note holders would collectively receive 25,000 shares of restricted common stock on the maturity date and every 30 days thereafter that the notes remain unpaid. As of the date of this filing, the notes have not been repaid.

The Company has an outstanding note payable to K-C Operations (an unrelated party) issued on October 15, 2009. The balance as of September 30, 2013 and December 31, 2012 was $326,333 and $398,000, respectively. The note matured on October 31, 2010 and accrues interest at a rate of 6% per annum and is convertible to shares of common stock at a rate of $0.20 per share.

The Company has an outstanding note payable to Robert Johnson (former officer and director) issued on September 30, 2006 with a balance as of September 30, 2013 and December 31, 2012 of $21,547 and $21,547, respectively. The note matured on September 30, 2007 and is convertible to shares of common stock at a rate of $0.20 per share.

The Company has an outstanding note payable to Lexicon (an unrelated party) issued on January 15, 2009. The note is due upon demand. The balance as of September 30, 2013 and December 31, 2012 was $10,317 and $12,817, respectively. The note bears an interest rate of 6% per annum and is convertible to shares of common stock at a rate of $0.01 per share.

During the nine months ended September 30, 2013, the Company issued 1,545,833 shares of common stock for the retirement of $74,167 of promissory notes payable and accrued interest. The Company recognized a loss on conversion of the above debt of $7,108,495 and $0 in the nine months ended September 30, 2013 and 2012 respectively.

X

- Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 22 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\T.#EE.#,T95\U-&4Y7S1D9&-?.#DV9%\Q,C,S M,F4R.&(R-3(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I% M>&-E;%=O#I% M>&-E;%=O#I.86UE/E-T871E;65N='-?;V9?3W!E M#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T871E;65N='-?;V9?4VAO8VMH;VQD97)S7T5Q=3PO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T871E;65N='-?;V9? M0V%S:%]&;&]W#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/C%?3W)G86YI>F%T:6]N7V%N9%]$97-C#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/C-?4')O;6ES5].;W1E#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/C1?0V%P:71A;%]3=')U8W1U#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/C5?4W1O8VM?0V]M<&5N#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/CA?0V]M;6ET;65N='-?86YD7T-O;G1I;F=E;F-I M93PO>#I.86UE/@T*("`@(#QX.E=O#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/C)?4W5M;6%R>5]O9E]3 M:6=N:69I8V%N=%]!8V-O=3$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/C1?0V%P:71A;%]3=')U8W1U#I7;W)K#I7 M;W)K#I3='EL97-H965T($A2968],T0B5V]R:W-H965T&-E;"!84"!O3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\T.#EE.#,T95\U-&4Y7S1D9&-?.#DV9%\Q,C,S,F4R.&(R-3(-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#@Y93@S-&5?-31E.5\T9&1C7S@Y M-F1?,3(S,S)E,CAB,C4R+U=O'0O:'1M;#L@8VAA2!);F9O2!);F9O M'0^)SQS<&%N/CPO2!296=I2!# M96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)S`P,#$U-3DS-38\'0^4V5P(#,P+`T* M"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M3QS<&%N/CPO2!#;VUM;VX@ M4W1O8VLL(%-H87)E'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPO'0^)SQS<&%N M/CPOF%T:6]N(&]F("0S M+#2`H3F]T92`X M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S6%B;&4\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO6%B;&4@3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3H\ M+W-T3PO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAAF5D/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XU,#`L,#`P+#`P,#QS<&%N/CPO'0O:F%V87-C3X-"B`@("`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`@("`@("`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`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^)SQS M<&%N/CPOF%T:6]N(&]F('-T;V-K M(&ES'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA M6%B M;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQP M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z M(#AP="!4:6UE&-H86YG92!#;VUM:7-S:6]N#0HH)B,Q-#<[4T5#)B,Q M-#@[*2P@87,@86UE;F1E9"!F;W(@:6YT97)I;2!F:6YA;F-I86P@:6YF;W)M M871I;VXN(%1H92!F:6YA;F-I86P@:6YF;W)M871I;VX@87,@;V8@1&5C96UB M97(@,S$L(#(P,3(@:7,@9&5R:79E9`T*9G)O;2!T:&4@875D:71E9"!F:6YA M;F-I86P@28C,30V.W,@1F]R;2`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`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z M(#AP="!4:6UE2<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`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`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`H86X@=6YR96QA=&5D('!A2`Q-2P@,C`P.2XF(S$V,#LF(S$V,#M4:&4@;F]T M92!I2XF(S$V M,#LF(S$V,#M4:&4-"FYO=&4@8F5A6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2<^/&9O;G0@2!N;W1E2<^/"]P/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQP('-T>6QE/3-$)VUA6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE2<^16%C:"!H;VQD97(@;V8@8V]M;6]N('-T;V-K(&ES(&5N M=&ET;&5D#0IT;R!V;W1E(&]N(&%L;"!M871T97)S(&%N9"!I2!C;&%S2!P87)T(&]F(&%N>2!N97<@;W(@ M861D:71I;VYA;"!IF5D(&]R('=H971H97(@:7-S=65D(&9O2P-"F9O M2!O M9B!D:79I9&5N9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE2<^07,@;V8@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"!397!T M96UB97(-"C,P+"`R,#$R+"!T:&4@0V]M<&%N>2!W87,@875T:&]R:7IE9"!T M;R!I'0M86QI9VXZ(&IU'0M:6YD96YT M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU65A M'!E8W1E9"!V;VQA=&EL:71Y(&]F(#$S,"4N/"]P/@T* M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL M93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU2!R96-E M:79E9"!P6QE/3-$ M)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^1F]L;&]W:6YG(&ES(&$@2!O9B!O=71S=&%N9&EN9PT*'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@ M0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)V)O'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M6QE/3-$)V)O6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H M=#H@,3$U)2<^/&9O;G0@6QE M/3-$)V)A8VMG6QE/3-$)W9E'0M86QI9VXZ(')I M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE/3-$)W9E'0M86QI M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E'0M86QI9VXZ(')I M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@ M6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)W9E6QE/3-$)W9E'0M86QI9VXZ M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H M=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^ M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG&5R8VES960\+V9O;G0^/"]T9#X-"B`@("`\ M=&0@6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^ M/&9O;G0@6QE/3-$)W9E M'0M86QI9VXZ(')I9VAT.R!L:6YE M+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^ M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM M97,@3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#LF(S$V M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE2!O M9B!O=71S=&%N9&EN9R!W87)R86YT'0M:6YD M96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@0V%L:6)R M:2P@2&5L=F5T:6-A+"!386YS+5-E6QE/3-$)W9E'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*("`@("`@("`\<"!S M='EL93TS1"=F;VYT.B`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`@("`\=&%B;&4@8VQA'0^)SQP('-T>6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&9O;G0@'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#AP="!4 M:6UE2!R96-O9VYI>F5D(&%N(&5X<&5N2X\+V9O;G0^/"]P M/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2<^/&9O;G0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE2<^ M/&9O;G0@'0M86QI9VXZ(&IU6QE/3-$)V9O M;G0Z(#AP="!4:6UE'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ(&IU6QE/3-$ M)V9O;G0Z(#AP="!4:6UE'0M:6YD96YT.B`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`Y)3L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W=I9'1H.B`Q M)2<^/&9O;G0@'0M86QI9VXZ(')I M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE/3-$)W=I9'1H.B`Q)2<^/&9O M;G0@6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@ M6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG M;CH@6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE M&5S/"]F;VYT M/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4 M:6UE'0M M:6YD96YT.B`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`N-6EN)SX\9F]N="!S='EL93TS M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE2<^/&9O;G0@2!O9B!C>71O:VEN97,L('=H M:6-H(&%R92!H;W)M;VYE2!C>71O:VEN92P@86UO;F<@;6%N M>2!O=&AE2!I6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&9O;G0@'0M86QI9VXZ(&IU M6QE/3-$)V9O;G0Z(#AP="!4:6UE2UO=VYE9"!S=6)S:61I87)Y(&]F('1H M92!#;VUP86YY+B!43DD@25`@=V%S(&%C<75I28C,30V.W,@8V]M M;6]N('-T;V-K#0IO9B!W:&EC:"`X+#`P,"PP,#`@&-H86YG92!F;W(@86QL(&]F M('1H96ER(')I9VAT+"!T:71L92!A;F0@:6YT97)E'0M:6YD96YT.B`P+C5I;CL@=&5X="UA;&EG M;CH@:G5S=&EF>2<^/&9O;G0@'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#AP="!4:6UE2!G;V]D=VEL;"!O2!W M97)E(&EM<&%I6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&9O;G0@'0M86QI9VXZ(&IU6QE M/3-$)V9O;G0Z(#AP="!4:6UE"!V:7)U2!D:6%G M;F]S960@87,@28C,30V.W,@ M8V]M;6]N('-T;V-K('=I=&@@82!F86ER(&UA2UF;W5R M(&UO;G1H('!E2!W:6QL('!A>0T*=&AE(&QI8V5N M2!P87EM96YT(&]F(#$E(&]F(&=R;W-S($U%3DL@2!A(#$E('-U8FQI8V5N2!S=6)L:6-E M;G-E(')E=F5N=64N/"]F;VYT/CPO<#X-"@T*/'`@6QE/3-$)V9O;G0Z(#AP="!4:6UE7-T96T@ M86YD#0IT:&4@:&5A;&EN9R!A;F0@&-H86YG92!F;W(@,S`P+#`P M,"!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S$T-CMS(&-O;6UO;B!S=&]C:PT* M=VET:"!A(&9A:7(@('9A;'5E(&]F("0R+#'!I M'!I6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&9O;G0@'0M86QI M9VXZ(&IU6QE/3-$)V9O;G0Z(#AP="!4:6UE2!A9W)E960@=&\@<&%Y('1O('1H92!M96UB97)S('1H92!A<'!L:6-A M8FQE(&UI;&5S=&]N92!P87EM96YT6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)W=I9'1H.B`Y-R4[ M('1E>'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#AP M="!4:6UE2<^/&9O;G0@2!W:6QL('!A>2`D,34P+#`P,"X\+V9O M;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$ M)V9O;G0Z(#AP="!4:6UE0T*("`@('1H92!& M1$$L('1H92!#;VUP86YY('=I;&P@<&%Y("0R-3`L,#`P+CPO9F]N=#X\+W1D M/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#AP="!4:6UE2<^/&9O;G0@2!W:6QL('!A>2`D-S4P+#`P,"X\+V9O;G0^/"]T9#X\+W1R M/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2<^/&9O;G0@6QE/3-$)W=I9'1H.B`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`P+C5I;B<^/&9O;G0@'0M86QI9VXZ M(&IU6QE/3-$)V9O;G0Z(#AP="!4:6UE&-L=7-I=F4@;&EC96YS:6YG(&%G2`Q."P@,C`Q,R!T M;R!L:6-E;G-E(&%L;"!O9@T*=&AE(&EN=&5L;&5C='5A;"!P2!D M979E;&]P960@8GD@1'(N($EA;B!3+B!:86=O;BP@1'(N(%!A=')I8VEA($HN M($UC3&%U9VAL:6X@86YD($1R+B!*:6QL(%`N(%-M:71H(&9O&-H86YG90T*9F]R(#,P M,"PP,#`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`P+C5I;B<^/&9O M;G0@'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z M(#AP="!4:6UE&]N92!I;B!T:&4@=')E871M96YT(&]F('!E9&EA=')I8R!P871I96YT6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&9O;G0@'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#AP="!4 M:6UE2XF(S$V,#LF(S$V,#M4:&4@;&EC96YS960@=&5C:&YO;&]G>2!I2!O9B!D:7-E87-E6UP:&]M M82!A;F0@8V%N8V5R(&%N9"`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`U('EE87)S('1H97)E869T97(@=6YL97-S(&5I=&AE<@T*<&%R='D@:7,@ M:6X@8G)E86-H(&]F('1H92!C;VYT7,F(S$T-CL@=W)I='1E;B!N;W1I8V4N#0I);B!T:&4@979E;G0@;V8@ M82!B2!M=7-T(&=I=F4@;F]T:6-E('1O('1H92!B7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)V9O;G0Z(#AP="!4:6UE M6UE;G0@86=R965M96YT('=I=&@@2F]S97!H($=R M:69F:6XL('1H92!B2P@=&AE(&=R M86YT(&]F(&$@8V]M;6]N('-T;V-K+"!A;F0@:&5A;'1H(&EN2!P86ED(&=R;W-S(&-O;7!E;G-A=&EO M;B!T;W1A;&EN9R`D-C(L,S,X+B8C,38P.R8C,38P.RX\+V9O;G0^/"]P/@T* M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE/3-$)V9O M;G0Z(#AP="!4:6UE2!T:&4@ M2!E;G1E6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE2`R,2P@,C`Q,RP@=&AE($-O;7!A;GD@96YT M97)E9"!I;G1O(&$@9F]R;6%L(&QO86X-"F%G6UE;G0@;V8@=&AE(&%M;W5N="!O=V5D(&]N($1E8V5M8F5R(#,Q M+"`R,#$R+B8C,38P.R8C,38P.U1H92!L;V%N(&)E87)S(&EN=&5R97-T(&%T M(&%N(&%N;G5A;"!R871E#0IO9B`V)2X@5&AE(&EN=&5R97-T(&ES(')E<&%Y M86)L92!A="!M871U2X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F M;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#AP="!4:6UE2!E;G1E6QE/3-$)V9O;G0Z(#AP="]N M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2`S+"`R,#$S+"!T:&4@0V]M<&%N M>2!F;W)M86QI>F5D('1H92!T97)M2!/)B,Q M-#8[0G)I96X@5VEL65D+B!-2!I;B`R,#$R(&%N9"!H97(@=&AR964M>65A2!P86ED(&=R;W-S#0IC;VUP96YS871I;VX@=&]T M86QI;F<@)#8S+#DP,RX@37,N(%=I;'-O;B!H87,@;F]T(')E8V5I=F5D('1H M92`U,"PP,#`@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`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`X<'0O,3$U)2!4 M:6UE6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W=I9'1H.B`Q M)3L@9F]N=#H@.'!T+S$Q-24@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F M;VYT.B`X<'0O,3$U)2!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X<'0O,3$U)2!4:6UE M6QE/3-$ M)V9O;G0Z(#AP="!4:6UE&5R8VES93PO9F]N=#X\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N=#H@.'!T M+S$Q-24@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z M(#AP="\Q,34E(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X<'0O,3$U)2!4:6UE M6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!F;VYT.B`X<'0O,3$U)2!4:6UE6QE/3-$)V9O;G0Z(#AP="\Q,34E(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0M86QI9VXZ M(&IU6QE/3-$)V9O;G0Z(#AP="!4:6UE2<^/&9O;G0@2<^/"]P M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU M6QE/3-$)V9O;G0Z(#AP="!4:6UE&-H86YG M92!#;VUM:7-S:6]N#0HH)B,Q-#<[4T5#)B,Q-#@[*2P@87,@86UE;F1E9"!F M;W(@:6YT97)I;2!F:6YA;F-I86P@:6YF;W)M871I;VXN(%1H92!F:6YA;F-I M86P@:6YF;W)M871I;VX@87,@;V8@1&5C96UB97(@,S$L(#(P,3(@:7,@9&5R M:79E9`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`X<'0O;F]R;6%L(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#AP="!4:6UE&-E M961S(&ET6EN9R!A;6]U;G0-"F%N9"!I=',@97-T:6UA=&5D M(&9A:7(@=F%L=64N)B,Q-C`[)B,Q-C`[3F\@:6UP86ER;65N="!L;W-S97,@ M=V5R92!R96-O9VYI>F5D(&9O6QE/3-$)V9O M;G0Z(#AP="!4:6UE'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#AP="!4:6UE M2!C;VUP2<^/&9O;G0@&5S/"]B/CPO9F]N=#X\+W`^ M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE/3-$ M)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE"!A65A`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`R*&(I M*#$I(&]F('1H92!*3T)3($%C="X\+V9O;G0^/"]P/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO2<^/&9O;G0@2!O9B!O=71S M=&%N9&EN9R!S=&]C:R!W87)R86YT2!D=7)I;F<@=&AE M('!E2<^/&9O;G0@2<^/"]P/@T*#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<&%D M9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`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`X<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ(')I9VAT.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX\9F]N M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(')I9VAT.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE'0M86QI9VXZ(')I9VAT.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX\ M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M'0M86QI9VXZ(')I9VAT.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX\9F]N M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M M86QI9VXZ(')I9VAT.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX\9F]N="!S M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI M9VXZ(')I9VAT.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX\9F]N="!S='EL M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E M6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E'!I6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP M="!4:6UE'0M86QI M9VXZ(')I9VAT.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX\9F]N="!S='EL M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ M(')I9VAT.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX\9F]N="!S='EL93TS M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(')I9VAT.R!V97)T:6-A M;"UA;&EG;CH@8F]T=&]M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E M6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)V9O M;G0Z(#AP="!4:6UE'0M86QI9VXZ(')I9VAT M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX\9F]N="!S='EL93TS1"=F;VYT M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/"]P/@T*#0H\<"!S='EL M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/"]P/CQS<&%N/CPO M2!O9B!O=71S=&%N9&EN9R!W87)R86YT'0^)SQT86)L92!C96QL6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)W9E'0M:6YD96YT.B`P+C5I;B<^/&9O;G0@'!I6QE/3-$)W9E6QE/3-$)W9E6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E'0M M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE M/3-$)W9E6QE/3-$ M)W9E6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$ M)W9E'0M86QI9VXZ(')I9VAT.R!F;VYT M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E M6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E'0M86QI9VXZ M(')I9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE M/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)W9E6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE M/3-$)W9E'0M86QI9VXZ(')I9VAT.R!F M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)W9E6QE/3-$)W9E6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E M6QE/3-$)W9E'0M86QI9VXZ M(')I9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E'0M86QI9VXZ(')I M9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)W9E6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B M;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0M6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M6QE M/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;FF4Z M(#AP="<^/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@F4Z(#$R<'0G/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0MF4Z(#$R M<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$ M)V)OF4Z M(#$R<'0[('1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;FF4Z(#AP="<^/&(^,C`Q M,CPO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@'0M86QI9VXZ(')I9VAT)SX\9F]N="!S M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/BT\+V9O;G0^/"]T9#X-"B`@("`\ M=&0@6QE M/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Y M)3L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@ M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT+7-I>F4Z(#$P<'0G/BT\+V9O;G0^/"]T9#X-"B`@("`\=&0^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\ M='(@6QE/3-$)V9O M;G0M&5S/"]F;VYT/CPO=&0^#0H@("`@ M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT+7-I>F4Z(#$P<'0G/BT\+V9O;G0^/"]T9#X-"B`@("`\=&0^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P M<'0G/BT\+V9O;G0^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T* M/'1R('-T>6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I M>F4Z(#$P<'0G/BT\+V9O;G0^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X- M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE M/3-$)V9O;G0M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.#EE.#,T M95\U-&4Y7S1D9&-?.#DV9%\Q,C,S,F4R.&(R-3(-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO-#@Y93@S-&5?-31E.5\T9&1C7S@Y-F1?,3(S,S)E M,CAB,C4R+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^ M)SQP('-T>6QE/3-$)VUA'0M:6YD96YT.B`P+C5I;B<^/&9O;G0@6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V)O6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE M/3-$)V9O;G0Z(#AP="\Q,34E(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)W9E6QE/3-$)W=I9'1H.B`Y,"4[ M(&9O;G0Z(#AP="\Q,34E(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X M<'0O,3$U)2!4:6UE6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="\Q,34E(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT M.B`X<'0O,3$U)2!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT.B`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`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L,3,S+#4T.3QS M<&%N/CPO7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO M&5R8VES92!P'!I&5R8VES92!P&5R8VES M960\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO M&EM M=6T\+W1D/@T*("`@("`@("`\=&0@8VQA7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC'1087)T7S0X.64X,S1E7S4T93E?-&1D8U\X.39D7S$R ..,S,R93(X8C(U,BTM#0H` ` end XML 23 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 35 146 1 false 9 0 false 3 false false R1.htm 0001 - Document - Document and Entity Information Sheet http://tnibiotech.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 0002 - Statement - Balance Sheets (Unaudited) Sheet http://tnibiotech.com/role/BalanceSheets Balance Sheets (Unaudited) false false R3.htm 0003 - Statement - Balance Sheets (Parenthetical) Sheet http://tnibiotech.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) false false R4.htm 0004 - Statement - Statements of Operations (Unaudited) Sheet http://tnibiotech.com/role/StatementsOfOperations Statements of Operations (Unaudited) false false R5.htm 0005 - Statement - Statements of Shockholders Equity (Unaudited) Sheet http://tnibiotech.com/role/StatementsOfShockholdersEquity Statements of Shockholders Equity (Unaudited) false false R6.htm 0006 - Statement - Statements of Cash Flows (Unaudited) Sheet http://tnibiotech.com/role/StatementsOfCashFlows Statements of Cash Flows (Unaudited) false false R7.htm 0007 - Disclosure - 1. Organization and Description of Business Sheet http://tnibiotech.com/role/OrganizationAndDescriptionOfBusiness 1. Organization and Description of Business false false R8.htm 0008 - Disclosure - 2. Summary of Significant Accounting Policies Sheet http://tnibiotech.com/role/SummaryOfSignificantAccountingPolicies 2. Summary of Significant Accounting Policies false false R9.htm 0009 - Disclosure - 3. Promissory Notes Notes http://tnibiotech.com/role/PromissoryNotes 3. Promissory Notes false false R10.htm 0010 - Disclosure - 4. Capital Structure-Common Stock and Common Stock Purchase Warrants Sheet http://tnibiotech.com/role/CapitalStructure-CommonStockAndCommonStockPurchaseWarrants 4. Capital Structure-Common Stock and Common Stock Purchase Warrants false false R11.htm 0011 - Disclosure - 5. Stock Compensation Sheet http://tnibiotech.com/role/StockCompensation 5. Stock Compensation false false R12.htm 0012 - Disclosure - 6. Discontinued Operations Sheet http://tnibiotech.com/role/DiscontinuedOperations 6. Discontinued Operations false false R13.htm 0013 - Disclosure - 7. Lincenses and Supply Agreements Sheet http://tnibiotech.com/role/LincensesAndSupplyAgreements 7. Lincenses and Supply Agreements false false R14.htm 0014 - Disclosure - 8. Commitments and Contingencies Sheet http://tnibiotech.com/role/CommitmentsAndContingencies 8. Commitments and Contingencies false false R15.htm 0015 - Disclosure - 9. Related Party Transactions Sheet http://tnibiotech.com/role/RelatedPartyTransactions 9. Related Party Transactions false false R16.htm 0016 - Disclosure - 10. Subsequent Events Sheet http://tnibiotech.com/role/SubsequentEvents 10. Subsequent Events false false R17.htm 0017 - Disclosure - 2. Summary of Significant Accounting Policies (Policies) Sheet http://tnibiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies 2. Summary of Significant Accounting Policies (Policies) false false R18.htm 0018 - Disclosure - 4. Capital Structure-Common Stock and Common Stock Purchase Warrants (Tables) Sheet http://tnibiotech.com/role/CapitalStructure-CommonStockAndCommonStockPurchaseWarrantsTables 4. Capital Structure-Common Stock and Common Stock Purchase Warrants (Tables) false false R19.htm 0019 - Disclosure - 6. Discontinued Operations (Tables) Sheet http://tnibiotech.com/role/DiscontinuedOperationsTables 6. Discontinued Operations (Tables) false false R20.htm 0020 - Disclosure - 11. Subsequent Events (Tables) Sheet http://tnibiotech.com/role/SubsequentEventsTables 11. Subsequent Events (Tables) false false R21.htm 0021 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative) Sheet http://tnibiotech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative 2. Summary of Significant Accounting Policies (Details Narrative) false false R22.htm 0022 - Disclosure - 4. Capital Structure-Common Stock and Common Stock Purchase Warrants (Details) Sheet http://tnibiotech.com/role/CapitalStructure-CommonStockAndCommonStockPurchaseWarrantsDetails 4. Capital Structure-Common Stock and Common Stock Purchase Warrants (Details) false false R23.htm 0023 - Disclosure - 6. Discontinued Operations (Details Narrative) Sheet http://tnibiotech.com/role/DiscontinuedOperationsDetailsNarrative 6. Discontinued Operations (Details Narrative) false false All Reports Book All Reports Process Flow-Through: 0002 - Statement - Balance Sheets (Unaudited) Process Flow-Through: 0003 - Statement - Balance Sheets (Parenthetical) Process Flow-Through: 0004 - Statement - Statements of Operations (Unaudited) Process Flow-Through: 0006 - Statement - Statements of Cash Flows (Unaudited) tnib-20130930.xml tnib-20130930.xsd tnib-20130930_cal.xml tnib-20130930_def.xml tnib-20130930_lab.xml tnib-20130930_pre.xml true true XML 24 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Balance Sheets (Parenthetical) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Statement of Financial Position [Abstract]

Accumulated depreciation $ 800 $ 118

Amortization $ 3,703,633 $ 1,570,114

Common Stock, Par Value $ 0.001 $ 0.001

Common Stock, Shares Authorized 500,000,000 500,000,000

Common Stock, Shares Issued 62,589,869 45,489,368

Common Stock, Shares Outstanding 62,589,869 45,489,368

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The cumulative amount of depreciation (related to long-lived, depreciable flight assets owned by the entity and used in the entity's principle business operations and capitalized assets classified as property, plant and equipment that are owned by the entity) that has been recognized in the income statement.

+ References

No definition available.

+ Details

Name: us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

8. Commitments and Contingencies
9 Months Ended

Sep. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

8. Commitments and Contingencies

Distribution and Production

Effective August 16, 2013, the Company executed a manufacturing agreement with Laboratorios Ramos, S.A. (“Laboratorios Ramos”) a current good manufacturing practice (“cGMP”) facility for IRT-103 low-dose naltrexone (“LDN”). Under the agreement, Laboratorios Ramos will produce LDN tablets, capsules and cream in accordance with the technical specifications provided by TNI, the FDA’s good manufacturing practices and the practices of Nicaragua and of any other regulatory governing body countries where the products will be exported. Laboratorios Ramos must obtain all permits and licenses necessary to carry out the manufacturing and packaging of LDN.

Supervision and Inspection of Manufacturing in Nicaragua

On April 23, 2013, the Company signed a contract with ViPharma for the Supervision and Inspection of Manufacturing Processes as part of its negotiations for a contract for the manufacturing of LDN in a tablet, capsule and/or cream. The contract sets out the terms and conditions under which ViPharma will carry out the services of inspecting and supervising the manufacturing and packaging processes of LDN and ensure compliance with the FDA’s good manufacturing practices and the Company’s specifications. ViPharma will carry out its obligations in whatever Latin American country the Company ultimately decides to manufacture LDN within. Under the contract, ViPharma has the exclusive rights to supervise and inspect all manufacturing processes of LDN in Latin America. The Contract began on April 23, 2013 and has a duration of 10 years, with automatic renewal every 5 years thereafter unless either party is in breach of the contract or either party terminates the agreement, without cause, with 90-days’ written notice. In the event of a breach by either party, the non-breaching party must give notice to the breaching party and the breaching party has a 45-day period to cure.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Statements of Shockholders Equity (Unaudited) (USD $)

Common Stock

Additional Paid-In Capital

Stock To Be Issued

Prepaid Services

Accumulated Deficit

Total

Beginning Balance, Amount at Dec. 31, 2012 $ 45,489 $ 196,632,775 $ 3,690,960 $ (6,082,771) $ (176,945,847) $ 17,343,837

Beginning Balance, Shares at Dec. 31, 2012 45,489,368

Return of Stock for prepaid services, Shares (350,000)

Return of Stock for prepaid services, Amount (350) (350)

Issuance of common stock in exchange for debt, Shares 1,545,833

Issuance of common stock in exchange for debt, Amount 1,546 7,128,615 7,130,161

Issuance of common stock for prepaid services, Shares 10,228,000

Issuance of common stock for prepaid services, Amount 10,228 51,193,872 (51,204,100)

Amortization of prepaid services 36,319,117 36,319,117

Issuance of common stock for Jill Smith/LDN license, Shares 300,000

Issuance of common stock for Jill Smith/LDN license, Amount 300 2,714,700 (2,715,000)

Issuance of common stock for Penn State License, Shares 300,000

Issuance of common stock for Penn State License, Amount 300 2,549,700 2,550,000

Issuance of common stock issued for charitable donation, Shares 100,000

Issuance of common stock issued for charitable donation, Amount 100 749,900 750,000

Issuance of common stock for loan expenses and interest, Shares 297,500

Issuance of common stock for loan expenses and interest, Amount 297 1,078,114 54,750 1,133,162

Issuance and modification of common stock warrants 6,932,057 6,932,057

Issuance of common stock for cash and exercise of warrants, Shares 4,679,168

Issuance of common stock for cash and exercise of warrants, Amount 4,679 3,688,809 3,693,488

Stock to be issued 478,125 478,125

Net loss (59,313,594) (59,313,594)

Ending Balance, Amount at Sep. 30, 2013 $ 62,589 $ 272,668,542 $ 1,508,835 $ (20,967,754) $ (236,256,210) $ 17,016,002

Ending Balance, Shares at Sep. 30, 2013 62,589,869

X

- Definition

custom:AmortizationOfPrepaidServices

+ References

No definition available.

+ Details

Name: TNIB_AmortizationOfPrepaidServices

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

custom:EffectOfReverseStockSplitAmount

+ References

No definition available.

+ Details

Name: TNIB_EffectOfReverseStockSplitAmount

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

custom:EffectOfReverseStockSplitShares

+ References

No definition available.

+ Details

Name: TNIB_EffectOfReverseStockSplitShares

Namespace Prefix: TNIB_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

custom:IssuanceOfCommonStockForCashAndExerciseOfWarrantsAmount

+ References

No definition available.

+ Details

Name: TNIB_IssuanceOfCommonStockForCashAndExerciseOfWarrantsAmount

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

custom:IssuanceOfCommonStockForCashAndExerciseOfWarrantsShares

+ References

No definition available.

+ Details

Name: TNIB_IssuanceOfCommonStockForCashAndExerciseOfWarrantsShares

Namespace Prefix: TNIB_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

custom:IssuanceOfCommonStockForJillSmithldnLicenseAmount

+ References

No definition available.

+ Details

Name: TNIB_IssuanceOfCommonStockForJillSmithldnLicenseAmount

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

custom:IssuanceOfCommonStockForJillSmithldnLicenseShares

+ References

No definition available.

+ Details

Name: TNIB_IssuanceOfCommonStockForJillSmithldnLicenseShares

Namespace Prefix: TNIB_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

custom:IssuanceOfCommonStockForLoanExpensesAmount

+ References

No definition available.

+ Details

Name: TNIB_IssuanceOfCommonStockForLoanExpensesAmount

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

custom:IssuanceOfCommonStockForLoanExpensesShares

+ References

No definition available.

+ Details

Name: TNIB_IssuanceOfCommonStockForLoanExpensesShares

Namespace Prefix: TNIB_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

custom:IssuanceOfCommonStockForPennStateLicenseAmount

+ References

No definition available.

+ Details

Name: TNIB_IssuanceOfCommonStockForPennStateLicenseAmount

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

custom:IssuanceOfCommonStockForPennStateLicenseShares

+ References

No definition available.

+ Details

Name: TNIB_IssuanceOfCommonStockForPennStateLicenseShares

Namespace Prefix: TNIB_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

custom:IssuanceOfCommonStockForWarrantsAmount

+ References

No definition available.

+ Details

Name: TNIB_IssuanceOfCommonStockForWarrantsAmount

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

custom:IssuanceOfCommonStockInExchangeForDebtAmount

+ References

No definition available.

+ Details

Name: TNIB_IssuanceOfCommonStockInExchangeForDebtAmount

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

custom:IssuanceOfCommonStockInExchangeForDebtShares

+ References

No definition available.

+ Details

Name: TNIB_IssuanceOfCommonStockInExchangeForDebtShares

Namespace Prefix: TNIB_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

custom:IssuanceOfCommonStockIssuedForCharitableDonationAmount

+ References

No definition available.

+ Details

Name: TNIB_IssuanceOfCommonStockIssuedForCharitableDonationAmount

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

custom:IssuanceOfCommonStockIssuedForCharitableDonationShares

+ References

No definition available.

+ Details

Name: TNIB_IssuanceOfCommonStockIssuedForCharitableDonationShares

Namespace Prefix: TNIB_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

custom:IssuanceOfCommonStockIssuedForPrepaidServicesAmount

+ References

No definition available.

+ Details

Name: TNIB_IssuanceOfCommonStockIssuedForPrepaidServicesAmount

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

custom:IssuanceOfCommonStockIssuedForPrepaidServicesShares

+ References

No definition available.

+ Details

Name: TNIB_IssuanceOfCommonStockIssuedForPrepaidServicesShares

Namespace Prefix: TNIB_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

custom:StockToBeIssued

+ References

No definition available.

+ Details

Name: TNIB_StockToBeIssued

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares issued which are neither cancelled nor held in the treasury.

+ References

No definition available.

+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568447-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4I

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4590271-111686

+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 27 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Balance Sheets (Unaudited) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Current Assets:

Cash and cash equivalents $ 207,709 $ 313,095

Prepaids and Other Current assets 45,000

Total current assets 252,709 313,095

Computer equipment, net of accumulated depreciation of of $800 and $118 respectively 4,612 944

Intangible Assets:

Patents and licenses, net of amortization of $3,703,633 and $1,570,114, respectively (Note 8) 19,265,260 18,688,270

Deposits 17,435 24,928

Total assets 19,540,016 19,027,237

Current Liabilities:

Accounts payable 629,797 286,698

Payable to officer 76,000 76,000

Accrued liabilities 654,892 427,211

Current portion patent liability 185,000 200,000

Notes payable 857,197 432,363

Total current liabilities 2,402,886 1,422,272

Non-current Liabilities:

Notes payable related party 121,128 121,128

Long-term portion patent liability 140,000

Total non-current liabilities 121,128 261,128

Total Liabilities 2,524,014 1,683,400

Stockholders' Equity:

Common stock - par value $0.001; 500,000,000 shares authorized; 62,589,869 and 45,489,368 shares issued and outstanding respectively 62,589 45,489

Additional paid in capital 272,668,542 196,632,775

Stock issuances due 1,508,835 3,690,960

Prepaid services (20,967,754) (6,082,771)

Accumulated deficit (236,256,210) (176,942,616)

Total stockholders' equity 17,016,002 17,343,837

Total liabilities and stockholders' equity $ 19,540,016 $ 19,027,237

X

- Definition

custom:CurrentPortionPatentLiability

+ References

No definition available.

+ Details

Name: TNIB_CurrentPortionPatentLiability

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

custom:LongtermPortionPatentLiability

+ References

No definition available.

+ Details

Name: TNIB_LongtermPortionPatentLiability

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

custom:PrepaidServices

+ References

No definition available.

+ Details

Name: TNIB_PrepaidServices

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

custom:StockIssuancesDue

+ References

No definition available.

+ Details

Name: TNIB_StockIssuancesDue

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_DepositsAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsGrossAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of obligation due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22, 23, 24, 25, 26, 27

-Article 5

+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13, 16

-Article 9

+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a)(5))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesPayableRelatedPartiesClassifiedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_OtherLiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

6. Discontinued Operations (Details Narrative) (USD $)
9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Discontinued Operations Details Narrative

Cash flows from operating and investing activities of discontinued operations $ 0 $ 260,746

X

- Details

Name: TNIB_DiscontinuedOperationsDetailsNarrativeAbstract

Namespace Prefix: TNIB_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

+ Details

Name: us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 29 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

7. Lincenses and Supply Agreements
9 Months Ended

Sep. 30, 2013

Notes to Financial Statements

7. Lincenses and Supply Agreements
Patent and Subsidiary Acquisition

The Company entered into a share exchange agreement April 24, 2012 to acquire all of the outstanding shares of TNI BioTech IP, Inc., (“TNI IP”) a biotechnology firm incorporated in Florida formed to acquire patents related to the treatment of cancer and HIV/AIDS and autoimmune diseases, using Met-enkephalin (“MENK”) and Naltrexone (“LDN”). The goal of TNI IP’s management is to enable mankind and civilization to combat fatal diseases by activating and mobilizing the body’s own immune system using TNI IP’s patented use of MENK.

The first patents acquired by TNI IP were acquired from Dr. Nicholas P. Plotnikoff and Professor Fengping Shan in 2012. Dr. Plotnikoff and Dr. Shan have been specializing in research activities directed toward the study of cytokines, which are hormones naturally produced by the immune system. The primary cytokine, among many others currently being studied by TNI IP, is MENK. The Company is focused on the treatment of cancer, HIV/AIDS and other infectious diseases through the use of our lead compounds.

TNI IP changed its name from TNI BioTech, Inc., to TNI BioTech IP, Inc. on April 23, 2012. TNI BioTech IP, Inc., is the wholly-owned subsidiary of the Company. TNI IP was acquired in exchange for 20,250,000 shares of the Company’s common stock of which 8,000,000 shares were issued for the acquisition of the patent and the remaining 12,250,000 shares were issued to the founders of TNI IP in exchange for all of their right, title and interest in their TNI IP shares. The goodwill arising on the acquisition of TNI BioTech IP, Inc. was valued at $98,000,000 and license agreements arising from the acquisition of TNI BioTech IP, Inc. was valued at $16,006,000.

At the time of the acquisition, the valuation of goodwill and other intangible assets were determined using the fair market price for the Company’s common stock which were exchanged for shares of TNI BioTech IP, Inc. In the fourth quarter of 2012, the Company performed an annual valuation to determine whether any goodwill or intangible assets that had been acquired by the Company were impaired. The result of this valuation was that material impairments were identified. The Company recognized an impairment of the goodwill arising on the acquisition of TNI BioTech IP, Inc. of $98,000,000.

Patent License Agreements

On August 13, 2012, the Company signed a License Agreement with Ms. Jacqueline Young for the intellectual property developed by Dr. Bernard Bihari relating to treatments with opioid antagonists such as naltrexone and Met-enkephalin for a variety of diseases and conditions including malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, chronic herpes virus infections, chronic herpes viral infections such as chronic genital herpes caused by the herpes simplex virus Type 2 and chronic infections due to the Epstein-Barr virus and a treatment method for humans infected with HTLV-III (AIDS) virus including patients clinically diagnosed as suffering from AIDS and those suffering from AIDS-related complex (ARC). The Bihari patents were acquired in exchange for 540,000 shares of the Company’s common stock with a fair market value of $972,000 and assumed liabilities of $400,000 which is payable to Ms. Young over a twenty-four month period in equal installments to reimburse her for the costs of a New York City office in accordance with the patent license agreement. The patent liability at September 30, 2013 totaled $185,000. The cost of the patent totaled $1,372,000. Additionally, the Company will pay the licensor a royalty payment of 1% of gross MENK sales and pay a 1% sublicense fee on any sublicense revenue.

On December 24, 2012, the Company signed an agreement for the acquisition of patent rights for the intellectual property of Dr. Jill Smith and LDN Research Group, LLC (the “Patent License Agreement”), whose members are Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Moshe Rogosnitzky and orphan drug designation by the FDA to a novel late-stage drug, trademarked “LDN,” for the treatment of Pediatric Crohn’s disease. The patent covers methods and formulations for treatment of the inflammatory and ulcerative diseases of the bowel, using naltrexone in low doses as an opioid antagonist. Endogenous opioids and opioid antagonists have been shown to play a role in stimulating and rebalancing the immune system and the healing and repair of tissues. These patents were acquired in exchange for 300,000 shares of the Company’s common stock with a fair value of $2,715,000 and expenses of $165,384, which totaled $2,880,384. The Company has an exclusive, worldwide license to make, have made, use, lease, import, offer for sale and sell Licensed Products and to use the method under the patent rights. The agreement will terminate on the expiration or abandonment of the last patent to expire or ten years after the sale of the first licensed product. The Company may terminate the agreement upon 90 days’ written notice, provided all sublicenses are terminated and all amounts due and owing are paid to the licensor parties. The licensor parties may terminate the agreement ten days' after notice to the Company if the Company is ten days late in payment or there is a breach that remains uncured for ten days after written notice of such breach.

In partial consideration of the Patent License Agreement, the Company agreed to pay to the members the applicable milestone payments listed below after substantial achievement of each milestone event is achieved by the Company, its Affiliates or Sublicensees.

A. Upon initiation of each phase III trial, the Company will pay $350,000.

B. Upon positive completion of each phase III clinical trial of the therapeutic use of an LDN compound in the field of Use, the Company will pay $150,000.

C. When an NDA is accepted for review by the FDA, the Company will pay $250,000.

D. When FDA approval to market the NDA is approved, the Company will pay $750,000.

E. Upon the first dosing of the first patient in a phase III clinical trial for each Licensed Product, the Company will pay 250,000 shares of the Company’s common stock.

F. Upon the first sale of each Licensed Product, the Company will issue 400,000 shares of the Company’s common stock.

G. Upon the achievement of $20 Million USD in cumulative sales for each licensed product covered by NDAs, the Company will issue 500,000 shares of the Company’s common stock.

The Company must pay an annual license fee in the low six-figure range and mid single digit percentage royalties on the net sales of each licensed product with an annual minimum royalty payment in the low six-figure range. The Company will pay a sublicense fee between 10-20% calculated on the payments the Company receives from any such sublicense.

As part of the Patent License Agreement, TNI BioTech has the right to apply to the Food and Drug Administration (FDA) for the transfer of the orphan drug status, the investigational new drug applications (INDs), and the right to acquire the relevant clinical data set from Dr. Smith. The FDA has designated orphan drug status for the use of low dose naltrexone in the treatment of pediatric patients with Crohn’s disease and ulcerative colitis.

The Patent License Agreement calls for the formation of a Development Committee to monitor the clinical progress of the Licensed Products and will consist of independent scientific and technical leaders who are highly regarded by the scientific community in the Field of Use of each Licensed Product. The development committee consists of at least one representative from the Licensor Parties and one representative from the Company in addition to outside experts in the field.

Naltrexone in low dose is a platform immunomodulatory technology that the Company expects to clinically test in the treatment of other immune-mediated or immune-deficient diseases for which it has previously acquired additional patents.

The Company signed an exclusive licensing agreement with The Penn State Research Foundation on January 18, 2013 to license all of the intellectual property developed by Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Dr. Jill P. Smith for the treatment of cancer titled “Opioid Growth Factor and Cancer” and “Combination Therapy with Opioid Growth Factor and Taxanes for the Treatment of Cancer” (the “Licensing Agreement”). These licenses were acquired in exchange for 300,000 shares of the Company’s common stock with a fair value of $2,550,000 and expenses of $160,539, which totaled $2,710,539.

The patent covers methods and formulations related to the treatment and prevention of different cancers. More specifically, the present inventions describe the use of drugs that interact with opioid receptors (naltrexone, naloxone and the pentapeptide growth factor Met-enkephalin) to inhibit and arrest the growth of cancer. Endogenous opioids and opioid antagonists have been shown to play a role in stimulating and rebalancing the immune system and the healing and repair of tissues. Such efficacy has been discovered to be partially due to the functional manipulation of the zeta opioid receptor through exogenous and endogenous Met-enkephalin. This receptor has been determined to be present in a variety of cancers, including pancreatic and colon cancer.

As part of the Licensing Agreement, TNI BioTech is working to acquire the orphan drug designation (IND) and clinical data set from Dr. Jill Smith.

The Licensing Agreement calls for TNI BioTech to (a) use commercially reasonable efforts to develop, commercialize, market and sell Licensed Products in a manner consistent with the Business Plan; (b) expend a minimum of $110,000 (per annum) to develop and commercialize Licensed Products as soon as practicable, consistent with sound business practices and judgment; (c) be responsible for obtaining all requisite regulatory approvals needed to use or sell Licensed Products in the Field of Use; and (d) make the first commercial sale of a Licensed Product by December 31, 2016.

The Licensing Agreement provides that the Company must make an initial license fee of $100,000 and the issuance of 300,000 shares and an annual license maintenance fee in the low ten thousand dollar amount range. The Company will also make payments to licensor upon the achievement of certain milestone events such as initiations of Phase II or Phase III clinical trials in a low hundred thousand dollar amount, acceptance of the NDA by the FDA in a low hundred thousand amount and FDA approvals in a high hundred thousand dollar amount. The Company will issue shares upon reaching certain milestones including the issuance of a mid ten thousand amount of shares upon the first dosing of patients in clinical trials, the issuances of a low hundred thousand number of shares upon the initial sale of a licensed product and a milestone fee of a low hundred thousand share amount upon reaching sales of $20 million in cumulative sales. If the Company achieves all of the milestones, an additional $1,350,000 will be paid and an additional 375,000 shares will be issued.

The Company will also pay the licensor a percentage of net sales in the mid single digit range of the licensed products each quarter subject to a minimum royalty payment in the low hundred thousand dollar range. The Company must also pay the licensor a low double-digit percentage of any payments received from any sublicenses.

The Licensing Agreement calls for the formation of a Development Committee to monitor the clinical progress of the Licensed Products, which will consist of independent scientific and technical leaders who are highly regarded by the scientific community in the Field of Use of each Licensed Product.

The Licensing Agreement terminates on the expiration or abandonment of the last patent to expire or become abandoned. The Company may terminate the Licensing Agreement at any time upon 60 days’ prior written notice and ceasing to make and sell all licensed products, the termination of all sublicenses and payment of all monies owed under the Licensing Agreement. The licensor may terminate the agreement 30 days after notice to the Company if the Company is 30 days late in payment or a breach that remains uncured for 45 days after written notice of such breach.

In confirmation letters dated April 3, 2013, the Company received acknowledgement from the Department of Health and Human Services confirming the Food and Drug Administration’s (FDA) receipt of the change in sponsorship of the investigational new drug application (IND) for Naltrexone HCL and the orphan drug designation for [met5]-enkephalin and the orphan drug designation for the use of low dose naltrexone in the treatment of pediatric patients with Crohn’s Disease.

On March 15, 2013 the Company executed a Patent License Agreement with Professor Fengping Shan. The Company obtained exclusive rights to develop and commercialize the licensed technology. The licensed technology is the intellectual property developed and owned by Professor Shan (i) relating to the treatment of a variety of diseases and conditions with MENK including multiple forms of lymphoma and cancer and (ii) a treatment method for humans infected with the HLTV-III (AIDS) virus including AIDS and AIDS related complex (ARC). The licensed technology includes the methods and formulations for these treatments including but not limited to all INDs, communications with regulatory agencies, patient data, and letters relating to these treatments. The licensed technology also includes the following patents: 200710158742.7 MENK, its application is in treating leukemia and other blood cancers; No. 200710051586.4 MENK, its application is in preparation of human and animal vaccines; No. 200610046249.1, a nasal spray formulation containing MENK; No. 201210290150.1 LDN, combined with MENK, its application is in preparation of an anticancer drug (Pending); No. 201210302259.2 LDN, combined with MENK, its application is in preparation of leukophoresis for anticancer (Pending); No. 200810229085.5 Compound MENK as a drug for colon cancer and pancreatic cancer; No. o. 200910011030.1, Naltrexone as well as analougues being anticancer drug. Under this license, the Company must issue a mid six-figure number of shares to Prof. Shan and a low hundred thousand dollar amount for the upfront license fee, and reimburse Prof. Shan for all out of pocket expenses in connection with the patents in mid five figure range. The Company will pay Prof. Shan a mid single digit percentage running royalty of gross sales subject to decreases if third party intellectual property is needed to complete such sale or product but in no event less than a high percentage of a low single digit percentage and a low single digit percentage of all sublicense revenue. This agreement shall last for the duration of each of the licensed patents however the Company may terminate the license agreement on 120 days' written notice to Professor Shan.

X

- Definition

custom:LincenseAndSupplyAgreementsTextBlock

+ References

No definition available.

+ Details

Name: TNIB_LincenseAndSupplyAgreementsTextBlock

Namespace Prefix: TNIB_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: TNIB_NotesToFinancialStatementsAbstract

Namespace Prefix: TNIB_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

10. Subsequent Events
9 Months Ended

Sep. 30, 2013

Subsequent Events [Abstract]

10. Subsequent Events

The following is a schedule of shares issued subsequent to September 30, 2013.

Shares

Shares issued for default on promissory notes 90,000

Shares issued to investors 48,000

Shares issued for warrant exercise 837,500

Shares issued for debt conversion 150,000

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

6. Discontinued Operations
9 Months Ended

Sep. 30, 2013

Notes to Financial Statements

6. Discontinued Operations
In April 2012, TNI BioTech, Inc., divested itself of certain assets and liabilities related to its previous activities in the hospitality business (“Resorts Club”) by transferring them to Resorts Club International Corporation Georgia. Accordingly, the operations of that business have been reflected as discontinued operations in the financial statements.

The result of this transfer was a Gain from discontinued operations in 2012 of $260,746. This transfer is not expected to affect the cash flow of the remaining operations.

These financial statements reflect the results of Resorts Club as a discontinued operation for all periods presented.

The net sales and earnings of discontinued operations were as follows:

Three Months Ended

September 30,

Three Months Ended

September 30,

Nine Months Ended

September 30,

Nine Months Ended

September 30,

2013 2012 2013 2012

Net Sales - - - -

Earnings before Income Taxes - - - 260,746

Income Taxes - - - -

Net Earnings from Discontinued Operations - - - 260,746

Cash flows from operating and investing activities of discontinued operations for the nine months ended September 30, 2013 and 2012 were $0 and $260,746, respectively.

X

- Details

Name: TNIB_NotesToFinancialStatementsAbstract

Namespace Prefix: TNIB_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

+ Details

Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

1. Organization and Description of Business
9 Months Ended

Sep. 30, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

1. Organization and Description of Business

TNI BioTech, Inc. (the “Company” or “TNIB”) was initially incorporated in Florida on December 2, 1993 as Resorts Clubs International, Inc. (“Resorts Club”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on June 27, 1998. The Company began trading in November 1999 through the filing of a 15C-211. On November 3, 2004, Galliano merged with Resorts Club International, Inc. Resorts Club was the surviving corporation. On August 10, 2010, Resorts Club changed its name to pH Environmental Inc (“pH Environmental”). On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012 pH Environmental executed a share exchange agreement for the acquisition of all of the outstanding shares of TNI BioTech, Inc.

TNI BioTech is a biopharmaceutical company focused on developing and commercializing therapeutics to treat cancer, HIV/AIDS and autoimmune diseases by combating these chronic and often life-threatening diseases through the activation and rebalancing of the body’s immune system. The Company has been developing active and adoptive forms of immunotherapies through the acquisition of patents, INDs (investigational new drug) and clinical data and all proprietary technical information, know-how, procedures, protocols, methods, prototypes, designs, data and reports, which are not readily available to others through public means, and which are owned, generated or developed through experiments or testing by Dr. Plotnikoff, Professor Shan, Dr. Bernard Bihari, Dr. Ian Zagon, Dr. Jill Smith, Dr. Patricia J. McLaughlin and Moshe Rogosnitzky. The Company currently has offices in Frederick, Maryland and Orlando, Florida.

Going Concern

The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through private equity financings and short-term debt. Management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its products and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources. Based on the Company’s operating plan, existing working capital at September 30, 2013 was not sufficient to meet the cash requirements to fund planned operations through September 30, 2014 without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business.

The Company has experienced a net loss from operations of $59,313,594 and has used cash and cash equivalents for operations in the amount of $4,456,111 during the nine months ended September 30, 2013, resulting in stockholders’ equity of $17,016,002.

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 34 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

6. Discontinued Operations (Tables)
9 Months Ended

Sep. 30, 2013

Discontinued Operations Tables

Schedule of discontinued operations
The net sales and earnings of discontinued operations were as follows:

Three Months Ended

September 30,

Three Months Ended

September 30,

Nine Months Ended

September 30,

Nine Months Ended

September 30,

2013 2012 2013 2012

Net Sales - - - -

Earnings before Income Taxes - - - 260,746

Income Taxes - - - -

Net Earnings from Discontinued Operations - - - 260,746

X

- Details

Name: TNIB_DiscontinuedOperationsTablesAbstract

Namespace Prefix: TNIB_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the classification and carrying value of the assets and liabilities comprising the disposal group, and the segment in which the disposal group was reported. Also may include the amount of adjustments to amounts previously reported in discontinued operations such as resolution of contingencies arising from the disposal transaction or the operations of the component prior to disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

+ Details

Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

9. Related Party Transactions
9 Months Ended

Sep. 30, 2013

Related Party Transactions [Abstract]

9. Related Party Transactions

Effective September 15, 2012, TNI BioTech, Inc. entered into a one-year employment agreement with Joseph Griffin, the brother of the Company's Chief Executive Officer, in which base salary, the grant of a common stock, and health insurance coverage were defined. As a signing bonus, Mr. Griffin received 250,000 shares of restricted common stock of the Company. For the nine months ended September 30, 2013, the Company paid gross compensation totaling $62,338. .

In 2012, Webfoot, Inc., provided financing to the Company and as of September 30, 2013, the Company owed Webfoot, Inc. $121,128. Webfoot, Inc., is owned by the son of Noreen Griffin. On February 21, 2013, the Company entered into a formal loan agreement to evidence the amount owed on December 31, 2012. The loan bears interest at an annual rate of 6%. The interest is repayable at maturity. The note matures on February 21, 2014.

In 2012, Noreen Griffin made payments on the Company's behalf covering the costs of incorporation and merger-related expenses. At September 30, 2013, the Company owed Ms. Griffin $30,000. On February 21, 2013, the Company entered into a formal loan agreement to evidence repayment of the amount owed on December 31, 2012. The loan bears interest at an annual rate of 6%. The interest is repayable at maturity.

In 2012, Griffin Enterprises, Inc. made payments on the Company's behalf covering the cost of incorporation and merger-related expenses. Griffin Enterprises, Inc. is wholly-owned by Noreen Griffin. At September 30, 2013, the company owed Griffin Enterprises, Inc. $46,000. On February 21, 2013, the Company entered into a formal loan agreement to evidence repayment of the amount owed on December 31, 2012. The loan bears interest at an annual rate of 6%. The interest is repayable at maturity.

On January 3, 2013, the Company formalized the terms under which Kelly O’Brien Wilson, the daughter-in-law of the Company's Chief Executive Officer has been employed. Ms. Wilson had been working with the Company in 2012 and her three-year employment agreement is effective as of December 1, 2012. The agreement was amended on September 1, 2013. The terms of the agreement define her base salary, a grant of a common stock, and health insurance coverage. As a signing bonus, Ms. Wilson is entitled to receive 50,000 shares of common stock of the Company. For the nine months ended September 30, 2013, the Company paid gross compensation totaling $63,903. Ms. Wilson has not received the 50,000 shares of common stock that were part of her original agreement and previously disclosed in our Form 10 Registration Statement.

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

4. Capital Structure-Common Stock and Common Stock Purchase Warrants (Details) (Warrants, USD $)
9 Months Ended

Sep. 30, 2013

Warrants outstanding beginning balance 7,260,000

Warrants issued 2,567,918

Warrants expired

Warrants exercised 3,324,168

Warrants outstanding ending balance 6,503,750

Exercise price Warrants outstanding beginning balance $ 1.02

Exercise price Warrants issued $ 2.56

Exercise price Warrants expired

Exercise price Warrants exercised $ 0.63

Exercise price Warrants outstanding ending balance $ 1.83

Minimum

Exercise price Warrants outstanding beginning balance $ 1.00

Exercise price Warrants issued $ 1.00

Exercise price Warrants exercised $ 0.50

Exercise price Warrants outstanding ending balance $ 1.00

Maximum

Exercise price Warrants outstanding beginning balance $ 1.50

Exercise price Warrants issued $ 1.50

Exercise price Warrants exercised $ 0.75

Exercise price Warrants outstanding ending balance $ 1.50

X

- Definition

Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Net number of share options (or share units) granted during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which option holders acquired shares when converting their stock options into shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 37 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

11. Subsequent Events (Tables)
9 Months Ended

Sep. 30, 2013

Subsequent Events Tables

Schedule of shares issued

The following is a schedule of shares issued subsequent to September 30, 2013.

Shares

Shares issued for default on promissory notes 90,000

Shares issued to investors 48,000

Shares issued for warrant exercise 837,500

Shares issued for debt conversion 150,000

X

- Details

Name: TNIB_SubsequentEventsTablesAbstract

Namespace Prefix: TNIB_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21553-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=27011957&loc=d3e177068-122764

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6403732&loc=d3e21300-112643

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Name: us-gaap_ScheduleOfStockByClassTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
9 Months Ended

Sep. 30, 2013

Nov. 14, 2013

Document And Entity Information

Entity Registrant Name TNI BIOTECH, INC.

Entity Central Index Key 0001559356

Document Type 10-Q

Document Period End Date Sep. 30, 2013

Amendment Flag false

Current Fiscal Year End Date --12-31

Is Entity a Well-known Seasoned Issuer? No

Is Entity a Voluntary Filer? No

Is Entity's Reporting Status Current? Yes

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 63,736,639

Document Fiscal Period Focus Q3

Document Fiscal Year Focus 2013

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

No definition available.

+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Details

Name: TNIB_DocumentAndEntityInformationAbstract

Namespace Prefix: TNIB_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

2. Summary of Significant Accounting Policies (Details Narrative) (USD $)
9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Amortization expense $ 2,133,549 $ 10,685

Computer equipment

Depreciation expense $ 682 $ 327

X

- Definition

custom:AmortizationExpense

+ References

No definition available.

+ Details

Name: TNIB_AmortizationExpense

Namespace Prefix: TNIB_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

ZIP 40 0001354488-13-006363-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001354488-13-006363-xbrl.zip M4$L#!!0````(``%^;D-'0%A8?60``)PS!``1`!P`=&YI8BTR,#$S,#DS,"YX M;6Q55`D``P$WA5(!-X52=7@+``$$)0X```0Y`0``[%UM<]LXDOY^5?-ZM MJ=TJR>([)3O)EF,G,YY);$_LF=F]+UL0"4FX4(26+[8UO_ZZ`5(B)4HB13IV M$J52B4T"W0\:#[H;(`B^^L?CU%?N:1@Q'KP^TH[5(X4&+O=8,'Y]]-MM]^SV M_/+R2/G'F__^+P7^O/J?;E=YSZCOG2@7W.U>!B-^JER1*3U1?J0!#4G,PU/E M=^(G<.77?UX&,5QS8W9/X:I45;11T8JJYJ MAJ*IOQK'CR/0=T%BN(L7>YK6T\P[73U1[1/+JJ@E)G$2+;2HCWT5-,`?6?W5 MXS#TV0G^JX"Y@NCD,6*OCR9Q/#OI]1X>'HX?C&,>CGM01^O]\^.'6W="IZ3+ M@B@F@4N/LEH^"SZ7U=,&@T%/W,V*KI5$Y9D.HX>WAR1:2D:`6\JO(8&[7KRH MD"]L]>3-0E%66M2615E6U*,KY2+J'H_Y?0]N]+!SNJK6-;2L>$A'&R';/;B; M%601-W7-V=8^62*KD$3=,2&S1841B8:B<'JC!`S<";E/H](ZXDY)I8`'03(M MQ^7%82^>SV@/"G6A%`V9NZBWNU*Q`F#`R^7HQ)T2=#A8%A7B@`T9CZD[.7;Y M5)3&<724C0YDU$DD>/N)CA1!QI.)Z"*LVLTJ'#]&WE%Z&Q6_/HK8=.8#LWJ9 M*#E:7`Y#_S%6F/?ZZ'W(IQD^58NY_'G07>I?5*-!S.+YXNKB.O/PSHC14!$H M:<&`&='.+W\Y>@/C5K.L@6'9KWJKE9?J>J7Z4FTS,#[WUE'`*`IC=#9OELW) M)"WOK56C@9>KA.U>JO<*5;+K!0#9Q=2DF^U\%EV/0(?>A;_`@Z_+MM)'Q6^6 M#5BH2.^T:J2ODX`Y(ZTPJ5TCI2-6SXU8_:LT6&'$ZON,6/TI1^QFS_COTAS'%K<\`/,X\YG+8HE5\1B4E$EE&G1/,,NB M6/_=?Q+`#>V;\0!^C673T)BNVUNY7O5(5>7B]K0 MWR^@O[]$Z"T+"6>>QV(P'O%O"/,N@W,R8S'QORL>;+7!(51L"Q4'^KPP^CQ3 M"#GPX.7RX+E"BPBL=_PMO8RBA'K?!1=P@>RDM.&'.+(MCARX\IQ<>::@<>CT M%]+ISQ4A;D(Z@U!Y2\-[YM+H^R%`:<,/$6);A#APY3FY\DP1XM#I+Z33GRM" M?*(Q80'UWI$P8,'X^V!`5JR\\8^ M]DTIVA<8'E_G'HN"#_DBJ8?S;6TCW\7)M_TE#Q[S]( M&,(`DJ%@W7Q&BT&RT/+=L;&.QD\D&*]H*UCTD+1O M2]H/U/R.J/E,TX,#Q[Y/CCW7RE4IWP[,:K^OOX%0=Z#%D[J`9P\SA_Y]TOY] M42Y^F5*0QT-*T6Y*D;?H(W_A@S;/`6S3O[7R=>1ML<`B*%5\Y/I#IA9/IY;U7O8A^ M^-C6_,H>6Q7^X["9BTT&^W%VMFF5(2)2%]DQZG<@)E,F'9K:(*E+9! M_NV$A#3:J")EBBBTMP[`=[-!C\?NH3_6;8MUK_!P%3RH:'V\UK#!*L8RJ3FE M%S3@4Q;L4KO;+JMZRP1G]PM6*#.H1]G).T'.3W3,HA@S)#P324G)\PD/@-EV M?,O=U:7R]O+Z[MWY3QWE\NK\^%5OD\QUG>??R%SBLKS8^]C=+R MZBZXFZ#30W=:68NF=G^5\O/5R\3>B.'W3GJPRO+S`76CM+RZ,[CK88GW/AE7 M5C,B?D2EAH*`O.3S)`SQ,HM`/P2W0'$> M4$^\8Q%65GO%\P38(&U=[>_<3P((4O/WS*=AM*>Z%2DE])9V^$1G/(Q9,);' MC%76]B_T`+NDK6L5:,[!W&,>5A]2MU/B0SUE(5[!1(,$\SR$@NBR@2"[7!+X M/5RKWMA?C>(@6).T61TRK)XR_+E,W4)2IFPQI8PB&D=I#Q34K!RYI*!S%3
=1D8-GI]!%H-/$'+>M4K%5I;8]:8;1IU2W?4046-Z2[V=X\SR$\II*'7 M\82&^[;\,6(G`?-?'\5ADC\3WDE9VFJ>K]O MUU%^Q6,:W9`Y`>+OVV;3T`W;6&K-RZRKKTHS^Y:C#9SM^L3+<&F;;S"+Y,$- M)(M!G)EDOC?3\3!>\"&[-33#4HGN?:LFEH57<%T.,X;,;!`EX`JD1UY[0\&$ M<:!I.4=4767+:*N8TK;,_D!O!>V[Z_;]J"_L2L;8ZA$)WW@Y'U4-0PY2^T=@.R^8>8[(R>SIKJ*TSI3 MUHU$`@/_8$'XYB&TW8#DF;F`M)V%0W1;+#* MKOEU/CZG+N&&A,(=^"2*\#&%US3M6NF+&BI;1KL/U15=S[($);CG7,[NUM8.OBK6Z,$G1+5O7U'WPE1VNL;>E;+6O M.XZ6NNP5J74U5FN[.K`=QS(KJ!0FT@N;.-&RTM MFSB?RJW;KHC=1VVUO-O:4RU$W.M0G)K@B:(W-!3/\RL;('O\GP-T>?7^Z(UZ MK*I:*:1-*EM"66JO+X)2ZCA+X@D/V9_4JV;##<@L-?U3BFY554-4ZS;[,JCD M@7Z-["1&G&'WMP"26AJ`J6P>,0[[=OE0K`7F.HEQHQ%^!>RIS9-3U116FX8J M@95[%%\;F-R&MAN8X1@0S0:%Y_XU++;Q*=3U`V1YZAILR@3+X M]Z3'K@6WIA#J$D2W5(6!Z>F#OK]HI^ERLXK69B5B6IAK%!]I;5#;&5W]=P,HO##XMN+J, MLTU-=_+[4Y_<=K5HU\1VM]3W(2C^2`,(CSZRU)NR0+S^&K/[-B>JAF':FCW( M,;":[O80U^6D90\T77L^O+4CK&[#G$]]1L2UF=M73X3>`>2HSI58+'7UV/UK;,"/=6GXN;=J19,*'I6[F= M1+5PM-Z([93=T`AMX*BV8VHOI1';F;VI)P8P+[),ZZ4T8OL`V-`(0^U;AJ8Y M+36BU/]G`>(Z@-LS'A'_>E1:\(DW3#P=N-I+_ZM[*=J!5O*8/:0DHA=4_G\9 MK+R@V,KB@&FH@^)N@.U*6T%9U^)]O6^IK8(LGO+2RM,IP[%49QO(HLXV,-9> M[',<=:L=RR&*X+K^:K76RD*\[MC]+("7Z-@'0^T5=]WJ.W9%#(OW5:CWGH?9 M`]56EHHUP]!L??6]F(*>+5`N>-#:XQ''RKVO6JYF'4EZ8G)*GE;880\,7;6< M/)`5+6M9YW5P2^/8I^UNZW!4RQH,\FGPNIXB57,/'2#^%DRX[8VQ??VX;6C` MXWMFKARS4[5*V]ED+F&!2B.W[F_B=A(=WXMD@;($TC MGQI7U]TNZCVR0NY1Z8E5RX[%J^P[\P:#P.O`F M74TPU9Y@6JJY\IY<;4S960#7H]RKC*UL"31@HK][<'!5^5JE$Z?VDUTI))A`+7NW?'DD^>I*6SO)"&2G M_14(Y>J:`:L=+<$TEKD/KNMP3()T/GK.@XC[S,LFISQH-#]51B#V1.G/8N6.36'$7]$'Y1.?DJ`C+W246VCOZ.B'<7R*HGLS M\=-?-"/])Z^NHK!398&K%-5"&Q&@'O+^!UU)QT%>NM8^5L\HQ@N;Y#=]']Q1!Q>A8^1$:RTC`BW"5#[%70)L56[=7 MT4H7U"'P,F.GG)*"*[@@;]8\%ECL`D/:*,J0P?I0X).)D":A[Q>^E6:'\ M0$EA"\PCAAO^%#Y2B*)9YUU=TXZ5ZUP-HZ/HJFIVELV9TG`,D!Y8/%GKF]*N MR?>':!HJA@%Z#[%*G'PAFPE5A.JS9`Q45C05->._A?HP^0Y0/8,+`7YR!KIQ M]I/R+KAG(0_0`Q!?P`'5>3.OE62958Z%*T*7\%7YI;3#;/7TZ\2_XE<5%D&' M#QF?06=-B4N3F+DIS7`,C_"#(E20R).[R+%GD5908HII->#[$Z_A=RG(3-2/ MD(TQQ-18<7&"$':4GRY_[YU=7MR*JB2).9M.P7L(*!ZDY@2G`T.<'D^'8HD- MY6$"`$XB8*XD\@AFMXK/1K0+OH/B7!<++JKG'0K!%%0^@,*J(1T27R:G&5.' MW%L$#OM4^HX4U**+HWD$X?Q8R7NU"7B.(:5%>Z`VZ<")QV?B%W3O@OQ"*)?F M86LP"P-I)N;O43I&KBXBY6],KH*,,[\=0-]Z83+^N^P$<)NBOR`Q(5(_C$6, M&"&C^'4?X)`[D458@)"$G([R.>`/W0E_Z&!AEWJ0IT3B9YC#<3]%,*7QA'O9 M]7@^PS(>C8"0^$.F,A1?W8$K#Q,&C$+?`>V%R^#X(\)\,:4'5@@[+&TP M2X8^].Z4$I2(PA8R!`*.!]ATE+'8"8[."1Q0:G<,G:D4^HB?D!-I%Q:(Y;(1 MTNDB/%9N?!X'[#,?C3H*3%E&-`(_KMQ.<'C@_;<8*4(/'!0,`2:O74+@^E\R M!DL)&'CI9P:6O9U"N)%%;D@<,J"_\O.Q\M']0``(=(9HPT<>0=]^XF,>02S^ M\_.\R*#TH%]?<@EPB0=8F(&$U(.&N)\[RD?H.U_T9^`)"-H`U.;!B#WQ")OTBMT(>Y2\'@OE*,6#&@8_'F M"X33:**,?/X@0FRV>TLAL?37'%QOOJD^NDKA6D22G<3@YH^5,YGZ+MQ1*D6( M%!9+579D2+CF3MA5"3H1#8'BX7IVRQ"+_'`VFAT@!@E M,XQ%^?;E8CSHC)!;(8@7ELA[Y2F9@YWO8:XA5=)B>R7H)/"A9>F/,63J3+;= MX\)<.7$/&"X6'030`BHG>R&!?`72A.QL5=&G!2HPF+P$7K3@F^RW'.6RP)5D*")+)6QBFZ710SLH,`0'G8I>[HVP]"CHK6Y`"QP:<%IGK M##>PH%LD491,9;)-XBWT75&4,/W%A0T4([2'U.4P M:N=97E]F2_F!+(0L_!/T=30B;N9T_-Q'+5)7&6"F[&P?1_M08=0S,ZUL!Z=1PQ7REY*!+N8&^#J#S$V@]_/6.\P17H8C*@3+)"")Q^3R=HSK M")7#Y_^W]R7,;1MIHG\%E;5K[2I*X2TJV=DJ698397UH(V=2^UZ]V@+)IH@Q M"#`X)#.__GU'=Z,!`A1O@A1FW\R3)0#]=?=WGVCNPY>"(3JY6#DRI!5H8_"1 M*2B,TG^!00?X._(3MNFEL$DY[)%A7$W0"V"GW/-75W>F:U[)LB!VI8T0B`=L M-:NX)GWX_/X<=@\:/0LW?.Q&>74Q9N^$(6(EPF*L=7]S;2Q5(^D_86:(C'7^ ME`S/$NO4N7^RR-F1Q%9:#>F*)DLBP`:Z!(E6$M2UY%['E,F*;Z%`[G^`I:U& MW5*3W`D*S;8PZ*`""/(#YH'XVAG?9+:OS_Q*'D;^9T-4=N7*9S]>R554M.1" MB9#?8L"&1D_]4T8;I.._Q6ZG1/0T.^I!!.++(/(IC-*0D"F__$S8@11;<\?, M-Y,@^T!S^8(C9NT65%YW"'A/[CP\:WCO7Z"NT:;-LUOM\)6S$!D^-OI[]L*9 M;M$6]J7V%XC(!YO+?Q!D<1`LB15E@H+R*::;I>.[`M5])K5++NK$B2)T MW`HPN8,7OC00"=6U<$"OSHSL@Y,0.+S3*L-:8IUZ4OIC@U M>AWDD<`Y"'3G8#`!5[0I-A2(,>S"(2])HM\@=`DD-$F7H@U!0DV^04V2F!*G M%L7&@3`GN62,L1;ZW-A_0D=-C2U,W`#`#<>`7@+#_GR#+$YZ$V!E:0H%*`]) MWS>>?4N`)+E1#"#TIW//*?H%5('V2K-HD+(\S@KX)2RAD84+:)T/OXZ2B)1G,TS*%D$X625F\2UQL;*/<4Z/J* M@2ZNXF`5ON)YI>!Y1N`O=-!K22K4V'D8`\]R';A,9"#ZVIBU^8$#L-FD:FE_ M`G.?(<6<1JC`4DT:,])`:/T&]!(*FP%CZXM$Y3,\MN?6=:$S5X46^K;WS1J* M"44>!"F7L#U.A*3TDC#Q=!#(!J09B)3NS<&\2$,NPV*^)V8J$Q,#19+A\ID@ M!Y\H-(.9Y?== MF?FC3L@\&-0,-<<'^$@K?<2!>Y7&=V#^B$$R3SH]E.YW#0:B$UF_.^&WBA,> M%G[M]9&^`$P),&*64Q_3\#A+/(S[_U)JEF*<')--;IB#OWR]`5PO46;")@KC M5&0AIEBR0X$Q/^14`>.3M000WQIAFAB&D9G9`!\*XP`]#C6E^&%^1,3IU$,Q MLC'VVI]E5$+3">8V>X@UDD;AIJB,KZ,_`PS%X/\;P36 M7V"4`G9@!"G-OQ3;!B5-!)Q*$LH]TN>D[ACRGXPT)]/;J7,^(J'96V$(XFDL MO.PV,(!%-C)9[V/;DWE'04#VM=YK-`;.GK^#\SPKD>44?J/[>=Y*>ONIRIO`A$"YO8R< M*U."T+&SZT/#GVC\DVD,R$2@ZOX@+UZ:'CKB9]Z*T!UC6$I(JQE984UZ`I)Y MO:A;ZR9+YU9J9#/E*R#C<#S6=FW*B<5$QS,7PSHR=_%1<#Q&N4LYQ!.'`C.C M7>"G.IK'`E#%Q!,',J7>JJQ)=%^@\H]1'XH]8](PY0J3UB`K<8`C,H<:C&TJ MD+0?,+[.">:>C$08J?&9O$V9_TGQLR2;KC""9:3*Z7P)BH5C@NZK;H^# MXJ]:S8N:S-P,,>>=!$L5)B\-T6B>EHRSYM@`(6G%TLJJED39S2[_PM6$NWN?$?_*L_2[-2#HUQ M&2(S5,U,K2PC#='I044@SO<(@_B2229HK`T-+)/1`@!WX?I/\&WTXJ!B[`<9 MGDUZIM0FI8,U1V-\OVH:<=I(2L[D5;-VT:C7.JU+VE=,>5)S]U)0C%UT*7S^ MY]:;>Y`CV/T(D[.*GU^^*2B5L<%63ZC1A6HA3+,#@.K5Z[5Z MO6X)&RZ'TN[T'H'H32%=V0-'R)TWEYT3U,1TC`?H[*/O/9Q]Q"Q7JY*D+T"2 M9EW[`@4',2`7,<$E3)`G$"VNO5< M?Z#JBUFSJ#,FYYP!N?$XWKP0$3C M81KW195+6(3J*H^9<@<.,)\P>D)MA*,J\U=CRXKB!%`SCIOKF,JNC;Y2$8@$ MON%J$E?F8:IW!GZ`XM7G+BY3ZI6%B$=9Y)4X.T(6N;$X4\-$-<8:(T4MMADJ M:790^.=NR"B]9^LAY14"/J747K-/`EEC\%@TFV+/&'?&R=X.U7"#*6*[=J`J MB?H@I$:4Z@)RXTQWH@DC8-M"=I#1OXTX.ULWAJQ1$YL4D%R1[L58F4N65,T: M"0H(.$,9L1%OE,+(#'P/U$;?5(6>>1Z;GP$CU#^3)6-E32:!94)_>%V/; M'1D(([!J/F(9"Y6;*UF+0CT;["$*$5V>$W MK+BE7DO8\TQ;[B"*Z@:H.D,_ M4%?A8!L&RD5EW$WI5N@L@0+XF?-O@8U&=E# MYRMJ1V;"*QV2'6$[.>4?2*"I:8()Q,@%>_2YU%NSWX&DORHSXM"FFH>M"#C\ M;7\_@=1\M;',#95@2T=BJHV`G6&+'PA1B"+D"<_&X)9 MB\KW5QQ:<=JA`&Y#GE;[>T$N1$H_YU9!0C>&B7B07`B?%YYL12(M1Q**25F3 M6"@P2);L M5H;0M"L9?AT/6(C9EI:RF%3M/U%H+ITR9U1Z8!8AYZ&!JCK?,-,"\HC M03M=&_9LOJ,E2A!H&YZ]QFD8%]W(1-A8X#@L/#7S!.SIU*6,1_@S^0F0(>+OI9)#3<>`A%/.!X)C/A(R MIG9.&(S'R7<)!-C52@-@^.H+`-D7#NVZ&NE(\$IK'33<]8S:?FE$`Q2P=6&Q M&AM!^$!S*I`W?_:],ZIPN)95*?96&J94'&%E[4>*!U5Z+HW)D,Q#?9%F9`^K MAZC7\QG+^BE;:!;V"1^&7$N-_@:P+OV9D!\>@B8TB,#@,ZQG#M3)Q[BODN5/ MI?FH]8@\1ZETOY(X265Y):=;A5V4`H'RO1=0C191;8LA0;)5T/S=Q->>\Y[B3E?T"54?7(P8\\ M^)A[0.T[YCNEL"2+XD=5 M:_Q3D?R'^NE(V('6.#[+6![.P46ZX#:QNX(CGS_,CD")5 MY0<9Q^1[U1E2Z@4[B@*G'T6N8M4X5WQADP.3C8]P4#>[X#DQ.R,-\2^&]W(S!F=P0D`!+@O_IO<)_6: M+C@*CB.98:'4DZJ6FGWJ/(!-!FQD]PIC(^>89\8S"V@G1E^W&O?XPL,%:]`( MJ*MR'7UB\L)C536IKH)O`E%4:IQ\@3GX8=2ZY"@7R8U+V[(2,"]5U/PN!BJE M*Z^LKI(Y^S=7N3:0?)O(9@QE6^"(*+R?A\!_BL9JIHVA2=NH_(Z(;P)7N1?< MU;!1;RB]^;=X,@4N$8`"&@?6.]D$&B\\B.)I*!$A,CMU_O;EW;T%OTMUZ\0$ M'=5\C=SQ9#^2B_=5`Q-)U7^I@YSG8802H`Y#U>I>4C`TW\U!@E,-K_2T$C1>34I2PF2KSRX*[@ MMP"GHUP^AC46ZHI3+M%,SKCYIO_V3>.M/FEY;)7]O#.(KV0J--Y8JB.5[_GH M1$W9A5)16:;0F#O$3J=@=W-]:A)P\@/.G.L+'HR4J$>FQY[2*^7)?O;&]P:I?]991Y8\;_6_4&/Y:T@U+A MY(Y4\:H?>=6/O.I'OI-^Y`N1G=N0L^Y0M2+'>%C*X;^U5N1E8M$;N4E.6\:M M"W_5`;WJ@%YU0,^S7):S0;*6RQ^A^#+2/;TWL5`:]:TQ![(A_N`VK$7]QI]G M5EL$Z##$*\:3+,$BEFE5UY0_S_C$;56_0NE`#3--T?HC-W M&?9_*JRBZLVMM,*7UIL[86=+,:PY+FT]QN&G\Z&=ZVTZ[:9=CIL7.Q MJJ]V:?IJ&^RDF#-DF0@VB:;^T,:85Z/5+[.@$PG$5`VQ3R`LL_'Q5-VWJ^[; M5??MJOOVKC,CEI*L67&L^FM1=RVP"'1OK:2[W.GH]MOOGUV&_1V[1E]UT#[V M#MH)#UJ"G60Y4-([]XH.&'B7$PGJ8GE2QD#5ZOKEJ?Y5J^NJU775ZOIT6UTG M@N]9*985>[_X_A"/`H1D]MW3S$JNVE6_=&E8M:O6[K.J7775KGK7(FEY"9.5 M3:K1+[QI-&&^8<&^N5%6`I^#EDJ[[CI=AKT>NX.HZCM=]9VN^DZ?4M_I1$@M M(6KF'8;8^O&K_?U$[:13ZQ5=&4558^BJ,735&+IJ#/W2NX-4C:$/[1,HTIVR M.M:-'7A`G^&="*C3X8F6LNRBK6,9]G?L%G_5]+%J^E@U?B];D]S(KYE68$D>WMA?-N\2#6O MXLGGXH\SU/GP:K`UF!_,S+H9)U"E&ASEP:A&Y$<\%N55D]E?XK9+QRB4YPB! M2V42V+J'!"E:!)!E\X?QW29S5:5@43,64.[)D9/2$:6N14V&E(YO8WJ)[:D* M=AV@P?`6=X_A_5')"WRPT;:&]BQ,0B2JOMV10X6*MF?)K3DCF00)V,Y9",CN M*>N;E4]Z4)=M(HQ/U)]BX+NNRL*SY%"8Y?._CX$`(Q06=&["&PRG%B'@*568TBL*/G\*SQM.8;2;3\4#X9Q1:_M?9M='9 MT7IC(P:D:B_?ZGEE7M)LD^BA?LE$HYH"V&EO.H&22C>?;P])N>>M9K?6:K5D M?=%ECZRE=.JY)DZ3-A4T\FMUU?@IB"G(QAYZ-EDBK"B5>-Q];7';%2^><*DP M=4]#KY0C3R4AN12=I3[SJG[>K"<^N<.@?#D'0!X?&?R.B!19O_EC+\2R>$S9 M(5\?U5>GA@::])!-$*UW9>=C11.J7B\;95I$$XA;S4:MT[Y@BN"?ER&(.7#H M"](&K'#\A>/X1_'=&2!R+^;QO]E>C!%RS>.+RG[H^UA-&S,H9/=S'Z["=PI$ MQ7,D06*B4:^U&I(F&LU:KY&EB8)%M8Y#K0'HF'3X=OLRH=XPZ67?6'::1'), M;?6Y.E%[O5:O4)24B$R_4^N!6E2`>"HB%XA(]H&Y`C\SR];F`)7O23()#;^>W??!)!B*OH2HUJCW:NW+CDZ2>E77,;65 M*A67*3D_>"9%@:-0^1._?KY]]],U5Z'>1T&,>=^"+Y8&4F/SO>1?=S*V^:<, M:V[H=]1;FD9Y!+YG,KO!HDZVA>>P&YNF89:[*X,.P(`?D85S"ALJ/1%9],RJ MU:/(I[%Y"SU*4WAQ"8YL8]^6<^NS;ZR84):THT=4035P[1#;_MOLYD[!@6)6 MKDX6.4;523K$?:X'HV4Q*T@WO0RT08\?GU*XB1>2P16S.1'Y.PI!D_4%`!ZE MEE,UMNYM:\N,"]/^LHX1<4SGJ)"V`BB8M%Y"E26MLU1W8V8,$!NV%/_-`-4_@(92T@/[ M(U2I1^]<>_#M['X`?!:^^%MLS$DD2M^R0S&J[6!N+<^J<=.*C[<.*.F2NIN\^>ACYS7J MXP:?;[3JKRO*-!1L=L%3$.(O,%>E.-;:=,HVUAIUM].L=5(>=8=ZG!9$$,:! M'S^,\Y/-%#K"A6$SYU`%$#26HO>?H%`/#"7S#;"$CAEOQ_"MZ!PY0]D65/@. M.CS7:.-+O6:WUH3W2+GY*T;TT/%(M9+2PQ4L%>)P@V`JH*%FN*C$A?%D@GX. MG(J2>$T(D@S#@7M;VE/!=A65YLU,%J6R#2-L(DD\ZJ?CN15.E1T(UPVG-C+% M?_Q0_X'^/47=5?Y[SKZZ!@#Z@5.S?A7N(UBI`QM`M;WP3,+[Y`RC,:;WU%__ M;/6QSW!PAH$P>QJ*GRSUTP\)/`A*H-8A71?$B-IFWX\B?Y(\C=86O3%4;YB' M@FF`(OC9PNY'9V-*C@5(&IW7>4<2#;?SU:UDINL,Y`6YBML"N+S'<"-YW'D``_4RJW'>@5,)?=<9IAG;'@Z8-C%Y+J^X5QW17O3`E\&HJ\7*L=AQR`29]G!,4J%5 M:S4Q?[JR/W8%+":]G-7/+SK'!/21G7"WV.:OQ%JU6&D7.P:QE@DZ';>[K5OK MU%NUB\H9M+^H4^?\N&)\":4>V;GW6HNJ%XLYSH^4[)CZU0$3,O>0,$M+WNN\):CJSV-HPZ_'4[V8?M[]CGI#" MJBR=RBJ27,(\!$1Y&9,5FSA=1O2[+IK[B$5S;ZA"[FTIV%&NB;J&\-_^Z=T+ MG`-G_;;QK,6?D(RBLDOE+!="4C=L\LF@TLTWYYIUM)B$I"'!NMGN_]PLHK M(>;-B.)DUL/CQS&C7:MU@%G+P3^?NCX)@FY4EL<"2N'AY MR+P7K+OL=6KMERB$7[*8:%1&Q)&1:;LR(I+#^.#'032NI,,^$M;;EXU:MUO) MAQXI%7-8ZO?;+.]T7 M+2&VD&A^.E=^%'3:/M][-+:\TF$^#E&)AUW%(6JM5B4=*NE0_KLIZ6?W)!W* M$'W(5D?EU_S,C9G"-^68K"W-OU+CM-34+2I9D'.5;V@N`GR(?OD.7A_>V3.< MD+;I_"R^L$;]X.,?\=V^=+5Y-$N:;[#=Y>NXE^-^<)`0_RB;QN'<"/C,HS-8 M7.#Q?$E7&4YAH_F$)=C`UH8%UFO-9B\S+=R<6U*SZ.:G/)[;"B4&\!ROI[$S M&*L!-S3^G8:<\Y>>'0I(4WMH=$DHU.I]I#F+!H+JZ3[)>!_\E0D<`<'SR(UA MX\*R'P)!@PV+@<#Q8[$;8:T`#G&W:)#*Q`?&1Q/,'N6L=B3VP!Y$:@P'3C_# M/>/CT6R*7-*=6=$3UOT1-'P)*PU$Y*D_'AP"#63)3+/3Q*>.GJ:Y-'`V8J-V MV>U8/X@$X,("IVYW:ZU&KW;1O<@` M0C"L-*4Q.Y0UGS*3>8FKAK>$Q8`/.((15G4\./AD MP'G.8,8CEP2W'EW1U31P7'G^(&*M=X[_50S&-0L.Y+R&D_=$B!..G"@4[HC8 M`Z@'MN-9=AB*B$6%Z]A]'#F%TP35?&`<*@=_!M1Y=/PX5,-M\!$Y/6OLAR3- MX>8(E'X<`KZ$H?5&":6+GW\7(:!B:%V[<5_]MO?S6YP-"(3IA2,1J%$Y$YK' M;3P/6P`3T+/EB,1K/YCZ`Z M&MRQ_8@3NH0'>Q^Y/(7+#GG4ET0D\WVY^Y'CV=[``<#""`Y,LJOC%$='+T_5 MM&?@0"`5^(J=4*,8#TRT?D&T)R:]X&Z34>S=>NVBW46.:GX*?O;\*)G7!DAK MCT;PL^::`SL<6R/7?U+R+!D&ERQ5H\JC8,4"Y+TA-A''2/$E0J9\ M%"+QB?-CU=POX)\A5DX.JPL_,&_P!+QNN](Z$G:`%!GR>-I\;H"C_/"R1S1` M+OQISP>@*FZ+FCGL[U+7Z*NQS+X7]-58['A.GDZ\'[L\DEQWR]X7Q,EX M/WYH:@38VG3S3/W]QOZ)KV.PX?0&LO_YQ#;%#=H4RWDCU)NEWG1Z=K,"&2RE MY_?XK%0$@FD:_K7]H5]I`*GHH**#B@Z.BPX^*[]61085&51D4)'! MT9*!FY<[L[J]HMZ0%I0>6$JC2G^V#D]698?/('NUX/.S7S-@[Q;Q=5O@`AP_ MSG,O.WQ'@1?-"B\JO*CX11G@.PJ\V#*_."(]:>\(40H#YG1W6QWO:2U8'6]U MO/N5$C];:\V$D='&3G/SG.S/(K+N,92\HBS6S8S_]!:O;/>4%J]L] MY05?UNUN2758X&G9=!,W*B>_+T9^(+"$S9\(ZZO]?6E/RRE>W+Z0=EG%]_3/ MN+K4$SSCZE)/\(Q/Z%)EO6EY-KXEA:'R-9P"=I9_[Z>_8'6[I[Q@=;NGO.#+ MNMTMJ0X[]#54OH7*8GD9"U:7>H(+5I=Z@@N^B$O=DFI0>15.`2_+O_?37["Z MW5->L+K=4U[P9=WNEE2''7H5L#!$9S%0IU&S';&5]",NSZ&>+`:72.=]:0M6 MEWJ""U:7>H(+ONQTANQ4&WCP%@4`=G5_5>=:%Q-!5YU9L.G="S;&@@4@?'6^` MLT-P]$4\G;JS*SW[Y%0&5>"[??SASHY@7W0/-)\H[H?.T+&#F74U^"MV0@=/ MC$Z\K\_^^-#]Z.E5]4M7LVZHF0U.$/%PU`%/^K'$]\'8]AZ,63V6G$32KO$( M!7P8KQ5;J+NN&H7@QU$8P>TCL2<3BXS!)=;MG9Q=0D`8HT3PH=L[]6\<(F); M?<>/X"4/#+N'F35R@@F.,Y*#0@AFZP/8?,[01J8QD>,:)%A3PL?4Q!,$,0J$ M'=&.<%B*#?09:)S]]?:?/U[=OK\G!F+'D>],)C$P(>!4P@[Q''&HR(/U241G MPOLFIF.X',\[//@VWB4!$_Z M/+H_AX`8GOW`EX$3*WRX.FK<#K__YB#`\-\!\%=7C0:"1P;^I&]'ULB.X,MJ M&SB>A5AQPJ,G/DZ(^5O.:@'K>C@SEB:`_"?/XO-(:"""D(K4$1!8IS%NU+`4:V)8GM$GP2#1\`GIW9V<@%@"8 M,-'VI"H@L?1<\PW;8">.EZ@8J.XWZ[5FIYX9=&A\Q10J)4QI(^F#R;*J%J$N1W11WJ>4Z.9!'C\&C\C/R&F-4CWPAT\.?,<.')*X3/:LOJ2WE7OQ>`5R MK"/H!*\ND_/B*7%DJACC&?4ZA&$YAV>L(K$S?Z5&%U;!_];WQD!2XKUB*KD; MN&)KC20'_$W/YTPNF:>2XDW:ZLX3)#3$">C\#P[JHC9/'20R&0K`Z8GCD?ZG M-$N:&0K[^B8BE)D#13_!,N0NZ9R^KHA+CM]<:&P8&L:M'.\'LBT:6W_%/(<> MWJ,9B_H\E(P%2U]:%J!]V)X7@QJ='`=P`+U)@$W0:>!K^I#\O-.A^81CD*ND MR9@Z5I01\`@S2''UY`NPLP+EG_"*3,G\):<(9.>I;^?-. MD]<4>XV*F<\"EF!(G)');2HEHD2NFH^2ZR>.JD)T""LBN5IS%V@].<#9/H'.\!O2IL#1\-;_@(+RH'4@U#9XN<`AW78F4*\W$^LC9"7]*>.[R`'B>P'WW-" M^'T8HV&%>JIV@:#8R/A/2#T"3A8X(II)SS`9)=HQ,_"]H:-F>$J/+-P"'CLL M9[FSR70,AUD#Y3B`I0?R-V",X<\B_B8F#OSU5W_X`,:9*5Z25W$=S_?.%CU$ M`*DU@-E/X28?G2`.M4GEA0D0R0/(C/4#^E34!A);\6X:Y.`'1Y;,D M'<>`E&H_``9=[:]?/_[S[/;VUGJ#EN1;`XKD.D"+=@@9!G"G_7;Q?:QA)-E?\B[:S(JN2= M]AHF!Q^(G5)D]`CT5Y<73?RD1ER0^#%J#^8(9GRN+15O.:,=764SP,=1:.A\CQH[2AOV)"KA`0R&5BA$\$PIGTXT!.0D6M1)'^ MP`]YY*E-+.A__.";=>T0V8V`D^`G;9JPC-X#WJMA(LW9"(6CU/4+O.\9V`$$ M2TX(1T\K;_0ZI!]87R6@&0,M>;#6XG/.GQ`]9%Z!&)AFFJ2_P$EK-8_W0^PG M\&?`I&;X9^5!:;PFA3?P0_;*&/-%X2EX!QX`PU<=RD@(5(J(.R>_#8"K>K$X MD-)3.3L7"-CW8L"HJ*(:^2+6,Z(@!5X$B:!DUH?/B%EX'(6K/L/?`"F9-"9` M;.U]08_G\026)^;5P6,``-Z.9'-3FC'(7D[ M4V#+ALN4M!]>']%X1L0PJ"'6,CYSX"K`:_& M-Z1I%MA#04QW:&P?3JF6;%4??\H;>B=`%N$6K.O`'Z>DN]0VI!^7CW*`K#>4 M\KIC4]H+CH6J,:IM]!XI!V2FXQ=5Z%84B2WZNMZ M`4VQ;`CD9NVBT=$^+ASK[LD;>-7H=FJM7EOY_[5T:=9ZO3K^I5"X*0XQYLN! M';APB8^"D?3)#UPPE8="BTLX[(G]3=3X%B:`PWCK\#\NXD,-+6X_B&HH@Z6H M1DE#$(?`011A4RAE&`\BOF7X*CKJ\8"D_D9.2'TM*:;$V&T;1@)\EUT7\)@R MYN%\'#GI'(5B'Y;Q/1.]75M'AR@"B<\+?!9^8\V`3P%HH\@`@C8B7^;8DJLV MPU&5*.V*F`!.)F!%*9CC*&]BQ,<,%Z"IP(E_=\T/;A-.&[CPZFB]B2 ML2;2F/F>_C['3-$S:T]`X8I8;28*>B*$IC"RHV/'6EV8V@&J<@QZ]K?I/>B3 M2/:!P.(>_IW/2@*N%M'AG5'ZGZ%^CW@CDH[658CAD6<:H^;`DQ"?T1?$OFSF M5[$WB`/E"5>?8@C21XCW138*?ZGRUQQH`[>LIA!:@08!1G`(>*WHD]&C2/2G M51G"/4)C5%PEHBE5@)!S.@4TYG0"!Y3<".601"_&'A?$"%JE`D438PT&?2(0 M,@@?_Q0_X'^+<<\T;]7WJ1J85VOOTZJ(FB]PO**R)_F%5"H MQ^476Z]W%)C(E;PKYKRJ+N(7.P+R#Y1&#NBWCB9(Q'H-#2B[0)#H-(G0&Y]O MB5JO6ITBI_@Z93'/W-LNSN'=-BYK9QQ32AV3>%-^0!@AO2KFN^,H4 MCT79:D]%C,Y$F1H!6A_:9BHQ0H9M0<,1[A#__@>J=?D7WCCV"[\NZX7_.<9P MFF=]!DN29,T`G4VL\`3BT8%7^S,-C[0YBZZI>>S7]+[4UX36/B@=H*HCM?G* MDXIW`=>GH<%KI*?$L.BB+M:XJ"4J`YJ5\G"`4 M7RWYW*SV.EZTX[W47TI_J1GK^%6S;GV"Z\*"&`7-'_?OD<0',3MA'X6,-FG" MSOK-V$?-IC2(S+`0&SI+8L/FI+Z'@KO%[+A*)CQX`8%VY,8DNV9&XIP9*)4& M$SJ30N?[VL)X2Z-^UJR_ MMH!%#F).9Y!0*_=:BFX#,1!`_+*0DF/)L)?D^R_$%5:^#5R%VAO[O//53(,< MVWS%%(BA$"=6@BHO[`??'\HBE_C!NAHB5H:1=/*^`3/IK1'0M+UP)(,KJN+. M"*J&D1W%4@[(HML'FS,A@$2>^"'IZ>4LH3>WG]^';VM)ZKL&41;1<3Z\*QXQ MS4JKG$,[LCFR`H2G2X`H?LT4@M8=;EN%><4P!U"]+^E343'/3"AT+I0[5:%< M>1\R[8BHNRBXFPW%#GQ,QGDI?N7R;4!)BR(*0G;I)AB"L7?M9;6M]YRI2`\" MXYQ@$JCK+[G1"K326$KL'_X;*@UG[EHJL[6(H9.81;./4*Y/Q4D_*UPX'#R M]("I!>M2Z?-8(85AE*>QSS5D0$,N,O('.Q@FD0[C?=2O8@^3HB1Z?T"WH:+J M/$YS5^!RM0U-+8_T-N7<'-R5T2A9=B$A_0[Q>HXD)V$^KJ8XZ.*6][)N*6* MZ2]Z28"S\Q8@W!MB#*$SY0RLB.]`&DL)CF:J9L%@*%$]!'4'* MXM0.?P(HYG+BBE%U36%D\^;QB@><9FAD>D9)\5*:6\L2$4H>.9L0ZY:6K*]_ M/11`%N3DT"DR2/DR.3(B43)%#ZX?A^XLR1ZQ=::?2B^ITNQ*A']9DR!)J-,9 M,U))IV2+=`([,KH[X7G6?839#CH+[@/&6Z0L\*S?;%#E`6$;/9U,FB2INKJ8 M?OFD=RN5!T>_R4]]TX7)F+^'5<^D_N0FGW'6.)7C!$E>&_XR>0\.M>_(#+JO%*":\<$5?O"K_=U6ME/M5KW5:ES+WBW$D MR?^Z:-!?*\%U8,:Q7#)F<8K6%!Y%3>J!Z7=$]$M0I*MFWN)V'6_L]!W>J!U0`3'5ZO&[N@G`N;5Q MHBCKR.LGBUI+)(K>HZ=#8!V"/>#D2H*#^D21JU/2*?S:DDE16&.25+J,8F\@ M]0%`+&)92, M1!R[,0J<)/+5++-\QAL@XDK[`IN9>NKZCI2,CYX/Y;A\Z!H2G>`UJ<1`]]AJ0%Z0NZ`5X-ZUW_+6A$6`RIO.&E'#5:;WDRIGMV+)V\- MX+2[)`5C7I)Z:(4^5D2A]89]>2C!M#8'6D@I5'T%G'Q65EK]*QX^X/$"N(.W MR%.QG1]^`"--2FOT^Y%LV8%*?R"X.`>??5`FK4HV"2U/B*'0Z?.8;)^?8V\Z M9V1.%ROA;X9O*9\_:?]!,=OD.'3XUI[[+)D9JNZHU2"KI5N1 M$`IM$0+8*@,T'=PB&C):JY!&!$H.U53"']-&CJ:G^4@9)N\#G=![F:@9INN# M/AR'^.;0=UT[D%4,A:$J0'XN1#%"3[XN7^`:@8*(-6@A2&'9E.ZDECE)A"4# MZT[FJ2!YW17DK$A^A9L9`P/0^EWNIFHRG4\=H4P4,XO'LE]+CD>>"_YHYIU) M`-!ANP0$.0?*\75IJM+14<$$XM'<@9F5ZUE\L"G<:=XHXP2#C=48QA(Y64-) M[35F$*0/N99:39;^YIX2L/D^]T(Q\%(OJ?`\86US\55;"A*%(I(4"I;C3I-R MC^G#X\P'Z3C!9(D))TOD)4B<6[?I0AF)N:'9ES*YA1I16>(WQ%IBZ22@*^W+ MBA]%C_I)@J5UT4EU@Y)O<$.H`W0VK!(35O=")JR0:F'25>!&E@&@CLXK4(QW M+BN!$Q94<5R&($(.XL@F0QPPC?O_$@,.L2Z3@#!'-9(EY;!XDDI%^V+'?PPZ MTQD!SG9-:K/4[DC)!9F&,#33$'017:6NE%!=V6?`5-:Y MVI.0]=Y%^\D4)S]7E-RJFP7!RY8DJ[=R*I)S"Y$MHPB9@&AWREZ'7,5V%]0F M`^/'MNR,P*Z`RP.N/J1H#/>8Y>9EK71RLM8N[,$WSW]RQ5#V-==I)N\%.ET5 MWO\J0#\:$S7\BNVI$(Y']!"9,"C#:E%"G1E`Y-PZ`F6JF8QL18$1#G0R^4$X M=J9);X_\G#HVUI*\.NG115EL]'[_]?JC=@84N8+QE?\[$5'G_YG]T99X2Q/T MNKETUC-Y=.]EDY0C1=>CIS?9LN@3Y4`T.BK;(967(P8Q];0HS$OENRWHQ_YL MMQ-VLHIADKU!(,FF1XE_V)KW#:>LHR2YJ'#)G&=EZ^GGTCBT,XW[4H,BF6R7 M6LB_<=ZFNQAF22*W$Z&5Z4+(/1:Q)YC1CS!V(V>:>*4GI$"KWH'\!4X"(2>R MX[Q=J0OBU#VC"B(P4O#(Q1F6T@- M&,'3CR,4[+`(V!]R5@KLF03FU]!)8WMX61N68_`0W6+QKU1J=WT6Z>7Q`^<"<+4Q@X M[#V@V"Z\K+I1)OV3^7!<%%LR+ORS]=D_EU^O=^#[W?/VPJ]/,9J>-`8A_)$N M+&="+8L'`PRN$`N*P!.T0Q MR$@A9E1?*ON(G=FV]''INA?M%6;_%3L^@<*0K2NDEY> MG?`_!47/:"P1_BLGGNX8R8Y#P^$W%'C5!"XU[PZ&E,4R*Q!I MCAFIE-TK!-E#?!/DAP^T\QVYJX.6DVRVXZ(#)^(]4(0CX^V3]4WY%5;)C18\ MH2XB;;#J9I<6)<@DQB6@#=K!:,$K'!C&"<61F3CG1)67-P93]U$$:815/3Q3 M1OU<=U+T+32:==EL*V-<2AQ.5(/BV7!+SW)3P]_4,#GVM=$S\-JUCP/DI"3+ M&1VWWB0XK7A.(^Q]N%H[\,/HT[#&CQYZ*-VEM>KM-3]_C]:@`^2BJF_EC"*D MHHTGU*VQLQ+Z%PYQ/S>C$0]I9-U5]C[OYKD/#$L'OA5CBF0O9R#2D;>>90WT!=/A_DAU=K23U+-Y^*4V+!>T"9`46&Z`\MH.`11!H)6P9I3&1=+O!-_M!1NCA M'M;RG1R$51X=\]#,'20SN@9#D[??>CS_E76-3ZE[@@O7>+=WSO\"+TJ-MC#G MC[4*)EN@-I3DTO_3N0/;8V)K!=*X:NNY:P;QCL0K*"<1E6ZEO](0-?'@Z]PE MGD6AEU:+I:F;Z9FSAYBY:MZ*H/R(EAYR5]7)7GZ,AO\H?H&J:^Z`"P[J<'!5 M;YJCK,AT]`="Z0/GH"OO77*>4!V-=(DOX$V*H MGU/"DQ8MG%E?M&.\*!_LC`=;C0&!(P+%'RV#C^A9L:XF@&5@]DIYD.HO:J%K M#N\LG2,,_NS.K-7Z M._N,L2Q\]A5[3MB#HFGGEK2:1GQ3M=?OGO+*^NQXX863=DA"$=?:'),4&->3** MK3XF_(:V"\IR31:DV8I>S;I-=OJ-.;KKH+PA.4/57NB&DF,$1^C&S1_U(B4H M*0U(HWW?PPXHGX)SM:$DV#S?\@X+YH#3ROA(4DZ:WG;NRA^D8N#A="T:RL.@ M8.;3T)J?!"!'BRG`DCYPJ5H8ED.+>/,-@7Q MJU:]<#;9)K3'HBY)H31HCU#=3);<+2$JZQF(T3(ISRJFNB/!Q".G'86"-W@A M8"*&^"R)ES7):',JDB`1D/-@.90#GLR1QUZFSTNPJZA0P@Y,JBP\#BXL:G=W M0J?62C3*M+13@5G1:#F\GJI94:[;DQ&(9G!K]V#*%_A?`LO&OR0.DG>!`W3R MI^.&:E#[$'L3P9MGCG?FVD\KF6])%PLV%3%4@E*-OY^,*U?-#;0ST.@(AQ@K M33IJK"'FC,^,#`-<%,K(E:JS)@%%`=G!9>A[F;"9Y7L&'Y!4RL_S\2E"TR^S M+)^_:X%932HZ69:LT9J8LL4RO'#+56-4%E M$G6^&=JJ7=9;&4P(*8U/V]7XU<504P4`&?.JE08Y%P('Z`MG1Z5L"M6T1S9[ M&[+3B=M%X03<#]BQKE&W?A M4[DE!W"UE92=JKS-)".3VAF&@[$8QER=+!&1"W-I4!F?*4KD>_=GUQ(H]%Y?4`_\L()`R6'>>!0MB^$=U M.>XJ,S8;Q_\9/W;]?7-S8]?B?', MU"M*;MCS=C<=W=78]_UL"G!VU-@A#OV2S+C3.?`M\8^GL1.)HQ*O/UL2=-+9 M%O`/:B*+9P4<#F[_LC/ M-H<1/#^Y=%D?IW;VP_]AWYC"&%%AH&\^:"B.RJ?#Z=L3B880,>Q4G$41C:U89!! M1JG"A)C3,!_BX8Y0V?0*3MG$\#/69PYCG?O"2?U4N.!Q0/6G>71:*D9TX%/< M.%EB2_`7AZ(XR)`;A0=PH[V]IF:E6BH_=&ZDJI$>SJ]6[K9W,A4 M$$INH4.4%)RL:&R7M_>G0"U##->SLTZ?J>[[FI\/TN]HST;$O>*PQW9Y=X$S MV`8#K@AO_W=WQ8FG>F.+[W(EM]?$&0[=+7NW]F?P[\*M:K5ZMV>F\/2KV^J=VJZ7*,S14RI5V M_&1\46MV-W)OEP?+7QW_;33.X2(TM$RKG?K/J&!5%U22"RHF^FWX`/)8Z9\8 M?%W$%K>BT![.'BD5DE9[J?92[65_.2@;\,6LBEEF%GE+R29)[HFW5/7JBNA1 ME,^SOB#=>-_-6J=[4;ML](Y?]J^JOI3P-E"_/'N9RF0)M]`\[W0K97('+I@2 M4EX977]'1S`O3&_:.W)7"IN9KX&C5HL#_L?&>3IEXCRG1#1[OY=38F;'N9=* M-SM%2BR5;E9QR!?'54YI+PLYY(9<;%/-M9=J+R782^5K3-(- M-7A%`U6.GX-V:YUZJW:Q<@2RA(+_1.+!N?F&G?-3R`A-V,\)1(L;Y[W6=OH\ M'*[X?<>+&7TFUFT?4=R'XKT33OW0=G\!,3,-;[V!&V,5+G8W]W'48"R&7Z:" M6[/CG_V)T`W:W]DNML^_'PL177G#JR'//;7=I#?Z=CI88/.-+1PIS882$8X) M$#S-5-@T@)KDTM#8,EVMK_?-#>]M'"F+C2S"GY;$A`W@5I5I15W&TR2SG>;@ MRX"[=G?P/$TE9R>Y_&O9Y\QNO:D_JT>V1JF9EM=]1J]`".N33[EO-YC[1I#V MZRNLL3 MN,N%GH7E1:]Z8T'7E4UP:]N?77NBA;':2D,KY'L]H^L;7:KV5R17O+S]51WV MRH?=K`Z[PNR3/.PM8_;N1<;.K;4M?KN"X9`PK(%P"UJU+U)?I#NBTWS]'`GJ M!JZ?163=HP=H1:K3LS%6YF(;OWF9-T]DZ0V?'<]&JR.JCJ@ZHAVPTJ>BS)J# M"9RB".C!1&`%^#WR)3+"EJ M53M\$3O$=F$7[>*Z]3TSDTI<5Y!7D)=<7%?BN=IAM<,CV6$EF(\,*RK(CPSR M\@AF]/!K6WH4^!/+3&>UDGS62FI7.ZQV>(Q&=9+\GY<=O[>D]F?F.[Z;7;MV MN&D.O,Y$6V$H5?O3\8&*[2^?$%:+`LJ!]'?/,DY&:#&GQ5$AY?IB/ M']),(C7/-M0C-G'._7P-V?D\ENUDY\49^1N<1@;MG]O%&JG]2R0\KIW9?U0# ME)\][X6\L.10KIW>M.R>5LI]6H5-<1YM,H5LG;2HLEW.6@IQ14KE@#*'E$H. M<4FAW*Y9N!4"4.'-XK\HP@C/UB561P:64]&RI7S>-N]36:@E>1H2ZA`E(X%H`KQQ,T?++'Y2/:* M%9P<*^BU+FJ=BA>*.ST6#4DIQM#B-8 M'!+*C<=DPS?OQ300`\?&@,^2L9K_E>_^[[4_F<:1"+`;TQ0#29\H0/&#%7L. M?^2/^_<_`&T.G(GMANBB_\]NKYG`:BZ^*F!-`[#F%@!K-2\6`_;U\^V[GZXF M/G#`Z1NL].[['4O5P%IKFN9CLW>X1'[WE44!4X_)E+^ZG_V M/80Y\%T7'KG%:`.8N0N.=O&57K3:+="##("W`L_^=KD,]30NZL`YZ\WCW>4R M9#*_;Z*0X]WT,H28(T"0!H]WT^JFDR2+.]L9WGK7]M2);'>)`VA<=KL@K"XZ MQWL(ZN;7/X3F1;,+TJI]`C1/*WSUWPF>++N,JM*]K%]VZ\>[=77_JV\=5/E> MKW7$J*]N_2X04\!YL``>G8$(E]CZ6;?>`[)O'._>U;6OL?O^R!O,:ID:CWFSVZO6ZM,?6`&[]S8'Q%WO1FG;M]]#YR7/< M?_P0!;'XP?IQ3V"LJ$72\:YSM@S4OC:UOH+4:30N6[V+9OGWN(8TZ#2:]79C M/>+(V=S-:"0&T9?1[P+=QX)>OY^Z3K1S*C]K=>H)D3\#QW(P;T2\Z6,&X)Z# M;)73W"4]KPFKZ>;Z,LI@RC;.L-5M-2X;C8LEN';`W26AO>7!H$ZOO- M<=W[B1.-W:'W$=[RX$9V356M>OT9R;D(L'6WM6>IN04@5J2QUCIGNJPLV<9V M-G$G--H79=_>ZM;R&>RKLQ8IK+"O.^%Y5$I4*O+.AVJM#6U/HC8[G35`W^`N M#LL.#K:1#1A!IWWY/"-8=V-:)[T&;'3(-'T/4"*H>S`HGT.]9Z';:(/;HZ*+ M9XGH63#VMY.5[=*CV=CZ1';1OKS<_3Z]F^^#L>T]"/C,>]'?O3'7Z+0[O59K MX;[R@5IC-ULDIT:KWN@V5@)[[4O8*>UTVMTR[F(#0FDT>]U&9R>;@L<_^K9* M[MB]0[-YB7S[&<$Z#]'*&]D>830:K5:CN]"#EKOV;D%>D2C@V,NV@0U"W_6+ M7J/1+MN&5C?,.NV+SBJTL,(VKNUP?.4-;V1*_)>1FI"X]]@;K!)6R\D0R#W<;AMD&2-)5FE?G^%M9>0R8L`Y$*?]\%_LB)/OKA5H(4 M9YW+5J/5N32R*Y(%5EMZU9SCLU:[V35S6M9=..\.ULDU6.4H2&*]LT,QQ(1S M$-1LH"(:/W!CI5GRR)T]PU]=/=G!\,N4VC`9:<.?8VKMLR!O1.6V2S)95BA? M-+OL+=D9T`.I_"FPAD8,KQY%8#\();7N`F<@5L8@ M_=M/CN=,XDD>C=P5.3S.=X18BW98HH-=B(35P>X(8Y<^PN9+/L)E&>3"(^RU M7O(1+LDW[>^KD_>.1,^1'.R2?/-4#S9\9MU?R`RZ]>Y$X/C#I0]WB8+-0PFH M[>WX6`][N6-MGG>ZU;&NA<,[9Q8E/NR;[U-'=_8]#"(7Y:]M<8^\@W+SQ?IV M<6JE31_QD2][N-U5]-'J<#?GD?7S5)GI08\P/6.'6DRW- MO8>K0>0\.I$CPOR.Y]MPDQJ4O1$L.]_8JD[89K=^T>[N:'?Y2,,(<>7!E[&E MLO,H[ES;"^]\UQG,UNL9?_C.[KA!VYM9$V%3SWP+C`I]_E!_01<70AXP\A`X`"4`NYW6,,>5(,Q5F5@Y_L) MCOL,A#UTW!F@8R2"B>-AHM>^VMKONX5]"2#.(*K<0+O[,V#48(!A-[S_*1,A M(J:@TDK`KQ#T.N+P1@=.O.K8C5#M)81\%-X0T!&>!N3FG"3ZR(/O#_F)4%:. M&',00D*?*7*;D/@9X-#5_;7UU9\Z`ZM3[YQUZC5+07I!VW=P+USU>4:V8VB%+H,>OYBLY M9"0U/F)<$B@'&SWA+]\XN2L4O6W>NK$H?A09E`M[*2+!YU2!A5Q]VPZHM,&U M+?VSR#+O8')+MA?1UJ#?]MGD6(3;/J!G+;XDC_=]'&!=-H'!K],?,TKAKJ^P MU6JV&ZEV4BM#F$X,B"?`F6=?1J:?4.8PK*3!'&RVR1::06XXTT&#V;UXK:7; MO*!<6D(><%2-)?^SX0ZV-UHDX0')!MZCH'.+AXU,EVN-F+WUR)^N?N6-UX?K M2/G"-S`_T49OJK>%32D,Y$P(O0/0A38<=_/"KZW:0$DVT-NFL-K19"FEM*2$ MT[;_\[PLV:)HW.UYD<^QDHW5!HY]`WL2[K^+B>UXRN>(F_CHC(3U9B;L('S[ M$D3\PL[\A[>M-A_=)<"*'6K@_CNV`T`F'#W:V>.E'B<9E@SJ11WX=[R11JW> M[*S1?O^$3K^">M&[KXXI#"KAFH];L5.*M@KK2W\IRZ,>)*A74A\;T$SOW4]??BEUPW1.[R9.'^H!T MWUIK$.X)G7T%]2DK<,FI8TG?,9W\<>)+!?6!M;C*"W=<6ERA%^[BQ"[RY*$^ M(-E?]CJU=J7V5U"?IA+7J!QP%=2GSL/;E0/NR%2W#WX<1.-*=SL!J`_I@*NU M+QNU;K?2WBJH3U9[.ZN\;Q74)\_*V^>M$SOWDU?AG"",\C2X4W.CGCS4!\V! MNZQU>NV7>_85U">MOW4J]UL%]:DS\?;YJ:6]G[KN5IS_5BEO1P;U0?/?:JU6 MI;M54%>Z6QD._#C1I(+ZP+K;J4G\'-WM1VH%B;]28R`7])C,-MR\Q58O(HQP M.N=GL>X$TN?:>BZQRA+MQXM6H4U?#0;PV^%'Q^X[+G4:_^`'=W$P&-LXF_5^ MXD3CCT/OSH[$=@:M-B\:G;J>3;[2\ML%?-.3N_8]P'KLH_QE1+/@O:&$25W; M5]\8NKKZV14-F6PWNFJ\ZXHP;!O^Q4?X7/-:"06M0(]R>UB\1N'!HG!S'YT! M]6W?UMDU.YUZ@GQ+K;T=:'=V4H&8`G.XE[V^MW90G4:SWFX\&UL550)``,!-X52`3>%4G5X"P`!!"4.```$ M.0$``-5=W5/C.!)_OZK['W39E]V'?,$P,[##;3$$ME+%DNR$N=NW*6$KB6H< M*6/90/:OWY9CF\2V+!GL6/``Q%&WNOO7'Y(LV9]^>UIYZ('X@G)VWAGV!AU$ MF,-=RA;GG:^S[L7L8;SSVW___2\$/Y_^T^VB:TH\]PR- MN-,=LSG_%=WB%3E#OQ-&?!QP_U?T/^R%<.7/O\8L@&M.0!\(7-WV>H:.>R,YXZ#LD97AW._Z,!J?'@Z/!\!@-!W\>]Y[FT-\(!_"MO-@?#OO#=W=' M@[/!^[.3$\->`AR$(NUE\/1Q`#W`SY;\DT?9]S/YZQX+@L"`3)P]"7K>60;! M^JS??WQ\[#T>][B_Z`/9L/_7'SU'WR9- M.XGXB3#?[P MJ'L\[#T)MY,8/[*@SSWRAPU=]^74?(`I7A`47 MS+UB`0TV$B]_%8D+*D3\ECZ9GWV"2_HOE M_(P]:=79DI!`Z`0K;-R()%/L@P&6)*`.]BJ)54A9EXPRT(B$1DSFD[7,%@") MUFSE5$W(-EMRY_N2>RYDK*L?(;A0%1G5U$W(>HG%\MKCCY7,F".J2[*)O\", M_AU!!/$W(L+QZ5I^FLP_AX(R(K2"5N%1FT7#U0K[&P"/+AB=@_-#_G`<'D(" M88LI]ZA#B=[$E;C4)?O4YRLJ!/47X@'>=R%.AUL[L"[A1Q>&V"MHZLOD]X+\B,$4UP]F""L M:G_8S%YOAF\JT[\\`][A>\_`C6OBWVQ6,]/%A+8IGS>3L)SJL/X_(@&FGKB5 M<,K9>CUQH.+:?CS$DC47$)D.FHV(JNA5XU(F.TP2G="+Z*%4?]^C($\!82YQ M$SY2@5=/^N&RY#(8#(:HBQ**W7\Q<]&6'.W1-RAX\<0^E?0(Q$MG7_!_W!QM MVZ.?OS(=/7,T=4>-8490N_:0DBGJG78W%!\ M3ST:P*12.R(H:MMF9=Q.B\44;^0$7S_"5K1OOW*J0!P,$."*'U8#LQ*3]FOP2\/1Q#@U`IQ??I+; M>+[%'4ZY+S6=@K^Q()%G4X"1)-+0M%]T]9`8J&%IB$5WBV,74L?0?BLS1$YL M")(B]:S#8$<;D_&IHKDE3K1S1U*BXV$AZ)P25YNG*S&Q:MA4,-)6>Z&A?9I/ MU3><+0+BKRKE:AV15<,B-2XFJMB?+(Q2A&6QHHB0UXY96O4SO4YO8"X>W>\L MW-^8=Z^BMFW>,WJ^8:N[/91KV7YPJ`V?O1VD4-,Z5[IP72KUQMX44W?,XOOM M)5,T%4'[86Z,CD;IYNMY).E8B%#>A1:CPC"0#0O:M3_KU9M9(?JAK!O?Q9L1 M_X$ZA:57-LNU:G_R:F99A7K6I98OY7TYRH2D5^EQ'YF0[Q.7JFM&0+VR47 MT?[[>`--R:PWW[+-^13Q@.=B>W[6DZOS[HHR*H+M-LQ8QI(YEB%]^_E.!5`V M^BL9Q+J:]84(`N(LH[-K#\3CT3X5+8P:LO9SN2%Z1NI;!]J(K'WBT.30X<5* MKO7]O;?UN'#_AYJH_:F2(6`&JEL'URUG?%M^V&+,H+#ITV0)28N*1$](($*? M'G(-VT_G6A`RCJ;0M<"YNNUZU^\P71(W7$#,3-C5D]0OI&(I\]AD/B+W)5-' M`]+V,WE5X(SM85^>(,%602E]26[8;]9J/DC$N`;4MB=)0[!W?IA>E"+TM!9D MC2)(=R^Z,4GK<`$D_D=?C*%4L?%@HQ2&50SR]@UW3=\RDQW3;M MY_D*.3QWU".CJG5)OC!YR5&2E'K"X.LU%]B#P5%10WWZKXM_^X7AQ5Y0KXFM M\R`04*9/\/4'"HG[\^:KD*=E)LFP_$(^-$^S=Z<*#TN65F#FL?:Y&SKF"RL9 MDO836W7H2A9<"@UBG;?N+1'MK`_%6\E)''*&*V5E#-K/6+7":V"L0^S?E!ES M1@(8UI6N86PW.Q8W;G\Y\^7`E.EU*!"B6YKQTT'BU99AV;Z;7-/V-XB\#H`R M`QQPSQ-QK[D_XDRUM+^W>RC3N/T]'S5`H#3"H4%(EH.-0'AN;`;"^S<"0M8( MS8.0/_NERD.%+H;]VP"R9//L&"C,CV[YCM/R*D=#5#0VF&XT;:.MY$]S3N^(7S(Z0^43YL MJ&3MO0(/:Y>P2L#-KM%7-EF=NSQ4)R_B9W!.YE/"6'2OZH8ZBH%2=):AA,#: MA2@#D'2ZU8](HSGGFC+,G-?EG$(>[=[/<=?06)M"#'`Q4,_6+++K2\D1P,E\YTRL68PI2*U=!W]9 ML)4:R+I!Z:[DZ5(R\1U:>MJCG,K:=?67`:HRBUT[J2J]XR?=CO1!/N>;"L?C M(O0)?!CVT"ZGZ-G?.[SD)J5G;DUNIZKVXI]4H8]9A8YZ*.85[1![YH:>V:%G M?@VJI'I-4"K[:5;VXQYZ)D(Q58,2UO`^H$29X2"KS+L>BOFC;`2CE$#K+E@7:9-!D1!J\A2H5_EQ7^8P_M,(C]>X]%@Z)K M7T^4RGV2E?NTAV)J%)&C??I&T[[BW46IL.]S%6L@,WQ"AA*ZUFN3LD8-C)0( M?I0KVL-A07`=2N97O1`IU2E7LRM&6]P#2KNP->RR+TA*+9`;"M03=W%_;02> M'O7<0*(L!%40QW,X^4N^BQFN_`-02P,$%`````@``7YN0WLW@A:)"P``4HT` M`!4`'`!T;FEB+3(P,3,P.3,P7V1E9BYX;6Q55`D``P$WA5(!-X52=7@+``$$ M)0X```0Y`0``[5U+<]LX$KYOU?X'K.:2/>AEV4[LB7?*KTQIR[$UEK,S-Q=$ M0A(J%*"`I"WOKU\`(BE*)$B0YDO:Y.#(%+KQ=7^-QH,`_/FWU<("+XC9F)*+ M5K_3:P%$#&IB,KMH?1NW+\?7PV$+V`XD)K0H01OO?P/\W^=_M-O@ M"T:6>0YNJ-$>DBG]%=S#!3H'OR."&'0H^Q7\!UHN?_+'7T/B\&>&@U\0?[JN M]1P,.B@LYKR^FZ@P[\5#[O] M?K=__'34.^^=GI^<:-;B0,>U@UIZJT\]7@/_MQ;_;&'R_5S\F$`;`>Y`8I^O M;'S1FCO.\KS;?7U][;P..I3-NERLW_WKZ]W8F*,%;&,B'&F@EB\EM,3)]<_. MSKKR6[]HI.1JPBR_CD'7AQ-HYM^:3B`0+GS277\9+HH35(=`V_CQP&M3H$3S!U MD#'O&'31%5]W.9ON`A'GDIBWQ,'.FZ"6+21<;H+4-V=H>M$2TFT1)2*$1*6_ MZ,@Z;TO>"&R\6%K<)=W<.*^@);PZGB/DV&G`8@N7@F0$&7?`'#G8@%8F6+&2 M16$4;1():NR'Z<-2)!9.2:K;DJ7*P#:>4^/[G%HF3VZW/UP>0EDPJJ7+P'H- M[?D7B[YF,+K!M4_9VS[])!:DH M7A2::[C$#K3&#G,-QV6H?4T7"TK&#F\4G,W0;R,^#)CS3N-/R!AW5"KP]VLN MKOWQ2GA]2T1LK2Y)*5`4HAML&U1$F8M,_Q=B(YN3-':72^OM M0!A1ZJ6X20;+1]':S1\#=&B4#XBB^=QD_?3SML3CVY; MC,0UN$Z3*RZ33FSTP^6NN'W185A5OMK,7FR&+RO3Y\^`3W!B:81Q0?K+S6IZ MMNC(EA7S>@B3I:J-_QOD0&S9]X).,;$OIAVHM-;?'CQDY36(G0K*;1%9VG&*B@?=U!9VZ0+B#."CDI7@%C6U%Z@Q02QC'"W1$;8E%C"[TEEODIB\T@LN5/H3V1S=^UVS,(EUWYT@59CNT_D<.' M=J_OK>O_XCU^#G!REZ$A_QAP8\$)LF3=SU[AN++=!D"7PVX-V%ZY7NGYCB9:$'8P!]("E/'( MNFCU>QLL%K61R8>.S(TQN0Z6UF$OEM`HD>['V%`40?[H M\KVY\+T,2B-5)`[J)3&TVO#5FW:I"(P4?2Z"7V"SW+,'FB5VAHVRXRE9X7 MA6/+/L=EY*:X.QFULH\IV,![%$BU!YBUD!).9FA-/(+[\\W&#>4E'KN+FN%YNQG/(D/W@.G*;)<><,#W9 M+?K\L1Y&].>0L8B5F:CF.>/N@LN0&)9KRA=33/K3<1B>N(Z8A#W1>TK$>).[ MC4.9R=VMR'82V"M$?_,I+\Y,938MML.ZG4Z1X3Q,'Y'8"XVD`>.EA9UU]"JZ MKA2IYO*D"U[E_9.*O'^Y$*^%LWI_+;6GW@^!5WG_M%COBU&B6*1_F(;F44-R MNS+FD,S0%\INT"2Y(611T6Q>,ENB(NE3'20EMI$C\&UO6>(&=N662.RPW86=/=DEZFDU0/G.4I%4Q MVHM'ESW-)>DY&-)T4MS':D@;(4*D?>]I9O%*]I.N!%N47%4Q"(R!EJMUQ2LY M#*XTVE7N=^&Y1GW7/'BP7**ZH43VM^\8LZN4[2%W>C8I.2QX^)<5XCL&[RIE MA\6A3CLL>/E5E2+N*.2S^J4\QI>K;XLJV$.NU'8H^2EX@58'5J[^+*I@__G1 M:3\5#>K](T6YN-D6WD]>8FQ0BW,**\0,;/.O?8RY$ER*MOUD M3<J='IH%/:YNV,%K^-[)8>(HA?V!&>'3A//#@E! M("6K.ON4Z?J>P(J/X@P?ML7!$YYLEWI$]CS M:=>>HP[P=,DC71MM8*,.;/259Y'J_I\`^MDN]$$';(2`)U4>P`+N^?%MZ?=V M;3GN`$\_V*T`2)TRT+8>^+6`335EGAQ4W104V-3?M>FDXR'=EBOQI&[RO4$! MTJ-=I*<=$)8%8>'RX-[I7"(4@![L@O[8`8$&&1UK'2"LI,36H'&U4(#]>!?[ MIPX(*?!B>TM%>]:?SS%X9G+>1A9<7P+SP\5+8Q`+;&'0-Q`G4=K,[2 MX"(7#R@-4;;0>O/M#5HR9."M!:(H0^%2SR<-7XZ/@"VZI]/8>.Z]_%>\5XHI MV5RO)@%6!G5=;SJ*NV8UF'I%EAZ+F>U[]?VZ9K5\T7+UMRHS@F[PM55BV,8^88@`D_@16 MVD"]G-KJF:?%TQMSA45)WFW<%&[_0ZG)D\2ZPJW)\T=OC)0V:]PJ5M.M=*5F M`IIL;C-[GD=A>7)W'RK2[*X^8DO3[B>2`%-O[@H7JJ=3C3HRQM';=C2N'\SJ MZR;W.AGX:')'\97[2@'52CF/?1>][IV;']=4C@6!V+_0[)@ M7ZC",N]=70T)RYC.OZ;8S(CD\`,TCT-449KW=HK&1.G:T/IC-`.._X<(S>H. M57R&;M&K=@=8QK]('6SSBAS63#KL%'.<1IKKF2I^3+B+^9/_`5!+`P04```` M"``!?FY#C?B[W2`L``!@C`(`%0`<`'1N:6(M,C`Q,S`Y,S!?;&%B+GAM;%54 M"0`#`3>%4@$WA5)U>`L``00E#@``!#D!``#=?6ESX\B1]O>-V/]0V^L(ST1( MW3I:ZNFVQP[JZN5:+L8;CHT)B"A*6(,`#8!JR;]^JPH'<=0)@E7)WGA? MNRUF)IZJ?"KKSOKCGU\6(7K&21K$T<]O#M\>O$$XFL5^$#W^_.;K='\T/1^/ MWZ`T\R+?"^,(__PFBM_\^4___F^(_-\?_V-_'UT%./0_H8MXMC^.YO$?T(VW MP)_09QSAQ,OBY`_H%R]DF#G]\\ M9=GRT[MWW[Y]>_OM^&VCI[P@MO/XAH1<[PFU*+6N'I'7[\ M^/$=^[44[4B^/"1A^8WC=R64P;N.9U[&>*#\#!)*T/^U M7XKMTS_M'Q[M'Q^^?4G]-V7ELQI,XA#?X3EBQ?R4O2X)M])@L0PI*/:WIP3/ M^6#")'E']=]%^)$XVZ^L#LKM+]1\];OF/]$0ZSM/S+/OW+_L%A$1W_L_CS;^?Q8A%'TRR> M_>,+7CS@ZB.LA#^_D?)_%" M^OFB@F*)T&_A0V4OKTGR20'PAEB"4];[&SFRCEY5>P6R14@DZ>@'1_M?IV_^ ME,LA)OC'=VM+[OA!QR=X@:/L\I^K('LE`)=D8!9EZ>@E2`6E5>C8Y(T6_#J' MI`I@^*2#LLVM7!2M9='?J?3_PN#9R/<#.A[TPELO\,?1N;<,2#;;6052)S'90H;8IT[(H>&#\H=,PQAXZ*?N-1*(&2LDAEG+.""6T-@V8++J/T1E&N?B6W'^;X"7AV10GS\$, MIV+W"P2MN5\*M'(_5PJ&^V70VNXO9%$I#*.7N<.9%T38O_22*(@>^611"=OL M5^2`ZQT*7](Y<;3@=;J0V6RU6(5T"H8N\#R8!1D,_OSJ)8D795+:M&1LLH4+ MKTZ2A@`8;O!0M2E1R`")(Z-O7N+?DZ](9D$M&:NC41Z\QNBS+@"&!SQ4G=!` M91`5`C5]^1)$P6*UD`:&EHQ-0G#AU0G1$`!#"!ZJ-B$*&1@TN"/(9#&A]KO5 M440;5F/@4/X(QNUM1&V7L]]A-7_O1=W\FS)6FS\/7J/YUP7`\("'JM/\*!BZR/%QEMJ9-,*E.`P.W2;Q M$B?9ZRU!FXTBORK-V:MBP*FE:9-;!D6I\TQ##0SG]+%V%TARS3W$=)$7^:C2 MWAMRA"M8-RMG5(?B%;..B+6U,@&X:I6L];MS/DA`B6:RZ'#+CCU2._;(F6./ M%(X]@NC8(SW''FW9L<=JQQX[<^RQPK''$!U[K.?8XRT[]KW:L>^=.?:]PK'O M(3KVO9YCWV_9L2=JQYXX<^R)PK$G$!U[HN?8DRT[]E3MV%-GCCU5./84HF-/ M]1Q[NF7'?E`[]H,SQWY0./8#1,=^T'/LARTY]B*>K>C4BD[2HBS(7NDI_&3! M#J&/'M*,7A7@P=?3LT8!DV)4O-!1@D$6`Z1M!I6J:$1GTDP9U;2'7-U)\>SM M8_S\SL=!OK!#_M%>SR%_^BU'<87&`*836:TA`!1@X],P(U" M&#%I1,1=L*.,8W0%D%.LYL^VN,`#55*@_AL(SW,`"3L+*N/2R]55*GJ/4%*6 MEIQMOW-AM@G0$`+%!!XR(25R83*$\-GE3A?L&!$@/@5S%7J/G'*U?K?%!BZL MD@6-'T%XGX>HL-"0MSN<5,!N M#BL%PB!(I(.PS:1Q6DY,/40U]_]!55&IF]^32/[LCE2_Q.$JRKSD]2H(<=(^ M:""1LTLB`5I"@$C#1R8C2Z6!F(I#AA3!\`XOXR0+HL<\?X5X^B40MSR' ME8)N366YLH#8(P4H)-'O4U1I%$E'4&')(9L8F\])/_H8)^(5D):47>YP(38I MTQ`!Q!0>+L'*!Q-%I:S#\+*^*#]]\DB53%89RP=$:"MN$5(ERZ%&HP"M@"/1 M`$0F#9BB5;5:4H,]E"NCFK;+Y9=\3)_/^*_(WW@]F436]C*,$&Y[*:8C"()) M*G3")9EBZE6LS#`5]ZRA$T$]SM0DW3"F`Y7/ETH,(%O:V%1<8=/TP9DR0"*5 MR?PJB+QH%I`6$*>!9/_93-5)6A6-PG"SJTCTG'.O!]AN\H-"%<5S5"FC4AO] MO=0'GD_A42%8FJHQ8B. MK'UB".!V^=$2!$83/CK1>G2N\PD&;4]?JM3B3XC0NR>DH@J&="=H.#8D2N[4TH__`:W48A"P2T%R^+'&4 M8E+(2?:$DT8[$U2*EJ;=>W3:16G>HU.J@2&B/E9!HJ&449%IE>N:R&/J,.BH M0SR'%%.2"29M=`C"TN6BV:"<$)PQO@I>L)]C:@'N_FSMQ#`'5'4PN/:;0`4AU/H`]%&$V@?=JZR8>#O+Y'ABW2Z<$^0P/TFS_.O`>@C#( M`IR2T2<[^?`4ASY.TCP+OV+(I:]NDRRFA:K325<7#.$,`;3T>G8VOQ_?C MRRD:W5R@Z?WD_"__-;F^N+R;_AY=_O7K^/Y_P%%5;]-'IN"(CAK;/V)IB)0S MVPBJ*0(9V8]FLWA%QH*WWJM'1HZ*94^!L-6.4`JXT3%R)<&02`J/DV>=":-E M+@V#/)>+91B_8GR'V9)+MUD(BJZA9Y-2VL6HLTNI!(9HNDB[LT1&-93%9!HX M)]/$!`;K6@V'=/KD+\G*@']&%AP&-YVB22*>3!T,.\TQ^G6311YZA0!T-2<\S2KA4EN0WR MOY/-!UR"4?IU'#UF.%GH#]-5&M;&Z7K0JX&Z7-PYB?0Q=A;EB=(^U0(^6.>& M;_4(P]7^LA2N8+3F:&?99,"FW%O.QVQ1K=\$-VZK%4==8&>L47`%+$.DO+B& MQ@7C76@H^\YF.\T[L+=LO)M<5_@]RE6`#,QK:2&D5[PZ8I8?.>.";+UNUI`! MPQ8!,,[Y99IE(V7/KN_3H3!ZIN+H=P=O#PX._X!.#@[V#O+_C](\"8>WRI[B M)/@7]O^`3H_V3G[ZN/?3Z4=V(._]R=Y[\C^/3W\JA0/VB#O[,5XG[P!XWGGD M^^R6M1?>>H$_CLZ]94`BLFBG0"1M=8=&#KFQ&\,7!4-7.;[.+DLEC=AS\4&$ M9KG"EJ9QK!W1/'L><4IZT0E8(B%KDS4AP&I^UI%P[GLI+&YGQJ()$T3^:N.U M<8&OBZN!4YP\![/.")@O8LW/`G"5EUN_P_`Q'Y3@2B9*"S$8W<(=SKP@POZE MET2DXTI'ZUL]%W@>S`+1.%A'T>IKSMH%:3SSK-1R3C%CJ)P]^]I%+28)@WO= M$;_VU,#U7$MOC@5KCB[$QY^JIXWI%68*,'BC.H6L7J,0J$$Z-ZY8_N'JP.*; M)EH^^VJ+AFQR!9>-PENUDV\D6C>B]/J2K*#*>MH"<3-:I[A:5Z9EAL#TQIN@ MEW?0:W$8_);<>JP!']5N,@JJK(\A(/=6%075O,LJL`*&T[VA=Y\/68O`('%M MN?#62R8)2T7HLY7#6YRP[+OJA4:QIJ-E6U51!"NY(C4P1-3'*ECO+;(J$V7$ MM,"1,,_W/*I6FM45T=5P1#H1=`'9VN(022;`*"=7D;)[K0649.SY%&V"E=). MR=6$+"56+@J75`U\6H3*-8"22?SP@)Z*4UH)'AW0D8=+,/6#`S9?&NA/M7$T MBQ>X2A&M.(4AE+9),`7D.K<$HF!H)TS-UW^!E'*^'QKO7/ M=GR? M^+)@.*,`V.;09(D3C[V\A0L%(*>WIC@D-A\_XX@`#.DM67\11.Q]='JBIRB> M:)=%4]GJ_I51@1I[6EJ:8!AH!+=S!"-7WD./N3K;=_`:!F#P\PZGF%0PS5%^ M0>)P&+.%9SDM%3IV^T$-^,W.4:(`AGLZ*+O=:*[#J.:OM*;&R$GWM\[.RX):/>TD**JUAQ":(PVW@S:=P1H8 M^@B`\7?AX\X0#09-JJ%C/A.]CE,14[B25N]6BZ$V+E-WQY-`GR=:@? MBN#T(Y#YXSC*,*DEQ8B\(V5WZ9(+L;EDV1"QPY>/.5\B_,C2ITE7+'GP.$G> MF12L4($?1&M6&GHV2:1=C#JME$I@`I,N M4FXG2"^=X2P+J_\6HG-OYP2#7>HAX M1;QW'D>D:"M2NDDU'I3N0,D5[6_NZ12DN\\GTP(3WK2AB@?YLTH)W'B_6;J+ M("VP8G]=OAM,`OF]]Z)502H3[KBI5S@Q2^7Z0/FJ!;K-7-JCY\SU:^K@N$M* MH5S7:,E8[8AY\!J=;UT`6(?+@=;)HH4S%)*?89!!A_9TRR%(EW'JA61D*FT9 MMS@Y\])@QE3"%9EDL0-!6L=M[(&`%DR'KV#3<#P<@IT*Z(,7N]W8F4J^_98K ML::/B/4\P\?&2TK"Q'G:(V0->8M)\_3&PTIAJRQ\QLE#G&)>QZ`+U/(@6,`: M.H"1-QA>\72TK#%(OP@5C]0JH-BD#7='AZ=E`H+R*DXKZ@JBO5++ZBLD>D5H MO$$B5P'3J^KA-.T&83#O5QP\/M$KB*0)>H_X9K5XP,EDWCD(STHCJ!]#&S99 MV:MX=8X:&0##V#ZHV_PM;2`O-X(B9H4NO!>)VF)H%QZJT_/WDNDW^*%H!X@D[8T0'*94@E!8\E M;6@2IE!1Q&2AT$7S5I[CJWA:]^_<7KHC0YT@]HFODTRV@*A[Z>X,/P81'8BA M,R^D*?W*FW=`>-/)QC..9N&*%JA('C_*LB1X6&4T-M['-.TWF9"0F@K95F5^ MJD+8LH8Q[C;%UR85(D\+ULG.H6&Q*I9S`1F4M5=Q3J0E>3:5<'CB5&B#[46FK4:G,'#R9UR[^CZ/+E]D3 M08JOXH0>1!.'*#-]:R3K4ZR*<2;*,.C7`W'G(&MA@K)Q5D]J']`;/+D=1E!Z MSG#+\4VO..)@9Z8/C)2",&BBO$NDE`9(0U(ZB)0LEPXI2BM%MVG`5)AQ3%&M M0BJ8*K4!F;`ZP+5YZV"P:%0JTYBJ,`.3MT815FIC!WG;+]XZ&)G6[QU/YAJ/ M2B@4K'%1"WC%.JDT#'[I0)1E:*5L:I/'9K`CC>"_@S"<+H+L*?2C:_+]B,S1 MS+IHN1&W@4ZG@/(P)[,`@X1]81N%.&H,,6OOKB]N4)C;<]%!\TMFV#W+C4#D MK$G7++.P4446P!'4,);RU7>+H/VC*(^@#I>3SDG;"-BNYD45:91'YAT^DZ4[>(?9>:Q);` M$KK7@I/(S&X2NNW/&WG0P=QD93#AJXJ8(+*\!H- M%T)BI4I9QZXU!,5I(T?CVGJQS,>T/&U0I#04_<>P,E(ZB92_>DGB M15D/0K8UG9.17Q0E$9MJL$G(Q2HD(*77(O:#>3"K%OD;C/Q6F+/,N7,O?6+9 M1W$R"U+R)YD$E24-4%++]`W0+6>E:Z^-4Y"820^F2< MVF*%]KR==^3@3M)E)$T*+`;9KO)+]K/)Y;QM.@#ZY3.(KAZV9"I^#-/U#GQ' MG(Q(R(#A*HR_J5X[DZLXN3!>'T.6TUKV+&@K]Z6A%3`D[@V] M\^#L:/I?Z.IZ\NL47=U-OJ#)[>7=Z'Y\\QF-SN_'OXSOQY=3&.3FINA_?8>KY(,2-3,GW\3!C@.U\RF:`W&9E MU9O)-KX#9J2QQ<)U+KJL/T77V)+R8[6HRFV:5#C"6;XB.VJK_T2":\RR3V5S/-=SI;\JY>Z>3"%KW1V1`&0V\50MG[G/!X5+\J M1M\;G-,HOU7;V$JRZ2,)78<6J4)(0]X,MNR%HY0JI]%HL;WO%2-W1 M]5*M0@DNFTIUG0>[GH!5%U$[!TLMW4S-YVO3ZLDV[CM\4DFK.?C%4!O9][MB M4(*4&J*]9_5D&^+%GGYQ^N]0N,W;D;.[-2Z`V=P?;PG!""$29/R=\N(XQ%`O M>LJ<7\6R\IB\L``<2;L$$$)M4J`C!H@$(FQ\&M2ZB/+"@14J"'*?2B4=48&W M,2P1@T@%19+0#A7*$]4PIE'CB`RSO11?X/R_:PL8Y]XRR+Q0_>Z6M@'+;V89 M%JRU!*RI[9R2O2%W]L18,K2TM7Z4DL%,?A4@#+R'(!QF+4DTW2*3/M).KM=? MX@YGN&+VID]BD.MI4E<&U+!6C*\S^\DEZ]Z'&KF*Z9SJ37N5FMLHQ2^$/#8U M=0!')"[0-N,*(19S\G>D9ZLDH9.I/!A!I1]I*?0`5GKKO4J>2]'0SB)_75(109V9&+!ZR<6X8(U+,-K:T`[4&2/O M#'`)J"_7+5<9&>/B4FE+4^ORHY-Y.^45;WXHD[8VT59#KN;;8E$H[-&# M*:-*-\$8C`"G'],W[A2@]M:;]=*PSI(:XU:.28-2]3L8DUX%D1?-!AB32@T! M8+E&0378+K$"?4RJAJX:DUZ-;T8WYR#'I$D\P]AGI\6KC>W\.K_D*K5$Q?+E M:B7XUG5KH3P8$FJ`[*Z3YBIY**VG8Q@V?<[PE..FJ]"H&(&>*_))BR%B(%<) M)`UE2.5<3+UPS4-X]+N),ZQ8I1>+NR(;#[2(8W59D-3B`)0S*J(*0ZW"BV;( MQ;S^B^?C271+YEGTX>U\U_.5.YN3*]B;)^L`7T^59=*P9LL:2#NT*730@BC1 MLYA+IE9M7[_""$?Z8\Z-!ZU09Q.;S2)V8LXLQBV<,R\+$^CA%*I@(;X:W M67RYO[T36Z&$_/KR?3KW>74S2Y0M52)AK?7$WNOHSNQY,;(#?( MRP/WMU[@BV_X=J3LGJKC0FR>H6N(@.$4'QE8:R)=!T>N2?ZXVK MR.<,R&G6FS!.5PE6!+O-S=H>F0Q1">VN=Q.;8#@^4$%,`NK-Y&:?!=7:0:6; M"^X6D;W+%?0*='4B@3T`>>T7ZRR\]1A#`PXO9&@43')50Z+MG,*](6OJ@>9#J:>JWQE*&ER5A7F>0T#A+ MIZEHD9$&!:GQ4$,+"OOTH78YQXB4*]>O[0Y_^LZ(9^I<,WIZCEFFR"ZCHP29 M8UKY9`J*I1V*#9U'9ICIU"1Y]*(B_0V)R&D.;92FW8#JMO=0PSH;(-3MTY%#]06T_@2X M).8;5=AZBGJ/7[*S4'R<:OC/[$SCDU328.V0\XWOHTF*"]9NG8=O4?U+K$5> MX'26!,NR09ZMTB#"\L=D+"87SB_YLE"-=KU`:#$.5 M$`7WL^E^9:D!+K!/@\>(O7$99=WRJ<*UKK+5#3:C`C7VU[0TP=#1"&Z;FD=O MT72U6'C)*UM)6YM"'-+"8"I=J='>#A$)VTV8*P/TO+6LSV?:R_ M1J"M96U)2[\(U8*66L4Y<TKE%MBY:NWHE@TF%5[JZN#5<%Z[75CDS"H/%@YVE1__Q85ME%E?+_< M+V`W[NA4M_&'ZOK^KZ#NXN6/42H&>&TAF_TQ'V"]&VY*.&>>%%;GX4XF!&[< MQC8S&L^5DO;"_GA&*.Q7:4]44U9C,U8GKST+V7EGV,`&&';V!-[F[\G;(KR1 M6$<3.4)Z%:9XS>YS$J^6:?7<+O=I.X-5\\W-6GXA<9!*:+V-N)%-,&U@H(*T MV\3I6U0W@2:#7*M,VH#V]1J9WGW\X-H+4%&"&7#GB#_/DZ-KYF*YLXFAF=K3:S8?4@=9_B M-4Y-FQAPSMI-4/,.NA0VBJE1S0KD%4RMPJO&#*9&P)%:.AXPL[!;M%9%YI_> M(BFU89#X#HH M(::'ZHK@`JFHA/I1U,@"!&9JQD\#=?!\U8^<']\B,7MA4':Z>DCQ/U)XXD:6[+W_MU%1U^\#]C+CG(R;8^^& MO_R0V41YR`S8:;,S+PW2R;Q5\-?\/U4A4E?99KPT*U`]>.II.B=O+[AMOC)E MELZ^=N08J3;/\>)PN49PT!M1%#=XNR?-OQ+DC_<9Y@/\CHOX2KH1(-N^O12NC- MQ6>A.!P&*C%RTAVL-6@DS#4058'!L"LO2'[QPA6N71$;1V1XNEJLFY>@/C1U M;;+.J#AU_FDI@F&B"=HV)ZDN8LK-B[0U?1C4%+[!-5XL21EDSZOI:%K.^JY; ME%8">)4:&$KJ8^7L*>?OI5T.]5[:8$D)"0%5J6;UOJ%>$Q@5$N0H8VNKAY#T% M@8SO0/Y";B5,4"2@H9=YVS?0F&Z MVYC27`4C9:X"E'\&1N"?SIZPOPII=GN*MG&)F>8@*4%/DKO@\4GCC&5_>U;' MW9L6NS'Z[FO,>7,9J@2=D7AACPZVXU66TBZ"]A7#/J"M.O0Y67^Y+(#TV"!7 MWOX!3@GL[C%-CK!S5NDB%!VY;)%FRW3AWU!7#Q[T]*S1QZ08%8UTE�R0!I M)Z\?/W\`T&[8*(]"OG97)08[\T*ZQ#%]PI@]#>+[`17SPO5-(H,.W"(2-UV_ M]:KF#QJLP7#>DMV77390\>MQ8KCGGX6CE-:U&66'H]*P.%+1@5X;J\C$G9-2 M'Z/ZAAS,+H6-Z<]>ST,O-9V_=;4 M)G@6L+@I*'=3Q&XNXBZX9@+B]>]@:,(!U4U;O19!.#]%L*V7+A=QDA7O3Q3G M%7C!E"MF[]5*,1&')%) MOI_O^::U!8.;U>(!)Z(0.OQWW&_]#U!-ZH,!&WS$:C,A8_`@]LF`/\FNC4\0 M;%[(=I.K%O#KJU,/^#&((O:O?#[R?33"SZRDX^B6N6!+%=_^R"XU/WX%#=GV MFE]PWC]MM5C"I@9I>+MIR4F''E1+&5MM6-PO[5+KDE35D$V,\YGOIIV)RR9L M;)BJ@&EM=%ZS'JJ`XF06D$D05V<.0U;;2NZ"-IF!L M!0[3^T*7$+D0E%$9N[-%PQK-(MM6+9I[_S>;M&T3NOQ10R:$F%T'>KWO0:E5?0^,]5A%ZJ,KDI2>.%0#;_IJMTBQ>?.(H.*G\GH=8856^$*"H\KL*KBM_,K]-\-(+_"E.GLGH MJWL55RH-UR$BJ!JNZ:BZ=U+M",%5G)BY3*H+V8$ZP+7<*37DPKG],W@(W[;> MW"0L*@Q6'@%#-K?OA#@Y+G9R:$UH'$7LUNAU,./VI%I:P-QO`%GD81T3<)RH MB.DZ2KO@0I,HKF/!C0/)]"9)6=]R@1_8[>Q\7#V.,DS`9O=Q+8)P?&FD#\VM M?<`+/6QDS(FS5TE"ZN.6#BCBZ):$CB@KIT^O7=?*I($Y4@.JR&TR51=.NIS/ M\2R;S.\PI1-F9)DN"1HR$%Q%W?5,A3PL1^F!%;A*H0S*67FDUW=6+K\CSFJ` M-756KNS"65?!"_;SQP`ZCJG]!LL)76"""J\)NJCVE_X,6RU??3<<+,5NZ&2^+(8!K8X>=OWGCYQITX?SK(,HGCI$_72V7 MX>OH,<'YU3?Q\38=)5CN-4`L\*>.!2<.C*/'#"<+S2,1- MH_)]L_-\TRR('B4;BS)A:$Y2(A6Z2*SIRD&3:(JS+&3M.C\$Q75-5PR>4X08 M)>[HZKAP!'T$+KV/KX*(=*`!/19*$XM+(9*Z\G"$6!>8.%4Z13X1Z+AQ3S8GI1#F]6'7]T9&`Y081/$'M M=\2=5CI;B"C7'L4UWQ`#6OT\C"H?-'3<.Z*\8J%P1"D&V1$MC%J.*'6<.>(^ M/L,Y&D$GS94"Z`8!1)D7VBK.G%!SL.!DV.=&G,`J) M##U]OXNN'L*S[AW9ZNQ50QQ8KN&#TQO6P$AI1?=]J_DWNU-Q[1RRLH\4E7T$N;*/3"K[R'UE M'RLJ^QAR91^;5/:Q^\I^KZCL]Y`K^[U)9;]W7]DGBLH^@5S9)R:5?>*^LD\5 ME7T*N;)/32K[U'UE?U!4]@?(E?W!I+(_.*GL,I5O;5Q:).&I5[E8RG+>^48) MBBK7`->N^IKH'BJ$W5?\#9'6JONU(,SJY^"3>F`M[]X)BJJ'6>$ZU>SJZ0VZ M?/$4ASY.TLM_KEJGI\12@"I:`JY=WW71WZ-<&(VR+`D>5NR"#,IB=.O!H#H] M_ZWE'94.(%]I0Y6T%)9I/A=WY*1R"YF3PEP@`L@%(F3M&B_ED)N4Y25U#,F]PQ9(9RJTAZI/H.(;G7ZO^1GDZ#1E64G"X]/PU@&-/`9N$!Z+^;M(?J%<@Q%Z%1^AKX*)E*A@R_R,_F:*U;A M98)G09DSI7I2IDA3CXL*X=)&3Q42+PP1=QQ?T]]#=0MLHE[98'[=O=NV[CL$ M'72\T3&,*[9]W]L#4N\R:.U*=__(WGJ-AS0Z+\47./_O<42PT;.`Z:WW2GMR M_I*50@E0T-+'VEW6RC70#Z7NCXCT4*4Z*O0=.:Z\PWL?CV9D2);@VX0N_62O MMZ00])D4.E!;+@1[4/K:@%S9`W3;IZ4).CXMC*#2RAYB=O:J56-F:GR)W7#YBNWXB5[#`J:D-J+'U`,U;&F6O`)=&T,,K^H': M(7'T1U290FM;NYXA`DJ;TP(I"HX0TD(H:%@D&>G9\CC:\%N>#+1ARZM,N6MY M]9?'>9ZC?P?0FKAP>"^=NUR:/B-=)7V0E&[SY1-R>A#MD4WGSE[7(D7['GWS M$G^R9"OJM77>FU7[?-[6/@+(L=LK&W=I??^!VD'U;Z':QV@SK7X/Y=_=?0+^BH/'IPS[HV><>(^XO&UXFP0S[BS4TJ>_3[)JE=@:A4LT MJ("#2CR(`>)PN_ZG:_(O\N?R3^0_Z*?)7_X?4$L#!!0````(``%^;D.J[-[H MQAH``+.3`0`5`!P`=&YI8BTR,#$S,#DS,%]P&UL550)``,!-X52`3>% M4G5X"P`!!"4.```$.0$``.U=6W?C-I)^WW/V/W![7K(/OJ>3=$^R<^1;'^VX M;8WM3F:?^M`D)&%#$0I(VE9^_0(D)5,D`11(0H!Z)P]IMQL%HNJK`@I`5>'G MO[TN(N\9T023^)=W)X?'[SP4!R3$\>R7=U\>#D8/%^/Q.R])_3CT(Q*C7][% MY-W?_NO?_\UC__W\'P<'WC5&4?C1NR3!P3B>DK]ZM_X"??0^H1A1/R7TK]ZO M?I2QW_SCG^,X9;\+4OR,V&^+KW[TS@[?A][!`:#/!Y+1`&TZ?+P=GWO''\Z. M3X]/SKR3XW^<';Y.V?8K MQZ\_';,OL/\*\I\C'/_^D?_OR4^0QP08)Q]?$_S+NWF:+C\>';V\O!R^G!T2 M.CMB9"='__Q\\Q#,T<(_P#$79(#>K:EX+VUT)Q\^?#C*_W7=M-'R]8E&ZV^< M':V'L^F9_2N6M*^,),$?DWQX-R3PTUP/E)_QA"WXWP[6S0[XKPY.3@_.3@Y? MD_#=6OBY!"F)T#V:>OS/+_?CS5?3&#]ADJ)@?AB0Q1'_YR,&4;9`<3J*PZLX MQ>F*XT47^7`9"WE_JX7_*-_@="FJR73[`0OEA$3R5'G<9[[ M$9?JPQRA-%$-K+6QD9%,?,H$,$`D(71UR_Y%.4A!\Z%&<^$O<>I'#RG-@C2C MZ.""+!8D?DB943`T*W^;L+5]SA:-WWQ*F:"4`^_?\W#VQS["OK=$<0):DH0$ M0XWH$B,A6Z?3U2/3[H2[UP"L573#S:1/"?HC M8Z*X>H8@+&J_VYE]V!G>U$S??09\])\B@!H/U+_960W&"X36E,[#1BBGVJW^ M7Z+4QU%RR^'DN_5A[$#4JWU[*$=FSB!J'S!K$;KHZ?4B&_N2HH3I;MX!6ZM_ MWR)!KRF*0Q2N.^(<]-[ULU_S7HZ/CT^\`V]-4?W1CT.O(/>J].6XUR./2+`U MV(@?AA"J$AT_@OHJ&^?H*4GYD=>ZH\A_0E'>_5=."R,]ZC+84K#Y\4R"@L,9 M>3X*$3[*S\78#SDC!\',7]BOOA9CN$)HF1]$'`1S'&T4:,JV+KJB+,5&%(Q4I_XY6,@P:38$@G+B'@H!K&S"L^7ADW;9+?[L%4.BG+@F] MC4>;LIX@B@GC(.0'^'*AUYH"I7_FHO1;N;8!PXB-)N0CNH[\6;OX:TV`8O_> M);&W,^?+C_X'^52J^.+60!#>NP2"BG=["^]O*(K^'I.7^`'Y M"8E1.$Z2#%'9`BPD`2+S@TO(@*1@#YY?2<3VE&RK>8TC1!,9+(VF0#A^=`\. M`=<6W=/"?N_1DE"^PR^NS*5>JH`"",I/[H$BEX$];'(=N6"3Z8Q0Z<:AUA"( MQ`?WD&CEV*)QO!T#/WXP+66]#X^:CUU-7@D6Q[S-+F M#/;4._`V@27LY[*Y5[3WOOL2^UF(4Q3^9Z?SUZI"3?WD*0SM;9 MK99/@;O[YC?_``O6<_XO>O MH_3"IW3%?)0\$%B,&9#/7*@ZH0&_Q=.D=TBVDQ MA"!B:X?,'0#4D(8;\`&!Z@;)\`?0'2`Q(GS!C?0U?D5A\4'!Q?-6"VM'R#IB M;(S:)?6=4+)$-%U-(K_P^]FLN>0+YBV23CLR*FO'Q_T7?8@XW`".<<;V(S?X M&85C)MMXAI\B5&C8)TH2@!\-[\':66=_0'7%Y#RX4KM4T5D[*NV*!AA,Y^SS M$BVYAB;E\$@ZQG.G*R3ETP0=*,AHH@L8\3&T8A"@Z?;Y41L(G M$W_%8_K5FUQ!>RA>PTULMX*B86R/I6T<;5RZ(7^=&:S'1'5J M;(>EC05H/F)L3!'[Q_"FD()PK/E`4Y+Z4=[2*I;Y_4N%O;?=N]J'A]!"L3:V M&^OIR\/EXX9M5F>-2BX]5]S(3Q(\Q2A4&JU6)U"$C=W2:$`DGF&!LC+D?MR0 M>)8BNM#R/U1$4&",;:/U@8&PY9*UM3('6@P[G/^>&ML_=[8@*?_[OC16F`-! M"@?2V*9Z"""_%?BZG#(/<*Y\MHO]7!=/9E].DRM1^:H`MT9+*$8&`Q(U41%Q MZP86HS#,KRW\:.+C#?D">;#Y%F-/#X]N6Q5 M?]ZPI1U4Q,8"`>$B%G!@5+)EZ.$#HL\X:%W2>;-&*ZA4#5XGZDA5P*4;T\D] M+]T3H_#*IS&.9\DH"+)%EF^\+M$4!UBR-$-HH5@9VXIJ3S)PB;B!8)-!'6<* MCI#!X,'>;M.WXB"K_,GNP1APG'=Q)=SS"E\JFT%UP'+:7'M-[4T.W9DBAVZ+ M_%]Y=+L/Z;Y[80O)U@+"E(4-OUJ63B/66][=_F;E]9*?&ZNP)$*P,O[1@I^@ M_JG`OTM?>YSVUUUT;D!?K>7ITSN:BR+,CPXFB.9E#$`')F)BV_F`/<#5$(YS M:!85*$99.B<4__FVADM1;!+93@8PP^5%Z=OAR\Y+P!2&_;L5.B03JQY1*4 M]TRB;`SS_#6O9Q21_%A`B:""S+:/IPD<2`ANX%4]H.$:!CKOD!+9]NTTL0(( MP`VDZGS!%R_[Y28T,1&QZ@80I4L>'XI]?8QF M>>ZF];OO3SZ.$SX9H.0NOGKE"I?A9%XQF7\K927S-1%:^49HS9YD&@Z,!,3FN]0(CV)`R5AQOF MN3W>]D?\;A&;61[]5RB2JEZLEPSIA2E,1FZ@RT8%V3O4FEDO-Z$[R;9Q^6U- MK.U*QX]]<+(DB1^QI5^JEQ-$S_T$!SE)E#&_+K]4@MYJ[&X>T\HSH$TE0GXE%`!K?$,CU3P`=A!`*H/6K M#"A#]F$()T;MI(\(C9T(,HF8WUJL+:$+:24K.!<,\S(69")N@F/?2H)AJ#U[1A2/1 M,97`IFZYVR!RJ\E3Y0@?Y96KZNU4IM;052/VI@5/(XEJFZ/J.;<+@#`C16/V MHV1#V];6,6"VU$J$0&7XU0IT+J!0J-(%62Q)S*>KT2N&`-).MH_8M'-2R::P MZ1QNC^V2+)AG+'$)VYL[AHI,X^HN83M#E>@#-^*(0*'`69[?C-+D"!)&&RF,8C.4=%;H)0^IMR%,VVML,NM40NX<.H MG&M%)Z1R%K2U'26I+6=E1DEVE'SKL;^&BD)'7/0S*_ M�V3W7W%I!JI'=BNLS?A&8#H*G]4]/F9G@F:B'((#:,>BO"KX\6_#4"7=&OJ6S'J?<4_3;SAD2_+O=V M-ZWLW\;QU6LP]^,9NB:41QM*34"O"R`HYI\VE(+212Q6$9):BEX7MN/4AT3( MH@WEFSTVC-JVI(,I*7JR'MO=V%LUJ^YN"JLB MJJ"Q'H$,PP+$^2ZMA6G`?^,H>EC@=!Z%\0T;1\Q\&.TY3MZ/]5CB'I8"D9!] MQ/1G-WD_4,2,)24.CI@]3X+/LBB.'HJ63D"8`\_7=R9]0!I,P!: M7=-NB!^O(T4[K6=M'5A_^JS?%"F6B45P.JUA;1U8#U`>#ARKEO.;3ZG/+UN[ M`%,GMOY"5C]0VF6Q8T`N_&2>Q[TC&N"$_?-Z5)WF-65OUM^]Z@<94%JN8-C) MRI2].?`NEA$,=V*'M8@J`3:-5@X\QP21N8`[-R)D)I1,<2K/-*^V<>`!(&"0 M0Y,S-R3>)R;IZZD##[]T#TOBPV]`T25FY"IVH,+1?H0EZ:B,19]P<)X-Z9G= MY$2^3%]'Y*6E4/NE$QVZ\]\.O:JT= ML2XN<1]_Q4M'JNH9V^T.ICB=RNWM93VP4?B_ M69+F7M@CN4?,"@(<"7B'^Q8FQ>[(8E>I2\_V0$M*PBR` ME^6OD=@.K#>*E[B@?ZO@W,.W&B3(WR`(`HK*%12&MK0#V]7F+6$/$*J#5>.V MXT6ED;N"0W2M'FSG=NQ"-[2%8O0FI'"='U":1DA:*GU=^K"ML>V$CUW!)A>6 M@^:;:U9YLU9&'IS(+KL:3:V_;K`K:&62,GD)N3'[=4B5#)Z6QM9S=W8*D%!: M.X%(F5#D)^@2%7]6F"S+V("*78/[@(*_B]>; MH;M9?1F9RM-B3C)3IAOL/^$H5S_1ZM7:TGI.5@=!$@5/]ET-4W98^KV`%YA4 ME%#NZ>`30%\ME_LX8?V0]Q'>U` MFF!OY="7F!M&+QCW.'YF/M\P`0C2OMQ).NP=@@"0F1N8L^FJW$6,@C\R3!'C MA.EINII$;-O,PWG9;_/'A24A"AI]6,]7[`$8ZMI44W(C`9SGP=KUS,Q M!5ZYC,#Z"S[]L56Q:!_(74_U0TSQ#F2[#F;V^I+;]P`$`H%">\JQ9$F< MW3POK'[,*-8-&8T[.>-PYU@M`S=663Y..2IP^9LOXZ0G_][VY%1U?S52.BFL M+EW>;^XR\M*U-V&Y"P/'7$G[`#\'9NQUZ:$@D<9H M`>1H"-,+$O,'0/*4@OSI@B++)..;I&+F>23RPSS>C78O4%R-.;4F<.TH2V/( MYE_*J]N\Y8G`[F"!M%`4C=V;F$%10VX[Q0Z4.@4CA2)G[%Q]=\B!,Z-V7S3G MCL[\^"V][Q(E`<7+(K_K/$MPC)*6&CH_>@?>FT#87TX.O6I/GA^'7J4O7EEG MTYL]9[$Z1#93)B3"X9KS246L=]-2`?SHK3J0VF,'7MD7GVXJO7EOW7F;_BS6NF@P!ZA8(:&Q>67)PPPPEC&B<)H:O\5KEI;Q_J]G9VZ+T1>065S4(03ZG.\8ZHO=5: M%M4A`;>]-8OUE_Q-I\9<.>76_(CT7.!.26$<-`M:@V5 M``J*S+3R7=P`'=LR02@0+7O7P<3IA,WF0V6CYHF'VSGW&U,\J9OB^\/2P+;H M[*T(165?]6)6;V>[:O=686*F//DOSYG*A)N$$H!SJ-V3Y66O':VV6M\=Y..$ M3;46J&Q9XT[KAO7#H5>E]2K$W_3*-5C%UKQ"Z"=*LF6R*?3=CH:>!]F[Y_U: MYP9CVR&C9#T$Q=M,;"+A-_VKT8RB0@Y-TSRKF^:/A]ZFA]S3+/KP*IU\TR8J M*C!6RJ1%J"KW$4:Z7X8#Y\LAR^`^*RX*".4>;'X,@^+6\\23[^N&\=.A5^F@ MW(15N[`8]2)F3"O$1:\;FV$^D)$"UCO=?BQ[E)UPKD?T=!*=$_9[CR*>_##Q M:;IZ9%O-Q`\$#N?[NO%^./1*:B\G][;H[2FRB"6UL:HI+=JG:'!:QJG5B67+ MA.)8,\8.]^M?^KV:I6H MHJ@64XJ]7-?.+)K=N9_@Y&Y:&^6J^#_`!J'T-G>%_3"NV:J>P-Q()OC"8Y^O MDA0O_%26QUIO9^W)JL%1:Y>`&^B43^_R/_C!^;,?\34`;(%`)-`<5P`LG!:3G.`ZLE+S<@%E8!'"^6C!M%)44(L;7'M`:'5T-6;H`[ M9F*.9_@I0J,D06G"E!+SK)-G%*IL%T!J[0FMP8$%R\D-6#\1$K[@*&(J6!\Y MV(?2ZUF#`ZTO.3<0OV<"9V.8YWD]SR@B^;13EF)7F3*(V-J[5X-CK"$K M-\`MWD!Y]%_!QBNFL/8.EH$Y62X5-[!["_>JQAG>+PG1#&ZY\&C.VDPFB.2]@@U82VGMD:W"4@4)R`]%;]%)AE)*8 M_1B@RFX.#+%^3_9>[1H<\ZYB=.(6J'O*R",OY]ER+]1(>!PB<<3[KOCG`?GK8=\1^_Q;`Z[Y>W>IX<])6SJ0<:U_/D798F;$O)HX_K*6.B2]-6$JM74(8P5'/MT'S?'CLNFLL; MR;3B!`DC,[1LM(KI%T;JQ-RJ%>9?;!TWD=#G?L3KHS_,$:!^B,MQ'3N3$ M7)&O3^>KB\A/.GA;34*[@3P0E.2NDD@4CE@*9)MYB5(?1\DM=Q?X"5#3DAH) MP)JA=N47O,TG+,3*A/35FZKVLK:B9MD[6E%H(TY4^79 M%X2F9:'*,G9"X(:VMK06>PT6J7#H#FV.NM\\E?YG6RC%7W>$MU>C%IZ%Z\U1KMD>RKXWWS7 MB%OUK`@&.5\UZJ?EG+RQ$X?<<;WU%\H=E)FON:$#K?H+BJ;KR[\3N[%R)5#M MP6K-K+OY!M6_AGVK@-S8H-US;N73;J6)&^8&FG(KHZ[L;FQ+6F4C6XWN44_:I)NY2S_PH2^78SVX=O`)&W M\>6&R)7KEVCY*B+XDTK\1F3)-J)II#6K]F&V?86=J)!&U([K$CR:+ MAP$O,\I#/XII,G\P,/_'#2>(!CA!,E7IT)=M5P:N"9T%Y0C0>^SV?#VU6%[% MNN?#N1_$][F*P_WW?*II%XBGR*!P](RH/T-KPYM0',CND'8U`&N%12QJ+`22 M_R<>O/`8M-7#-*3+0P["6OV4P?5Y>&CV9(U7,=[BKEI23.V16*O\LG/M[`C2 M-Z.B!6_V%51K'-8JVEA0SPX`[8ER?B.^J<9^RD#!'4?=4X/;+%>2O]7Y9XW' MN&1IX&:3S6`L=,H-=S*9C)=%GE#RC!G.YZLO3)?'<3GD>#8*V#AQ6CZ1(W[Q ML+W*=(]NWA!RW9BC3U3?F:<=2S' MAN=/<'-!ID0\>_S3P7 M/1$A*673EVNFH,U6](E`:S!,#W5;!PYJ M-BO(''!?V"06^'![?88Z1]W.7L?J(JOSJ=N:C6"\"ZR@5S>V+:MM[3_L=7J= MP][!0<51%%:^C$?IS-YU8`3XJ\;^D4H[9C[Z=CJ5;V?W],NXS][Y=U^_J(\# M//\P&/:=^8>O\\'7QYGZP]K__>'QWV)^*N\IQ;?GZNGBZ^][UU\^705#'DM[ M0CR,`!TF3QH3I::]=OO[]^^M[]T6%^,VJ&>UOWR\&1BZ1D#8F[F4/>:16T=' M1VW3&Y%F*&=#X4:BNVW=/<22Q)*AEY;04R859O82O:-BAB3Q03OH7"*EN:2' M`2F-2'W9'&,\C6E'6`X-;=C1UE.@V;&:72O!(KA+9"Z/Z93T@:B)E`10>V8;S73,@/HH)OSM3,].=KI51`S*$:'E"MB3UHV]PRU7B"P MC%WB$::NN/`NR`C[+J#QS<?&;8=Z@BSK]>?:OD'19@V80H"OKF.'JYO]CK MW15>7Y*SJYZ/'23[H_Y4IR4P7CB]"_J*/;Z?\OA"`.(CM!#Q.N.7_#Z8,D(WON$MM M2J(E4HVV&)]W:7SV6B@4:F+60BQ:R$61X!U%Z$YPCTK)Q?P6>D(HTHW%/C]* M^[S;0@MN9-AWU+/G>$H5=@=*^+8"YS3/N>=Q-E"P=4+T27R[\X4]@?/_'U@( MF)TA"#_`7XB7U4GCM=]"X4`H/1(RPDU46VJ(AD/1>#L*L/$&>&9*F$P_JPA9)"$D>+'74WB+9A MQA$)P67@3Z?N_'0L2)!T!DXOI2AV?3?M^KZT2&WD2?=O71QN9'@`<\=,D/'R1"*<4`9X[< MVSA.H#?!N+N*>GYNFT2TE*(8K>"*$Q=>:MCA:YT66?'RO`60Y8YF*^YU3^\JU(6PQAYA%#V<[V5UZ;^I\N);LG(V1*T'JZ ML.FD(:DW=77!F&F;"#(Z:6C4FE'-T9]@6FOFN1&)%EU2@F8@3GLC'#@2@86= MD9(ID0,A'+!1$#7;D?*1`$659K]+#*,?'#U"3&AOPV07#]LX"+7)Y](?F@KGJ^*4ELF7CYS*VB:MDU/*#VF3+ M6S=7Q\C:0)\*E;U59DJ2\S9@U%/E2$\5Z_`'E=E,D55:A.7!)M?1!<5_FJ3Q M@9^1:RDA/?E(O"$1#:-F^`(QIY.ZKCX@0KP3O@XNNDJ\!T&'I"OZ4'] M-#W,U_2P?IJ^S=?T;7TT+;MV<0HR]<6N2/UJM#C\%-FTOHT!!4BA;+P%$Z_H MC#BG4IJ[#X$E2TVU4_C<%[J\_PXR"&"]PPJ^W%`\I*ZIKPY,6$6TTH@@Z591 MUS"X8G#2L`5QJ%HVS>.,*"SF6S#NAK.Q(L(KMVXE55W-,TF43J#T:/+"S*=% M=I7JJ*L1J9RJ(-6JL0$W7,HKP;V@NL2'99DLY(JF6"G-^I$9PC+T#R98D"V8 M\![B>Z1B445:8$@ERNX+9F%QQ<4&&*=S6Y'EN$*NI MNXSHFCPO#%YSY`<;4C&^"LJK6.L)=H'653!?Q5I;Z$%#2*>"6T/]4<$NOXJH MMM;E@@4P?0"-!QY5$]=A-]24_U:8UBL8:SFI\W6N,*57,+XXR.\(8^;JXEIX M%W+5%>RTPM60+N1Z63#'8?@1[65GLM12[A3RE9;X;D<+P[6Z&EI-9LSU"_.7GV[7C]:G1%A M4PG=D4G5YO1J]KI.\$+-JR&_FKVV4R'URK7@36R=+5@^+92>C_(/&*M8-K?< M(<.?_(BQSP9$J:"G/]+'_^3#Q=S>V@)I<`A73KAW6$OS,=M7;UOB.14E.)DG M\>G>%V*/^;U%(E6^/8G>VMIS:MN@D1.]SZ%$QE,MOZNVED3UU_U1^E05OS0I MHZBO77AN[NA^Q`[I%[VD6T546^NRDTQO/3%0YC'(C1-:5#PSRYEJ:_TY9^&/ MP0:[$N1.H6U1['C@B0PK?N&\-MMSYYNA-H&X.,,H6*=5B>MI5'ZF59'VN4TR MO];SP*\H@_E/]6V;Z$?'TA4H52CK5\Z1ND-D5[X&2V;JS$TNP6U(VK3D2$4R MMI$\AS_#D?.#'AFC*]+6P:SU+K"G)_>FW'^A"6\NHJ;]LC5QM7-4C'C?5[I. M1O\B^^+'N%*S(I^F#M.^[%IXIH:P$FT-DYU=P>54-31KD_O+FP6N8BFU M[#%PMGM5RKA^W@]M%\/%_ M4$L!`AX#%`````@``7YN0T=`6%A]9```G#,$`!$`&````````0```*2!```` M`'1N:6(M,C`Q,S`Y,S`N>&UL550%``,!-X52=7@+``$$)0X```0Y`0``4$L! M`AX#%`````@``7YN0W;-#'`C"P``[GL``!4`&````````0```*2!R&0``'1N M:6(M,C`Q,S`Y,S!?8V%L+GAM;%54!0`#`3>%4G5X"P`!!"4.```$.0$``%!+ M`0(>`Q0````(``%^;D-[-X(6B0L``%*-```5`!@```````$```"D@3IP``!T M;FEB+3(P,3,P.3,P7V1E9BYX;6Q55`4``P$WA5)U>`L``00E#@``!#D!``!0 M2P$"'@,4````"``!?FY#C?B[W2`L``!@C`(`%0`8```````!````I($2?``` M=&YI8BTR,#$S,#DS,%]L86(N>&UL550%``,!-X52=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@``7YN0ZKLWNC&&@``LY,!`!4`&````````0```*2!@:@` M`'1N:6(M,C`Q,S`Y,S!?<')E+GAM;%54!0`#`3>%4G5X"P`!!"4.```$.0$` M`%!+`0(>`Q0````(``%^;D.YOQ%4G5X"P`!!"4.```$.0$``%!+ 4!08`````!@`&`!H"```QS@`````` ` end

Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
Statements of Operations (Unaudited) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]
Revenues, net
Operating expenses:
Selling, general and administrative	12,608,401	280,456	33,461,690	569,121
Research and development expense	6,412,711	26,514	15,510,310	26,514
Depreciation and amortization expense	719,040	10,863	2,134,231	11,012
Total operating expenses	19,740,152	317,833	51,106,231	606,647
Loss from operations	(19,740,152)	(317,833)	(51,106,231)	(606,647)
Interest expense	(205,416)		(1,098,868)
Loss on settlement of debt			(7,108,495)
Total other income (expense)	(205,416)		(8,207,363)
Loss from continuing operations	(19,945,568)	(317,833)	(59,313,594)	(606,647)
Gain from discontinued operations				260,746
Net loss	$ (19,945,568)	$ (317,833)	$ (59,313,594)	$ (345,901)
Loss from continuing operations	$ (0.34)	$ (0.01)	$ (1.08)	$ (0.03)
Gain from discontinued operations				$ 0.01
Basic and diluted loss per share	$ (0.34)	$ (0.01)	$ (1.08)	$ (0.02)
Weighted average number of shares outstanding	59,334,545	30,853,117	55,127,859	19,706,741

Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
Statements of Cash Flows (Unaudited) (USD $)	Sep. 30, 2013	Sep. 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (59,313,594)	$ (342,671)
(Gain) loss from discontinued operations		260,746
Loss from continuing operations	(59,313,594)	(606,647)
Adjustments to reconcile loss from continuing operations to net cash flows used in operating activities:
Depreciation	682	327
Amortization	2,133,549	10,685
Amortization of stock issued for prepaid services	36,318,767	53,745
Loss on settlement of debt	7,055,994
Stock warrant expense	6,932,057
Stock issued for donation	750,000
Stock issued for interest	1,133,162
Changes in operating assets and liabilities:
Accrued liabilities	227,681	125,876
Prepaid and other current assets	(37,507)	27,700
Accounts payable	343,098	82,850
Net cash used in operating activities from continuing operations	(4,456,111)	(305,464)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of computer equipment	(4,350)	(1,062)
Purchase of Penn State License	(160,539)
Net cash used in investing activities from continuing operations	(164,889)	(1,062)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of stock warrants	3,640,363
Proceeds from sale of stock	531,250	212,680
Proceeds from notes payable	499,001	250,400
Payments made on patent liability	(155,000)	(15,000)
Net cash provided by financing activities from continuing operations	4,515,614	448,080
Net Increase (decrease) in cash	(105,386)	141,554
Cash, beginning of period	313,095	12
Cash, end of period	207,709	141,566
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Accrued liabilities for purchase of Smith LDN patent	$ 2,715,000
Conversion of debt and accrued interest to common stock	74,167
Common Shares issued for Penn State License	2,550,000
Common shares issued for prepaid services	51,204,100

Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 800	$ 118
Amortization	$ 3,703,633	$ 1,570,114
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares Issued	62,589,869	45,489,368
Common Stock, Shares Outstanding	62,589,869	45,489,368

Statements of Shockholders Equity (Unaudited) (USD $)	Common Stock	Additional Paid-In Capital	Stock To Be Issued	Prepaid Services	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 31, 2012	$ 45,489	$ 196,632,775	$ 3,690,960	$ (6,082,771)	$ (176,945,847)	$ 17,343,837
Beginning Balance, Shares at Dec. 31, 2012	45,489,368
Return of Stock for prepaid services, Shares	(350,000)
Return of Stock for prepaid services, Amount	(350)					(350)
Issuance of common stock in exchange for debt, Shares	1,545,833
Issuance of common stock in exchange for debt, Amount	1,546	7,128,615				7,130,161
Issuance of common stock for prepaid services, Shares	10,228,000
Issuance of common stock for prepaid services, Amount	10,228	51,193,872		(51,204,100)
Amortization of prepaid services				36,319,117		36,319,117
Issuance of common stock for Jill Smith/LDN license, Shares	300,000
Issuance of common stock for Jill Smith/LDN license, Amount	300	2,714,700	(2,715,000)
Issuance of common stock for Penn State License, Shares	300,000
Issuance of common stock for Penn State License, Amount	300	2,549,700				2,550,000
Issuance of common stock issued for charitable donation, Shares	100,000
Issuance of common stock issued for charitable donation, Amount	100	749,900				750,000
Issuance of common stock for loan expenses and interest, Shares	297,500
Issuance of common stock for loan expenses and interest, Amount	297	1,078,114	54,750			1,133,162
Issuance and modification of common stock warrants		6,932,057				6,932,057
Issuance of common stock for cash and exercise of warrants, Shares	4,679,168
Issuance of common stock for cash and exercise of warrants, Amount	4,679	3,688,809				3,693,488
Stock to be issued			478,125			478,125
Net loss					(59,313,594)	(59,313,594)
Ending Balance, Amount at Sep. 30, 2013	$ 62,589	$ 272,668,542	$ 1,508,835	$ (20,967,754)	$ (236,256,210)	$ 17,016,002
Ending Balance, Shares at Sep. 30, 2013	62,589,869

Balance Sheets (Unaudited) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current Assets:
Cash and cash equivalents	$ 207,709	$ 313,095
Prepaids and Other Current assets	45,000
Total current assets	252,709	313,095
Computer equipment, net of accumulated depreciation of of $800 and $118 respectively	4,612	944
Intangible Assets:
Patents and licenses, net of amortization of $3,703,633 and $1,570,114, respectively (Note 8)	19,265,260	18,688,270
Deposits	17,435	24,928
Total assets	19,540,016	19,027,237
Current Liabilities:
Accounts payable	629,797	286,698
Payable to officer	76,000	76,000
Accrued liabilities	654,892	427,211
Current portion patent liability	185,000	200,000
Notes payable	857,197	432,363
Total current liabilities	2,402,886	1,422,272
Non-current Liabilities:
Notes payable related party	121,128	121,128
Long-term portion patent liability		140,000
Total non-current liabilities	121,128	261,128
Total Liabilities	2,524,014	1,683,400
Stockholders' Equity:
Common stock - par value $0.001; 500,000,000 shares authorized; 62,589,869 and 45,489,368 shares issued and outstanding respectively	62,589	45,489
Additional paid in capital	272,668,542	196,632,775
Stock issuances due	1,508,835	3,690,960
Prepaid services	(20,967,754)	(6,082,771)
Accumulated deficit	(236,256,210)	(176,942,616)
Total stockholders' equity	17,016,002	17,343,837
Total liabilities and stockholders' equity	$ 19,540,016	$ 19,027,237

6. Discontinued Operations (Details Narrative) (USD $)	9 Months Ended
6. Discontinued Operations (Details Narrative) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Discontinued Operations Details Narrative
Cash flows from operating and investing activities of discontinued operations	$ 0	$ 260,746

4. Capital Structure-Common Stock and Common Stock Purchase Warrants (Details) (Warrants, USD $)	9 Months Ended
	Sep. 30, 2013
Warrants outstanding beginning balance	7,260,000
Warrants issued	2,567,918
Warrants expired
Warrants exercised	3,324,168
Warrants outstanding ending balance	6,503,750
Exercise price Warrants outstanding beginning balance	$ 1.02
Exercise price Warrants issued	$ 2.56
Exercise price Warrants expired
Exercise price Warrants exercised	$ 0.63
Exercise price Warrants outstanding ending balance	$ 1.83
Minimum
Exercise price Warrants outstanding beginning balance	$ 1.00
Exercise price Warrants issued	$ 1.00
Exercise price Warrants exercised	$ 0.50
Exercise price Warrants outstanding ending balance	$ 1.00
Maximum
Exercise price Warrants outstanding beginning balance	$ 1.50
Exercise price Warrants issued	$ 1.50
Exercise price Warrants exercised	$ 0.75
Exercise price Warrants outstanding ending balance	$ 1.50

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2013	Nov. 14, 2013
Document And Entity Information
Entity Registrant Name	TNI BIOTECH, INC.
Entity Central Index Key	0001559356
Document Type	10-Q
Document Period End Date	Sep. 30, 2013
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		63,736,639
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2013

2. Summary of Significant Accounting Policies (Details Narrative) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Amortization expense	$ 2,133,549	$ 10,685
Computer equipment
Depreciation expense	$ 682	$ 327